



CompuGroup Medical

Annual Report 2022

Synchronizing Healthcare.
Creating the future of e-health.

**Nobody should suffer
or die just because at
some point
medical information
was missing.**

Frank Gotthardt
Founder

TABLE OF CONTENTS

OUR PURPOSE..... 2

FOR OUR SHAREHOLDERS..... 4

CEO letter.....4

Share information.....7

Managing Directors9

Report of the Supervisory Board 11

Report of the Joint Committee of
CompuGroup Medical SE & Co.
KGaA..... 16

COMBINED MANAGEMENT REPORT..... 18

1. Foundations of the group 18

1.1. Group business model 18

1.2. Changes to the composition
of the group 21

1.3. Objectives and strategies..... 21

1.4. Management system 21

1.5. Research and development 22

2. Economic report 24

2.1. Macroeconomic and industry-
specific conditions..... 24

2.2. Business performance 25

2.3. The group's position 33

2.3.1 Results of operations of the
group 33

2.3.2 Financial position 37

2.3.3 Net assets of the group 41

2.3.4 Net assets, financial position and
results of operations of
CompuGroup Medical SE & Co.
KGaA..... 42

2.3.5 Overall assessment of the course
of business and the group's and
the company's situation 45

2.4. Financial and non-financial
performance indicators 46

3. Guidance, risk and
opportunity report..... 52

3.1. Guidance report 52

3.2. Risk report 54

3.2.1 Risk management system 54

3.2.2 Risks 57

3.3. Report on opportunities 66

4. Internal control and
risk management system 73

4.1. General* 73

4.2. Accounting-related (section 289 (4)
and section 315 (4) of the German
Commercial Code (HGB)) 74

4.3. Effectiveness* 77

5. Risk reporting in relation to the use
of financial instruments..... 78

6. Takeover-related disclosures..... 79

7. Declaration on
Corporate Governance..... 88

8. Separate non-financial report
for the group 89

9. Final declaration on the
dependency report..... 90

TABLE OF CONTENTS

CONSOLIDATED FINANCIAL STATEMENTS FOR FINANCIAL YEAR 2022 91

Consolidated statement of financial position	91
Consolidated income statement.....	93
Consolidated statement of total comprehensive income	94
Changes in consolidated equity.....	95
Consolidated statement of cash flows.....	96

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS..... 97

A. General disclosures	97
B. Key accounting principles and measurement methods	99
C. Principles of consolidation	102
D. Summary of the principal accounting and measurement methods and underlying assumptions	126
E. Notes on items on the statement of financial position and income statement	152
F. Segment reporting.....	200
Segment report.....	201
G. Other disclosures	203

FURTHER INFORMATION 240

Responsibility statement.....	240
Independent Auditor's Report.....	241

FINANCIAL CALENDAR 254

IMPRINT..... 255

MEUR 1,130

Revenues

MEUR 234

EBITDA adjusted

EUR 1.80

EPS adjusted

>9,200

Employees

Major locations



Our unique customer base:



Physicians
Dentists
Hospitals



Laboratories
Pharmacies



Payers
Institutions
Industrie



Patients
Rehabilitation
& Care

FOR OUR SHAREHOLDERS

CEO letter



CompuGroup Medical – We create the future of eHealth

Michael Rauch

Spokesman for the Managing Directors and
Chief Financial Officer (CFO)

Dear shareholders,

The ancient Greek physician Hippocrates vowed to work for the well-being and health of his patients some 2,400 years ago. And for physicians all over the world, the Hippocratic Oath still forms the basis of their ethical conduct today. At CompuGroup Medical, we are not doctors, we are software experts. But we also feel bound by the ancient oath. It continues to be the principle that guides us and our customers worldwide. The vision of our founder, Frank Gotthardt, was that nobody should suffer or die because at some point information was missing. This vision motivates us every day to offer the best possible products and services for our customers and thus contribute to people's health.

Digitization drives growth

In this quest, digitization offers enormous opportunities for the healthcare sector. CompuGroup Medical plays a pioneering role in realizing the digital patient journey, supporting our customers with solutions that facilitate daily work in practices, clinics and pharmacies. With more than 9,200 employees at sites in 20 countries around the world, we are working together to ensure that patients receive the right health information at every stage of their lives. And to providing physicians with what they need most: time for their patients. The future medical world will be even more digitized, even more data-driven, even more connected and even more effective. Based on our unique experience and close partnerships with our customers around the world, we will actively contribute to shaping the future of eHealth.

Successful financial year 2022

We have achieved further milestones on our path to sustainable, profitable growth in financial year 2022, which underlines that CompuGroup Medical is on the right track to a continued successful future.

In the third year of the global COVID-19 pandemic, CGM continued to support healthcare professionals with smart solutions to better manage the impact of the pandemic. Our software modules made it easy for medical practices and pharmacies to create digital immunization records. And our newly developed solutions already enable our German customers to make full use of electronic prescriptions (e-prescriptions). In France, we are leveraging our excellent market position and supporting our customers to integrate the digitization requirements of the new government initiative SECUR into the daily routines at medical practices. Our innovative CLICKDOC platform facilitates uncomplicated interaction and coordination of appointments between doctors and patients in many European medical practices. Our e-MEDIX billing software enables our customers in the USA to bill health insurers quickly, securely and without errors.

In the hospital segment, CompuGroup Medical was able to establish sustainable business relationships with new customers in various European countries. In line with the German initiative to modernize and digitize hospitals, as required by the new Hospital Future Act (KHZG), we have initiated our first major projects in Germany and secured a highly dynamic order intake for the future.

In the pharmacy segment, we supported our German customers by introducing e-prescriptions and launched a new product generation in Italy that has already been very well received.

One of the most exciting growth areas is our data business. The aggregation and analysis of anonymized health data will play an increasingly important role in the future and contribute to patients' quality of life, obviously in strict compliance with data protection regulations. With the successful acquisition of INSIGHT Health, we have reached a milestone in this respect. This was followed in the fourth quarter by the announcement of the acquisition of the GHG business. The technologies and products acquired represent an enormous competitive advantage in terms of development. And finally, we initiated our international expansion in the data business with the acquisition of shares in the Italian company New Line.

Our key financial figures also reflect a very successful financial year 2022. CGM achieved an impressive 10 % increase with record sales of EUR 1.130 billion. Operating income (EBITDA, adjusted) rose to mEUR 234. The 2022 guidance was thus fulfilled for all relevant key figures at group level. The adjusted guidance for 2022 was thus met for all relevant key figures at Group level.

A fabulous team

The CGM family has grown dynamically again in the past year and forms the basis of our success. We are very grateful to the entire CGM team around the world – thank you so much for your great dedication and commitment in the past financial year!

Looking ahead

Our goals for financial year 2023 are again ambitious. We intend to achieve organic revenue growth of 5 % again. The investments that we have made in the past are now paying off. Adjusted EBITDA is expected to be in the range of mEUR 260 to mEUR 300.

FOR OUR SHAREHOLDERS

CEO letter

We have also set ourselves ambitious ESG targets in 2022. And we will continue to work intensively on implementing and realizing these goals in 2023.

In 2023 and beyond, we will continue to drive our growth for the benefit of our customers and patient health, and remain at the forefront of digital transformation in healthcare.

Thank you to our valued Shareholders. We appreciate your trust in us!

Yours,

A handwritten signature in black ink, appearing to read 'M. Rauch', with a stylized, cursive script.

Michael Rauch

Spokesman for the Managing Directors and
Chief Financial Officer (CFO)

March 20, 2023

Share information

The CompuGroup Medical shares have been listed since June 2020 as registered shares in the Prime Standard of the Frankfurt Stock Exchange under the new securities identification number A28890 (ISIN DE000A288904). In financial year 2022, they were listed in the SDAX (previously MDAX) and TecDAX under the ticker symbol COP (FRA: COP) effective from March 21, 2022. 53,734,576 shares were outstanding as at December 31, 2022, each representing EUR 1.00 of the share capital.

Key data

		2022	2021
Year-end price	EUR	35,98	71,15
Year high	EUR	71,85	84,35
Year low	EUR	31.64	62.50
Market capitalization*	mEUR	1,933	3,823
Earnings per share, adjusted	EUR	1.80	1.95
Dividend per share**	EUR	0.50	0.50

* At December 31.

** 2022 as proposed to the Annual General Meeting.

Share price

The performance of the stock market and the CGM shares was again heavily impacted by the global COVID-19 pandemic in financial year 2022. This was compounded by inflationary and recessionary tendencies and exacerbated by the macroeconomic impact of the Russia-Ukraine war. After the CGM share had commenced the stock market year at its annual high of EUR 71.85 on January 3, 2022, the above factors led to share price losses in the first two months of the year. A slight recovery towards the end of the first quarter was followed by an even more pronounced downturn as investors increasingly sold shares in technology and growth companies due to ongoing macroeconomic uncertainties and rising interest rates. The Capital Markets Day only brought a brief respite to the downward share price trend, even though CGM presented its progress towards sustainable growth after the investment phase. While both the CGM share (EUR 31.64 on November 2, 2022) and the benchmark indices reached their annual lows during the fourth quarter, share prices recovered slightly towards the end of the year. The year-end closing price of the CGM share was EUR 35.98, corresponding to a market capitalization of EUR 1.95 billion. The CGM share price was thus roughly 50 % below the prior year's year-end price. The performance of the relevant indices for the reporting year, SDAX and TecDAX, was – 27 % and – 25 % in the same period.

Dividend

The total dividend payout in financial year 2022 amounted to mEUR 26.1. This corresponded to a dividend of EUR 0.50 per share. For financial year 2022, a dividend of EUR 0.50 per share will be proposed to the Annual General Meeting on May 17, 2023. Subject to the approval of the Annual General Meeting, the distribution will amount to mEUR 26.1. The total distribution amount stated above does not take into account any change in the number of shares entitled to dividends as a result of any capital measures and share buybacks. Based on the closing price for 2022 (EUR 35.98), this is equivalent to a dividend yield of 1.39 %.

FOR OUR SHAREHOLDERS

Share information

Share buy-back programs

On November 25, 2021, CompuGroup Medical SE & Co. KGaA announced a share buy-back program with a term until the end of January 2022 that was completed on January 10, 2022. During this period, 500,000 shares with a total volume of mEUR 34 were bought back, thereof 96,122 in financial year 2022.

Shareholder structure as at December 31, 2022

	share in %
Frank Gotthardt (Founder and Chairman of the Administrative Board)	33,37
Prof. Dr. Daniel Gotthardt (Member of the Administrative Board)	6,66
Dr. Brigitte Gotthardt	6,29
Dr. Reinhard Koop	3,72
Treasury shares	2,79
Free float (German Stock Exchange definition)	47,16

Investor relations

The goal of investor relations activities is to provide investors and the capital markets with information that is comprehensive, relevant and precise at the same time.

The Investor Relations section on the company website (www.cgm.com/ir) provides comprehensive information such as financial reports, stock exchange information, relevant news as well as the financial calendar and company presentations. Conference calls for investors and analysts are held upon the publication of quarterly and annual figures. On September 1, 2022, the Managing Directors and the CEO of the US business presented the corporate strategy for CGM at the annual Capital Markets Day in Koblenz. In addition, the presentations by the Managing Directors, in which they provided information on the milestones achieved following the investment initiative, were also streamed live on the company website. All of this content is available on the website as a video webcast or as a PDF download. CompuGroup Medical also participated in various national and international capital market conferences as well as virtual events.

At year-end, thirteen analysts followed the company's business performance on a regular basis. They issued ten Buy recommendations and three Hold recommendations.

Managing Directors



Hannes Reichl

Emanuele Mugnani

Michael Rauch

Angela Mazza Teufer

Dr. Eckart Pech

Michael Rauch

Spokesman & Chief Financial Officer (CFO)

Michael Rauch has been Spokesman for the Managing Directors of CompuGroup Medical since July 1, 2022. Furthermore, he has been in charge of CompuGroup Medical's finance division since summer 2019 and has been appointed as Managing Director until July 31, 2027.

Angela Mazza Teufer

Managing Director Ambulatory Information Systems DACH, Connectivity & CLICKDOC

Angela Mazza Teufer has led Ambulatory Information Systems DACH since February 2022 and is also responsible for Connectivity Germany. Angela Mazza Teufer has been appointed as Managing Director until February 28, 2025.

Emanuele Mugnani

Managing Director Ambulatory Information Systems Europe

Since February 2022, Emanuele Mugnani has been responsible for Ambulatory Information Systems Europe and for the Pharmacy Information Systems Segment (PCS). He joined the CGM Italy Group in 2014 as General Manager for Pharmacy Information Systems in Italy and has been appointed as Managing Director until February 14, 2025.

Managing Directors

Dr. Eckart Pech

Managing Director Consumer and Health Management Information Systems

Dr. Eckart Pech has been in charge of the Consumer and Health Management Information Systems segment since November 2019 and has been appointed as Managing Director until October 31, 2027.

Hannes Reichl

Managing Director Inpatient and Social Care

Hannes Reichl has been responsible for the hospital and laboratory business of CompuGroup Medical since 2018, which he previously led as Senior Vice President and has been appointed as Managing Director until October 31, 2027.

Report of the Supervisory Board

The Supervisory Board of CompuGroup Medical SE & Co. KGaA (Supervisory Board) performed the duties incumbent upon it under the law, the Articles of Association and the rules of procedure in financial year 2022. The Supervisory Board monitored the management of the company as carried out by the general partner (represented by its Managing Directors). In accordance with its responsibilities, the Supervisory Board was involved in the key decisions that were of fundamental importance to the company.

The Managing Directors of the general partner consistently informed the Supervisory Board in written and oral reports in a timely and comprehensive manner about all important issues of corporate planning and strategic development, about the business performance, the general position of the group, including any risks, and about risk management.

The Supervisory Board received regular reports from the Managing Directors on the measures taken to increase sales revenue and improve earnings, as well as on major completed company acquisitions.

The Supervisory Board established an Audit Committee. The Committee held a total of seven virtual meetings within the reporting period. Among other matters, the Audit Committee discussed the general partner's interim financial reports and risk reports, prepared Supervisory Board resolutions and discussed key topics with the general partner. In various discussions with the auditors KPMG and the CFO, the Audit Committee has been monitoring the quality of the audit on an ongoing basis. The meetings of the Audit Committee are regularly attended by representatives of the audit firm KPMG.

During the reporting period, the Supervisory Board held five meetings by video conference and one face-to-face meeting; one further resolution was passed by written circulation:

February 16, 2022:

At this meeting, the Supervisory Board was informed about personnel and organizational changes at the level of the general partner's Managing Directors and about the current business performance. The Supervisory Board discussed and approved the update of its competence profile and its rules of procedure. The annual Declaration on Corporate Governance was discussed and approved.

April 5, 2022:

At the meeting, the Supervisory Board discussed the annual financial statements and the consolidated financial statements with the representatives of the general partner (Dr. Dirk Wössner (CEO), Michael Rauch (CFO)) and the auditor (KPMG AG, Berlin, Frankfurt am Main branch). Following the discussion and also based on the preliminary audit and the recommendation of the Audit Committee, the Supervisory Board approved the annual financial statements of CompuGroup Medical SE & Co. KGaA, the consolidated financial statements of CompuGroup Medical group, the dependency report of the general partner, the remuneration report and the non-financial report for financial year 2021. The Supervisory Board also resolved that the annual financial statements of CompuGroup Medical SE & Co. KGaA be submitted to the Annual General Meeting on May 19, 2022 for approval. The Supervisory Board concurred with the general partner's proposal for the appropriation of profits. The Supervisory Board resolved to propose to the Annual General Meeting that the actions of the general partner and the members of the Management Board of the legal predecessor, CompuGroup Medical SE, as well as the actions of the members of the Supervisory Board of the company and of the legal predecessor, CompuGroup Medical SE, be formally approved for financial year 2021. The

Report of the Supervisory Board

Supervisory Board's report to the Annual General Meeting was approved. On the basis of the German COVID-19 Mitigation Act and after considering the pandemic situation and the interests of the shareholders and other participants, the Supervisory Board decided to hold the Annual General Meeting as a virtual general meeting again. The agenda and the proposed resolutions for the Annual General Meeting were discussed and approved by the Supervisory Board. The Supervisory Board received the general partner's current risk report and discussed it with the Managing Directors.

The Supervisory Board discussed and unanimously approved an update of the Declaration of Conformity to be carried out in the course of the year.

May 18, 2022:

In this meeting, the Supervisory Board discussed current topics in connection with the Annual General Meeting to be held the following day.

June 2, 2022:

The Supervisory Board discussed and unanimously approved the conclusion of a termination agreement with Dr. Dirk Wössner.

July 6, 2022:

The Supervisory Board unanimously approved by circular resolution the update of the Declaration of Conformity during the year.

September 19, 2022:

The spokesman for the Managing Directors Michael Rauch reported to the Supervisory Board on the current business performance and discussed it with the Supervisory Board. Philip Heßen (CHRO) provided information on current HR topics, while Managing Director Emanuele Mugnani (AIS Europe) explained growth opportunities for international business areas in his area of responsibility. The Supervisory Board discussed and approved a related party transaction that required its approval.

December 12, 2022:

The spokesman for the Managing Directors Michael Rauch reported to the Supervisory Board on the current business performance and discussed it with the Supervisory Board. Derek Pickell (CEO Northern America & India) presented strategic direction and current topics of the USA & India business unit to the Supervisory Board. At the meeting, the Supervisory Board discussed and unanimously approved the current draft of the joint declaration of compliance pursuant to section 161 German Stock Corporation Act (AktG). The updated competence profile of the Supervisory Board was discussed and the current status of its implementation was documented. On the basis of the new provisions in the German Stock Corporation Act (AktG), the Supervisory Board discussed the concept for the Annual General Meeting 2023 and approved the Annual General Meeting to be held as a virtual Annual General Meeting. At the same meeting, the Supervisory Board discussed the assessment of its own activities and their effectiveness. Based on the evaluation of a questionnaire that had been filled in prior to the meeting, possible areas for improvement were discussed and debated with the general partner.

Report of the Supervisory Board

Conflicts of interest:

There were no conflicts of interest in the Supervisory Board during the reporting period.

Changes in the composition of the Supervisory Board:

The member of the Supervisory Board Dr. Michael Fuchs passed away on December 25, 2022. It is with great sadness that the Supervisory Board learned of his passing and remains grateful to Dr. Fuchs for his valuable contributions.

Mr. Reinhard Lyhs was appointed as a new member of the Supervisory Board with effect from March 1, 2023 by the Koblenz Local Court pursuant to Section 104 Par. 2 German Stock Corporation Act (AktG). The Supervisory Board intends to propose Reinhard Lyhs as the successor of Dr. Michael Fuchs at the Annual General Meeting on May 17, 2023.

Overview of attendance at meetings of the Supervisory Board and the Audit Committee, including the respective meeting formats:

Member/Meeting/Resolution	Supervisory Board (Meeting attendance)					
	Feb 16, 2022	April 5, 2022	May 18, 2022	Jun 2, 2022	Sep 19, 2022	Dec 12, 2022
Date						
Meeting format	Virtual	Virtual	Virtual	Virtual	Presence	Virtual
von Ilberg, Philipp (Chair)	YES	YES	YES	YES	YES	YES
Weinmann, Stefan (Vice Chair)	YES	YES	YES	YES	YES	YES
Basal, Ayfer	YES	YES	YES	YES	YES	YES
Betz, Frank	YES	YES	YES	YES	YES	YES
Fuchs, Michael, Dr. (verstorben am 25.12.2022)	YES	YES	YES	YES	YES	YES
Handel, Ulrike, Dr.	YES	YES	YES	YES	YES	YES
Hegemann, Adelheid	YES	YES	YES	YES	YES	YES
Johnke, Lars	YES	YES	YES	YES	YES	YES
Köhrmann, Martin, Prof. Dr.	YES	YES	YES	YES	YES	YES
Mole, Julia	YES	YES	YES	YES	YES	YES
Störmer, Matthias	YES	YES	YES	YES	YES	YES
Volkens, Bettina, Dr.	YES	YES	YES	YES	YES	YES

Report of the Supervisory Board

Member/Meeting/Resolution	Audit Committee (Meeting attendance)						
	Feb 2, 2022	Mar 9, 2022	Apr 4, 2022	May 3, 2022	Aug 2, 2022	Nov 2, 2022	Dec 15, 2022
Date							
Session format	Virtual	Virtual	Virtual	Virtual	Virtual	Virtual	Virtual
Störmer, Matthias (Chair)	YES	YES	YES	YES	YES	YES	YES
von Ilberg, Philipp	YES	YES	YES	YES	YES	YES	YES
Basal, Ayfer	YES	YES	YES	YES	YES	YES	YES
Johnke, Lars	YES	YES	YES	YES	YES	YES	YES

Audit of the 2022 financial statements:

The Managing Directors of the general partner submitted to the members of the Audit Committee and the Supervisory Board the annual financial statements and consolidated financial statements for financial year 2022, the Combined Management Report of CompuGroup Medical SE & Co. KGaA and the entire group for financial year 2022, the remuneration report for financial year 2022, the separate non-financial report for the group and the dependency report of the general partner once this had been prepared.

The auditing firm (KPMG) elected and appointed as auditor by the Supervisory Board at the Annual General Meeting of CompuGroup Medical SE & Co. KGaA on May 19, 2022 audited the annual financial statements of CompuGroup Medical SE & Co. KGaA, the consolidated financial statements and the Combined Management Report of CompuGroup Medical SE & Co. KGaA and the group as at December 31, 2022, including the accounting system, in accordance with the statutory provisions and issued an unqualified audit opinion.

At meetings on March 8, 2023 and then on March 20, 2023, the members of the Audit Committee discussed in detail the annual financial statements, the consolidated financial statements, the Combined Management Report of CompuGroup Medical SE & Co. KGaA, the remuneration report and the separate non-financial report for the group as well as the auditor's findings. The auditor reported on the main findings of the audit. On this basis, the Audit Committee proposed to the Supervisory Board to approve the financial statements prepared by the general partner.

The Supervisory Board was informed of the audit results at a meeting on March 8, 2023 and took note of the Audit Committee's recommendation. At its meeting on March 22, 2023, the Supervisory Board was presented with the annual financial statements for financial year 2022 as prepared by the general partner, the consolidated financial statements and the management report of CompuGroup Medical SE & Co. KGaA and the group, as well as the general partner's proposal for the appropriation of net profit, the dependency report, the remuneration report, the separate non-financial report of the group and the corresponding auditor's findings and report. The Supervisory Board examined the documents submitted. Employees of the auditing firm KPMG personally answered all the Supervisory Board's questions in detail.

Report of the Supervisory Board

The Supervisory Board acknowledged the auditor's findings and raised no objections.

In accordance with section 171 (1) German Stock Corporation Act (AktG), the Supervisory Board has reviewed and approved the annual financial statements of the parent company and the group, and the management reports of CompuGroup Medical SE & Co. KGaA and the group, in addition to the proposal for the appropriation of net profit and the risk report. In accordance with section 286 (1) German Stock Corporation Act (AktG), the annual financial statements of CompuGroup Medical SE & Co. KGaA are forwarded to the company's Annual General Meeting for adoption. The consolidated financial statements were approved. The Supervisory Board approved the general partner's proposal for the appropriation of profits. The remuneration report and the separate non-financial report were approved.

The general partner submitted its report on relations with associated companies (dependency report) in accordance with section 312 German Stock Corporation Act (AktG), and its declaration in accordance with section 312 (3) German Stock Corporation Act (AktG), to the Supervisory Board. The auditor has reviewed the dependency report and issued the following opinion on the corresponding findings:

"Based on our audit and assessment, which we have carried out in accordance with professional standards, we hereby confirm that the factual statements made in the report are correct, the company's compensation with respect to the transactions listed in the report was not inappropriately high."

The Supervisory Board acknowledged and approved the auditor's findings and also reviewed the dependency report. According to the final results of the review by the Supervisory Board, there are no objections to the declaration by the general partner at the end of the dependency report.

The Supervisory Board would like to thank all Managing Directors and all employees of CompuGroup Medical SE & Co. KGaA and its associated companies for their commitment and hard work in the past financial year.

Koblenz, March 22, 2023



Philipp von Ilberg
(Chairman of the Supervisory Board)

Report of the Joint Committee of CompuGroup Medical SE & Co. KGaA

CompuGroup Medical SE & Co. KGaA (CGM) has the Joint Committee, as a voluntary additional body, which, pursuant to article 16 of the Articles of Association of CompuGroup Medical SE & Co. KGaA, consists of six members, namely three members delegated by the general partner CompuGroup Medical Management SE and three further members delegated by the Supervisory Board of CompuGroup Medical SE & Co. KGaA. The members of the Joint Committee that are delegated by the Supervisory Board must themselves be members of the Supervisory Board and include two shareholder representatives and one employee who represents the employees of the company. The Annual General Meeting of CompuGroup Medical Management SE appointed Dr. Klaus Esser, Frank Gotthardt, Dr. Dirk Wössner (until June 30, 2022) and Michael Rauch (from July 1, 2022) as members of the Joint Committee. The Supervisory Board appointed Dr. Michael Fuchs, Philipp von Ilberg and Frank Betz as members of the Joint Committee. The Chair of the Joint Committee is Dr. Klaus Esser.

The Joint Committee meets regularly to discuss the annual budgets of the company as well as significant acquisition projects and other matters of the company requiring approval as set out in the Articles of Association. It meets at least once a year, or more frequently as required.

Three meetings were held in financial year 2022, at which the following topics were discussed and the following resolutions passed:

March 25, 2022:

At this meeting, the Joint Committee discussed the approval of the acquisition of the INSIGHT Health Group. The Joint Committee received background information on the transaction, its structure, the financing of the proposed acquisition and the current status of negotiations, and had the opportunity to ask questions about the transaction. Following the discussion, the Joint Committee approved the acquisition of the INSIGHT Health Group by a subsidiary of CompuGroup Medical SE & Co. KGaA.

November 14, 2022:

At this meeting, the Joint Committee discussed the approval of the acquisition of all shares in GHG Services GmbH and other assets from Gotthardt Health Group AG ("GHG"). GHG must be considered a related party of CGM as it is majority-owned by Professor Dr. med. Daniel Gotthardt, who is also a member of the Administrative Board of CompuGroup Medical Management SE. Furthermore, the Chairman of the Administrative Board, Frank Gotthardt, holds a substantial minority interest in GHG. The Managing Directors and members of the M&A team explained the project and the rationale for the planned acquisition by a subsidiary of CGM. The purchase price mechanism was explained to the members of the Joint Committee. The discussion was based on a valuation report and a fairness opinion issued by an independent audit firm. Following the discussion, the Joint Committee approved the transaction.

FOR OUR SHAREHOLDERS

Report of the Joint Committee CompuGroup Medical SE & Co. KGaA


December 12, 2022:

Pursuant to article 18 (1) (b) of the Articles of Association of CompuGroup Medical SE & Co. KGaA, the Joint Committee discussed the budget for 2023 of the CompuGroup Medical Group as prepared and adopted by the general partner and, in doing so, discussed related opportunities and risks with respect to implementation with the spokesman of the Managing Directors and CFO Michael Rauch. Following the discussion, the Joint Committee approved the budget for financial year 2023.

Attendance overview of the Joint Committee members:

Member/Meeting/Resolution	Joint Committee (Meeting attendance)		
	Mar 25, 2022	Nov 14, 2022	Dec 12, 2022
Date			
Meeting format	Virtual	Virtual	Virtual
Esser, Klaus, Dr. (Chair)	written vote	YES	YES
Gotthardt, Frank	written vote	YES	YES
Wössner, Dirk, Dr. (to Jun 30, 2022)	YES	n/a	n/a
Rauch, Michael (from Jul 1, 2022)	n/a	YES	YES
Betz, Frank	YES	YES	YES
Fuchs, Michael, Dr. (Deceased on Dec 25, 2022)	YES	YES	YES
von Ilberg, Philipp	YES	YES	YES

Koblenz, January 2023



Dr. Klaus Esser
(Chair of the Joint Committee)

1. Foundations of the group

1.1. Group business model

CGM group

CompuGroup Medical SE & Co. KGaA (CGM) develops and sells efficiency and quality-enhancing software plus information technology services for the healthcare sector. The company is one of the leading players in the development of global eHealth solutions and is a key provider in Europe as well as in the US. CGM's software products and related services are designed to assist in all medical and organizational activities in private medical practices, hospitals, pharmacies, medical laboratories, and other healthcare facilities. The digitization of doctor-patient interaction is another focus area. Its portfolio of products also includes information services for health insurance companies and pharmaceutical producers. Headquartered in Koblenz, Germany, the company has a wide and global reach with offices in 20 countries worldwide. More than 9,200 highly qualified employees support customers with innovative solutions for the steadily growing demands of the various healthcare systems.

We endeavor to write our reports in a gender-neutral way. However, we would like to point out that to aid readability, we have used the generic masculine or gender-neutral wording instead of the simultaneous use of feminine and masculine forms. All references to persons apply equally to all genders.

Figures in the following sections are presented in either millions (mEUR) or thousands of euro (kEUR). Rounding may result in minor deviations in totals and the calculation of percentages in this report.

Organizational structure

The CGM group consists of a large number of entities in various countries, all of which are controlled directly or indirectly by the ultimate parent company CompuGroup Medical SE & Co. KGaA. A complete list of all group companies and interests in other companies is provided in section C.4. Scope of consolidation of the notes to the consolidated financial statements.

Operating segments

The four operating segments outlined below comprise our full portfolio of products, solutions and services, and form the basis for our IFRS segment reporting (IFRS: International Financial Reporting Standards). As at January 1, 2022 and 2023 respectively, individual profit centers were reclassified which resulted in a minor adjustment of the segment reporting to the management structure of CGM. The effects are shown in the segment reporting section.

Ambulatory Information Systems (AIS)

In terms of third-party segment revenues, the Ambulatory Information Systems segment is the largest of our segments and includes developing and selling practice management software for registered physicians, medical care centers and physician networks. Customers are generally primary care providers who are active in ambulatory care and who provide health services to outpatients visiting a healthcare facility and are discharged again on the same day following successful treatment or consultation. For these healthcare providers, products and services are packaged into an end-to-end solution that covers all clinical, administrative and billing-related functions needed to operate a modern healthcare facility. We also offer supplementary Internet and Intranet solutions to ensure that patient data can be shared between physicians in a secure way. Sales cycles and decision-making processes are short and straightforward, while software solutions can generally be installed and made available within a very short space of time. Our product portfolio also delivers solutions for larger medical facilities such as medical care centers and practice associations.

Hospital Information Systems (HIS)

This operating segment focuses on developing and selling clinical and administrative solutions for the inpatient sector, where healthcare services are provided over an extended time period in highly specialized, primary and secondary care facilities. Customers include acute care hospitals, rehabilitation centers, welfare institutions, multi-location hospital networks, healthcare regions, regional care organizations, medical laboratories and radiologists. The software solutions and related services facilitate patient administration, resource and personnel management, medical-care documentation, invoicing and financial and medical controlling. The use of certain clinical software applications also supports various specialist departments, laboratories, radiologists and radiology networks. As a full-service provider, CGM pursues an integrated care approach, providing customized software solutions for virtually every aspect of administration, planning and the provision of care in outpatient and inpatient nursing care facilities.

Consumer & Health Management Information Systems (CHS)

In addition to physicians and pharmacies, the products and services in the Consumer & Health Management Information Systems segment target pharmaceutical companies, health insurance companies, other IT companies in the healthcare sector as well as patients and consumers. With the data-based products in its portfolio, CGM provides healthcare companies with valuable information for them to improve and optimize their services. The product range also comprises software interfaces for data exchange, portals for retrieving relevant data from the German outpatient healthcare market, medical decision support tools, medication and treatment databases for healthcare service providers, solutions for the insurance industry, and digital healthcare applications, consumer portals and mobile apps. Moreover, the CHS business unit includes the Telematics Infrastructure business, which provides secure links for service providers and forms the basis for further digitization in the healthcare sector. Security solutions for service providers are another element in this segment's portfolio of products.

Pharmacy Information Systems (PCS)

This operating segment focuses on developing and selling integrated administrative and billing related software applications for pharmacies. The software solutions and related services provide accurate information and helpful decision-making support to manage every aspect of the supply chain for medication from procuring and shipping the medication, managing and controlling inventory efficiently, through to planning, performing and monitoring retail activities. Medication is dispensed to patients in a safe and cost-efficient way by means of advanced medication safety and control functions, and decision-making support tools for using generic substitution and cost optimization strategies.

The primary sources of revenue in the AIS and PCS segments come from software maintenance and other recurring revenues. Other revenues comprise (one-time) revenues from the sale of licenses (accrued over the minimum term of the software maintenance agreement), training and consulting services, and other revenues from third-party software licenses together with the associated hardware, equipment, etc. Customer relationships are generally formed for the long term.

The focus in the HIS segment is on a project-oriented business model. Hospitals and care facilities in Europe are largely managed by the public sector, meaning that they are subject to the regulatory requirements applicable to public calls for tenders. Lead times are long for projects to be awarded and for decision-making cycles, with project terms amounting to anywhere between several months and several years from the time software solutions are installed to when they are put into operation by the customer. Revenues from consulting, training and other services are higher than in the AIS and PCS operating segments.

The business model of the Consumer & Health Management Information Systems business segment in the data area is based primarily on cooperation agreements, service and software offerings, and revenue from contracts for the collection and brokerage of medical data. In addition, revenues are generated based on project business (license sales and service business), technical support, and performance-based revenues (based on the cost and quality of services provided to patients). In the area of telematics infrastructure, the business model is essentially based on the sale of hardware and associated services, for which recurring revenues are generated.

1.2. Changes to the composition of the group

The composition of the group has changed in the reporting year as a result of acquisitions, mergers and name changes involving group companies. Mergers and name changes do not have an impact on the group and are not presented in this management report. Note C.4. Scope of consolidation of the notes to the consolidated financial statements contains further information about the changes to the consolidation group.

1.3. Objectives and strategies

The unchanged strategic objective of CGM is to further expand its position as a leading international provider of IT solutions for the healthcare sector and to benefit from the advance of digitization. The key elements of its corporate strategy are summarized as follows:

- organic growth by selling new products and services to existing customers and winning new customers;
- supplementing organic growth with targeted acquisitions to complement the portfolio in the four core operating segments;
- consistent leading position in technology and innovation.

1.4. Management system

The company is managed, both in terms of its strategy and its operations, by the Managing Directors and responsible managers for the business units within the segments. The strategic targets and resulting goals are defined once a year in the course of the budget planning process and monitored on a monthly basis as part of a management information system, which includes detailed reports on key performance indicators that reflect growth, profitability, capital efficiency and the company's ability to innovate. Any deviations from the planned targets are discussed at the segment level every month, with corresponding measures being derived and implemented where appropriate.

The most relevant key financial and non-financial indicators are outlined in section 2.4 of the management report.

Unless stated otherwise, all financial data are audited figures from the IFRS consolidated financial statements. Please refer to section E of the notes to the consolidated financial statements for more detailed disclosures.

1.5. Research and development

Software development at the CompuGroup Medical group can be broken down into the four main divisions and areas specified below:

- development of individual components of the existing physician, dentist, hospital and pharmacy information systems, performed both centrally and locally;
- development of platform products that are incorporated into the more general information systems as independent products via interfaces. Examples include electronic archiving systems or systems for managing appointments and organizational optimization;
- development of a new generation of international physician, dentist, hospital and pharmacy information systems, based on a shared data model and shared technology platform (G3). The separation of business logic from user interface makes it possible to implement core functions through one-off development and maintenance work. These functions can later be used in different products and their individual user interfaces;
- development of additional functions related to the Telematics Infrastructure with a view to meeting the statutory specifications of the German healthcare agency gematik. Gematik is an institution with the legal mission to coordinate and to specify the Telematics Infrastructure applications in German healthcare to lay a foundation for a secure data network; and
- development of innovative data-based products and solutions that serve to collect and communicate clinical data and are thus necessary for business transactions based on data.

Individual components are increasingly being processed across sectors by central development teams. Training sessions run by external instructors ensure that the teams stay up-to-date with technological developments. Group companies are constantly working to provide customers with state-of-the-art software solutions and services. Our developer teams work with the latest tools and in accordance with internationally recognized standards to ensure the quality of the products offered. Furthermore, external contract developers in Germany and abroad provide development services either on the basis of employment agreements ("extended workbench") or contracts for works and services, thereby being involved in efforts to develop new software solutions and software generations.

Future generations of software developed by CGM will be characterized by a custom front-end solution uniquely adapted to the individual CGM product lines, while back-end modules will be developed for all main product ranges across all platforms. This can be described as a building block principle. What this means in the medium term is that those development activities will become as centralized as possible, especially for the back-end. By way of contrast, developing and updating front-end systems will continue to be the responsibility of the subsidiaries close to markets and customers.

Capitalized in-house services

In accordance with IAS 38, capitalized in-house development services (approximately 804 thousand working hours; prior year: approximately 714 thousand working hours) are capitalized as an asset; this lifted CGM's EBITDA by mEUR 45 (prior year: mEUR 37) in 2022. The increase in capitalized development costs is mainly due to new development projects launched in 2022. Amortization of capitalized development services amounted to mEUR 13 in financial year 2022 (prior year: mEUR 15).

The main part of the capitalized development costs is attributable to G3 developments in the AIS, HIS and PCS segments as well as developments in connection with new gematik specifications. Most of the hours of development work were recognized under expenses in the year under review. This essentially involves research costs not eligible for capitalization and expenses associated with the adaption/continuous improvement of software products in line with new or amended legal or contractual requirements that are not eligible for capitalization either. Depending on the area of specialization or current regulations, updates are typically required each quarter. The share of capitalized development costs relative to total R&D costs was 19 % in the reporting period (prior year: 18 %). An average of 2,683 (prior year: 2,408) employees worked in software development and maintenance in the group in 2022. In addition, we also use external service providers to support our development teams in the research and development activities described above.

2. Economic report

2.1. Macroeconomic and industry-specific conditions

Macroeconomic conditions

The global economy has slowed in almost all sectors, more than previously expected, and inflation is higher than it has been in decades. The outlook is severely clouded by the cost-of-living crisis, restrictive monetary policies in most regions, the war between Russia and Ukraine, and the continuing impact of the COVID-19 pandemic. According to the International Monetary Fund (IMF), global growth is expected to slow from 3.4 % in 2022 to 2.9 % in 2023 before moderately increasing again in 2024 to 3.1 %. This puts growth for 2023 0.2 percentage points above the IMF's October 2022 estimate, but below the historical average of 3.8 % from 2000 to 2019. This increase is a pleasant surprise and is due to better-than-expected resilience in many economies. Global inflation is expected to fall from 8.8 % in 2022 to 6.6 % in 2023 and to 4.3 % in 2024 (source: www.imf.org).

In its report for 2022, which was released in January 2023, the IMF assumes global economic growth of + 3.4 %. CGM's key markets, comprising the European markets (particularly the German market) and the US market, performed better than anticipated. The IMF expects economic output to increase by 1.9 % in Germany and by 3.5 % in Europe. For the USA, an increase of 2.0 % is estimated for 2022.

Industry development

The healthcare sector, in particular the market for healthcare information technology (HCIT) and related services, is one where demand is growing substantially. The growth in HCIT solutions, which has been steady for years, is being shaped by the rapidly growing volume of data in healthcare, the need for fast and efficient processes and patients' growing need for data accessibility and self-determination when it comes to healthcare matters. The COVID-19 pandemic that marked the years 2020 to 2022 and the immense strain it has put on the healthcare system have once again accelerated demand for HCIT solutions and added certain momentum to specific fields of application. It is of paramount importance to keep the healthcare system in a fully functioning state without being tied to a physical location and to enable care to be provided remotely, especially in times of a pandemic. HCIT solutions such as video consultations, online platforms to facilitate the networking of healthcare providers, or apps for patients to stay healthy and monitor their own condition have a key role to play here.

This growth trend has also been fueled by legislative drives and government aid in recent years. Particular highlights in Germany include aid to further expand the Telematics Infrastructure and the adoption of the German Hospital Future Act (KHZG), which is set to release up to EUR 4.3 billion in funding for further investments in digitization and IT security at hospitals in the coming years. As part of the French government's digitization initiative (Ségur), it will spend up to EUR 2.0 billion on the modernization, interoperability, reversibility, convergence and security of health information systems. The objective is to normalize the smooth and secure exchange of health data between health professionals and users in order to improve prevention and health care.

2.2. Business performance

Group

CompuGroup Medical again closed the financial year 2022 with double-digit growth.

- Group revenues of mEUR 1,130 (original guidance: mEUR 1,075 – 1,125; August: mEUR 1,100 – 1,150; October: mEUR 1,100 – 1,130)
- Revenue growth of 10 % (original guidance: 5 % – 10 %; August: 7 % – 12 %; October: 7 % – 10 %)
- Organic revenue growth of 4.1 % above prior-year level: (original guidance: 3 % – 8 %; August: 4 % – 8 %; October: 4 % – 6 %)
- Recurring revenue of 65 % (unchanged guidance: greater 65 %)
- Adjusted EBITDA of mEUR 234 (original guidance: mEUR 235 – 260; August: mEUR 240 – 260; October: mEUR 220 – 240)
- Adjusted earnings per share – diluted – of EUR 1.80 (original guidance: EUR 1.90 – 2.10; revised in October: EUR 1.70 – 1.90)
- Investments (CAPEX) in the amount of mEUR 76 (guidance: unchanged mEUR 70 – 80)
- Free Cash flow of mEUR 69 (original guidance: > mEUR 100, adjusted in October to mEUR 40 – 70)

COMBINED MANAGEMENT REPORT

Segments

At segment level, the guidance is as follows:

- AIS revenue of mEUR 502 (guidance: mEUR 490 – 510)
- HIS revenue of mEUR 277 (guidance: mEUR 280 – 295)
- CHS revenue of mEUR 220 (original guidance: mEUR 185 – 195; adjusted in August: mEUR 210 – 220; adjusted in October: > mEUR 200)
- PCS revenue of mEUR 131 (guidance: mEUR 120 – 125)

Key financial figures

kEUR	2022	2021	Change
Revenues	1,129,739	1,025,322	+ 10 %
Recurring Revenues in %	65 %	65 %	0 ppt
Organic growth in %	4 %	6 %	- 2 ppt
EBITDA	216,351	213,390	+ 1 %
EBITDA margin	19 %	21 %	- 2 ppt
EBITDA adjusted	234,004	224,310	+ 4 %
EBITDA margin adjusted	21 %	22 %	- 1 ppt
EPS (EUR) - diluted	1.40	1.30	+ 8 %
EPS adjusted (EUR) - diluted	1.80	1.95	- 8 %
Cash flow from operating activities	145,027	165,274	- 12 %
Cash flow from investing activities	- 145,414	- 163,976	- 11 %
CAPEX	76,058	64,166	+ 19 %
Free Cash flow	68,969	101,108	- 32 %
Net debt	696,003	634,018	+ 10 %
Leverage	3.12	2.80	
Equity ratio	35 %	34 %	+ 1 ppt
Number of shares outstanding ('000)	52,235	52,331	

Significant events

In addition to a sound development in the operating segments, which was unchanged also during the COVID-19 pandemic, a number of acquisitions (see note C.4. Scope of consolidation) were carried out in financial year 2022. In addition, the following cross-segment and segment-specific events had a significant impact on 2022:

Digitization continues to promote growth

CompuGroup Medical sees increased demand from the healthcare industry for digitization across all segments. In financial year 2022, CGM continued to support its clients in implementing digitization. Healthcare professionals today need to manage electronic health records and e-prescriptions, digitize medication and emergency records, issue electronic sick notes, conduct medication risk assessments and virtualize and mobilize their patient communications. Secure e-mail communication with KIM makes it possible to send e-sick notes and secure messages ensuring better and more digital patient communication.

Cyber attack

In December 2021, CGM was the target of a ransomware attack. CGM responded by resolutely protecting its systems, employees and customers, and working with public agencies and external experts to take steps to counter the ransomware attack. All essential systems and processes were restored within a few weeks, causing further expenses to be incurred in financial year 2022.

War in Ukraine

At the end of February 2022, the attack on Ukraine began and continues to this day. In financial year 2022, CGM had from this no material direct impact on the recognition and measurement of assets and liabilities as at the reporting date. However, future effects on the net assets, financial position and results of operations cannot be ruled out at the present time.

Additional financing line

In June 2022, CGM secured an additional credit line of mEUR 200 from the European Investment Bank (EIB) with a term until July 11, 2028. This additional credit line from the European Investment Bank is for the specific purpose of financing up to 50 % of CGM's research and development costs.

Changes in the Managing Directors

In June 2022, the Administrative Board of CompuGroup Medical Management SE and CEO Dr. Dirk Wössner agreed by mutual consent to terminate their contract on June 30, 2022 due to differences of opinion regarding the long-term corporate strategy. CFO Michael Rauch was appointed spokesperson for the Managing Directors and appointed to the Administrative Board as of July 1, 2022.

Customer acquisition

CGM achieved strategic client acquisitions in the outpatient and inpatient business. In southern Germany, CGM won a tender project with emergency practices to fully equip them with CGM M1 PRO, enabling a uniform workflow for cross-practice use. In the field of hospital information systems, demand for the next generation of technology continues unabated, as proven by recent strategic customer acquisitions such as the Centre for Dentistry at the University of Zurich or the Biedenkopf Hospital in Germany.

International digitization in medical practices and hospitals

In France, the rollout of the first phase of the state-supported digitization program for medical practices “Séjour de la santé” was successfully completed. In the hospital business, order intake in connection with the German Hospital Future Act (KHZG) reached a new record of approximately mEUR 90 at the end of the year. CGM expects revenues of mEUR 90 to mEUR 110 in the coming years arising from the German Hospital Future Act.

Positioning the data business for future growth

To strengthen CGM’s innovative data-driven product range and further advance the analysis of data to improve healthcare, CGM acquired 100 % of the shares in INSIGHT Health Group, domiciled in Waldems, Germany, at the beginning of May. Founded in 1999, INSIGHT Health offers innovative solutions for market and healthcare research in the German healthcare sector, taking into account the highest level of data protection compliance. Its customers include well-known companies in the pharmaceutical industry, pharmacies, doctors’ associations, health insurance companies, and scientific and political institutions. In the second half of the year, CGM and INSIGHT Health launched a joint portfolio of products for pharmaceutical companies.

The acquisition of the GHG business announced in November and carried out in January 2023 complements CGM’s portfolio of innovative, data-based solutions for the healthcare sector. The company is domiciled in Heidelberg, Germany and offers electronic health applications that improve the quality of life of patients and help doctors provide the best possible treatment with the aid of digital solutions.

By acquiring 20 % of the shares in the Italian company New Line RdM Società Benefit S.p.A. (New Line) in December, CGM strengthens its position in the Italian data market. This investment represents the first foundation stone for CGM in opening up international markets for our innovative data solutions.

Ambulatory Information Systems (AIS)

Successful implementation of the Doctors First program

The Doctors First Initiative introduces a new level of customer orientation so that CGM can react even faster to changes and customer needs and support its customers in the AIS Germany division. The transformation from a business unit-led organization to a function-based organization is designed to ensure that dedicated sales teams can fully focus on customers while efficiency is improved through process optimization.

IT systems fully protected – with CGM PROTECT

The number of attacks on IT systems is increasing, also among medical practices. In order to offer healthcare professionals the greatest possible protection, another new product line, CGM PROTECT, was successfully launched in 2022. It bundles the complete range of measures to safeguard IT solutions in practices and to protect patients' data. In future, our customers will receive everything from a single source: firewall, virus protection, consulting and more. CGM PROTECT already includes our new IT security products CGM Firewall and CGM Endpoint 360° and further products and solutions will be added in the future.

Signing of a contract with the Association of Statutory Health Insurance Physicians in Baden Wuerttemberg, Germany

In 2022, the multi-year managed service contract between the Association of Statutory Health Insurance Physicians of the State of Baden Wuerttemberg and CGM M1 was signed, which covers more than 90 emergency practices.

Product advancements in Austria

Starting March 2022, electronic prescriptions were rolled out nationwide in Austria. The e-prescription completely replaces paper prescriptions in Austria's medical practices ("Ordnationen") and pharmacies. CGM AT already succeeded in providing > 93 % of all customers with e-prescription solutions by the end of May and consequently made a significant contribution to the spread of e-prescriptions. In addition to the e-prescription, a module was developed to check and verify prescriptions or medicines before they are actually dispensed – in accordance with the legal requirements. The number of Customers for the BEFUND-COCKPIT (results cockpit), which gives physicians a quick overview of test results stored in ELGA (Electronic Health Record) continued to rise. In addition, the work was intensified on "CGM MAXX", a third-generation physician software specifically developed for Austrian physicians working in the public health insurance system. Most of the Austria-specific features, such as e-card connection, ELGA or billing with the health insurance funds, have been successfully integrated and everything is ready for the planned pilot launch in January 2023.

Project Ségur de la santé project in France

In the fourth quarter of 2022, the implementation of the Ségur software version for the two main French AIS versions (HelloDoc and Axisanté) successfully got under way. The launch of the Ségur product was part of the national program "Ma Santé" (my health) launched by the French government and funded by the European Recovery and Resilience Facility with a total investment of 2 billion euro. Installing the Ségur product with French doctors enables CGM to play a key role in the digitization of healthcare in France.

EBZ – electronic request and approval solution for dentists in Germany

In the third quarter of 2022, CGM started the delivery of EBZ, an electronic dentist request and approval solution for dental prostheses, periodontology, mandibular fracture/temporomandibular joint disorders and orthodontics. Using the EBZ solution, dental practices can electronically communicate via an encrypted process to the statutory health insurance company, leading to considerable savings on time and money.

CLICKDOC digital platform

The CGM product CLICKDOC, which supports the full range of patient care as a central communication and information platform, has been continuously developed and will be integrated into the ambulatory information systems in France and Germany in 2021. The customer base is growing steadily, with more than 10,000 healthcare providers now using video consultation, around 5,000 providers in France and Germany using the online calendar.

Hospital Information Systems (HIS)

German Hospital Future Act

The German Hospital Future Act (KHZG), along with continued brisk business in Poland and Spain, has led to CGM achieving a new order record in the HIS segment in financial year 2022. Despite initial delays in the German Hospital Future Act approval process, the program picked up speed as the year progressed. CGM covers a wide range of the eligibility criteria described in the act. The order volume from the German Hospital Future Act amounted to more than mEUR 90 by the end of financial year 2022. These orders will be delivered to the customers in the following years. In addition to a large number of orders from existing customers, new customers were also acquired as a result of this program. The newly launched patient portal is also selling well due to the German Hospital Future Act.

Customer acquisition

During financial year 2022, a large number of new orders were won internationally. In Poland, a contract was successfully concluded with the Pomorskie region, which includes 13 hospitals with more than 5,800 beds. SERMAS (Public Healthcare Board in the Region of Madrid) has signed a 5 years contract including CGM Selene HIS Support Services in 20 hospitals of the region (5.200 beds) . In Sweden, the general services agreement with the Stockholm region was extended for a further four years. These and many other orders ensure that we have a stable and growing customer base in the years to come.

M&A and integration projects

The acquisitions of Visus Health IT GmbH (image archiving and communication systems as well as healthcare content management) and KMS Vertriebs- und Service AG (knowledge management and business intelligence solutions), which were made in financial year 2021, were successfully integrated. And a large number of new orders from existing and new customers have already been won.

Product innovation

In the financial year under review, the new product CGM VIYU was successfully launched on the market. CGM VIYU is a cloud-based product for outpatient care services. This includes, among other things, route planning, timesheets, service planning, master data maintenance and prescription management.

Consumer and Health Management Information Systems (CHS)

Telematics Infrastructure (TI)

In September 2022, the first certificates for our KoCoBox MED+ eHealth connectors expired. When the validity period of the certificate expires, the connectors are no longer operational. Therefore, the replacement of these devices with new G4 eHealth connectors already started in September, in order to provide the affected medical practices with a secure connection to the telematics infrastructure.

Customers highly satisfied with the expansion of our data business product portfolio

CompuGroup Medical offers customers intelligent data-based products while maintaining the highest standards for data protection and data security.

The successful acquisition and integration of INSIGHT Health GmbH und Co. KG sets the stage for becoming a European best-in-class & end-to-end health data provider. With the launch of DARWIN, a new generation of data products was introduced to the market, which offers users deep and comprehensive insights into the daily care routine as well as into the patient and therapy journey, and thanks to the newly gained data transparency, facilitates a fully comprehensive understanding of the market.

The acquisition of the practice services business units and the artificial intelligence-based solution “MEDICAL BRAIN” from GHG (Gotthardt Health Group) completes the CHS portfolio and provides the basis for a centralized and workflow-integrated medical information & data suite for doctors. Potential major areas of application include analyzing medical data, detecting rare diseases and assessing patients’ suitability for clinical trials.

The acquisition of 20 % of the shares of the Italian company New Line RdM Società Benefit S.p.A. (New Line) is the first foundation stone for the development of international markets in the field of innovative data solutions.

Pharmacy Information Systems (PCS)

Consolidation of 4K S.r.l. in Italy

4K S.r.l. has been consolidated in the CGM Group since June 1, 2022, finalizing the second phase of the M&A deal initiated in mid-2021. With the brand “Pharmap”, 4K S.r.l. focuses on home delivery of medicines, based on a robust mobile and web platform and digital services for healthcare providers, mainly pharmacies. The acquisition of this company complements CGM’s business activities with a specialized player in the patient journey and particularly on the last mile that delivers directly from PCS and medical practices to the patient’s/citizen’s home.

Launching CGM STELLA in Italy

CGM STELLA for pharmacies is the new cloud-based version of the previously successfully used pharmacy program. It was officially released in July 2022 as originally planned. Further installations were carried out during the year, covering a wide range of customer requirements.

Electronic prescriptions in Germany

The electronic prescription service was rolled out for all Winapo customers in Germany from mid-2022. This new functionality complies with the mandatory legal requirements in Germany and enables pharmacies to reduce time and effort by introducing paperless processing of prescriptions.

2.3. The group's position

2.3.1 Results of operations of the group

mEUR	2022	2021
Group revenues	1,129.7	1,025.3
Other income	19.4	24.8
Capitalized in-house services	44.8	37.3
Expenses for goods and services purchased	- 216.4	- 191.4
Personnel expenses	- 546.7	- 497.7
Other expenses*	- 214.5	- 184.8
EBITDA	216.4	213.4
in %	19.2 %	20.8 %
EBIT	104.0	102.7
in %	9.2 %	10.0 %
EBT	106.8	97.9
in %	9.5 %	9.5 %
Consolidated net income	74.1	69.0
in %	6.6 %	6.7 %

* Contrary to the income statement, the item for Net impairment losses on financial assets and contract assets in the amount of mEUR - 5 (prior year : mEUR - 7) was reclassified to Other expenses.

Revenues increased by mEUR 104 (10 %) to mEUR 1,130 in financial year 2022. Company acquisitions contributed mEUR 51 to revenues (prior year: mEUR 140). Organic growth in this period was 4 % compared to the prior year. Acquisitions boosted recurring revenues by 10 % to mEUR 730 in 2022.

Other operating income decreased from mEUR 25 to mEUR 19 in financial year 2022. More information on Other operating income is provided in note E. 25 to the consolidated financial statements.

At group level, key developments in operating expenses in financial year 2022 can be summarized as follows:

- Expenses for goods and services purchased increased from mEUR 191 to mEUR 216 year-on-year. At 81 %, the gross margin (revenues less expenses for goods and services purchased/revenues) is on par with the prior year's level.
- The increase in personnel expenses from mEUR 498 in 2021 to mEUR 547 in 2022 is mainly attributable to newly acquired companies (mEUR 23) as well as a net increase in headcount and general wage and salary increases.

- Other expenses including impairment losses on financial assets and contract assets increased from mEUR 185 in 2021 to mEUR 215 in 2022 due to the increased use of external development capacities, software maintenance as well as travel expenses. One-off effects in 2022 amount to approximately mEUR 13. More information on Other expenses is provided in note E. 28 to the consolidated financial statements.

Depreciation of property, plant and equipment and right-of-use assets increased by mEUR 5 to mEUR 43 in 2022.

Amortization of intangible assets was down by mEUR 3 year-on-year to mEUR 70. This decrease is due to lower amortization of intangible assets acquired in company acquisitions.

At mEUR 23, financial income was mEUR 19 higher than in the prior year (mEUR 4), mainly due to the measurement of a financial instrument without hedging relationship at fair value. Financial expenses increased from mEUR 9 in 2021 to mEUR 15 in financial year 2022. This was mainly due to higher interest expenses. Further information on the financial income and expenses is provided in note E. 31 to the consolidated financial statements.

The effective consolidated tax rate was 31 % in financial year 2022 (prior year: 30 %). Consolidated net income for the reporting year increased by mEUR 5 to mEUR 74 in 2022 (prior year: mEUR 69).

Development of results in the business segments

Ambulatory Information Systems (AIS)

mEUR	2022	2021	Change
Revenues to third parties	502.3	475.8	6 %
thereof organic revenues*	481.1	475.8	1 %
thereof recurring revenues	385.7	360.1	7 %
Share of recurring revenues	77 %	76 %	
EBITDA adjusted	136.5	118.3	15 %
in % of revenues	27 %	25 %	

* Adjusted for currency effects and revenues from companies consolidated for the first time in the reporting period or of companies consolidated for the last time in the prior-year period.

- The software business with physicians and dentists generated revenues of mEUR 502 in 2022 and was thus up 6 % year-on-year. This increase was supported by currency effects and acquisitions.
- Organically, revenues were slightly higher than in the prior year (1 %).
- Recurring revenues in the AIS segment increased by 7 % with an increase in the share of recurring revenues from 76 % to 77 %, mainly due to increased software maintenance revenues and hotline revenues.
- Adjusted EBITDA increased by 15 % to mEUR 137, based on lower expenses for hardware.

COMBINED MANAGEMENT REPORT

Hospital Information Systems (HIS)

mEUR	2022	2021	Change
Revenues to third parties	277.2	257.4	8 %
thereof organic revenues*	265.7	257.4	3 %
thereof recurring revenues	189.9	165.7	15 %
Share of recurring revenues	69 %	64 %	
EBITDA adjusted	25.3	43.2	- 41 %
in % of revenues	9 %	17 %	

* Adjusted for currency effects and revenues from companies consolidated for the first time in the reporting period or of companies consolidated for the last time in the prior-year period.

- In 2022, HIS segment revenues increased by 8 % to mEUR 277. This revenue growth was positively influenced by the acquisitions of the VISUS Group and KMS Vertrieb und Services AG in financial year 2021 which for the first time operated year-round.
- Adjusted for acquisitions and currency effects, organic growth for the year was 3 %, based in particular on strong business performance in Spain and Poland.
- Recurring revenues rose to mEUR 190, representing 69 % of total revenue, mainly due to increased software maintenance revenues and hotline revenues.
- Adjusted EBITDA was mEUR 25, down 41 % on the prior-year figure, due in particular to increased investments in G3 technology and additional expenses for major projects.

Consumer and Health Management Information Systems (CHS)

mEUR	2022	2021	Change
Revenues to third parties	219.6	173.7	26 %
thereof organic revenues*	194.0	173.7	12 %
thereof recurring revenues	70.3	62.1	13 %
Share of recurring revenues	32 %	36 %	
EBITDA adjusted	44.1	39.9	11 %
in % of revenues	20 %	23 %	

* Adjusted for currency effects and revenues from companies consolidated for the first time in the reporting period or of companies consolidated for the last time in the prior-year period.

- In financial year 2022, the CHS segment generated revenues of mEUR 220. This represents a rise in revenue of 26 %, primarily driven by the replacement of TI hardware connectors and the consolidation effects from the acquisition of INSIGHT Health.
- In organic terms, growth was 12 %, which was largely driven by one-time revenues from the Telematics Infrastructure. Excluding one-time revenues from the Telematics Infrastructure, organic growth was 4 %.

COMBINED MANAGEMENT REPORT

- Recurring revenues amounted to mEUR 70, representing 32 % of total revenue (prior year: 36 %). The percentage decrease is mainly due to the one-time revenues in connection with the connector exchange.
- Adjusted EBITDA was mEUR 44, up 11 % on the prior year. The year-on-year decline in the EBITDA margin is due to the postponement of the upcoming connector software upgrade to 2023.

Pharmacy Information Systems (PCS)

mEUR	2022	2021	Change
Revenues to third parties	130.5	118.2	10 %
thereof organic revenues*	126.5	118.2	7 %
thereof recurring revenues	84.0	78.6	7 %
Share of recurring revenues	64 %	66 %	
EBITDA adjusted	39.8	33.7	18 %
in % of revenues	30 %	29 %	

* Adjusted for currency effects and revenues from companies consolidated for the first time in the reporting period or of companies consolidated for the last time in the prior-year period.

- In 2022, PCS segment revenues increased by 10 % to mEUR 131, supported by acquisition effects in Italy.
- Organic growth was 7 %, resulting in particular from a strong business performance in Italy.
- Recurring revenues rose by 7 % to mEUR 84 compared to the same prior-year period, representing a 64 % share of recurring revenues (prior year 66 %), mainly due to increased software maintenance revenues and hotline revenues.
- Adjusted EBITDA was mEUR 40, up 18 % on the prior-year level and was supported by efficient cost management.

Other business activities and consolidation

mEUR	2022	2021	Change
Revenues to third parties	0.1	0.1	0 %
EBITDA adjusted	- 11.7	- 10.8	- 9 %

- Adjusted EBITDA in the Other business activities and consolidation segment was down mEUR 1 compared to the prior-year level in 2022.
- Adjusted special items of mEUR 9 mainly comprised extraordinary effects in connection with changes in management as well as with share option programs.

2.3.2 Financial position

2.3.2.1 Statement of cash flows

In financial year 2022, cash flow from operating activities amounted to mEUR 145 compared to mEUR 165 in the prior year. Changes compared to 2021 relate to the following items in particular:

At mEUR 69, free cash flow in 2022 was mEUR 32 lower than in the same period last year. The decrease in free cash flow in the reporting period compared with the free cash flow in the prior-year period resulted mainly from expenditures for the connector exchange, payments related to management changes, and restructuring costs.

Adjusted for non-cash income/expenses and cash payments for taxes, gross cash flow from operating activities before changes in working capital rose from mEUR 154 in the prior year to mEUR 188 in 2022 in the reporting period. This increase is mainly due to the change in provisions and income tax liabilities and to the change in deferred taxes and, in the opposite direction, to the change in derivative financial instruments.

Changes in working capital in 2022 contributed mEUR 43 to the decrease in cash flow from operating activities. Compared to 2021, where the changes in working capital led to an increase of mEUR 11 in cash flow from operating activities. This development is mainly due to changes in trade payables, contract liabilities, and trade receivables.

Cash flow from investing activities was mEUR 145 in 2022, compared to mEUR 164 in the prior-year period. This movement was mainly caused by lower payments for company acquisitions compared to 2021.

The cash flow from financing activities was mEUR - 16 in financial year 2022 (prior year: mEUR 30). This change results mainly from the purchase of treasury shares in 2021 and, in the opposite direction, from lower net borrowing in 2022.

2.3.2.2 Principles and objectives of financial management

Financial management of the group is essentially based on three pillars:

- Ensuring liquidity while maintaining financial independence
- Transparency, mitigation and active management of financial risks
- Continuous improvement and cost optimization of processes

Cash and cash equivalents are optimized both at group level and at the level of the individual companies, whereby the target values are based in equal measure on liquidity and efficiency considerations.

In order to support the achievement of these targets, cash pools were set up in many European countries to allocate surplus liquidity to the parent company while keeping group-wide borrowings to an absolute minimum.

The key principle of the cash pooling approach is the management of the highest-level bank account at CompuGroup Medical SE & Co. KGaA (pool leader), the parent entity of the group. Usually, this company also holds all material liabilities to banks, including the flexible revolving loans and short-term credit lines used for the group's day-to-day liquidity management.

CompuGroup Medical SE & Co. KGaA's liabilities to banks are usually denominated in euro with variable interest rates. Based on the implementation of an interest rate swap with a notional volume of mEUR 200, loans were switched to fixed interest payments; with this measure, the group strives to counteract the emerging changes in the interest rate environment. Moreover, an interest rate cap with a nominal volume of mEUR 400 and a remaining term until May 7, 2031 had already been concluded in 2021 in order to limit interest rate risks at an early stage.

Given the group's international focus, incoming and outgoing payments may be paid in currencies other than the euro. The company generally strives for natural hedging through its choice of suppliers and locations. In addition, forward exchange transactions may be used for hedging purposes. Where appropriate, intra-group financing transactions of individual companies outside the euro zone are hedged against currency risks with FX swaps. In order to optimize costs and mitigate potential risks, the application, limit review, hedging and contractual documentation processes for these intra-group financing transactions were redesigned. The development of the relevant items that are exposed to currency risks is continuously monitored to ensure an appropriate response to significant changes.

CGM is very much a growth-oriented company, which is why surplus financial resources are primarily used to finance further growth in the best possible way. Accordingly, the CGM's dividend policy is aligned with its corporate strategy. Future dividends are linked to long-term, sustainable profits. CGM strives to gradually and steadily increase its annual dividend payout. The dividends reported and approved by the shareholders are distributed each year in the course of the Annual General Meeting.

2.3.2.3 Capital structure

Company acquisitions in the financial year were financed via debt capital, as well as self-generated cash flows. In terms of capital structure, the company's goal is to prevent the equity ratio from falling below 25 % for extended periods through appropriate management of group profits, dividends and capital measures such as share placements and share buybacks.

On December 31, 2022 the group's gross debt, which consists mainly of liabilities to banks and lease liabilities, financial liabilities to third parties and lease liabilities under IFRS 16, amounted to mEUR 787 (prior year: mEUR 741). The group held cash amounting to mEUR 91 (prior year: mEUR 107). In addition to a syndicated credit facility, the group has further loans and current accounts. For further information on liabilities to banks and the structure of debt, please refer to note E.16 Financial liabilities.

On January 28, 2020, CGM took out a credit facility of mEUR 1,000 with a term of at least five years; the facility comprises a revolving multi-currency credit facility of mEUR 600 and a mEUR 400 term loan. The syndicate of banks includes BNP Paribas, Commerzbank, Deutsche Bank, Landesbank Baden-Württemberg, SEB and Unicredit

On July 11, 2022, CGM entered into a new six-year credit facility for mEUR 200 to secure future liquidity. This is a loan from the European Investment Bank that supports research and development initiatives related to the digitization of the healthcare sector.

Concerning the revolving credit facility in the amount of mEUR 600, the option of extending the contractual term by one year was exercised effective January 28, 2021. This results in an extension of the credit term until January 28, 2026. We exercised the extension option for the last time with effect from January 28, 2022. The revolving credit facility now expires on January 28, 2027.

As at December 31, 2022, the full amount of the term loan (mEUR 400) was drawn (prior year: mEUR 400). while an amount of mEUR 50 of the mEUR 600 revolving credit facility was utilized (prior year: mEUR 180) as at December 31, 2022.

The loans are subject to compliance with a financial covenant (leverage). Various German subsidiaries have issued joint and several payment guarantees for this syndicated credit facility (default liability for nonpayment by CompuGroup Medical SE & Co. KGaA).

2.3.2.4 Investments

In financial year 2022, the investments of CGM refer to the following:

mEUR	2022	2021
Company acquisition	57.9	88.5
Purchase of minority interest and past acquisition	6.9	5.7
Capitalized in-house services and other intangible assets	50.6	44.4
Joint ventures and other equity investments	4.6	6.1
Office building and property	6.6	10.4
Other property and equipment	18.9	9.3
Sale of subsidiaries and business operations	0.0	-0.4
Total	145.5	164.0

2.3.2.5 Liquidity

The group has a solid liquidity position driven by stable cash flow from operating activities. Free cash flow amounted to mEUR 69 in financial year 2022. It is defined as cash flow from operating activities less the cash flow from investing activities (not including proceeds from and payments for company acquisitions and joint ventures, the disposal of subsidiaries and business units, the acquisition of non-controlling interests and the settlement of purchase price claims from company acquisitions in prior periods).

Furthermore, a considerable share of recurring revenues derives from prepayments, boosting working capital at the beginning of the annual, quarterly and monthly payment periods. The group is increasingly using direct debit for such recurring revenue payments in order to continuously improve the security and speed of incoming payments. To date, the group has always been able to properly satisfy its payment obligations when due. The company assumes that no liquidity problems will arise in the future and that payment obligations entered into will always be satisfied.

Given its good liquidity profile, the group strives to keep its cash position in balance. On December 31, 2022 the group is using a term loan of mEUR 400, a revolving credit facility of mEUR 50 and a bilateral loan of mEUR 200 from the European Investment Bank. In addition, other credit lines and bilateral loans were used amounting to mEUR 78. Furthermore, short-term credit lines amounting to mEUR 98 were used to compensate for the typical seasonal liquidity fluctuations. The facilities under the syndicated loan and the short-term credit lines and bilateral loans are used in conjunction with cash pooling instruments to adequately meet the group's liquidity requirements. As at December 31, 2022, CGM has non-utilized short-term credit lines of mEUR 94 and an open amount in the revolving credit facility of mEUR 550.

2.3.3 Net assets of the group

Total assets increased by mEUR 154 year-on-year to mEUR 1,944 at the end of the reporting period. Intangible assets represent the largest asset item in terms of value, amounting to mEUR 1,294 as at December 31, 2022 compared to mEUR 1,214 as at December 31, 2021. Intangible assets essentially comprise intangible assets identified in connection with company acquisitions. These disclosed intangible assets mainly relate to customer relationships, order backlogs, software, trademarks and goodwill. They account for 66.5 % (prior year: 67.8 %) of total assets as at the reporting date. The increase in intangible assets is mainly due to the capitalization of goodwill in the course of the acquisition of the INSIGHT Health Group and the capitalization of internally generated software.

Property, plant and equipment increased by mEUR 7 to mEUR 107 year-on-year, mainly due to investments in buildings. As at December 31, 2022, right-of-use assets amount to mEUR 53. Derivative financial instruments rose from mEUR 7 to mEUR 37, primarily due to the interest rate cap and the newly concluded interest rate swap.

In current assets, inventories increased from mEUR 21 at December 31, 2021 to mEUR 29 at December 31, 2022 due in part to the increased stocking of the new connector generation. Inventories mainly comprise goods for CGM's trading business with hardware and peripheral devices as well as components for the telematics infrastructure. For billing-related reasons, trade receivables increased from mEUR 147 as at December 31, 2021 to mEUR 189 as at December 31, 2022. Income tax receivables increased by mEUR 18 to mEUR 49 in the reporting period, partly due to loss utilization for prior years, high tax prepayments and credible taxes. As at December 31, 2022, cash and cash equivalents amounted to mEUR 91 (prior year: mEUR 107). Cash and cash equivalents fell mainly due to the mEUR 32 decrease in free cash flow compared with the prior year.

All other assets were subject to only marginal changes in financial year 2022.

Including the generated consolidated net income of mEUR 74 for the period from January 1 to December 31, 2022 and the dividend of CompuGroup Medical SE & Co. KGaA paid in 2022 in the amount of mEUR - 26, the purchase of treasury shares in the amount of mEUR - 6, other changes totaling mEUR - 2, exchange rate changes, interest rate changes (actuarial losses) as well as impacts in connection with effective derivative financial instruments with a total value of mEUR 22, the consolidated equity increased from mEUR 612 at December 31, 2021 to mEUR 674 at December 31, 2022. The equity ratio rose from 34.2 % as at December 31, 2021 to 34.7 % as at December 31, 2022.

In the reporting period, current and non-current liabilities increased from mEUR 1,179 as at December 31, 2021 to mEUR 1,271 as at December 31, 2022. Significant individual changes are the increase in liabilities to banks of mEUR 54 due to increased borrowings, the increase in trade payables by mEUR 19 due to balance sheet date, and changes in deferred tax liabilities of mEUR 8 as well as the increase in income tax liabilities of mEUR 14, which is mainly due to additions to the scope of consolidation and higher withholding tax liabilities in connection with profit distributions. Furthermore, purchase price liabilities increased by mEUR 10, mainly due to the acquisition of the INSIGHT Health Group in the first quarter of 2022.

On the whole, the net assets of the group can still be considered solid.

2.3.4 Net assets, financial position and results of operations of CompuGroup Medical SE & Co. KGaA

2.3.4.1 Results of operations and financial position of CompuGroup Medical SE & Co. KGaA

The figures stated are based on the annual financial statements of CompuGroup Medical SE & Co. KGaA prepared in accordance with commercial law. As a holding company, the company's results of operations are substantially dependent on the performance of its operating subsidiaries.

The result for the year breaks down as follows:

mEUR	2022	2021
Operating income	-38.0	-28.7
Investment income	82.1	75.2
Net write-ups and write-downs of financial assets	0.0	-0.1
Net interest result	-9.1	-5.3
Tax result	-2.5	-5.4
Profit before tax	32.5	35.7
Other taxes	-0.2	-0.2
Annual result	32.3	35.5

The deterioration in the operating result by mEUR 9.3 to mEUR –38.0 in the reporting period was mainly due to higher expenses for software maintenance in the other operating expenses, including for the Telekom Cloud Services project. This resulted in additional expenses of mEUR 5.4. In addition, there were higher expenses for other audit and consulting fees of mEUR 3.5.

Net income from equity investments is made up of income from profit and loss transfer agreements and expenses from loss absorption, write-downs of financial assets as well as income from investments. Compared to the prior year, the net income from equity investments improved by mEUR 6.9 to mEUR 82.1.

The following changes compared to prior year are based on the profit and loss transfer agreements:

- The result of CGM Clinical Deutschland GmbH improved by mEUR 2.0 to mEUR 3.0. The main factor here is the profit and loss transfer agreement of Aescudata GmbH coming into force for the first time.
- The 2022 annual result of Lauer-Fischer GmbH contributes with an improvement of mEUR 7.6 to mEUR 16.2. A significant one-off factor is the sale of CGM Immobilien Stuttgart GmbH to CGM Deutschland AG, which generated a profit of mEUR 3.2.
- In addition, there is the positive result of CGM Clinical Europe GmbH of mEUR 0.4.
- CGM Deutschland AG's contribution to earnings decreased to mEUR 6.9 due to CGM Software GmbH's higher loss of mEUR 24.7.
- The result of Ifap GmbH deteriorated by mEUR 7.2 to a negative result of mEUR 10.7, among other things due to the loss absorption of docmetric GmbH of mEUR 1.5 and CompuGroup Medical Mobile GmbH of mEUR 7.2.

Income from investments increased by mEUR 32.6. The distributions of mEUR 66.2 consist of profit distributions from the following subsidiaries:

- Profdoc AS, Norway, in the amount of mEUR 11.8
- CompuGroup Medical CEE GmbH, Austria, in the amount of mEUR 12.0
- CompuGroup Imagine Editions SAS, France, in the amount of mEUR 4.1
- CompuGroup Medical Italia Holding S.r.l, Italy, in the amount of mEUR 7.8
- CompuGroup Medical Česká republika s.r.o., Czech Republic, in the amount of mEUR 2.0
- CompuGroup Medical Polska SP., Poland, in the amount of mEUR 1.7
- MB Invest SAS, France, in the amount of mEUR 3.2
- CGM LAB International GmbH, Germany, in the amount of mEUR 23.6

There were no impairments on investments in the reporting year (prior year: kEUR 100).

The following effects occurred in net interest result in the reporting year:

mEUR	2022	2021
Interest income from loans granted	3.8	2.8
Other interest and similar income	1.6	1.5
Interest and similar expenses on loans taken	-14.5	-9.6
Net interest result	-9.1	-5.3

The deterioration in the net interest result is due to higher interest expenses, which in turn is due to increased interest rates and newly concluded non-current loans.

Income taxes for the reporting period amount to mEUR 2.5 (prior year: mEUR 5.4). This corresponds to a tax rate of approximately 7.0 %; this development is driven by trade tax effects such as the addition for the costs related to the Managing Directors as well as valuation differences in fixed assets.

The net income of the company in the reporting year amounted to mEUR 32.0 (prior year: mEUR 35.0).

2.3.4.2 Net assets of CompuGroup Medical SE & Co. KGaA

With a share of around 67.3 % (prior year: 69.7 %), financial assets are the most significant asset item in the statement of financial position in terms of value; a fact that is congruent with the company's function as a holding. Intangible assets almost exclusively refer to capitalizations in connection with the group-wide SAP implementation program "OneGroup".

Compared to the prior year, the carrying amount of financial assets decreased from mEUR 1,077 in the prior year to mEUR 995 on the reporting date, mainly due to the repayment of loans in the amount of mEUR 82. As in the prior year, a material line item within the financial assets item is shares in associated companies, amounting to mEUR 959.

The equity ratio was 29.3 % in the reporting period and thus slightly above the prior-year level (prior year: 28.1 %).

Liabilities to associated companies decreased by mEUR 128 to mEUR 248 in the reporting period. This is mainly due to the repayment of loans received in the amount of mEUR 109.

Share buy-back program in financial year 2021

On November 25, 2021, CompuGroup Medical SE & Co. KGaA announced a share buy-back program with a term until the end of January 2022 that was completed on January 10, 2022. During this period, 500,000 shares with a total volume of mEUR 34 were bought back. 96,122 shares thereof with a total volume of mEUR 6 were bought back in financial year 2022.

As at December 31, 2022, the company holds 1,500,000 treasury shares, which are deducted separately from equity at their notional value (nominal value per share EUR 1.00).

Liabilities to banks

As at December 31, 2022, CompuGroup Medical SE & Co. KGaA has liabilities to banks in the amount of mEUR 728. The "EUR 1,000,000,000 Term and Multicurrency Revolving Credit Facility" newly concluded in January 2020 consists of a „revolving“ loan and a „term loan“. As at the reporting date December 31, 2022 this syndicated credit facility was utilized in the amount of mEUR 450. Thereof, mEUR 400 relates to the term loan, which is therefore utilized by 100 % as at the reporting date. In addition, mEUR 50 was drawn of the total revolving credit facility of mEUR 600 as at the reporting date. Furthermore, the company applied for the second prolongation option for this syndicated revolving credit facility in December 2021. The related prolongation of the term, which was originally five years (until January 2025) was thus prolonged by another additional year, thus totaling 7 years (January 2027); this was confirmed in January 2022. In addition to the syndicated loan, the company has a loan with the European Investmentbank in the amount of mEUR 200 and other credit lines with a total value of mEUR 72,9 (prior year: mEUR 81,9).

2.3.5 Overall assessment of the course of business and the group's and the company's situation

The business performance of CompuGroup Medical SE & Co. KGaA was positive overall in financial year 2022, driven by organic growth and supported by acquisition effects. The share of recurring revenues in total revenue amounts to 65 % and is therefore in line with CGM strategic goals and business model that are largely based on long-term customer relationships. The development of the key earnings figures was influenced primarily by the operating activities, but also by higher investments in order to secure the group's innovative power and future growth.

As a holding company, the business performance and position of the company is largely dependent on the evolution of its operating subsidiaries.

2.4. Financial and non-financial performance indicators

Since financial year 2020, CompuGroup Medical SE & Co. KGaA has been reporting adjusted performance indicators for operating income (EBITDA) and earnings per share. These key performance indicators are not defined under the International Financial Reporting Standards (IFRS) and should thus be regarded as supplementary information. The adjusted EBITDA, and adjusted earnings per share do not include effects from the acquisition and disposal of major subsidiaries, business units and investments (including effects from the subsequent measurement of contingent purchase price liabilities), write-downs and write-ups on investments, effects from the acquisition, construction and disposal of real estate, write-downs and write-ups on owner-occupied real estate, expenses in connection with share-based compensation programs for the Managing Directors, taxes attributable to the above effects and other non-operating effects or one-off effects referring to other periods.

CGM has a comprehensive planning and performance management system that uses the above financial performance indicators. Group-wide planning and reporting software has been customized to CGM's individual requirements to consolidate financial and performance related information and deliver it to management. These are communicated to management in the form of a reporting package that also includes planned targets. Cascading business review meetings that analyze and discuss results and perform structured comparisons of projected and actual figures are held monthly from the level of business unit managers up to the Managing Directors. Any significant deviations from planning trigger a deeper and more detailed analysis to identify the causes and initiate corrective measures.

Financial performance indicators:

The company management approach focuses on the following key performance indicators for measuring growth, profitability, capital efficiency and innovative strength:

Main financial indicators:

1. Revenues/revenue growth

Revenues are defined as sales revenues generated with third parties ("revenues"). Revenue growth is defined as the year-on-year change, i.e., compared with the same period twelve months ago, and reported as a percentage change.

2. EBITDA (adjusted)/EBITDA margin (adjusted):

Earnings before interest, taxes, depreciation and amortization (EBITDA) (adjusted) and the (adjusted) EBITDA margin, which measures EBITDA as a percentage of revenues, are used as indicators of operating profitability.

kEUR	2022	2021
EBITDA reported	216,351	213,390
Adjustments:		
M&A Transactions	2,827	1,806
Share-based option programs	2,643	5,716
Restructuring program expenses	3,401	0
Other non-operative, extraordinary or one-time effects	8,782	3,398
EBITDA adjusted	234,004	224,310
EBITDA adjusted margin	21%	22%

Adjustments for share-based option programs also include non-recurring effects from changes in management. Other non-operating extraordinary and non-recurring effects in the reporting year include adjustments for expenses in connection with changes in management, such as severance payments, and costs of the cyber attack.

Additional financial indicators

3. Recurring revenues

Recurring revenues include revenues from all software maintenance contracts plus subscriptions for services such as Internet access, electronic data interchange, electronic data processing, business process outsourcing, data center hosting, hardware leases, software as a service-contracts, etc.

kEUR	2022	2021
Revenues or software maintenance & hotline	474,909	432,983
Other recurring revenues	254,968	233,468
Recurring revenues	729,877	666,451
Recurring revenues in %	65%	65%

4. Organic growth

Organic growth is defined as the year-on-year increase in revenue, adjusted for revenues from companies consolidated for the first time in the reporting period and from companies consolidated for the last time in the prior reporting period and for currency translation effects.

kEUR	2022	2021
Group revenues	1,129,739	1,025,322
Ambulatory Information Systems (AIS)	21,222	83,894
Hospital Information Systems (HIS)	11,547	56,307
Consumer and Health Management Information Systems (CHS)	25,561	-929
Pharmacy Information Systems (PCS)	4,070	121
Group organic revenues	1,067,339	885,928
Organic growth (in %)	4.1%	5.8%

5. Free cash flow

The free cash flow (for the definition we refer to C.2.3.2.3 Liquidity) is derived as follows:

kEUR	2022	2021
Operating cash flow	145,027	165,274
Cash flow from investing activities	- 145,414	- 163,976
./ Net cash outflow for company acquisitions (less acquired cash and cash equivalents and prepayments in previous periods)	57,881	88,507
./ Cash outflow for acquisitions from prior periods	6,887	5,650
./ Cash inflow from the disposal of subsidiaries and business units	- 43	- 400
./ Cash outflow for capital expenditure for joint ventures and other equity investments	4,631	6,053
Free Cash flow	68,969	101,108

COMBINED MANAGEMENT REPORT

6. Earnings per share (adjusted)

Adjusted earnings per share are defined as the consolidated net income for the period attributable to the shareholders of the parent company divided by the weighted average number of shares as at the reporting date calculated in accordance with IAS 33.

kEUR	2022	2021
Consolidated net income for the period	74,117	69,032
of which: allocated to non-controlling interests	- 706	- 62
Consolidated net income for the period (allocated to shareholders of the parent company)	73,411	68,970
Adjustments:		
M&A Transactions	29,618	30,415
Share-based option programs*	2,643	5,716
Restructuring program expenses	3,401	0
Other non-operative, extraordinary or one-time effects**	- 10,797	3,398
Taxes attributable to these effects	- 4,128	- 5,179
Adjusted consolidated net income for the period (allocated to shareholders of the parent company)	94,148	103,319
Adjusted undiluted earnings per share (in EUR)	1.80	1.95
Adjusted diluted earnings per share (in EUR)	1.80	1.95
weighted average of outstanding shares acc. to IAS 33 - undiluted ('000)	52,236	52,948
weighted average of outstanding shares acc. to IAS 33 - diluted ('000)	52,289	52,971

* Including non-recurring items in connection with changes in management.

** Income and costs related to the interest rate cap, changes in management, and the cyberattack.

7. CAPEX

CAPEX refers to capital expenditure for fixed assets, in particular in connection with research and development and internally generated software.

kEUR	2022	2021
Cash outflow for capital expenditure for intangible assets	50,560	44,393
Cash inflow from disposals of property, plant and equipment	- 349	- 7,276
Cash outflow for capital expenditure for property, plant and equipment	25,847	27,049
CAPEX*	76,058	64,166

* Without IFRS 16 CAPEX and CAPEX from acquisitions.

8. Equity ratio

The equity ratio is the percentage of equity capital in total capital. In financial year 2022, the equity ratio 34.7 % (prior year: 34.2 %).

9. Leverage

Leverage is the ratio of net debt to EBITDA last-twelve-months (LTM). Net debt is defined as current and non-current liabilities to banks, financial liabilities to third parties and lease liabilities resulting from the application of IFRS 16 less cash and cash equivalents adjusted for restricted cash.

The EBITDA LTM is defined as EBITDA of the last twelve months plus the EBITDA of newly acquired companies extrapolated to twelve months and less the EBITDA of companies or parts of companies divested in the period under review.

From financial year 2022 onwards, the leverage calculation will be based on reported EBITDA adjusted for restructuring expenses. This makes the definition of leverage identical to the "bank leverage" defined in the loan agreements.

The following table shows the leverage calculated based on LTM EBITDA:

kEUR	2022	2021
a. Liabilities to banks (non-current)	699,371	582,441
b. Liabilities to banks (current)	29,104	92,476
c. Financial liabilities to third parties (non-current and current)	4,646	9,172
d. Lease liabilities (non-current and current)	53,344	57,217
e. Cash and cash equivalents	-90,517	-107,343
thereof restricted cash	55	55
Net debt	696,003	634,018
Leverage EBITDA (LTM)*	223,146	226,750
Leverage	3.12	2.80

* EBITDA Last-Twelve-Months (LTM) = reported EBITDA of the last twelve months adjusted for restructuring expenses and the EBITDA of newly acquired companies extrapolated to twelve months and corrected for the adjusted EBITDA of divested companies.

Non-financial indicators

Customer reach

The customer base is an important benchmark for assessing our size and relative importance in the healthcare sector. CGM uses the annual revenue from software maintenance, software leases and software as a service as its best estimate of the size and reach of its customer base. Growth in annual revenue from software maintenance, software leases and software as a service is used as an indicator of growth in the customer base.

kEUR	2022	2021
Software maintenance	474,909	355,183
Software rental and software as a service	46,324	31,781
Customer reach	521,233	386,964

No special financial indicators are used for managing CompuGroup Medical SE & Co. KGaA. The decisive factor here is to ensure the ability to distribute a dividend.

3. Guidance, risk and opportunity report

3.1. Guidance report

The global fight against inflation, Russia's war in Ukraine, and a resurgence of COVID-19 in China impacted the global economy in 2022, and are expected to continue to influence it in 2023. In its outlook for 2023 published in January 2023, the International Monetary Fund (IMF) forecasts real economic growth of only 1.4 % in the US and 0.7 % in Europe. In Germany, the IMF only expects 0.1 % growth year-on-year. These forecasts represent a slowdown in economic growth compared with 2022, when global real economic growth was estimated at 3.4 %.

According to an analysis by Markets and Markets, the global healthcare IT (HCIT) market is expected to grow from USD 394.6 billion in 2022 to USD 974.5 billion by 2027, corresponding to average annual growth (CAGR) of 19.8 %. Growth drivers in Europe and the US are primarily the increasing use and acceptance of electronic prescriptions, telemedicine, billing simplifications in the medical practices, digital networking and improvements in efficiency through the increased use of HCIT applications in the hospital business, remote monitoring solutions for patients, the data business, and the need to ensure compliance with government regulations.

Group

Since financial year 2020, CompuGroup Medical has been reporting adjusted key figures for operating income (EBITDA) and earnings per share. These key performance indicators are not defined under the International Financial Reporting Standards (IFRS) and should thus be regarded as supplementary information. The adjusted EBITDA and adjusted earnings per share do not include effects from the acquisition and disposal of subsidiaries, business units and investments (including effects from the subsequent measurement of contingent purchase price liabilities), write-downs and write-ups on investments, effects from the acquisition, disposal and construction of real estate, write-downs and write-ups on owner-occupied real estate, expenses in connection with share-based compensation programs for the Managing Directors, taxes attributable to the above effects and other non-operating effects or one-off effects referring to other periods.

CompuGroup Medical expects organic revenue growth (adjusted for acquisition and currency effects) of approximately 5 % for financial year 2023.

The share of recurring revenues in total revenues is expected to be between 60 % and 70 %.

Adjusted EBITDA is expected to range between mEUR 260 and mEUR 300.

Adjusted earnings per share (diluted) are expected to increase by at least 10 %.

Free cash flow is expected to be at least mEUR 100.

Segments

The following performance is forecast for the reporting segments in financial year 2023:

- In the AIS segment, organic revenue growth is expected in the mid-single digit percentage range.
- The HIS segment is expected to generate organic revenue growth in the mid to high single digit percentage range.
- In the CHS segment, organic revenue growth is expected in the low to mid-single digit percentage range.
- The PCS segment is expected to generate organic revenue growth in the lower single digit percentage range.

The above guidance for the current financial year was published on February 9, 2023 and does not take into account any effects from company acquisitions not yet completed at that date or potential transactions to be carried out in the course of financial year 2023. The guidance for 2023 is based on the management's best estimate of future market conditions and the development of the business segments of CompuGroup Medical in this environment; it may be influenced by delays or changes in the implementation of the Telematics Infrastructure that are beyond the control of the company. Moreover, uncertainty remains with regard to the further impact of the global economic environment, the Russia-Ukraine war and the COVID-19 pandemic. The guidance for 2023 may also be influenced by foreign exchange effects (especially changes in the USD/EUR conversion rate).

Guidance for CompuGroup Medical SE & Co. KGaA

Due to its holding function, the company is dependent on the results achieved by its subsidiaries and is therefore not managed on the basis of financial performance indicators. Net income from equity investments is expected to show a positive development in line with the planned growth trajectory of the group. If the current high level of interest rates persists, net interest income will deteriorate further despite the existing interest rate hedge, as the hedge only applies above a certain interest rate level. The company therefore expects net profit within the range of mEUR 30 to mEUR 40 for its separate financial statements for 2023 prepared in accordance with the German Commercial Code (HGB). The above guidance for the current financial year was prepared in March 2023 and does not take into account any effects from company acquisitions not yet completed or potential transactions to be carried out in the course of financial year 2023. The guidance for 2023 is based on a management assessment of future market conditions and the development of the business segments of CompuGroup Medical SE & Co. KGaA in this environment.

3.2. Risk report

3.2.1 Risk management system

As an internationally operating group, CGM is subject to a variety of different risks. CGM is aware of the need to take risks, which also allows the group to seize opportunities. The risks and opportunities presented below also apply to CompuGroup Medical SE & Co. KGaA.

The risk management system of CGM is implemented at the level of the individual companies, the business areas and at group level. A significant component of the risk management system is the group-wide early warning system, for example in the form of internal benchmark and cost efficiency analyses and performance gap analysis for the group's relevant performance indicators. The Internal Audit department is responsible for reviewing adequacy, effectiveness and efficiency of the risk management system. Within the framework of corporate governance, the internal control system also contributes to CGM's risk management system.

The risk reporting system encompasses the systematic identification, quantification, documentation and communication of risks. The corresponding principles, processes and responsibilities are documented in a group-wide risk management policy. New and relevant information is taken into account in the ongoing development of our policies and systems for the continuous improvement of the risk management system. Management is expected to be able to identify risks that endanger CGM's growth or its continued existence as a going concern early on, and to minimize their impact as far as possible.

Consciously taking predictable risks as part of our risk strategy is an unavoidable aspect of doing business. Risks that endanger the group as a going concern may not be taken and must be excluded by risk management. If this is not possible, such critical risks must be minimized or transferred, for example by taking out adequate insurance. Risks are controlled and monitored at the level of the individual companies, the business areas and at group level.

We understand risks as potential future developments or events that could lead to a negative impact on the financial figures overall and CGM's earnings projections in particular. The risks identified are essentially assessed for CGM's one-year guidance horizon.

The annual risk reporting process begins by identifying all major risks within defined risk categories. CGM has defined eleven risk categories:

- Strategic risks
- Macroeconomic and political risks
- Operational risks
- Financial risks
- Regulatory risks
- Personnel risks
- Data processing risks
- Project risks
- M&A risks
- Tax risks
- Other risks

The eleventh risk category “Other risks” was added in 2022 to include risks that are not included in the established catalog of business risks.

We assess the identified risks in a two-stage process based on their probability of occurrence and potential loss. The gross loss is initially estimated by the risk managers at the local companies. The risk managers also document measures for risk avoidance and minimization in addition to options for transferring risk. Risk identification and risk assessment are supported by the management of the respective company or business unit. The risks identified at local level are then analyzed by Risk Management. After completing its analysis of the identified, reported and quantified risks, Risk Management aggregates the risks by means of a Monte Carlo simulation and produces an overall assessment.

The loss value per risk category and the loss value for the group’s overall risk situation produced from this Monte Carlo risk aggregation is taken as the expected annual loss (on risk occurrence). The value-at-risk method reveals information on the potential maximum annual loss associated with the group’s overall risk situation.

Subsequent risk reporting is addressed directly to the General Counsel and to the Chief Financial Officer of CompuGroup Medical SE & Co. KGaA, who informs the Managing Directors and the Supervisory Board of the group's risk situation. The CFO is informed without delay of material unforeseen changes. He must then inform the Managing Directors and the Supervisory Board of such significant unforeseen developments. Group Risk Management is responsible for coordinating the whole process and for analyzing the inventoried risks. A quarterly risk report is submitted to the Managing Directors by the risk manager in charge (Group Risk Management).

The risks for the group's eleven risk categories for the period from January 1, to December 31, 2022 were communicated to the Managing Directors. The group's risk categories are ranked as follows according to the severity of the risks reported:

1. Data processing risks	(1)
2. Operational risks	(3)
3. Financial risks	(10)
4. Regulatory risks	(2)
5. Strategic risks	(4)
6. Personnel risks	(7)
7. Macroeconomic and political risks	(5)
8. Project risks	(6)
9. Other risks	(new)
10. M&A risks	(8)
11. Tax risks	(9)

The numbers in parenthesis show the ranking of the risk categories in 2021 for comparison. The ranking of our risk categories changed in the reporting period as a result of the reassessment of potential risk categories and individual risks. In particular, the reassessment of potential risk categories and individual risks in the risk inventory resulted in higher risk assessments due to changing market and general conditions in relation to individual risks in the risk categories of financial risks and new other risks.

The risk categories apply to all operating segments. They do not differ from segment to segment, and the group does not report them differently. All segments essentially operate in the same general economic environment and on the same markets (exclusively in healthcare), and the nature of their products and services are also fundamentally the same (software and related services).

The risk reporting process is supported by an intranet-based risk management system that ensures transparent communication throughout the group. It provides for transparent communication processes in the entire group. In addition, Internal Audit assessed the quality and functionality of our risk management system in financial year 2022.

3.2.2 Risks

Data processing risks

These risks arise primarily from a lack of coordination and alignment of the IT strategy with corporate objectives, insufficient data protection for IT systems, inadequate documentation, etc. The analysis shows an expected potential annual loss for all identified risks in this category of approximately mEUR 16 (prior year: mEUR 10).

CGM's customers use the products and services it offers to store, process and transmit highly confidential information about the health of their patients. Given the sensitivity of this information, security features are highly important as an integral part of our products and services. If, despite all efforts, the security features offered by CGM's products do not work properly, claims for damages, fines, penalties and other liabilities due to a violation of applicable laws or regulations could arise. The continuously increasing offer of online services and the accompanying increase in the use of the same led to a noticeable increase in risks in this context.

Also, substantial costs for fixing any defects and re-engineering could arise. This could also damage CGM's image as a trustworthy business partner.

To avoid such security vulnerabilities, high demands are placed on quality management in both software development and maintenance. CGM also places high demands on its internal information security management system, and has therefore had this audited by an independent third party and certified in accordance with ISO/IEC 27001 – the internationally recognized standard for information security management systems. The continuous expansion of internal structures and the resulting steady increase in transparency gradually led to risks being more extensively identified and assessed in the course of 2021. Thus, the ransomware attack that occurred in December was also an already identified risk and is not the cause of the increase in potential losses in the risk category.

To ensure compliance with the EU General Data Protection Regulation (GDPR), appropriate technical and organizational measures have been implemented to protect personal data against unauthorized access, unlawful processing, unlawful disclosure and accidental loss or destruction.

Operational risks

Operational risks refers to risks associated with research and development, markets and customers. The expected potential annual loss for all operational risks identified in the analysis is approximately mEUR 14 (prior year: mEUR 16).

Research and development

There is a risk that products and modules will not be created with the necessary quality within the time and budget allotted. To avoid this risk, the group conducts systematic and regular reviews of project progress and compares the results against the original targets, ensuring that measures can be taken to compensate for impending losses whenever this results in any deviation. Given the broad range of our research and development activities, there is no discernible risk concentration on any specific products, patents or licenses.

Market and customer risks

Given the complexity of our products and the considerable legal requirements, distribution by sales and service partners entails certain risks. Special training is offered to ensure that the sales and service partners comply with our quality requirements. The selection of the sales and service partners is subject to strict requirements.

The eHealth market is highly competitive and characterized by advancing market maturity. This competitive situation may lead to price pressure on our products and services, as well as to increasing expenses for customer retention and acquisition. In the current financial year, as in the prior financial year, CGM expects a consistently good business performance with manageable risks that could affect the results of operations.

Financial risks

These risks are in particular liquidity and refinancing risks, currency risks and control risks. The expected potential annual loss for all financial risks identified in the analysis is approximately mEUR 8 (prior year: mEUR 2).

Liquidity and refinancing risks

Business models that are not exclusively financed by equity are exposed to the risk of the leveraged portion being dependent on the refinancing options available on the capital market. As a precaution against this risk factor, CGM uses credit lines provided by national and international house banks.

The syndicated credit facility (see notes to the consolidated financial statements for further information) covers the group's basic capital requirements. It consists of a revolving loan and a term loan. For additional capital requirements, the CGM group can use the new loan from the European Investment Bank taken out in the summer of 2022 with a volume of mEUR 200 as well as further credit lines that serve to cover the short- and medium-term liquidity requirements of operating activities and the resulting expenses.

A financial covenant has been agreed in the syndicated credit facility. A breach of the financial covenant can result in the loan being called due immediately. This creates liquidity and refinancing risks. There was no such breach as at the balance sheet date. An additional short-term liquidity risk results from the risk of misjudgments in working capital planning that could mean that short-term trade receivables or payables are not received or settled on time.

Corporate Treasury prepares a rolling liquidity plan with varying time horizons (daily, monthly and quarterly) to monitor and manage short-term liquidity risks. Short-term fluctuations in working capital requirements are monitored on a daily basis and can be absorbed adequately by existing credit lines. Structural or short- and medium-term liquidity requirements can generally be met by utilizing the revolving credit line.

Working capital is monitored on an ongoing basis to address any resulting liquidity risks.

The medium-term liquidity risk is monitored and managed with the help of 12-month liquidity planning. Compliance with financial covenants is systematically monitored as part of budget planning and in retrospect, and the results are regularly reported to both the management and the banks. Please refer to the respective sections in the notes to the consolidated financial statements for further information on the financial covenants.

CGM considers changes in interest rates to be its primary market risk. The risk management strategy therefore aims to balance out all relevant cash flow risks. The fact that most of the company's non-current financial liabilities are entered into on the basis of floating interest rates, an interest rate risk arises for rising short-term interest rates, while the development of long-term interest rates only moderately influences the cash flow profile.

Despite all the preventive measures taken, particularly the interest rate cap concluded in 2021 and the interest rate swap concluded in 2022, it cannot be entirely ruled out that refinancing interest rates to be paid by the company will be subject to an unfavorable development or refinancing from leverage will not be granted in the medium term. Given the ECB's changes in the key interest rate, the interest environment has already started to be more unfavorable and further rate hikes are expected. This is the reason for the increase in the expected potential loss for the year for all identified financial risks from mEUR 2 in the previous year to mEUR 8 now. As things stand at present, there are no indications that future refinancing or that borrowing in general are at risk.

Further financial risks relate to the risk of bad debts. Given the group's diversified markets and customer structure, there are no cluster risks. On average, the risk of bad debt is generally low in the long term thanks to the predominantly high credit rating of our customers.

Currency risks

Given the group's international focus, incoming and outgoing payments are performed in various currencies. The group compares and offsets its cash flows in the individual currencies. The company generally strives to achieve extensive natural hedging based on a careful selection of its suppliers and locations. CGM currently makes selective use of derivative financial instruments to hedge currency risks, in particular with respect to intergroup loan relationships. The development of the relevant positions is monitored regularly to ensure an appropriate response to significant changes.

Regulatory risks

These are in particular legal and politics risks as well as data privacy risks. The expected potential annual loss for all regulatory risks identified in the analysis is approximately mEUR 8 (prior year: mEUR 10).

Legal and political risks

CGM's business activities are strongly influenced by the regulatory environment of the public healthcare systems in the individual national markets and thus also by the corresponding market structures. On the one hand, the regulatory structure of the European healthcare sector, which is currently the company's primary market, is based on regulations such as the laws and directives issued by the respective states and, on the other, by supra-national structures that are essentially adopted by the European Union and lifted or amended by court decisions. In particular, the group is thus exposed to the risk that amendments to existing regulations, or the adoption of new ones, at national or supra-national level (the latter primarily meaning the EU level) could adversely affect market conditions relevant to CGM and thus have an adverse effect on the business activities of the group or its individual subsidiaries. Exact forecasts with regard to the introduction and extent of potential amendments to national and supra-national regulations or their impact on CGM's key markets are not possible as the introduction and extent of such regulations are dependent on the political process in the individual countries, and their subsequent impact is greatly influenced by the response by the respective market participants affected.

There are currently no known or threatened legal disputes that could have a significant impact on the financial situation of the group.

CGM is highly dependent on its intellectual property-related information and technology. However, it is not possible to completely exclude risks that may arise from the unlawful use of intellectual property. CGM, however, believes that the options currently available are sufficient to protect its property rights in order to prevent illegal use that could lead to significant quantitative and qualitative losses.

Data privacy risks

Regulatory risks also include data privacy risks. Like in the previous year, the corresponding risk assessment continues to be based on the deterministic model. Given the increase in potential fines calculated from a revenue-based daily rate, this risk has risen slightly.

Strategic risks

CGM defines strategic risks as risks that could jeopardize the financial result arising from the company focusing inadequately on the respective business environment. The expected potential annual loss for all strategic risks identified in the analysis is approximately mEUR 7 (prior year: mEUR 7).

Strategic risks may result from an inadequate strategic decision-making process, from unforeseeable market developments or from poor implementation of the chosen company strategy. The strategic direction of the CGM group is set at the level of the Managing Directors and is subject to regular controls.

- Risks related to changes in the healthcare market are of material importance to the CGM group. This primarily concerns the development of new products and services by competitors, the financing of healthcare systems and reimbursement in the healthcare sector.
- The eHealth market is characterized by rapidly changing technologies, the introduction of new industry standards, and new software launches or new features. This may lead to existing products and services becoming obsolete and therefore becoming less competitive.
- Regulatory developments or the introduction of new industry standards could impact the market positioning of CGM to the extent that the products and services offered no longer fully comply with these new statutory requirements or industry standards.

CGM's future success will depend in part on its ability to improve existing products and services and to interconnect them in order to respond in a timely manner to new product launches by competitors as well as to meet changing customer and market requirements.

Furthermore, CGM would incur additional costs for product development and further development due to products and services quickly becoming obsolete, which could have an adverse impact on the annual result.

Since the Telematics Infrastructure was introduced, CGM has been manufacturing the connector technology itself with the help of subcontractors. As this means that CGM is operating as a hardware producer, this can give rise to risks typical for a production company.

Personnel risks

These are in particular risks arising from the concentration of company-relevant expertise on individual employees, staff fluctuation, overstaffing and understaffing, poor working atmosphere, etc. The analysis shows an expected potential annual loss for all identified risks in this category of approximately mEUR 6 (prior year: mEUR 6).

The commercial success of the group is linked to a large extent to the management and strategic leadership of the Managing Directors and also several employees in key positions. Despite the fact that management duties are also performed by other employees in addition to the Managing Directors, it can be safely assumed that the business activities of the company and its financial position and results of operations would be negatively impacted by the loss of individuals in key positions.

The group considers the performance of its employees to be essential for growth and development. In this respect, the company competes with other companies to attract highly qualified specialists and managerial staff. The group therefore offers an attractive remuneration system and individually tailored continuing professional development to attract employees and retain them over the long term. At present, there are no known significant risks that could have an impact on the recruitment of specialists and management staff and that could thus jeopardize the growth targets that have been set.

CGM considers its employees to be an integral part of the group's public image. Non-compliance with the ethical principles firmly anchored in CGM's management culture could give rise to risks with a negative impact on the company's image and reputation. The risk of non-compliance increases temporarily, especially when new companies are acquired.

Macroeconomic and political risks

In particular, these are risks arising from political changes and the effects of macroeconomic developments. The analysis shows an expected potential annual loss for all identified risks in this category of approximately mEUR 4 (prior year: mEUR 14).

The products and services offered by CGM are currently marketed from offices in 19 countries. Both the establishment of business relationships in these countries and the business activity itself entail the usual risks for international business. In this context, particular attention must be paid to the prevailing general economic or political situation in the individual countries, the clash of different tax systems, legal hurdles such as import and export restrictions, competition regulations, and statutory provisions governing the use of the Internet or guidelines for the development and provision of software and services.

CGM counteracts these risks by regularly consulting with local law firms and tax advisors in countries where it is entering the market or adding additional business activities and by maintaining contact with local public authorities. Risks that may arise from changes in macroeconomic factors can never be completely ruled out.

While terms of use with the customer contractually prohibit misuse of the source code or other trade secrets, there is a residual risk that source codes or trade secrets may come into the possession of third parties and that they may unlawfully benefit from them. It is also conceivable that this could enable third parties to independently develop similar or better products based on CGM's protected technologies or designs. This risk can never be completely ruled out.

COVID-19 pandemic risk

In 2022, CompuGroup Medical no longer compiled the developments and risks related to the COVID-19 pandemic in quarterly reports collected from all business units worldwide, as the risks from COVID-19 have continued to decline.

This is thanks to vaccination rates and the fact that procedures have been adapted to the situation. Measures and rules are in place to ensure that personal contacts are made safely or even avoided and replaced by virtual meetings.

In summary, overall risk assessment now takes into account general pandemic risks with a markedly reduced probability of occurrence. Therefore, the expected potential annual loss arising from this risk category has been significantly reduced.

Project risks

These risks arise in particular from non-compliance with agreed schedules, a lack of or inadequate employee resources, a lack of or inadequate material resources, a lack of customer acceptance of the project services rendered, etc. The analysis shows an expected potential annual loss for all identified risks in this category of approximately mEUR 3 (prior year: mEUR 4).

The group generates some of its revenues from project business. There are potentially long time periods between an order being placed and billed, during which the company must render advance services. During these periods, the company especially bears the credit risk of its customers. Furthermore, in project business, the company is exposed to the risk of a continuous need for new orders/ projects to be able to generate the necessary revenues or growth. Owing to the very high initial implementation costs of the software solutions and the associated long product life cycle, there is a risk, especially in the HIS segment, that lucrative new business will be delayed for a longer time. The company therefore strives to maintain long-term business relationships with its customers, mostly by performing software maintenance, in order to be available as a contact partner and to be able to participate in the bidding process for new orders/projects. Risks may also arise if the market is inadequately monitored, resulting in an insufficient number of offers and orders for the company. In the event of a lack of new business and the termination of software maintenance contracts, the company could suffer a loss of revenue, which would have a negative impact on the group's results of operations.

Other risks

Other risks are mainly those risks that cannot be or have not yet been allocated to any of the above categories. This category serves to recognize and disclose both newly identified risks and novel developments that might be of a temporary nature. The expected potential annual loss for all other risks identified in the analysis is approximately mEUR 3 (prior year: mEUR 0).

Two types of risk were classified as other risks in the reporting period: potential effects from the war in Ukraine as well as general risks related to climate change and weather events that exceed the company's normal macroeconomic and political risk context.

M&A risks

These are in particular acquisition and integration risks. The expected potential annual loss for all M&A risks identified in the analysis is approximately mEUR 3 (prior year: mEUR 4).

Going forward, CGM also plans to further expand its presence in the national and international market. These plans include further company acquisitions that the company always prepares with utmost care and diligence. Nevertheless, every acquisition entails a risk which, if it materializes, may have an impact on the group's earnings.

The risks from the acquisition undertaken during the financial year under review have already been included in the established risk management process and are based on information gained during the due diligence.

Intangible assets purchased in acquisitions account for a significant share of the group's assets. In accordance with the group's mandatory accounting policies, goodwill is tested for impairment at least once per year, and other assets are tested after triggering events. If such testing determines that assets are impaired, this necessarily results in a corresponding adjustment of the carrying amounts of these assets. Various factors, such as changes in legislation or the competitive environment, can have a significant impact on the value of intangible assets. If intangible assets are subject to impairment, extraordinary depreciation must be recognized, which results in a corresponding reduction in profit or loss for the period.

Tax risks

These are in particular risks from subsequent payment of taxes (also for acquired companies), pricing of goods and services between associated companies and inaccurate legal structure as a result of inaccurate tax planning. The expected potential annual loss for all tax risks identified in the analysis is approximately mEUR 1 (prior year: mEUR 1).

The risk of further claims arising from external audits by tax authorities, for which the company has recognized only insufficient provisions if at all, cannot be ruled out entirely. From today's perspective, the group has recognized sufficient provisions for general risks arising from ongoing tax audits.

Presentation of the overall risk position

On a cumulative basis, the total potential annual loss for the group is mEUR 73 (prior year: mEUR 74). The potential maximum annual loss at group level within a 95 percent confidence level amounts to approximately mEUR 107 (prior year: mEUR 110) with a 5 percent probability of higher, unexpected losses.

Based on an assessment of the currently identified risk positions, the continued existence of CompuGroup Medical SE & Co. KGaA and the group as a going concern are not at risk. The cumulative potential annual loss could be covered by the group's expected cash flow from operating activities.

3.3. Report on opportunities

Increasing amounts of data are being collected in the healthcare system – in private medical practices, hospitals and by health insurers. Physicians also want to share detailed insights and information with their peers, always with the aim of providing each patient with the individual optimal care. At the same time, indications and treatment options are becoming more differentiated and thus more complex. Both the time pressure and the amount of medical information available are constantly increasing: it is becoming more and more difficult to have all information available with perfect precision at all times.

For more than 30 years, CGM has been helping its customers to reduce increasing bureaucracy and paperwork and to ensure that important medical information is available where it is needed. This relieves the burden on physicians and healthcare professionals, freeing up more time for what matters most: providing their patients with the required care. To this end, information sharing and interaction between general physicians and specialists, hospitals, pharmacies, and other healthcare stakeholders are paramount.

Opportunities in operations

Technological leadership and innovation

CGM is well positioned to continue its trend-setting position in technology and innovation in the future. As an experienced pioneer, CGM constantly develops innovative solutions to facilitate healthcare communication, learn from data and share new insights with the overall healthcare sector.

Customer retention and expert knowledge

Customer retention and expert knowledge are strong entry barriers for new competitors. This is especially true of hospital systems where technical implementation is highly complex. Such systems are only entrusted to providers with the necessary expertise and resources, as well as appropriate experience in realizing comparable projects. Moreover, given the high implementation risks in terms of technical changes and user training, the costs involved in switching systems for hospitals are particularly high.

G3 technology

The development of our products is based on a consistent platform approach, summarized under G3. The objective is to standardize our product development across all segments based on uniform principles, architectures and components. For this purpose, we use state-of-the-art technologies and a uniform design system that facilitates the integrated use of each product for our customers. Where already possible today, we also use international standards for interoperability to facilitate interfaces between our products as well as interfaces to current or foreseeable digital eHealth ecosystems.

G3 solutions can be offered as software as a service (SaaS) or in the cloud and are suitable for almost any use from single clinic deployment to regional and national solutions.

Organizational and process-related improvements

The goal of “OneGroup” is to introduce a single centralized IT platform and thus standardize and optimize roles, structures and processes across all our companies and business units worldwide. All other existing internal IT solutions will be migrated and gradually phased out after successful implementation of the standardized solution. In this way, CGM is creating a synthesis of all collective knowledge on the basis of defined standards and is making it available centrally in the form of an IT solution. CGM uses the possibilities offered by information technology to organize, automate and synchronize business processes in a global system. “OneGroup” therefore ensures that CGM addresses its markets with a unique, uniform and customized approach in the areas of marketing, sales, support, professional services and other customer-facing activities. Behind the scenes, finance, human resources and other administrative functions provide senior managers with maximum transparency to help make qualified decisions and support frontline colleagues. The fully standardized IT-based organization will help CGM increase operational efficiency, improve profitability, grow faster and further enhance customer satisfaction.

Strategic opportunities

Leading market position in Ambulatory Information Systems

CGM is a provider of ambulatory information systems (AIS) in Germany. CGM is also among the leading AIS providers in Denmark, France, Sweden, Norway, Austria, Italy and the Czech Republic. In 2022, the group also managed to carry out smaller, targeted acquisitions to further scale up its already attractive and sizable presence in the US, the world’s largest healthcare market. Thanks to the size of its AIS business, CGM has direct access to many registered physicians in medical practices. This has a number of significant benefits. CGM’s strategically favorable positioning makes it possible to take a lead role in other efficiency-enhancing areas of healthcare. A good example is the connectivity market, where the value and success of connecting physicians, hospitals and other healthcare participants is closely related to the number of participants.

The more members a network has, the more attractive it becomes for potential new members to join and use paid services in the future. CGM’s existing base of physicians gives it a key competitive advantage in this market. Long-term service and software maintenance contracts also play an important role in the AIS business and yield the corresponding stable recurring revenues, which form a good basis for financing investments and developing new products and services.

The Telematics Infrastructure in Germany

The telematics infrastructure represents a long-term growth opportunity for CGM. With a full national rollout now prescribed by German law, CGM has the opportunity to sell new solutions to all existing customers in Germany. More importantly, the telematics infrastructure fits perfectly with CGM's strategy to provide even more products and services to its own customers, such as eServices, online prescriptions, electronic health records, electronic sick notes, physician networks, online clinical pathways, web hosting services, etc.

Ségur project in France

The roll-out of the Ségur software version for the two main French products HelloDoc and Axisanté was initiated successfully in the fourth quarter of 2022. The Ségur product launch was initiated in the context of the "Ma Santé" program introduced by the French government and funded by the European Resilience Investment Plan. The installation of Ségur with French physicians reinforces CGM's crucial role in the digitization of the French healthcare system.

CLICKDOC

With CLICKDOC, CGM offers a platform that ensures a direct patient-doctor communication interface. Physician and patient are in direct contact - whether appointment request, online consultation or retrieval of findings.

The CLICKDOC, which supports the entire patient care process as a communication and information platform, has already been integrated into the outpatient information systems in France and Germany since 2021. The customer base has grown steadily, with more than 10,000 healthcare providers now using the video consultation, around 5,000 providers in France and Germany using the online calendar, and more than 100,000 vaccination modules or functions in use in several European countries.

EBZ – electronic request and approval solution for dentists in Germany

Rollout of the new EBZ, an electronic request and approval solution for dentists, was initiated in Germany in the third quarter of 2022. Using the EBZ solution, dental practices are now able to send their requests electronically via an encrypted process to the statutory health insurance company, which then sends its response back to the practice, leading to considerable savings on time and money.

Pharmacy Information Systems (PCS)

Consolidation of 4K S.r.l. in Italy

4K S.r.l. has been consolidated in the CGM Group since June 1, 2022, finalizing the second phase of the M&A deal initiated in mid-2021. With its "Pharmap" brand, 4K S.r.l. focuses on the home delivery of medicines based on a solid mobile and web platform, as well as on digital services for healthcare providers, in particular pharmacies. This acquisition rounds off CGM's business activities with a specialized player in the patient journey and particularly on the last mile that delivers directly from PCS and medical practices to the patient's/citizen's home.

Electronic prescriptions in PCS in Germany

The electronic prescription service is being rolled out for all Winapo customers in Germany since mid-2022. This novel functionality complies with the statutory requirements in Germany and enables pharmacies to reduce time and effort by introducing paperless processing of prescriptions.

Clinical decision support

Clinical decision support can sustainably support healthcare providers in patient dialog, e.g., in the diagnosis of rare diseases as specific information can be made available depending on the context. Due to a continuously increasing number of medical findings, more and more complex and individual disease patterns and a simultaneous shortage of possibilities for comprehensive medical care, clinical decision support helps to provide relevant medical data at the right time and the right place, true to the vision of the founder of CGM. A modern cloud-based medical product called THERAFOX serves as the basis for improving drug therapy safety.

Financial opportunities

Acquisitions are crucial for strengthening existing market positions and entering new markets. CGM has acquired and successfully integrated a large number of companies from a variety of countries and operating segments in the last few years.

As CGM acquired the INSIGHT Health Group and the GHG business, it strengthened its position in the growth area of innovative data-driven solutions. With the investment in the Italian New Line RdM Società Benefit S.p.A., CGM has laid the foundation for developing the international markets with innovative data solutions.

Smaller acquisitions in the USA have strengthened CGM's position on the US healthcare market. This is completed and enhanced by the successful integration of further companies acquired in recent years, such as KMS Vertrieb und Services, VISUS Health IT and Meta-it.

Legislative and political opportunities

Overall political perspective

The demand for IT solutions is universal across all healthcare systems in Western industrial countries as they are facing the same challenges associated with an increasingly elderly population and rising treatment costs. This means that there is a transnational demand for IT solutions for the healthcare industry. Thanks in particular to the company's many years of experience, CGM's business model can be applied to a variety of different markets worldwide. CGM is constantly expanding its international presence and currently maintains sites in 20 countries across the world.

The COVID-19 pandemic has shown that digitization in the healthcare industry must be further advanced and is accelerating this development. CGM is available as a partner and has the products and the competence to promote this process.

German Hospital Future Act (KHZG)

In Germany, the Bundestag passed the German Hospital Future Act (KHZG) in November 2020. This program published by the government will drive digitization in German hospitals over the next few years. Orders have been placed since 2021. By the end of 2022, the overall order volume already amounted to approximately mEUR 90. First implementation projects had already been initiated in 2021. The focus of implementation is on the years 2023 to 2025.

Personnel opportunities

Successful and experienced management team

CGM has a strong international management team whose members have a wealth of experience in the industry. The management team comprises the spokesman for the Managing Directors & Chief Financial Officer (CFO) Michael Rauch and the Managing Directors Angela Mazza Teufer (Ambulatory Information Systems DACH, Connectivity & CLICKDOC), Emanuele Mugnani (Ambulatory Information Systems Europe), Dr. Eckart Pech (Consumer and Health Management Information Systems) and Hannes Reichl (Inpatient and Social Care).

Attractive employer

More than 9,200 employees at CGM are behind our innovations and developments. With these products and services, our employees have a significant impact on the lives of millions of people in Europe, the USA and South Africa. This is something we are aware of, which is why we see it as our obligation to provide a safe and healthy working environment where people can give their very best.

Compared to the end of 2021, the number of employees worldwide has increased by 7 % in the reporting year. Given the prevailing shortage of IT specialists, it is important to CGM to actively do something against this lack of skilled labor (in addition to external recruiting). Therefore, we are investing sustainably in the training and promotion of junior talent. Moreover, taking into account individual needs and skills, this increases early talent retention and helps strengthen expertise in our industry.

CGM can also look back on a successful financial year 2022 when it comes to junior talent management. In Germany alone, CGM hired 60 new trainees and dual-program students, thus having 185 trainees and dual-program students under contract at the end of the reporting year.

The fact that we were able to take on 79 % of all apprentices in Germany after their graduation in 2022, the majority of them in IT occupations, is very encouraging.

To ensure our employees can develop greater personal, professional, methodological and, as the company becomes more international, intercultural skills, it is our mission to provide and secure the ideal framework conditions here. One of our most important measures to promote continuous professional development for individuals is the annual performance and development reviews that must be held for all employees in all companies, as stipulated by internal CGM guidelines. This is a dialog between employees and their managers, which is supported digitally. The goal of the dialog is to identify development potential, define goals, and identify and initiate appropriate training and qualification.

In addition to the internal courses available, which are offered in particular on our learning platform, CGM also provides further online education and training opportunities for managerial staff, specialists and project managers. These allow the greatest possible flexibility for employees in terms of the training period and location.

CGM takes responsibility as an employer to provide its employees with stability and security. The top priority here is to protect and support our employees. Our occupational health management offering includes traditional sports and exercise programs as well as occupational health and special training programs.

A good work-life balance is a crucial basis for satisfaction and performance, benefiting employees and the company alike. CGM has set up a childcare center at the company's headquarters in Koblenz to make work-life balance easier for young families. Children of company employees are given priority. The center is open ten hours a day, which is convenient even for employees on flextime schedules.

Data-related opportunities

Ambulatory information systems made CompuGroup Medical big, but the company has already been in the business of supporting the healthcare sector with further smart, digital solutions and data driven services for many years. Data security and GDPR compliant data processing play a dominant role here. Services such as Therafox keep physicians informed about potential risks related to the prescription of a specific medication, and the Arznei Aktuell app enables them to check this medication. With further specialized tools, we make it easier for physicians to diagnose rare diseases. Our INSIGHT Health data service provides valuable insights into pharmaceutical developments. CGM has excellent connections in all healthcare sectors and intends to develop data-driven solutions for all these sectors.

Overall assessment of opportunities

CGM is in an excellent position to take advantage of the opportunities offered by modern information technology, to enhance efficiency, reduce costs, optimize workflows and improve services for patients. The healthcare market is growing – even under difficult general conditions – and CGM is one of the world's leading eHealth providers. CGM has an outstanding customer base of physicians, dentists, hospitals and pharmacies around the world. CGM has structural, long-term growth opportunities and has a solid, resilient market position. The eHealth market in total has enormous potential.

The group's opportunities have not changed significantly compared to the prior year in the reporting period, and continue to be viewed as consistently positive.

4. Internal control and risk management system

4.1. General*

The systematic and responsible management of risks and opportunities is an important part of corporate governance for CGM. The company-wide risk management, compliance and control system is based on the "Three-Lines of Defense" model, which describes the overlapping risk structures and responsibilities at different levels.

At the first level (1st Line), activities (including the management of financial and non-financial risks) and the deployment of resources are managed in line with external and internal requirements. Risks are to be prevented or recorded and reduced where they can arise, i.e. at the operational level. Risk owners, i.e., the heads of the business divisions, the general Manager of the CGM subsidiaries and the heads of the group functions, establish processes in accordance with the requirements of the second level (2nd Line) to ensure the identification, evaluation, monitoring and development of measures to mitigate risks. Through the management of the business units and Group functions, there is a regular exchange with the Managing Directors on planned, actual and expected results in relation to the organization's objectives, as well as on risks.

At the second level (2nd Line), the framework for the design of the internal control system, the risk management system and the compliance management system is set by defining corresponding minimum governance requirements, systems and processes for application at the first level. The specific design of this governance is risk-based and at the discretion of the Managing Directors. The Managing Directors and the Audit Committee of the Supervisory Board receive regular reports on risk management, the financial internal control system and compliance. For further information on governance and the implemented processes of risk management, compliance management and the financial internal control system, please refer to the "Opportunity and Risk Report" and to the corporate governance practices and working methods of the Managing Directors and the Supervisory Board, which is published in the Corporate Governance Statement on the Company's website at <http://www.cgm.com>.

At the third level (3rd Line), the Group function Internal Audit monitors the regularity, security, appropriateness and effectiveness of the existing governance and implemented processes, internal controls and risk management through independent audits. This is done as part of the risk-based annual audit plan or, in individual cases, as part of event-driven audits during the year. It supports the Managing Directors in the performance of their monitoring function and reports directly and independently to the Managing Directors. Internal Audit's independence ensures that both the planning and execution of its activities are free from hindrance and bias, and that there is unimpeded access to the necessary people, resources and information. The Head of Internal Audit involves the Managing Directors in the distribution of all audit announcements and audit reports. He also provides quarterly summary reports to the Managing Directors, the Board of Directors and the Audit Committee of the Supervisory Board.

These quarterly reports relate to the completion of all audits and the follow-up of related actions. The Head of Internal Audit submits them in advance and explains them during meetings of the aforementioned bodies. A professional exchange with the appointed auditing firm also supports compliance with auditing guidelines.

The "three lines of defense" model is supplemented with regard to accounting by the activities of the external auditor. With the "Three-Lines-of-Defense" model described above, the Managing Directors have implemented a control framework for CGM aimed at ensuring appropriate and effective internal control and risk management. The measures implemented in this context are also aimed at the effectiveness and appropriateness of the internal control, compliance and risk management and are explained, for example, in the opportunities and risks report within the combined management report. As part of the implementation of the "three lines of defense" model and the legal framework, independent monitoring and audits also take place, in particular through the Internal Audit audits described above and other external audits. In particular, the dynamic development of requirements in the area of non-financial reporting and non-financial risks makes it necessary to review the monitoring systems for this area at regular intervals and adjust them as necessary.

** The contents of this section are unaudited contents that have been critically read by the auditor.*

4.2. Accounting-related (section 289 (4) and section 315 (4) of the German Commercial Code (HGB))

In financial reporting, there is a risk that the annual, consolidated and interim financial statements may contain misstatements that could potentially have a substantial impact on the decisions of their addressees. Our accounting-related internal control system (ICS) aims to identify potential sources of error and limit the resulting risks. It covers financial reporting throughout the entire CGM group. This gives us reasonable assurance that the annual and consolidated financial statements are prepared in accordance with statutory requirements. The main features of the accounting-related internal control system and the risk management system (for the group) are described below:

A clear management and corporate structure has been implemented within the CGM group. Key functions that serve all regions and sectors are managed centrally by CompuGroup Medical SE & Co. KGaA. The operating subsidiaries are granted a high degree of autonomy. The functions of the areas involved in the accounting process – Accounts Payable and Accounts Receivable (AP/AR Services), Financial Reporting, Treasury, Human Resources, IT, Risk Management, Group Controlling, Preparation and Financial Management of the Separate Financial Statements, Consolidated Financial Statements, Procurement and Investor Relations – are clearly separated. Responsibilities are well defined.

The departments involved in the accounting process pursue both the quantitative and qualitative goals of the group.

Accounting is predominantly organized and managed centrally by CompuGroup Medical SE & Co. KGaA. The Shared Service Center at the Koblenz site is responsible for the accounting of the subsidiaries in Germany, Switzerland, France, Belgium, Sweden, Norway, Denmark, South Africa, Poland, Spain and Romania. The subsidiaries in other countries are not incorporated into this central organizational structure, but local group companies sometimes take over accounting and other financial functions for their subsidiaries or affiliated companies. As the ultimate parent entity of the group, CompuGroup Medical SE & Co. KGaA exercises central supervisory and general control functions in the areas of accounting and finance. These include consolidation, accounting for pension provisions, accounting for business combinations, accounting for internally generated software, accounting for leases in accordance with IFRS 16, and goodwill impairment testing as well as the newly adopted reporting in accordance with the so-called EU Taxonomy Regulation (EU) 2020/852. Furthermore, CompuGroup Medical SE & Co. KGaA is responsible for the management, accounting and monitoring of financial instruments, balance sheet management of the subsidiaries, payment transactions, investment and German tax group accounting. External service providers and advisors are consulted whenever required.

Internal policies designed according to the group's requirements have been implemented (including a group-wide accounting policy, risk management policy and a research and development policy). Appropriate safeguards have been installed to protect the financial systems against unauthorized access. The financial systems mainly use standard software.

Uniform planning, reporting, controlling and early warning systems and processes are used in the group to ensure group-wide analysis and management of risk factors relevant to income and risks jeopardizing the continued existence of the company.

Financial reporting in particular is centrally organized and pools the group's (global) information in one place. Group financial reporting is constantly monitored by senior management, the heads of the business units, the general Manager of the subsidiaries and ultimately by the Managing Directors.

CGM uses a group-wide uniform reporting system to prepare financial statements, corporate budgets and the guidance. It is used by all consolidated group companies and forms the basis for a standardized data reporting process within the group.

The Managing Directors of the CGM group take the so-called balance sheet oath for the full year and sign the Responsibility Statement, thereby confirming that the prescribed reporting standards have been complied with and that the figures give a true and fair view of the net assets, financial position and results of operations. The financial reporting process is reviewed by Internal Audit.

The required financial reporting-related processes are subject to regulated analytical reviews. The group-wide risk management system is regularly adapted to current developments and reviewed for adequacy in terms of quantity and quality. To ensure that (group) financial reporting-related processes comply with standards, the function of the regional Vice President Finance or Team Leader Finance has been implemented throughout the group. They report on all financial and accounting matters to the Senior Vice President Finance, who in turn reports to the CFO of the CGM group. The Chief Financial Officer informs the Managing Directors, the Supervisory Board and the Administrative Board about critical or high-risk issues and advises them on corrective measures, as necessary. Depending on the subject matter, other departments, such as Accounts Payable and Accounts Receivable (AP/AR Services), Financial Reporting, Treasury, Human Resources, IT, Risk Management, Group Controlling, Preparation and Financial Management of the Separate Financial Statements, Consolidated Financial Statements, Procurement and Investor Relations, are involved in the financial reporting process to implement or track activities. Furthermore, complex and significant changes in underlying accounting-related topics (e.g., receivables management, impairment testing, balance sheet analysis for compliance with financial covenants, the viability of further acquisitions and the initial consolidation of subsidiaries) are regularly reviewed. The impact of accounting-related risks is assessed in terms of their influence on financial reporting by means of impact analysis. These analyses are also used to review measures introduced to limit identified risks in order to be able to assess the effectiveness of the measures.

The Supervisory Board established an Audit Committee for key financial reporting and risk management issues, and to monitor and control audit engagement.

The four-eyes principle is applied to all material financial reporting processes.

The accounting-related internal control and risk management system, the main features of which have been described above, ensures that business matters are correctly recorded, prepared and evaluated in the financial statements and included in external reporting. Group Accounting is the central department, which monitors all these processes. This in turn is monitored by the CFO and the Audit Committee, which are supported in their monitoring function by the Internal Audit department.

A strict organizational, corporate, control and monitoring structure forms the basis for efficient work processes. The staffing and resources of the accounting-related areas, both in terms of personnel and equipment, are in line with group requirements and ensure effective and accurate work. Legal and corporate directives and guidelines ensure that the financial reporting processes carried out by the accounting-related areas are standardized and appropriate. The clear definition of responsibilities and various control and verification mechanisms ensure correct financial reporting and the reliable handling of potential business risks. The group-wide risk management system, which is in accordance with statutory requirements, serves to identify risks at an early stage, assess them and communicate them appropriately.

4.3. Effectiveness*

Internal Audit continued to report to the Managing Directors in 2022 on the control systems implemented. In this context, identified improvement and optimization potentials and corresponding ongoing projects were presented to the Managing Directors. Finally, Internal Audit provided the Managing Directors with an assessment of the appropriateness and effectiveness of the respective control system, where applicable against the background of recommended improvement options. On the basis of this assessment, as well as on the basis of the review of the non-financial internal control system, the Managing Directors are currently not aware of any indications with regard to significant issues that speak against the adequacy and effectiveness of the system as of December 31, 2022. Due to the multi-layered process landscape and the high rate of change in the catalog of requirements for non-financial information, the maturity of the internal control system in the non-financial area does not yet correspond to that of the (Group) accounting-related internal control system. Based on the regular review of the financial internal control system, compliance and risk management, as well as internal audit reporting, the Managing Directors are currently not aware of any indications with regard to significant matters as of December 31, 2022 that would speak against the adequacy and effectiveness of these systems.

* The contents of this section are unaudited contents that have been critically read by the auditor.

5. Risk reporting in relation to the use of financial instruments

Risks arising from the use of financial instruments

The CGM Group is exposed, with respect to default risks, price change risks and cash flow fluctuation risks on the assets, liabilities and planned transactions, primarily to liquidity and default risks as well as the risk of changes in foreign exchange rates and interest rates. Risks arising from the use of financial instruments are continuously monitored as part of risk management.

Currency and interest rate risks are minimized in part through the use of derivative hedging instruments. Derivative financial instruments are used exclusively for micro hedges of risks arising in the normal course of business. Derivative financial instruments are used exclusively for hedging purposes, never for speculative purposes, and are only concluded with established financial institutions whose risk profile is solid and is reviewed on a daily basis. The effectiveness of the hedging relationship between the underlying transactions and the hedging instrument is verified by using effectiveness tests.

Foreign currency risks result from investments, financing measures and operating activities. CGM currently hedges only intercompany financial loans and deposits through derivative financial instruments in order to minimize intercompany currency risks. The hedging relationships used by CGM are presented in the consolidated financial statements as hedge accounting.

Interest rate risks result primarily from Group financing. CGM currently uses derivative financial instruments to hedge long-term loans with final maturities against possible negative interest rate developments. These interest rate derivatives are partly designated as cash flow hedges and are contracted in order to fix or cap the amount of interest payments for variable-interest liabilities.

CGM strives to minimize related credit risks. Measures taken by the company to achieve this goal include the establishment of a dunning system. Furthermore, credit risks are avoided by agreeing prepayments for a significant share of the contracts relevant to recurring revenues. The maximum (earnings) risk resulting from financial instruments basically corresponds to the carrying amounts of the respective capitalized financial instruments.

For further detailed information on market risks, default risks and liquidity risks, please refer to G.6 Credit risk, G.7 Currency risk, G.8 Interest rate risk and G.9 Liquidity risk of the notes to the consolidated financial statements.

6. Takeover-related disclosures

Composition of subscribed capital

As at the reporting date, the share capital of CompuGroup Medical SE & Co. KGaA amounts to EUR 53,734,576.00 and is divided into 53,734,576 no-par registered shares with the securities identification number A28890 (ISIN: DE000A288904). All shares represent the same rights and obligations; these result from the statutory provisions and the company's Articles of Association. The shares have been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since May 4, 2007. They are traded on the XETRA electronic securities trading system. The share has been listed in the TecDAX since September 23, 2013. From September 23, 2019 to March 20, 2022, the share was listed in the MDAX. The shares have been listed on the SDAX since March 21, 2022.

Restrictions affecting voting rights or the transfer of shares

The provisions of the German Stock Corporation Act (AktG) may require restrictions on the voting rights of the shares. This primarily means that shareholders, under certain circumstances, can be prohibited from voting and, in accordance with section 71b German Stock Corporation Act (AktG), the company may not exercise the voting rights of its treasury shares.

The "Gotthardt family/Dr. Koop" shareholder group, consisting of the natural persons Frank Gotthardt (Germany), Dr. Brigitte Gotthardt (Germany), Professor Dr. Daniel Gotthardt (Germany) and Dr. Reinhard Koop (Germany) together with the legal persons classed as their related parties, hold a total of 51.49 % of all ordinary shares with voting rights.

Based on two separate pool agreements, one between Frank Gotthardt, GT 1 Vermögensverwaltung GmbH, Dr. Brigitte Gotthardt and Professor Dr. Daniel Gotthardt and the second between GT 1 Vermögensverwaltung GmbH and Dr. Reinhard Koop, 24,312,663 shares, corresponding to a percentage of voting shares of 46.55 %, are attributable to the shareholder group "Gotthardt family/Dr. Koop". One of the purposes of the two pooling agreements is to ensure that voting rights of the two pools are exercised consistently with regard to the shares of CompuGroup Medical SE & Co. KGaA. Frank Gotthardt and GT 1 Vermögensverwaltung GmbH hold further shares in addition to the shares attributable to the pools.

Shareholdings exceeding 10 % of the voting rights

With the exception of the aforementioned "Gotthardt family/Dr. Koop" shareholder group, the company has not been informed of any other direct or indirect capital investments that would exceed 10 % of voting rights as at the reporting date. The shareholdings of which we have been notified that still exist as at the reporting date are shown in the notes to the annual financial statements of CompuGroup Medical SE & Co. KGaA under the disclosures pursuant to section 160 (1) no. 8 German Stock Corporation Act (AktG).

Shares with special rights conferring powers of control

The company has not issued any shares with special rights conferring powers of control.

Type of voting rights control through employee shareholdings

Employees, who hold shares of CompuGroup Medical SE & Co. KGaA, exercise their control rights in the same way as other shareholders in accordance with the statutory provisions and the Articles of Association.

Legal provisions and provisions of the Articles of Association on the appointment and dismissal of managing directors and on amendments to the Articles of Association

In the legal form of a partnership limited by shares (KGaA), the general partner has the legal authority to manage and represent the company. As part of the change of legal form, CompuGroup Medical Management SE, a monistic European stock corporation (Societas Europaea, SE), has joined the company as the sole general partner and has assumed the management and representation of CompuGroup Medical SE & Co. KGaA through its Managing Directors.

The appointment and dismissal of the Managing Directors of CompuGroup Medical Management SE is carried out by the Administrative Board in accordance with article 14 of the Articles of Association of CompuGroup Medical Management SE.

In article 10, the Articles of Association of CompuGroup Medical SE & Co. KGaA provide more detailed provisions on a possible withdrawal of the general partner and the further continuation of CompuGroup Medical SE & Co. KGaA.

Any amendment to the Articles of Association requires a resolution of the Annual General Meeting in accordance with sections 278 (3), 179 German Stock Corporation Act (AktG). The authority to make amendments that only affect the wording has been conferred on the Supervisory Board pursuant to article 14 (6) of the Articles of Association of CompuGroup Medical SE & Co. KGaA. In addition, the Supervisory Board has been authorized by resolutions of the Annual General Meeting to amend article 4 of the Articles of Association of CompuGroup Medical SE & Co. KGaA in accordance with the respective utilization of capital, and after expiry of the respective authorization or utilization period.

Resolutions by the Annual General Meeting require a simple majority of votes unless a larger majority is prescribed by law or by the Articles of Association. Under sections 278 (3), 179 (2) German Stock Corporation Act (AktG), amendments to the Articles of Association require a majority of at least three quarters of the share capital represented at the Annual General Meeting when the resolution is adopted, unless the Articles of Association stipulate a different capital majority. Amendments to the Articles of Association are subject to sections 278 (3), 179 to 181 German Stock Corporation Act (AktG) and article 26 (3) of the Articles of Association.

Authorization of the general partner to issue and buy back shares

Authorized capital

The general partner is authorized, with the approval of the Supervisory Board, to increase the share capital of the company on one or more occasions until May 12, 2025 by up to a total of EUR 26,094,449 by issuing new shares against cash and/or non-cash contributions (Authorized Capital 2020). The general partner is authorized, with the approval of the Supervisory Board, to determine the content of the share rights, the details of the capital increase and the conditions of the share issues, in particular the issue price, from the Authorized Capital 2020.

The new shares may also be issued by one or more banks or companies within the meaning of section 186 (5) sentence 1 German Stock Corporation Act (AktG) with the obligation to offer them to the shareholders (indirect pre-emptive subscription rights).

Shareholders must be granted pre-emptive subscription rights when utilizing Authorized Capital 2020. However, the general partner is authorized, with the approval of the Supervisory Board, to exclude shareholders' subscription rights

- to exclude fractional amounts from the subscription rights;
- in the case of capital increases against non-cash contributions in particular in the context of business combinations or the acquisition of companies, parts of companies or equity interest in companies or of other assets or of receivables from the company or from dependent companies within the meaning of section 17 of the German Stock Corporation Act (AktG);
- in the event of a capital increase against cash contributions, if the issue price of new shares is not significantly lower than the stock market price of the shares already listed and the total pro rata amount attributable to the new shares for which subscription rights are excluded does not exceed 10 % of the share capital at the time of this authorization becoming effective or – if this value is lower – at the time it is exercised. The pro rata amount of share capital must be offset against the maximum limit of 10 % of share capital (i) whenever such pro rata amount refers to shares that are sold during the term of the Authorized Capital 2020 on the basis of an authorization to sell treasury shares pursuant to sections 71 (1) no. 8 sentence 5 and section 186 (3) sentence 4 German Stock Corporation Act (AktG) with an exclusion of pre-emptive subscription rights, (ii) whenever such pro rata amount refers to shares that are issued to fulfil subscription rights or conversion or option rights or conversion or option obligations under convertible bonds and/ or bonds with warrants, profit participation certificates and/or profit participation bonds (or a combination of such instruments) if the corresponding bonds are issued during the term of the Authorized Capital 2020 by applying section 186 (3) sentence 4 German Stock Corporation Act (AktG) with an exclusion of shareholders' pre-emptive subscription rights and (iii) whenever such pro rata amount refers to shares that are issued during the term of the Authorized Capital 2020 on the basis of other capital measures with an exclusion of shareholders' pre-emptive subscription rights by directly or indirectly applying section 186 (3) sentence 4 German Stock Corporation Act (AktG);
- if the exclusion of subscription rights is required in order to grant the holders or creditors of convertible bonds, bonds with warrants, profit participation certificates and/or profit participation bonds (or a combination of such instruments) with option and/or conversion rights or option and/or conversion obligations that are issued by the company or any other company associated with or under the direct or indirect majority shareholding of the company a subscription right to new shares to the same extent to which they would be have been entitled after exercising their conversion or option rights or fulfilling their conversion or option obligations.

Contingent capital

Contingent Capital 2017 of CompuGroup Medical SE & Co. KGaA is still equivalent to the previous Contingent Capital 2017 of CompuGroup Medical SE; however, the Management Board has now been replaced by the general partner and it also needs to be taken into account that – unlike the shares of CompuGroup Medical SE previously – the shares of CompuGroup Medical SE & Co. KGaA are now registered shares and not bearer shares. Contingent Capital 2017 was utilized exclusively for the issuance of shares to the bearers or creditors of bonds that had been issued by the company based on the authorization resolution of the Annual General Meeting on May 10, 2017 in connection with the resolution on the change of legal form of May 13, 2020.

The share capital was therefore contingently increased by up to EUR 21,287,740.00 by issuing up to 21,287,740 new registered shares with dividend entitlement from the start of the financial year in which they were issued (Contingent Capital 2017). The contingent capital increase is only performed to the extent that the bearers or creditors of convertible bonds, bonds with warrants, profit participation certificates or profit participation bonds (or combinations of these instruments) exercise their conversion rights or warrants on the basis of bonds issued by the company in return for cash up to and including May 9, 2022 as a result of the authorization resolution of the Annual General Meeting from May 10, 2017, or to the extent that conversion or warrant obligations under such bonds are fulfilled and to the extent that no other forms of fulfillment are used to service these rights. The general partner was authorized until and including May 9, 2022, with the approval of the Supervisory Board, to determine the further details of the implementation of the contingent capital increase up to a total nominal amount of EUR 500,000,000.00 in accordance with the resolution of the Annual General Meeting of May 10, 2017 in connection with the resolution on the change of legal form of May 13, 2020.

Shareholders would generally be granted pre-emptive subscription rights to the bonds when Contingent Capital 2017 is utilized. The general partner was, however, authorized, with the approval of the Supervisory Board and on the basis of the authorization resolution of the Annual General Meeting of May 10, 2017 in connection with the resolution on the change of legal form of May 13, 2020, to exclude shareholders' subscription rights for bonds as follows:

- for fractional amounts;
- to the extent necessary to grant subscription rights to the holders of previously issued bonds with conversion rights, warrants or conversion or warrant obligations on company shares in the amount to which they would be entitled after their conversions rights or warrants have been exercised;
- to the extent in which bonds are issued with conversion rights, warrants or conversion or option obligations in return for cash and the issue price is not significantly lower than the theoretical market value calculated in accordance with recognized financial and mathematical methods and only insofar as the shares issued to service conversion rights, warrants or conversion or option obligations do not exceed 10 % of the share capital either at the point at which the subsequent authorization becomes effective or – if the number of shares is lower – when the authorization is exercised;

- insofar as the shares are issued in return for contributions in kind, provided that the value of the contribution in kind is appropriate in relation to the market value of the bonds as calculated in accordance with the above bullet.

Insofar as profit participation certificates or profit participation bonds would have been issued without conversion or option rights or obligations, the general partner was authorized, on the basis of the authorization resolution of the Annual General Meeting of May 10, 2017 in connection with the resolution on the change of legal form of May 13, 2020, and with the approval of the Supervisory Board to exclude shareholders' subscription rights in full if these profit participation certificates or profit participation bonds had features similar to those of a debenture. In this case, the interest calculation and issue price of the profit participation certificates or profit participation bonds would have had to be in line with current market conditions for comparable borrowing as at the time of issue.

As at December 31, 2022, CompuGroup Medical SE & Co. KGaA had not made use of the option to issue bonds under this authorization.

Contingent Capital 2019 of CompuGroup Medical SE & Co. KGaA is still equivalent to the previous Contingent Capital 2019 of CompuGroup Medical SE; however, the Management Board has now been replaced by the general partner and it also needs to be taken into account that – unlike the shares of CompuGroup Medical SE previously – the shares of CompuGroup Medical SE & Co. KGaA are now registered shares and not bearer shares. The sole purpose of the Contingent Capital 2019 continues to be to service share options based on the authorization resolution of the Annual General Meeting of CompuGroup Medical SE from May 15, 2019 in connection with the resolution on the change of legal form of May 13, 2020.

The share capital is therefore contingently increased by up to EUR 5,321,935.00 by issue of up to 5,321,935 new no-par value registered shares representing pro rata share capital of EUR 1.00 each (Contingent Capital 2019). The sole purpose of the contingent capital increase is to grant pre-emptive subscription rights (share options) to the Managing Directors of CompuGroup Medical Management SE and eligible employees of CompuGroup Medical SE & Co. KGaA, and to executives of its subsidiary associated companies and their eligible managers, until May 14, 2024, in accordance with the more detailed provisions of the authorization resolution of the Annual General Meeting of May 15, 2019 in connection with the resolution on the change of legal form of May 13, 2020. The contingent capital increase will only be implemented to the extent that subscription rights are exercised in accordance with this authorization resolution and the company does not pay the consideration in the form of cash or treasury shares. The new shares participate in profits for all financial years for which a resolution on the appropriation of profits has not been adopted at the time of their being created. The shares granted to eligible Managing Directors of CompuGroup Medical Management SE and eligible employees of CompuGroup Medical SE & Co. KGaA, in addition to eligible executives of their subsidiary associated companies and their eligible employees, from the date of the resolution on Contingent Capital 2019 for the purpose of servicing subscription rights (share options) from treasury shares of the company (section 71 (1) no. 8 German Stock Corporation Act (AktG)) must be deducted from Contingent Capital 2019. On the basis of the authorizing resolution of the Annual General Meeting of May 10, 2017 in connection with the resolution on the change of legal form of May 13, 2020, the share options can only be issued to Managing Directors of CompuGroup Medical Management SE (Group 1) and to senior managers of CompuGroup Medical SE & Co. KGaA, and to executives of its subsidiary associated companies and their senior managers, all of whom must belong to the group of Senior Vice Presidents or the group of General Managers (Group 2).

The total volume of share options (up to 5,321,935) is divided between the two groups as follows:

- Group 1 members together receive a maximum of 3,547,957 share options and the resulting subscription rights.
- Group 2 members together receive a maximum of 1,773,978 share options and the resulting subscription rights.

Members of both groups do not receive any additional subscription rights for their membership in Group 2.

As at December 31, 2022, CompuGroup Medical SE & Co. KGaA had exercised this authorization to grant share options and created share option programs for a total of 1,400,000 share options for members of Group 1 and 362,500 share options for members of Group 2.

Authorization to acquire and use (including cancellation of) treasury shares

By resolution of the Annual General Meeting of May 19, 2021, the company was authorized to acquire treasury shares.

CompuGroup Medical SE & Co. KGaA is authorized by resolution of the Annual General Meeting of May 19, 2021 to acquire treasury shares up to a total of 10 % of the share capital existing at the time of the resolution or, if this amount is lower, of the share capital existing at the time this authorization is exercised. Acquired shares together with other treasury shares of the company that are held by the company or are attributable to it in accordance with sections 71d and 71e German Stock Corporation Act (AktG) must not at any time exceed 10 % of the existing share capital at the time the resolution is adopted. The acquisition can also be exercised by group companies dependent on the company within the meaning of section 17 German Stock Corporation Act (AktG) or by third parties for their account or for the account of the company. The authorization may not be used for the purpose of trading in treasury shares. The authorization can be exercised in full or in part, on one or more occasions and in pursuit of one or more objectives by the company or by third parties acting on its behalf. The authorization became effective on May 19, 2021 and is valid until May 18, 2024. At the discretion of the general partner, the acquisition will be implemented on the stock market or by a public purchase offer to all shareholders or a public invitation to all shareholders to submit offers for sale, whereby the explicit provisions of the resolution of the Annual General Meeting must be complied with.

The general partner is authorized to utilize the treasury shares acquired on the basis of this or prior authorizations as follows:

1. In addition, the shares can also be canceled without the cancellation or execution requiring a further resolution by the Annual General Meeting. Cancelling the shares generally leads to a reduction in capital. In deviation of the above, the general partner may determine that the share capital shall remain unchanged upon such cancellation and that instead the cancellation shall increase the proportion of the share capital represented by the remaining shares in accordance with section 8 (3) German Stock Corporation Act (AktG). In this case, the general partner and the Supervisory Board shall be authorized to adjust the number of shares specified in the Articles of Association.
2. They can also be disposed of in another manner than via the stock exchange or an offer to all shareholders if the shares are sold for cash and at a price that is not significantly less than the stock market price of the company's shares as at the time of disposal. However, this authorization applies only subject to the proviso that the shares that are disposed of under exclusion of subscription rights in accordance with section 186 (3) sentence 4 German Stock Corporation Act (AktG) may not in total exceed a pro rata amount of 10 % of the share capital, neither at the time this authorization becomes effective nor at the time it is exercised. Shares issued during the term of this authorization from authorized capital under exclusion of subscription rights in accordance with sections 203 (1) sentence 1, 186 (3) sentence 4 German Stock Corporation Act (AktG) shall count towards this limit. In addition, shares to be issued to satisfy bonds and/or profit participation certificates with conversion or option rights or a conversion or option obligation shall count towards this limit, provided that the bonds and/or profit participation certificates are issued during the term of this authorization under exclusion of subscription rights when applying section 186 (3) sentence 4 AktG.
3. They may be disposed of in return for contributions in kind, in particular for the acquisition of companies, parts of companies or equity interests in companies or other assets, including receivables from the company or its group companies. In particular, treasury shares can be disposed of as consideration for the transfer to the company or one of its subsidiaries of industrial property rights or third-party intellectual property rights, such as patents or trademarks, to market and develop products of CompuGroup or as consideration for licenses to such rights being granted.
4. They may be used to satisfy conversion or option rights granted by the company or a domestic or foreign company in which the company directly or indirectly holds a majority of the votes and capital when issuing bonds and/or profit participation certificates, or to satisfy conversion or option obligations arising from bonds and/or profit participation certificates issued by the company or a domestic or foreign company in which the company directly or indirectly holds a majority of the votes and capital.
5. They may be used to satisfy option rights from share options granted by the company in accordance with the authorization granted by resolution of the Annual General Meeting of May 15, 2019 under agenda item 6 and adjusted in the context of the change of legal form resolution of the General Meeting of May 13, 2020 under agenda item 7 to grant subscription rights (share options) to former members of the Management Board and former executive employees of CompuGroup Medical SE, the legal predecessor of CompuGroup Medical SE & Co. KGaA, to Managing Directors of CompuGroup Medical Management SE, to executives of CompuGroup Medical SE & Co. KGaA as well as to members of the management of CompuGroup Medical SE & Co. KGaA's subordinated associated companies and their executive employees. To the extent that treasury shares are to be transferred to former members of the Management Board of CompuGroup Medical SE, the legal predecessor of CompuGroup Medical SE & Co. KGaA, in this context to satisfy share options issued prior to the conversion of CompuGroup Medical SE into CompuGroup Medical SE & Co. KGaA, the above authorization applies to the Supervisory

Board. To the extent that treasury shares are to be transferred to Managing Directors of CompuGroup Medical Management SE in this context to satisfy share options issued after the conversion of CompuGroup Medical SE into CompuGroup Medical SE & Co. KGaA, the above authorization applies to the Administrative Board of the general partner. Those shares granted to eligible former members of the Management Board and eligible former employees of CompuGroup Medical SE, the legal predecessor of CompuGroup Medical SE & Co. KGaA, eligible Managing Directors of CompuGroup Medical Management SE, eligible employees of CompuGroup Medical SE & Co. KGaA as well as eligible executives and employees of the subordinated associated companies of CompuGroup Medical SE & Co. KGaA as from May 19, 2021 to satisfy such subscription rights (share options) from contingent capital (section 192 (2) no. 3 AktG) are to be counted towards this authorization for the use of treasury shares.

The aforementioned authorizations can be utilized on one or several occasions, in full or in part, individually or collectively, and the authorizations in accordance with no. 1. to 5. can be utilized in accordance with instructions issued by the general partner but also by dependent companies or companies in which the company holds a majority interest, or third parties acting on the company's account.

Shareholders' subscription rights to treasury shares are excluded if these shares are used as per the above authorizations in no. 1. to 5.

At the end of the reporting year, the company held 1,500,000 treasury shares. For more information on the acquisition of treasury shares, we also refer to the disclosures pursuant to section 160 (1) no. 2 of the German Stock Corporation Act (AktG) in the notes to the company's annual financial statements.

Significant agreements of the company in the event of a change of control and compensation agreements with the Managing Directors or employees in the event of a takeover bid

A "change of control case" exists if

- CompuGroup Medical Management SE pursuant to article 10 of the Articles of Association of CompuGroup Medical SE & Co. KGaA in the currently valid version (the "Articles of Association") departs as general partner from CompuGroup Medical SE & Co. KGaA; or
- an acquirer within the meaning of article 10 (1) of the Articles of Association acquires a controlling influence over CompuGroup Medical Management SE.

If the Managing Director, provided that the employment contract has a remaining term of less than two years at the time of the Change of Control Event, is not made a legally binding offer to extend his employment contract by at least two years from the time of such offer on at least comparable economic terms within six months after the Change of Control Event, or if the acquirer of the control substantially restricts the powers of the Managing Director within a period of six months after the date of the Change of Control Event (each a "CoC Termination Event"), the Managing Director shall be entitled within two months after the CoC Termination Event to terminate the employment relationship extraordinarily with a notice period of four weeks and to resign from his office as Managing Director with effect as of the expiry of the notice period.

If the Managing Director exercises his special termination right, he will receive a cash compensation in the amount of 150 % of the fixed compensation and short-term variable compensation until the regular termination date of the employment contract, but for a maximum period of two years, whereby the 150 % of the short-term variable compensation is calculated on the basis of the target amount in the event of an assumed 100 % target achievement.

The cash compensation is paid in 24 monthly instalments of the same amount and is credited against any waiting allowance owed. The employment contracts stipulate that, in principle, share options already granted up to the effective date of the special right of termination do not expire. Option rights may be exercised after expiry of the waiting period once the general option conditions have been met.

The contracts do not provide for any severance if a contract is terminated prematurely for good cause for which the respective Managing Director is responsible. Share options that have already been granted lapse without replacement or compensation. The contracts do not contain any regulations governing regular termination.

7. Declaration on Corporate Governance

The Declaration on Corporate Governance in accordance with section 289f German Commercial Code (HGB) and section 315d German Commercial Code (HGB) is available on the company website at <http://www.cgm.com>. It contains the Declaration of Conformity pursuant to section 161 German Stock Corporation Act (AktG) and details of key corporate governance practices and the working methods of the Managing Directors and the Supervisory Board.

The following shareholdings currently exist on the basis of the information available to the company:

Supervisory Board of CompuGroup Medical SE & Co. KGaA:

Prof. Dr. Martin Köhrmann	8,000 shares (approx. 0.01 %)
---------------------------	-------------------------------

Matthias Störmer	1,300 shares (approx. 0.00 %)
------------------	-------------------------------

Adelheid Hegemann	34 shares (approx. 0.00 %)
-------------------	----------------------------

Stefan Weinmann	25 shares (approx. 0.00 %)
-----------------	----------------------------

Administrative Board of CompuGroup Medical Management SE:

Frank Gotthardt	17,931,565 shares (approx. 33.37 %)
-----------------	-------------------------------------

Prof. Dr. Daniel Gotthardt	3,580,411 shares (approx. 6.66 %)
----------------------------	-----------------------------------

Dr. Klaus Esser	140,000 shares (approx. 0.26 %)
-----------------	---------------------------------

Michael Rauch	9,000 shares (approx. 0.02 %)
---------------	-------------------------------

Stefanie Peters	800 shares (approx. 0.00 %)
-----------------	-----------------------------

Managing Board of CompuGroup Medical Management SE:

Michael Rauch	9,000 shares (approx. 0.02 %)
---------------	-------------------------------

Hannes Reichl	4,000 shares (approx. 0.01 %)
---------------	-------------------------------

Dr. Eckart Pech	2,000 shares (approx. 0.00 %)
-----------------	-------------------------------

Emanuele Mugnani	300 shares (approx. 0.00 %)
------------------	-----------------------------

8. Separate non-financial report for the group

Employees

At the end of financial year 2022, the CGM group had 9,229 employees worldwide, which is a 7 % increase over the prior year (8,598).

Employees	2022	2021	2020
Headcount	9,229	8,598	7,814
of which from acquisitions as at the acquisition date	231	438	1,832

In Germany, currently the strongest market in terms of revenues, CGM employed a total of 4,099 employees in financial year 2022, which, in relation to the total number of employees in the group, corresponds to a percentage share of 44 %.

Corporate social responsibility reporting

CGM's report on non-financial and diversity information (Corporate Social Responsibility "CSR Report") within the meaning of Section 289b of the German Commercial Code (HGB) and Section 315b of the German Commercial Code (HGB) is published separately on the company's website <http://www.cgm.com/ir>. The CSR report is prepared in accordance with EU Directive 2014/95/EU and the respective regulations under German law.

9. Final declaration on the dependency report

The Managing Directors have submitted the report on relations with affiliated companies (dependency report) required by section 312 German Stock Corporation Act (AktG) to the Supervisory Board, with the following declaration pursuant to section 312 (3) AktG. "Based on the circumstances known to the Managing Directors at the time when the legal transactions were entered into, our company received appropriate consideration for each legal transaction. The company neither took nor refrained from measures that are subject to reporting requirements as set out in section 312 German Stock Corporation Act (AktG)."


Koblenz, March 20, 2023

CompuGroup Medical SE & Co. KGaA

Represented by the Managing Directors
of CompuGroup Medical Management SE




Michael Rauch



Angela Mazza Teufer



Emanuele Mugnani



Dr. Eckart Pech



Hannes Reichl

CONSOLIDATED FINANCIAL STATEMENTS FOR FINANCIAL YEAR 2022

Consolidated statement of financial position

Assets

kEUR	Notes	Dec 31, 2022	Dec 31, 2021
Non-current assets			
Intangible assets	E.1	1,293,910	1,214,347
Property, plant and equipment	E.2	107,478	100,070
Right-of-use assets	E.3	53,411	57,930
Investments in associates and joint ventures (valued at-equity)	E.4	7,300	5,483
Other investments	E.4	3,158	3,123
Finance lease receivables	E.8	15,984	17,048
Other financial assets*	E.10	2,111	9,316
Derivative financial instruments*	E.11	36,560	6,594
Other non-financial assets	E.12	1,200	1,200
Deferred taxes	E.5	2,519	4,924
		1,523,631	1,420,035
Current assets			
Inventories	E.6	29,438	20,642
Trade receivables	E.7	189,439	147,227
Finance lease receivables	E.8	9,152	8,757
Contract assets	E.9	23,282	26,566
Other financial assets	E.10	2,842	2,719
Derivative financial instruments	E.11	574	0
Other non-financial assets	E.12	27,003	26,971
Income tax receivables	E.5	48,560	30,553
Cash & cash equivalents	E.13	90,517	107,343
		420,807	370,778
		1,944,438	1,790,813

* Derivative financial instruments were previously reported under Other financial assets.
(The accompanying notes are an integral part of the consolidated financial statements.)

CONSOLIDATED FINANCIAL STATEMENTS FOR FINANCIAL YEAR 2022

Consolidated statement of financial position

Equity

kEUR	Notes	Dec 31, 2022	Dec 31, 2021
Equity	E.14		
Subscribed capital		53,735	53,735
Treasury shares		- 105,205	- 98,796
Reserves		723,890	657,135
Capital and reserves allocated to the shareholders of the parent company		672,420	612,074
Non-controlling interests		1,403	210
		673,823	612,284
Non-current liabilities			
Provisions for post-employment benefits and other non-current provisions	E.15	32,656	40,628
Liabilities to banks	E.16	699,371	582,441
Contract liabilities	E.20	15,529	9,307
Purchase price liabilities	E.18	5,539	4,262
Lease liabilities	E.17	33,741	38,544
Other financial liabilities	E.22	53	4,640
Other non-financial liabilities	E.22	42	37
Deferred taxes	E.5	108,210	100,325
		895,141	780,184
Current liabilities			
Liabilities to banks	E.16	29,104	92,476
Contract liabilities	E.20	66,898	79,086
Purchase price liabilities	E.18	16,046	7,453
Trade payables	E.19	112,613	93,193
Income tax liabilities	E.5	32,316	18,675
Other provisions	E.21	60,920	51,756
Derivative financial instruments	E.11	901	0
Lease liabilities	E.17	19,603	18,673
Other financial liabilities	E.22	8,478	15,130
Other non-financial liabilities	E.22	28,595	21,903
		375,474	398,345
		1,944,438	1,790,813

(The accompanying notes are an integral part of the consolidated financial statements.)

CONSOLIDATED FINANCIAL STATEMENTS FOR FINANCIAL YEAR 2022

Consolidated income statement

kEUR	Notes	2022	2021
Revenues	E.23	1,129,739	1,025,322
Capitalized inhouse services	E.24	44,819	37,294
Other income	E.25	19,396	24,771
Expenses for goods and services purchased	E.26	-216,397	-191,426
Personnel expenses	E.27	-546,704	-497,723
Net impairment losses on financial and contract assets		-4,961	-7,378
Other expenses	E.28	-209,541	-177,470
Earnings before interest, taxes, depreciation and amortization (EBITDA)		216,351	213,390
Depreciation of property, plant and equipment and right-of-use assets	E.29	-42,770	-37,837
Earnings before interest, taxes and amortization (EBITA)		173,581	175,553
Amortization of intangible assets	E.29	-69,551	-72,876
thereof from purchase price allocations		-45,882	-48,900
Earnings before interest and taxes (EBIT)		104,030	102,677
Result from companies accounted for using the equity method	E.30	-99	33
Financial income	E.31	22,719	3,854
Financial expenses	E.31	-14,584	-8,690
Net impairment losses on financial*	E.31	-5,250	0
Earnings before taxes (EBT)		106,816	97,874
Income taxes for the period	E.32	-32,699	-28,842
Consolidated net income for the period		74,117	69,032
of which: allocated to shareholders of the parent company		73,411	68,970
of which: allocated to non-controlling interests		706	62
Earnings per share	E.33		
undiluted (EUR)		1.41	1.30
diluted (EUR)		1.40	1.30

* Impairment losses for financial assets were previously disclosed under financial expenses.
(The accompanying notes are an integral part of the consolidated financial statements.)

CONSOLIDATED FINANCIAL STATEMENTS FOR FINANCIAL YEAR 2022

Consolidated statement of total comprehensive income

kEUR	Notes	2022	2021
Consolidated net income for the period		74,117	69,032
Items that will not be reclassified to profit or loss:			
Actuarial gains and losses arising from post-employment benefits		4,577	6,118
Change in actuarial gains and losses	E.15	6,616	7,152
Deferred income taxes for the period	E.32	- 2,039	- 1,033
Items that may be reclassified to profit or loss:			
Cashflow hedges		7,537	0
Changes in equity	E.11	10,767	0
Deferred income taxes for the period	E.32	- 3,230	0
Currency conversion differences	E.14	9,449	18,984
Changes in equity		9,449	18,984
Operating income and expense recognized directly in equity (Other comprehensive income)		21,563	25,102
Total comprehensive income		95,680	94,134
of which: allocated to shareholders of the parent company		94,974	94,072
of which: allocated to non-controlling interests		706	62

(The accompanying notes are an integral part of the consolidated financial statements.)

CONSOLIDATED FINANCIAL STATEMENTS FOR FINANCIAL YEAR 2022

Changes in consolidated equity

KEUR	Notes	Subscribed capital	Treasury shares	Reserves			Equity attributable to shareholders of CompuGroup Medical SE & Co. KGaA	Non-controlling interest	Consolidated equity
				Other	Cashflow Hedges	Currency translation			
Balance as at Dec 31, 2020		53,735	0	611,259	0	-26,328	638,667	270	638,937
Consolidated net income for the period		0	0	68,970	0	0	68,970	62	69,032
Other comprehensive income		0	0	6,118	0	18,984	25,102	0	25,102
Actuarial gains and losses	E.15	0	0	6,118	0	0	6,118	0	6,118
Currency conversion differences	E.14	0	0	0	0	18,984	18,984	0	18,984
Total comprehensive income		0	0	75,088	0	18,984	94,072	62	94,134
Transactions with shareholders		0	-98,796	-21,868	0	0	-120,664	-124	-120,788
Dividend distribution	E.14	0	0	-26,367	0	0	-26,367	-170	-26,537
Stock option program		0	0	4,544	0	0	4,544	0	4,544
Non-controlling interests from acquisitions	C.4	0	0	0	0	0	0	91	91
Additional purchase of shares from non-controlling interests after control	E.14	0	0	-45	0	0	-45	-45	-90
Buyback of treasury shares		0	-98,796	0	0	0	-98,796	0	-98,796
Balance as at Dec 31, 2021		53,735	-98,796	664,479	0	-7,344	612,074	210	612,284
Consolidated net income for the period		0	0	73,411	0	0	73,411	706	74,117
Other comprehensive income		0	0	4,577	7,537	9,449	21,563	0	21,563
Derivative hedging instruments (effective)	E.14	0	0	0	7,537	0	7,537	0	7,537
Actuarial gains and losses	E.15	0	0	4,577	0	0	4,577	0	4,577
Currency conversion differences	E.14	0	0	0	0	9,449	9,449	0	9,449
Total comprehensive income		0	0	77,988	7,537	9,449	94,974	706	95,680
Transactions with shareholders		0	-6,409	-28,219	0	0	-34,628	487	-34,141
Dividend distribution	E.14	0	0	-26,117	0	0	-26,117	-175	-26,292
Stock option program		0	0	-2,011	0	0	-2,011	0	-2,011
Non-controlling interests from acquisitions	C.4	0	0	0	0	0	0	588	588
Additional purchase of shares from non-controlling interests after control	E.14	0	0	-91	0	0	-91	74	-17
Buyback of treasury shares		0	-6,409	0	0	0	-6,409	0	-6,409
Balance as at Dec 31, 2022		53,735	-105,205	714,248	7,537	2,105	672,420	1,403	673,823

(The accompanying notes are an integral part of the consolidated financial statements.)

CONSOLIDATED FINANCIAL STATEMENTS FOR FINANCIAL YEAR 2022

Consolidated statement of cash flows

kEUR	Notes	2022	2021
Consolidated net income for the period		74,117	69,032
Depreciation of property, plant and equipment and right-of-use assets and amortization of intangible assets	E.29	112,321	110,713
Earnings on sale of fixed assets	E.25	-163	-1,689
Change in provisions (including income tax liabilities)		15,882	-7,147
Change in derivative financial instruments*		-18,871	-6,594
Deferred tax income/expense	E.32	352	-4,665
Other non-cash earnings/ expenditures		4,561	-5,391
		188,199	154,259
Change in inventories		-8,788	-2,280
Change in trade receivables and other receivables		-28,761	-7,703
Change in income tax receivables		-17,819	-14,008
Change in other receivables		8,419	770
Change in trade payables		15,565	23,911
Change in contract liabilities		-10,377	6,654
Change in other liabilities		-1,411	3,671
Operating cash flow		145,027	165,274
Cash outflow for capital expenditure for intangible assets		-50,560	-44,393
Cash inflow from disposals of property, plant and equipment		349	7,276
Cash outflow for capital expenditure in property, plant and equipment		-25,847	-27,049
Net cash outflow for company acquisitions (less acquired cash and cash equivalents and prepayments in previous periods)	C.4	-57,881	-88,507
Cash outflow for acquisitions from prior periods		-6,887	-5,650
Cash inflow from the disposal of subsidiaries and business units		43	400
Cash outflow for capital expenditures for joint ventures and other equity investments		-4,631	-6,053
Cash flow from investing activities		-145,414	-163,976
Buyback of treasury shares		-9,109	-96,096
Dividend paid	E.14	-26,117	-26,367
Capital paid to non-controlling interests	E.14	-175	-169
Acquisition of additional shares from non-controlling interests	E.14	-17	-10
Downpayment of lease liabilities		-25,530	-21,144
Cash inflow from borrowing of loans	E.16	340,000	265,081
Cash outflow from the repayment of loans	E.16	-295,411	-91,142
Cash flow from financing activities		-16,359	30,153
Cash and cash equivalents at the beginning of the period	E.13	107,343	75,910
Change in cash and cash equivalents		-16,746	31,451
Changes due to exchange rate fluctuations		-80	-18
Cash and cash equivalents at the end of the period	E.13	90,517	107,343
Interest paid		6,157	4,178
Interest received		687	560
Income taxes paid		39,034	49,280

* Change in derivative financial instruments previously reported under changes in other receivables
(The accompanying notes are an integral part of the consolidated financial statements.)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

A. General disclosures

A.1 Company information

CompuGroup Medical SE & Co. KGaA (hereinafter also referred to as “the company” or “CGM”) is a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) registered in Germany in the commercial register of the Local Court of Koblenz under HRB no. 27430. The domicile of the company is Maria Trost 21, 56070 Koblenz, Germany. The company is the parent company for these consolidated financial statements and prepares the consolidated financial statements for the smallest consolidated group. The company and its subsidiaries are also included in the consolidated financial statements of GT1 Vermögensverwaltung GmbH, which prepares the consolidated financial statements for the largest group of companies.

The purpose of the company and its main activities are divided into the following business units:

- Ambulatory Information Systems (AIS)
- Hospital Information Systems (HIS)
- Consumer and Health Management Information Systems (CHS)
- Pharmacy Information Systems (PCS)

These business units form the basis for the segment reporting. The four business units provide the following range of services:

- AIS: Develops and sells practice software solutions and renders services for registered physicians and dentists. It also renders Internet services for physicians and other healthcare professionals.
- HIS: Develops and sells clinical software solutions and renders services.
- CHS: Inter-connects service providers (physicians, dentists, clinics and pharmacies) with other key market participants in the healthcare sector, for example health insurance companies and pharmaceutical companies.
- PCS: Develops and sells software solutions and renders services for pharmacies.

For more details on the business units, please refer to section 1.1 Group business model of the management report.

A.2 Basis of reporting and fundamental principles

These consolidated financial statements combine the financial statements of CompuGroup Medical SE & Co. KGaA and those of its subsidiaries (hereinafter also referred to as "the CGM group"). As in the prior year, the CGM group's consolidated financial statements as at December 31, 2022 were prepared in accordance with section 315e of the German Commercial Code (HGB) and in compliance with the International Financial Reporting Standards (IFRS).

All International Financial Reporting Standards (IFRS) – formerly International Accounting Standards (IAS) – as well as the interpretations of the International Financial Reporting Interpretations Committee (IFRS IC) – formerly Standing Interpretations Committee (SIC) – required for the reporting period ending December 31, 2022 as applicable in the EU have been applied. How the individual standards are applied is indicated in the comments on the individual items of the consolidated financial statements.

In addition, the provisions of commercial law pursuant to section 315e German Commercial Code (HGB) have also been observed.

The Managing Directors of CompuGroup Medical Management SE prepared the consolidated financial statements on March 20, 2023 and approved them for publication.

The consolidated income statement and the consolidated statement of financial position adhere to the classification rules set out in IAS 1, whereby the income statement was prepared using the nature of expense method.

The group's accounting policy requires the individual subsidiaries to use the same accounting principles and measurement principles.

In general, the consolidated financial statements are based on cost-based measurement. Unless stated otherwise, assets and liabilities are recognized on the basis of historical cost less necessary impairment (fair value).

The estimates and assumptions used in preparing the IFRS consolidated financial statements affect the measurement of assets (in particular, goodwill and deferred tax assets) and liabilities (provisions and purchase price liabilities) as well as the disclosure of contingent assets and liabilities at the respective reporting dates and the amount of income and expenses in the reporting period. Although these assumptions and estimates have been made to the best of the Managing Directors' knowledge, the actual results may differ from these estimates.

Unless otherwise stated in individual cases, all amounts in the consolidated financial statements are given in thousands of euro (kEUR). Rounding may result in minor deviations in totals and the calculation of percentages in this report.

B. Key accounting principles and measurement methods

B.1 Principles for the preparation of the consolidated financial statements

The consolidated financial statements of CGM were prepared on the basis of historical purchase and manufacturing cost. This does not apply to certain financial instruments that are measured at the remeasured amount or fair value as at the reporting date. Corresponding information can be found in the respective accounting principles and measurement methods.

In general, historical purchase and manufacturing costs are based on the fair value of the consideration paid in exchange for the asset.

The fair value is the amount that would be received to sell an asset or paid to transfer a liability between market participants on the measurement date. It is irrelevant whether the amount can be observed on the market directly or is estimated based on the best possible measurement method.

When measuring the fair value of an asset or liability, the group takes into account certain characteristics thereof, such as the condition and location of the asset or any restrictions on the sale or use thereof, provided that the market participants would also take these characteristics into account when determining the purchase price of an asset or the transfer of a liability as at the reporting date. In these consolidated financial statements, the fair value to be used for measurement and/or the disclosure requirements is generally calculated on the basis of the principles described above. This does not apply to:

- share-based payment transactions within the scope of IFRS 2 Share-based Payment;
- leases within the scope of IFRS 16 Leases; and
- measurements similar to but not the same as the fair value. This includes, for example, net realizable value in IAS 2 Inventories or value in use in IAS 36 Impairment of Assets.

The fair value is not always based on a direct market quote; hence, it is often necessary to calculate it based on various measurement parameters. Depending on the availability of observable parameters and the relevance of these in determining the fair value as a whole, the fair value is assigned to Level 1, 2 or 3. The following factors determine the assignment to these levels:

- **Level 1 parameters:** The market value of assets and liabilities is calculated on the basis of quoted and unadjusted prices for these or identical assets and liabilities listed on active markets. Tradability on the principal or the most advantageous market on the measurement date is key.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

- **Level 2 parameters:** The market value of assets and liabilities is calculated using parameters for which either directly or indirectly derived quoted prices are available on an active market. Examples: Price quotations on non-active markets; observable interest rates and curves; implied volatilities; credit spreads and adjusted Level 1 inputs.
- **Level 3 parameters:** The market value of assets and liabilities is calculated using parameters for which no observable market data is available. Interest rates calculated using models; historical volatilities; financial forecast based on a company's own data and adjusted Level 2 input factors.

B.2 New and amended standards, applicable to financial year 2022

CompuGroup Medical SE & Co. KGaA has implemented all financial reporting standards adopted by the EU that are to be applied from January 1, 2022. New or amended standards that have been endorsed by the EU and became mandatory on January 1, 2022 are described below:

Standard (published on)	Content	Effective for financial years beginning on or after (EU)
Amendments to IFRS 3, IAS 16, IAS 37 and annual improvements to the IFRS standards 2018–2020 (May 14, 2020)	Amendments to IFRS 3 comprise references to the conceptual framework, IAS 16 deals with proceeds before intended use and IAS 37 specifies which costs an entity includes in determining the cost of fulfilling a contract for the purpose of assessing whether the contract is onerous. Amendments made within the scope of the annual improvement process comprise amendments to IFRS 1, IFRS 9, IFRS 16 and IAS 41	January 1, 2022

In all other respects, the same accounting principles and measurement methods as well as consolidation principles have been applied to prepare these consolidated financial statements and determine the prior-year figures as in the 2022 consolidated financial statements. The amendments had no material effect on consolidated earnings.

B.3 Standards, interpretations and amendments to published standards to be applied at a later date which have already been adopted into European law ("endorsement")

Standard (published on)	Content	Effective for financial years beginning on or after (EU)
Amendments to IFRS 17 Insurance contracts: Initial Application of IFRS 17 and IFRS 9 – Comparative Information (December 9, 2021)	The amendment contains an option for the first-time application of IFRS 17 with regard to comparative information in order to avoid temporary mismatches in the recognition of financial assets and liabilities from insurance contracts.	January 1, 2023
Amendments to IAS 12 Income Taxes: Deferred Tax related from a Single Transaction (May 7, 2021)	The main amendment for deferred tax relating to assets and liabilities arising from a single transaction is an additional backstop regarding IAS 12.15(b) and IAS 12.24. The amendment clarifies how entities account for deferred tax on transactions such as leases and retirement obligations.	January 1, 2023
Amendments to IAS 1 and IFRS Practice Statement 2 (February 12, 2021)	The amendments address the disclosure of significant accounting principles and measurement methods and the application of the materiality concept.	January 1, 2023
Amendments to IAS 8 (February 12, 2021)	The amendments clarify how entities should distinguish changes in accounting principles and measurement methods from changes in accounting estimates.	January 1, 2023

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Standard (published on)	Content	Effective for financial years beginning on or after (EU)
IFRS 17 (May 18, 2017), including amendments to IFRS 17 (June 25, 2020)	This standard creates a uniform international accounting standard for the insurance business. Its objective is to enhance the transparency and comparability of accounting by insurance companies.	January 1, 2023

CGM currently assumes that the adoption of the amendments will not have any significant impact on the consolidated financial statements.

B.4 Standards, interpretations and amendments to published standards to be applied at a later date which have been published by IASB, but not yet adopted into European law

IASB and IFRIC have adopted further standards and interpretations that are not yet mandatory in the EU as at January 1, 2022. The application of these IFRSs and IFRIC is still subject to endorsement by the EU.

Standard (published on)	Content	Effective for financial years beginning on or after (EU)
Amendments to IFRS 16 Leases: Lease Liability in a Sale and Leaseback (September 22, 2022)	The amendments clarify how a seller-lessee makes subsequent measurements of sale and leaseback transactions that are accounted for as a sale in accordance with IFRS 15.	January 1, 2024
Amendments to IAS 1 Presentation of Financial Statements (January 23, 2020, July 15, 2020 and October 31, 2022)	The amendments for the classification of liabilities as current or non-current only affect the presentation of liabilities in the statement of financial position - not the amount or timing of recognition of assets, liabilities, income or expenses. The IASB has decided to amend IAS 1 with respect to the classification (as current or non-current), presentation and disclosure of liabilities for which an entity's right to defer settlement for at least twelve months is conditional on the entity meeting certain conditions after the reporting period.	January 1, 2024

Early application of individual standards is permitted. CompuGroup Medical SE & Co. KGaA does not use the early application option. CompuGroup Medical SE & Co. KGaA constantly examines the effects of the first-time application of these standards and amendments.

It is not currently assumed that the adoption of the other standards, amendments and interpretations will have any significant impact on the consolidated financial statements.

C. Principles of consolidation

C.1 Date of consolidation

The group's reporting date is December 31, in line with that of the annual financial statements of the parent company and its subsidiaries.

C.2 Consolidated subsidiaries

The consolidated financial statements include the financial statements of the parent company and the companies controlled by the parent company, including their structured entities (subsidiaries), as at December 31 of each year.

The company achieves control when it:

- has power over the investee;
- is exposed to variable returns from its involvement; and
- can use its power to affect the amount of returns.

The company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three aforementioned criteria for control.

In the event that the company does not hold the majority of the voting rights, it still controls the investee if its voting rights give it the practical ability to direct the relevant activities unilaterally. When assessing whether its voting rights are sufficient to give it power, the company considers all facts and circumstances, including:

- the extent of the company's possession of voting rights relative to the extent and proportion of those held by other parties;
- the potential voting rights of the company, as well as of those held by other parties;
- rights from other contractual arrangements; and
- any additional facts and circumstances that indicate the investor has, or does not have, a present ability to direct the relevant activities at the time that decisions need to be made, including voting patterns at previous shareholders' meetings.

Consolidation of a subsidiary begins from the date the company obtains control of the subsidiary and ends when the company no longer has control of the subsidiary. The results of the subsidiaries acquired or sold during the year are recognized in the consolidated income statement as other comprehensive income from the actual acquisition date to the actual disposal date.

Profit or loss and each component of other comprehensive income are attributed to the shareholders of the parent company and to the non-controlling interests. This applies even if this results in the non-controlling interests having a deficit balance.

If necessary, the annual financial statements of the subsidiaries are adjusted so that their accounting principles and measurement methods match those of the group.

The principles of purchase accounting applied by the CGM group are as follows:

a) Changes in ownership interest held by the group in existing subsidiaries

Changes in the ownership interests in subsidiaries within the CGM group that do not trigger a loss of control over the respective subsidiary are accounted for as equity transactions. The carrying amounts of interests and non-controlling interests held by the CGM group are adjusted to reflect the changes in their relative interests in the subsidiaries. Any differences between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received are recognized directly in equity and attributed to shareholders of the parent company.

If the company loses control of a subsidiary, the deconsolidation gains or losses are recognized in profit or loss. A distinction is made between:

- the total fair value of the consideration received and the fair value of the retained interests; and
- the carrying amount of the assets (including any goodwill), the liabilities of the subsidiary and any non-controlling interests.

All amounts reported in other comprehensive income in connection with this subsidiary are accounted for as if the assets were sold, resulting in reclassification to the income statement or a direct transfer to retained earnings.

Any investment that the company retains in the former subsidiary is recognized at its fair value at the date when control is lost. This value represents the cost of the shares, which depending on the degree of control in subsequent measurement, is measured in accordance with IFRS 9 Financial Instruments: Recognition and Measurement or the regulations for associated companies or joint ventures.

b) Acquisition of subsidiaries

The CGM group accounts for the acquisition of companies and businesses using the acquisition method. Consideration transferred in a business acquisition is measured at fair value. This is calculated as the total of the fair values, as at the acquisition date, of the assets transferred and the liabilities assumed as well as the equity instruments issued by the group in exchange for obtaining control of the acquiree. Transaction costs associated with the business combination are recognized in profit or loss when incurred.

The identifiable assets acquired and liabilities assumed are measured at fair value with the following exceptions:

- deferred tax assets or deferred tax liabilities as well as assets or liabilities for employee benefits are recognized and measured in accordance with IAS 12 Income Taxes and IAS 19 Employee Benefits;
- liabilities or equity instruments based on share-based payment transactions or compensation for share-based payment transactions by the CGM group are measured in accordance with IFRS 2 Share-based Payment as at the acquisition date; and
- assets (or disposal groups) classified as held for sale are measured in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations.

Goodwill is the residual of the total amount of the consideration transferred, the amount of any non-controlling interests in the acquiree and, if available, the fair value of the equity interest in the acquiree previously held by the acquirer, less the fair value of identifiable assets acquired and liabilities assumed as at the acquisition date. If the measurement of an acquisition of a subsidiary results in negative goodwill, this is recognized immediately as income in profit and loss after a further review of all measurement methods applied for the business combination.

If there are non-controlling interests that convey ownership interests and ensure the shareholder's right to receive a pro rata share of the net assets of the entity in the event of liquidation, these interests are initially measured either at fair value or in the amount of the corresponding share of the identifiable net assets. This option can be exercised individually for each business combination. If non-controlling shareholders hold other components of interests, they are measured at fair value or by applying the requirements of other applicable standards. Liabilities from put options on non-controlling interests are initially measured at their fair value (anticipated acquisition method). As the initial recognition of these liabilities in equity has not yet been conclusively regulated, the equity share of non-controlling interests is reduced or written off regardless of the transfer of risks and rewards of ownership of the shares concerned. This also applies to a liability resulting from a forward.

If contingent consideration is a component of the consideration transferred for the acquisition of the subsidiary, this is measured at fair value as at the acquisition date. Changes arising in the fair value of the contingent consideration are adjusted retrospectively within the measurement period and offset against goodwill accordingly. Corrections to be made within the measurement period for business combinations are adjustments reflecting additional information on facts and circumstances that existed on the acquisition date, but could not yet be conclusively assessed. In principle, the measurement period must not exceed one year from the acquisition date.

Changes in the fair value of contingent consideration not measured as an adjustment during the measurement period are accounted for depending on the classification of the contingent consideration. Contingent consideration classified as equity is not remeasured on future reporting dates after initial recognition and its subsequent settlement is accounted for within equity. Contingent consideration classified as an asset or liability is measured at future reporting dates, if applicable, in accordance with IFRS 9 or IAS 37 Provisions, Contingent Liabilities and Contingent Assets. Any resulting gains or losses are recognized in profit or loss (in financial expenses/income if the contract parameters change, e.g., EBITDA, and in other expenses/income if a change results from a contractual amendment between parties).

If a business combination is achieved in stages, the equity interest that the company had previously held in the acquiree is remeasured at fair value as at the acquisition date. The resulting gains or losses are recognized in profit or loss.

Changes in the value of the equity interests held in the acquiree prior to the acquisition date to be recognized in other comprehensive income are reclassified to the income statement when the company obtains control of the acquiree.

If the first-time accounting of a business combination has not yet been completed by the end of a financial year, CGM provides preliminary values. If new information arises within the measurement period regarding circumstances as at the acquisition date, the preliminary amounts used are corrected, or if necessary, additional assets and liabilities are recognized.

The results of the subsidiaries acquired or sold during the year are included in the statement of comprehensive income from the acquisition date or until the loss of control.

Purchase price liabilities: changes due to negotiations are reported in the operating result; changes due to contractual adjustments are reported in the financial result.

c) **Goodwill**

Goodwill resulting from a business combination is initially recognized at cost which is measured as the difference between the consideration transferred and the identifiable assets and assumed liabilities. Goodwill is subsequently measured at cost less cumulative impairment losses.

For the purpose of impairment testing, goodwill is allocated to each of the cash-generating units, or groups of cash-generating units within the group that are expected to benefit from the synergies of the combination.

Cash-generating units (CGUs), to which part of goodwill has been allocated, are tested for impairment at least annually (IAS 36). If there are specific indications that a CGU is impaired, it is tested for impairment more frequently. If the recoverable amount of a cash-generating unit is less than its carrying amount, the resulting impairment loss is initially allocated to the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro rata on the basis of the carrying amount of each asset in the unit. Any impairment loss on goodwill is recognized directly in the income statement. Impairment losses recognized on goodwill cannot be reversed in future periods.

In the event of the disposal of a cash-generating unit, the goodwill attributable to it is taken into account when calculating the gain or loss on disposal.

C.3 Associated companies and joint ventures

The CGM group accounts for associated companies using the equity method. An associated company is an entity over which the group is able to exercise significant influence through participation in its financial and operating policy decisions but not control. Significant influence is presumed when the group holds 20 % or more of the voting rights, thereby establishing its status as an associated company.

A joint venture is a joint arrangement whereby the parties that share control of the arrangement hold rights to the net assets of the arrangement. Joint control is the contractually agreed sharing of control over an economic arrangement. Joint control exists only when decisions about the relevant activities require the unanimous consent of the parties that collectively control the arrangement. The results, assets and liabilities of joint ventures are included in these financial statements using the equity method.

An investment in an associated company or joint venture is accounted for using the equity method from the date on which the requirements for an associated company or joint venture are fulfilled. Any surplus of the share acquisition cost in excess of the acquired share of the fair value of the identifiable assets, liabilities and contingent liabilities is recognized as goodwill. Goodwill arising on the acquisition of an associated company or a jointly controlled entity is included in the amortized carrying amounts of the associated companies or jointly controlled entities and is not tested separately for impairment.

The regulations of IFRS 9 are applied accordingly to determine any indications requiring impairment on investments in associated companies or joint ventures. If an impairment test is to be carried out, the carrying amount of the interest (including goodwill) is tested for recoverability in accordance with IAS 36 by comparing the recoverable amount of the investment to its carrying amount. Any resulting impairment loss is offset against the carrying amount. Impairment losses are not allocated to assets, including goodwill, contained in the carrying amount of the interest. If the recoverable amount rises again in subsequent years, impairment losses are reversed in accordance with IAS 36.

The CGM group no longer uses the equity method from the date when its investment ceases to be an associated company or joint venture, or the investment can be classified as held for sale in accordance with IFRS 5. If the CGM group retains an interest in the former associated company or joint venture and this interest is a financial asset as defined by IFRS 9, this interest is measured at fair value upon initial recognition. The difference between the prior carrying amount of the associated company or the joint venture at the date the equity method ceased to be applied and the fair value of any retained investment and any proceeds from disposing of part of the interest in an associated company or joint venture is included in the calculation of the gain or loss on disposal.

Furthermore, the CGM group accounts for all amounts related to these associated companies or joint ventures previously recognized in other comprehensive income in the manner that would be required if the associated company or joint venture had sold the assets or liabilities directly. This means the CGM group reclassifies gains or losses, which the associated company or joint venture to date has recognized in other comprehensive income and then reclassified in the income statement when the assets or liabilities are sold, from equity to the income statement following the discontinuation of the equity method. In the event of a disposal of an associated company or jointly controlled entity, the attributable amount of goodwill is taken into account in determining the deconsolidation result.

If an investment changes from being an associated company to becoming a joint venture, or vice versa, the group continues to apply the equity method and does not remeasure its fair value on account of the change in investment category.

If the group's ownership interest in an associated company or a joint venture changes but the group continues to apply the equity method, the portion of the gain or loss attributable to the change in the ownership interest, which was previously recognized in other comprehensive income, is reclassified to profit or loss if this gain or loss would have to be reclassified to profit or loss upon disposal of the assets and liabilities in question.

For transactions between a CGM group company and an associated company or joint venture of the CGM group, gains and losses are eliminated to the extent of the group's portion of the corresponding associated company or joint venture.

Within the CGM group, seven associated companies and four joint ventures are accounted for using the equity method. Where necessary, the accounting principles and measurement methods for associated companies were changed to guarantee uniform accounting policies throughout the group.

C.4 Scope of consolidation

All included financial statements of the CGM group are prepared in accordance with uniform accounting policies. The consolidated financial statements are prepared at the level of CompuGroup Medical SE & Co. KGaA, Koblenz (parent company).

a) Changes to the consolidation group

In addition to CompuGroup Medical SE & Co. KGaA, the consolidated financial statements included 93 (prior year: 103) fully consolidated companies in 2022:

	Germany	Foreign countries	Total
As at January 1, 2022	33	70	103
Additions	3	3	6
Disposals / Merger	10	6	16
As at December 31, 2022	26	67	93

The disposals from the group of consolidated companies result from the intra-group mergers of MS IT-Systeme GmbH into CGM Systemhaus GmbH, the merger of VISUS IT Services GmbH into VISUS Health IT GmbH, the merger of HABA Computer AG, CGM Immobilien Stuttgart GmbH and n-design Gesellschaft für systematische Gestaltungen mbH into CompuGroup Medical Deutschland AG, the merger of Meta-it GmbH into CompuGroup Medical Software GmbH, the merger of CompuGroup Medical Managementgesellschaft mbH into CGM Clinical Deutschland GmbH, and the merger/accretion of INSIGHT Health Management GmbH, INSIGHT Health GmbH & Co. KG and GfsG Gesellschaft für statistische Gesundheitsforschung mbH into INSIGHT Health GmbH (formerly EBM Medienholding GmbH), all in Germany.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Further disposals resulted from the intra-group mergers of Small Business Computers of New England, Inc. with CompuGroup Medical Inc. in the USA, of Imagine Assistance S.a.r.l. with Imagine Editions SAS, of Aatlanta SAS with CompuGroup Medical France SAS in France, the merger of farma3tec S.r.l. with Studiofarma S.r.l., and the merger of Mondofarma S.r.l. and Vega Informatica e Farmacia S.r.l. with Pharmaone S.r.l. (formerly Qualità in Farmacia S.r.l.), all in Italy.

The additions result from the acquisitions made by the CGM group in financial year 2022 of the already merged INSIGHT Health Management GmbH, INSIGHT Health GmbH & Co. KG and GfsG Gesellschaft für statistische Gesundheitsforschung mbH, in Germany. In addition, there are the foreign acquisitions of the already merged Small Business Computers of New England, Inc. in the USA, the acquisition of 4K S.r.l. in Italy, and the new establishment of 4K Services Belgium S.a.r.l. in Belgium.

Together with other business combinations that had no impact on the consolidation group, the additions from company acquisitions shown in the table below use the values as at the acquisition date and their effects on the consolidated financial statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

b) Company acquisitions and disposals

The following table lists the business combinations that the CGM group conducted in financial year 2022 using the values as at the acquisition date and the effects on the consolidated financial statements:

kEUR	Total	Small Business Computers of New England, Inc.	INSIGHT Health group*	4K S.r.l.	Other additions
Acquisition date		2/16/2022	5/10/2022	6/1/2022	
Shares acquired in %		100%	100%	60%	
Assets acquired and liabilities assumed that were recognized as at the acquisition date					
Non-current assets	41,227	1,997	31,961	2,731	4,538
Standard and special software	14,198	587	12,847	764	0
Customer relationships	23,156	1,232	15,791	1,601	4,532
Trademark rights	405	176	0	229	0
Order backlog	1,604	0	1,604	0	0
Property and buildings	6	0	6	0	0
Other equipment, plant and office equipment	441	0	422	13	6
Right-of-use assets	756	0	756	0	0
Other non-current financial assets	651	2	535	114	0
Deferred tax assets	10	0	0	10	0
Current assets	13,928	271	10,126	3,531	0
Inventories	0	0	0	0	0
Trade receivables	8,244	54	6,335	1,855	0
Other current financial assets	211	0	0	211	0
Other current non-financial assets	368	0	295	73	0
Income tax receivables	188	0	188	0	0
Cash and cash equivalents	4,917	217	3,308	1,392	0
Non-current liabilities	1,573	0	864	709	0
Pensions	67	0	0	67	0
Liabilities to banks	19	0	0	19	0
Lease liabilities	756	0	756	0	0
Other financial liabilities	108	0	108	0	0
Deferred tax liabilities	623	0	0	623	0
Current liabilities	14,830	659	12,102	2,069	0
Contract liabilities	1,927	307	1,059	561	0
Trade payables	3,475	196	2,684	595	0
Liabilities to banks	33	0	0	33	0
Other provisions	868	0	789	79	0
Income tax liabilities	7,339	0	7,000	339	0
Other financial liabilities	400	0	0	400	0
Other non-financial liabilities	788	156	570	62	0
Net assets acquired	38,752	1,609	29,121	3,484	4,538
Purchase price paid in cash	62,799	3,929	46,344	4,294	8,232
Liabilities assumed (receivable for purchase price reimbursement)	16,022	1,402	14,500	0	120

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

kEUR	Total	Small Business Computers of New England, Inc.	INSIGHT Health group*	4K S.r.l.	Other additions
of which contingent consideration	16,022	1,402	14,500	0	120
Fair value of the equity interest in the acquiree held by acquirer immediately before the acquisition date	3,651	0	0	3,651	0
Result on disposal of investment accounted for using the equity method	-98	0	0	-98	0
Total consideration transferred	82,374	5,331	60,844	7,847	8,352
Non-controlling interests	588	0	0	588	0
Currency-related effects	169	151	0	0	18
Goodwill	44,379	3,873	31,723	4,951	3,832
Acquired cash and cash equivalents	4,917	217	3,308	1,392	0
Purchase price paid in cash	62,799	3,929	46,344	4,294	8,232
Payments for acquisitions from prior periods	6,887	0	0	0	6,887
Cash outflow for acquisitions (net)	-64,769	-3,712	-43,036	-2,902	-15,119
Effects of the acquisition on CGM's results					
Sales revenues included in the consolidated statement of comprehensive income since acquisition date	34,248	1,080	27,616	3,719	1,833
Result included in the consolidated statement of comprehensive income since acquisition date	3,388	140	2,278	584	386
Sales revenue for the financial year (notional acquisition date January 1)	55,003	1,296	41,424	6,375	5,908
Result for the financial year (notional acquisition date January 1)	5,486	168	3,417	1,001	900

- Transaction costs of kEUR 972 were recorded in connection with the acquisition of the INSIGHT Health group; the remaining transaction costs incurred for the other acquisitions are not material.

Acquisition of Small Business Computers of New England, Inc., USA

In February 2022, CompuGroup Medical, Inc. a wholly owned subsidiary of CompuGroup Holding USA, Inc. acquired 100 % of Small Business Computers of New England Inc. (hereinafter APeasy) domiciled in Manchester, USA.

APeas is a laboratory information system for anatomical pathology laboratories. Since it was established, APeas has helped over 700 pathology labs worldwide to organize data, manage workflow and generate reports for both customers and internal use.

APeasy was consolidated for the first time as at March 1, 2022. APeasy's reported revenue in 2021 amounted to approximately kEUR 1,543, and reported EBITDA came out to kEUR 767. The consideration to be paid amounted to kEUR 5,331, and the amount was paid in the amount of kEUR 3,929 as at the reporting date. The outstanding amount is recognized under purchase price liabilities.

The current assessment reports goodwill of kEUR 3,873, which is mainly attributable to the expansion of the distribution network for the AIS segment in the USA as well as to the expertise of the employees. Recognized goodwill is not deductible for income tax purposes.

The fair value of acquired intangible assets not including goodwill amounts to kEUR 1,995 and relates to customer relationships, software and trademark rights. For receivables acquired as part of the acquisition, the fair value is the carrying amount assumed as at the acquisition date based on the expected term of the receivables and the best estimate of the addition of contractual cash flows. An initial analysis of the financial information available identified no uncollectable receivables.

No contingent liabilities or contingent assets have been identified to date.

Acquisition of INSIGHT Health group, Germany

As at May 10, 2022, CompuGroup Medical Deutschland AG, a wholly owned subsidiary of CompuGroup Medical SE & Co. KGaA acquired 100 % of the shares in INSIGHT Health Management GmbH, INSIGHT Health GmbH & Co. KG and GfsG Gesellschaft für statistische Gesundheitsforschung mbH (hereinafter referred to as INSIGHT Health) domiciled in Waldems, Germany.

Founded in 1999, INSIGHT Health offers innovative solutions for market and healthcare research in the German healthcare sector, taking into account the highest level of data protection compliance. Its customers include well-known companies in the pharmaceutical industry, pharmacies, doctors' associations, health insurance companies, and scientific and political institutions.

INSIGHT Health was consolidated for the first time as at May 1, 2022. INSIGHT Health's reported revenue in 2021 amounted to approximately kEUR 36,271, and reported EBITDA came out to kEUR 5,444. The consideration to be paid amounted to kEUR 60,844, and the amount was paid in the amount of kEUR 46,344 as at the reporting date. The outstanding amount is recognized under purchase price liabilities.

The current assessment reports preliminary goodwill of kEUR 31,723, which is mainly attributable to the expansion of the distribution network for the CHS segment in Germany as well as to the expertise of the employees. In the future, recognized goodwill is deductible for income tax purposes in the amount of kEUR 45.934.

The preliminary fair value of acquired intangible assets not including goodwill amounts to kEUR 30,242 and relates to customer relationships, software and order backlog. For receivables acquired as part of the acquisition, the fair value is the carrying amount assumed as at the acquisition date based on the expected term of the receivables and the best estimate of the addition of contractual cash flows. An initial analysis of the financial information available identified no uncollectable receivables.

No contingent liabilities or contingent assets have been identified to date.

The measurement of the INSIGHT Health acquisition was performed provisionally, as the measurement of the acquired customer relationships, software and order backlog is to be regarded as not yet complete since some information has not been fully received or evaluated to date.

Acquisition of 4K S.r.l., Italy

Effective June 1, 2022, CompuGroup Medical Italia Holding S.r.l., a wholly owned subsidiary of CompuGroup Medical SE & Co. KGaA, purchased further shares (30 %) in 4K S.r.l. (hereinafter referred to as 4K), domiciled in Milan, Italy, as part of a successive share acquisition and now holds 60 % of the shares.

4K runs the on-demand pharmaceutical delivery service "Pharmap" in Italy.

4K was consolidated for the first time as at June 1, 2022. 4K's reported revenue in 2021 amounted to approximately kEUR 3,284, and reported EBITDA came out to kEUR 1,178. The total consideration to be paid was kEUR 7,847, and the amount was paid in full as at the reporting date.

The current assessment reports preliminary goodwill of kEUR 4,951, which is mainly attributable to the expansion of the distribution network for the PCS segment in Italy. Recognized goodwill is not deductible for income tax purposes.

The preliminary fair value of acquired intangible assets not including goodwill amounts to kEUR 2,594 and relates to customer relationships, software and trademark rights. Based on the identifiable net assets, non-controlling interests amount to kEUR 588. For receivables acquired as part of the acquisition, the fair value is the carrying amount assumed as at the acquisition date based on the expected term of the receivables and the best estimate of the addition of contractual cash flows. An initial analysis of the financial information available identified no uncollectable receivables.

Deferred tax liabilities of kEUR 623 are recognized on the fair value of the acquired intangible assets not including goodwill. No contingent liabilities or contingent assets have been identified to date.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The measurement of the 4K acquisition was performed provisionally, as the measurement of the acquired customer relationships, software and trademark rights is to be regarded as not yet complete since some information has not been fully received or evaluated to date.

Other additions

The remaining additions include the following business combinations:

Business combination	Acquisition date	Shares acquired in %	Description of how control was achieved	Reasons for the business combination
curacom Praxistechnik	Jan 1, 2022	n/a	Asset Deal	Extension of the customer platform in the AIS business segment in Germany and expansion of market reach
Advanced Consulting Soutions, LLC	Jun 1, 2022	n/a	Asset Deal	Extension of the customer platform in the AIS business segment in the USA and expansion of market reach
Systech Systemhaus GmbH	Jul 1, 2022	n/a	Asset Deal	Extension of the customer platform in the AIS business segment in Germany and expansion of market reach
Pre-Billing Consultants, Inc.	Aug 24, 2022	n/a	Asset Deal	Extension of the customer platform in the AIS business segment in the USA and expansion of market reach
Medicus Laboratory Information Systems	Nov 21, 2022	n/a	Asset Deal	Extension of the customer platform in the AIS business segment in the USA and expansion of market reach
Fablab S.r.l.	Jan 1, 2019	100%	Purchase price payment in 2022 resulting from the acquisition of 100 % of the shares in 2019	Extension of the customer platform in the CHS business segment in Italy and expansion of market reach
Meta-it GmbH	Jun 1, 2021	100%	Purchase price payment in 2022 resulting from the acquisition of 100 % of the shares in 2021	Extension of the customer platform in the HIS business segment in Germany and establishment of a strong sales and service structure
HABA Computer AG	Sep 30, 2017	100%	Payment of the outstanding price resulting from squeeze-out of outstanding shares in 2021	Extension of the customer platform in the CHS business segment in Germany and expansion of market reach
Innomed Gesellschaft für medizinische Softwareanwendungen GmbH	Nov 20, 2009	90%	Payment of price to exercise a put option for the acquisition of a further 9.9% of the shares in 2022	Extension of the customer platform in the AIS business segment in Austria and establishment of a strong sales and service structure
Barista Software BVBA	Aug 15, 2017	100%	Annual payment of the price of contingent consideration in the form of an earn-out agreement resulting from the acquisition of 100 % of shares in 2017	Extension of the customer platform in the AIS business segment in Belgium and expansion of market reach

Acquisition of the assets of curacom Praxistechnik, Germany

In a business combination, MS IT-Systeme GmbH, a wholly owned subsidiary of CGM Systemhaus GmbH, acquired the business operations of curacom Praxistechnik (hereinafter curacom) effective from January 1, 2022, based on the transfer of net assets (asset deal).

Curacom supports its medical sector customers with eHealth IT products comprising in particular TURBOMED, which is an information system for physicians, as well as CGM-TI and medical technology products.

The business unit was included in the consolidated financial statements for the first time as at January 1, 2022. curacom's reported revenue in 2021 amounted to approximately kEUR 753, and reported EBITDA came out to kEUR 186. Total consideration to be paid amounts to kEUR 401, and an amount of kEUR 281 was paid in as at the reporting date. The outstanding amount is recognized under purchase price liabilities.

Net assets acquired amount to kEUR 206. The current assessment computes goodwill of kEUR 195, which is attributable in particular to the expansion of distribution channels and the associated upselling opportunities in the AIS business in Germany. Recognized goodwill will be deductible for income tax purposes in the future.

The fair value of acquired intangible assets not including goodwill amounts to kEUR 200 and relates to customer relationships. No contingent liabilities or contingent assets have been identified to date.

Acquisition of the assets of Advanced Consulting Solutions, LLC, USA

In a business combination, CompuGroup Medical, Inc. a wholly owned subsidiary of CompuGroup Medical Holding USA, Inc. acquired the business operations of Advanced Consulting Solutions, LLC (hereinafter ACS) as at June 1, 2022, based on the transfer of net assets (asset deal).

ACS specializes in supporting healthcare providers to obtain maximum reimbursement for their claims. The company's concepts connect and synchronize clinical, administrative, and revenue solutions across all practice areas.

The business unit was included in the consolidated financial statements for the first time as at June 1, 2022. ACS's reported revenue in 2021 amounted to approximately kEUR 640, and reported EBITDA came out to kEUR 340. The total consideration to be paid was kEUR 1,699, and the amount was paid in full as at the reporting date.

Net assets acquired amount to kEUR 939. The current assessment computes preliminary goodwill of kEUR 768, which is attributable in particular to the expansion of distribution channels in the AIS business in the USA. Recognized goodwill will be deductible for income tax purposes in the future.

The preliminary fair value of acquired intangible assets not including goodwill amounts to kEUR 939 and relates to customer relationships. No contingent liabilities or contingent assets have been identified to date.

The measurement of the ACS asset deal was performed provisionally, as the measurement of the acquired customer relationships is to be regarded as not yet complete since some information has not been fully received or evaluated to date.

Acquisition of assets of Systech Systemhaus GmbH, Germany

In a business combination, CGM Systemhaus GmbH, a wholly owned subsidiary of CompuGroup Medical Deutschland AG, acquired the business operations of Systech Systemhaus GmbH (hereinafter Systech) effective from July 1, 2022, by means of the transfer of net assets (asset deal).

Systech supports its medical sector customers with eHealth IT products comprising in particular Turbomed, which is an information system for physicians, as well as CGM-TI and medical technology products.

The business unit was included in the consolidated financial statements for the first time as at July 1, 2022. Its reported revenue in 2021 amounted to approximately kEUR 477, and reported EBITDA came out to kEUR 107. The total consideration to be paid was kEUR 93, and the amount was paid in full as at the reporting date.

The current assessment computes preliminary goodwill of kEUR 93, which is attributable in particular to the expansion of distribution channels in the AIS business in Germany. Recognized goodwill will be deductible for income tax purposes in the future.

No contingent liabilities or contingent assets have been identified to date.

The measurement of the Systech asset deal was performed provisionally, as the measurement is to be regarded as not yet complete since some information has not been fully received or evaluated to date.

Acquisition of assets of Pre-Billing Consultants, Inc., USA

In a business combination, eMDs, Inc., a wholly owned subsidiary of eMDs Holding Inc., acquired the business operations of Pre-Billing Consultants, Inc. (hereinafter PBC) effective from August 24, 2022, by means of the transfer of net assets (asset deal).

PBC is a small Revenue Cycle Management (RCM) provider domiciled in New Jersey with a strong regional presence in the north eastern parts of the US. PBC has been providing billing, coding, licensing and IT consulting services to hospitals and physicians for nearly two decades.

The business unit was included in the consolidated financial statements for the first time as at September 1, 2022. PBC's reported revenue in 2021 amounted to approximately kEUR 1,856, and reported EBITDA came out to kEUR -25. The total consideration to be paid was kEUR 2,375, and the amount was paid in full as at the reporting date.

Net assets acquired amount to kEUR 1,225. The current assessment computes preliminary goodwill of kEUR 1,002, which is attributable in particular to the expansion of distribution channels in the AIS business in the USA. Recognized goodwill will be deductible for income tax purposes in the future.

The preliminary fair value of acquired intangible assets not including goodwill amounts to kEUR 1,225 and relates to customer relationships. No contingent liabilities or contingent assets have been identified to date.

The measurement of the PBC asset deal was performed provisionally, as the measurement of the acquired customer relationships is to be regarded as not yet complete since some information has not been fully received or evaluated to date.

Acquisition of assets of Medicus Laboratory Information Systems, USA

In a business combination, CompuGroup Medical, Inc. a wholly owned subsidiary of CompuGroup Medical Holding USA, Inc. acquired the business operations of Medicus Laboratory Information Systems (hereinafter Medicus LIS) as at November 22, 2022, by means of the transfer of net assets (asset deal).

Medicus LIS domiciled in Weston, Florida has been a known and trusted brand for more than 15 years in developing laboratory management software for medical laboratories within the non-acute US market. With all the tools needed to manage testing, specimen processing, compliance requirements and sending patient lab results to the medical provider, Medicus LIS has been installed in more than 1,000 laboratories across the United States.

The business unit was included in the consolidated financial statements for the first time as at December 1, 2022. Its reported revenue in 2021 amounted to approximately kEUR 1,899, and reported EBITDA came out to kEUR 150. The total consideration to be paid was kEUR 3,784, and the amount was paid in full as at the reporting date.

Net assets acquired amount to kEUR 2,168. The current assessment computes preliminary goodwill of kEUR 1,774, which is attributable in particular to the expansion of distribution channels in the AIS business in the USA. Recognized goodwill will be deductible for income tax purposes in the future.

The preliminary fair value of acquired intangible assets not including goodwill amounts to kEUR 2,168 and relates to customer relationships. No contingent liabilities or contingent assets have been identified to date.

The measurement of the Medicus LIS asset deal was performed provisionally, as the measurement of the acquired customer relationships is to be regarded as not yet complete since some information has not been fully received or evaluated to date.

Acquisition of Fablab S.r.l., Italy

In 2022, kEUR 2,590 of the contingent consideration was paid, resulting from the acquisition of 100 % of the shares in Fablab S.r.l. in 2019.

Acquisition of Meta-it GmbH, Germany

In the first half of 2022, current purchase price liabilities of kEUR 750 were paid, resulting from the acquisition of 100 % of the shares in Meta-it GmbH in 2021.

Acquisition of HABA Computer AG, Germany

In the first half of 2022, current purchase price liabilities of kEUR 80 were paid, resulting from the squeeze-out acquisition of the shares in HABA Computer AG (2 %) in 2021.

Acquisition of Innomed Gesellschaft für medizinische Softwareanwendungen GmbH, Austria

In 2022, CGM paid current purchase price liabilities of kEUR 2,778 that resulted from the exercise of the put option on the part of the non-controlling shareholders for 9.9 % of the shares in Innomed Gesellschaft für medizinische Softwareanwendungen GmbH. The exercise price is based on clearly defined revenue amounts.

Acquisition of Barista Software BVBA, Belgium

In 2017, CompuGroup Medical Belgium BVBA, a subsidiary of CompuGroup Medical SE & Co. KGaA (99 %) and of CompuGroup Medical Deutschland AG (1 %), acquired 100 % of the shares in Barista Software BVBA, domiciled in Hasselt, Belgium. In addition to the initially agreed fixed purchase price, which had been paid out as at December 31, 2017, contingent considerations in the form of earn-outs were agreed in the purchase agreement. These provide for an additional annual purchase price payment, which is calculated on the basis of fixed revenue figures in the years post completion. In 2022, a final purchase price payment of kEUR 559 was made for financial year 2021.

Change in purchase price allocation

Purchase price allocation for the acquisition of the VISUS group in Germany and Switzerland in 2021 was completed in 2022. This resulted in the following changes to purchase price allocation:

VISUS group in kEUR	Before change of purchase price allocation	Change of purchase price allocation	After change of purchase price allocation
Non-current assets	33,626	0	33,626
Current assets	8,302	63	8,365
Non-current liabilities	14,062	0	14,062
Current liabilities	9,182	793	9,975
Net equity acquired	18,684	-730	17,954
Total consideration transferred	50,693	0	50,693
Goodwill	32,009	730	32,739

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

c) Subsidiaries included in the scope of consolidation

Company name	Participation held by	Registered Office	Equity voting rights in %
Vollkonsolidierte Beteiligungen			
Participations in the region Germany			
1 AESCU DATA Gesellschaft für Datenverarbeitung mbH	10	Hamburg	100
2 CompuGroup Medical Deutschland AG		Koblenz	100
3 CompuGroup Medical Dentalsysteme GmbH	16	Koblenz	100
4 docmetric GmbH	5	Koblenz	100
5 ifap Service Institut für Ärzte und Apotheker GmbH		Martinsried	100
6 Intermedix Deutschland GmbH	3	Koblenz	100
7 IS Informatik Systeme Gesellschaft für Informationstechnik mbH	8	Koblenz	100
8 LAUER-FISCHER GmbH		Fürth	100
9 CGM IT Solutions und Services GmbH	2	Koblenz	100
10 CGM Clinical Deutschland GmbH		Koblenz	100
11 CGM Systemhaus GmbH (vormals: Turbomed Vertriebs- und Service GmbH)	2	Koblenz	100
12 CGM Mobile Software GmbH	2	Koblenz	100
13 Meditec Marketingservices im Gesundheitswesen GmbH	2	Koblenz	100
14 KoCo Connector GmbH		Berlin	100
15 CompuGroup Medical Mobile GmbH	5	Koblenz	100
16 CGM LAB International GmbH		Koblenz	100
17 CGM LAB Deutschland GmbH	16	Koblenz	100
18 CGM Mobile Services GmbH	20	Koblenz	100
19 LAUER-FISCHER ApothekenService GmbH	9	Koblenz	100
20 CompuGroup Medical Software GmbH	2	Koblenz	100
21 La-Well Systems GmbH	20	Bünde	100
22 factis GmbH	10	Freiburg im Breisgau	100
23 CGM Clinical Europe GmbH	28	Koblenz	100
24 KMS Vertrieb und Services GmbH	10	Unterhaching	100
25 VISUS Health IT GmbH	10	Bochum	100
26 INSIGHT Health GmbH (vormals: EBM Medienholding GmbH)	2	Waldems-Esch	100
Participations in the region Western Europe			
27 AESCU DATA Gesellschaft für Datenverarbeitung mbH AT	1	Steyr/Austria	100
28 CompuGroup Medical CEE GmbH		Vienna/Austria	100
29 CGM Arztsysteme Österreich GmbH	28	Wiener Neudorf/Austria	100
30 HCS Health Communication Service Gesellschaft m.b.H.	28	Steyr/Austria	100
31 INNOMED Gesellschaft für medizinische Softwareanwendungen GmbH	28	Wiener Neudorf/Austria	90
32 Intermedix Österreich GmbH	28	Wiener Neudorf/Austria	100
33 CGM Clinical Österreich GmbH	28	Steyr/Austria	100
34 VISUS IT Solutions AG	25	Zürich/ Switzerland	100
35 CompuGroup Medical Schweiz AG	28	Bern/Schweiz	100
36 CompuGroup Medical Norway AS	37	Lysaker/Norway	100
37 Profdoc AS		Lysaker/Norway	100
38 CompuGroup Medical Sweden AB	37	Solna/Sweden	100

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Company name		Participation held by	Registered Office	Equity voting rights in %
39	Lorensbergs Communication AB	40	Gothenburg/Sweden	100
40	Lorensbergs Holding AB	37	Gothenburg/Sweden	100
41	CompuGroup Medical LAB AB	38	Borlänge/Schweden	100
42	CompuGroup Medical Denmark A/S	37	Aarhus/Denmark	100
43	CompuGroup Medical Belgium BVBA	b)	Wetteren/Belgium	100
44	CompuGroup Medical Holding Coöperatief U.A.	c)	Echt/Netherlands	100
45	CompuGroup Medical Nederland B.V.	44	Echt/Netherlands	100
46	Qualizorg B.V.	44	Deventer/Netherlands	100
47	Portavita B.V.	44	Amsterdam/Netherlands	100
48	MGRID B.V.	44	Amsterdam/Netherlands	100
49	Compufit BVBA	43	Ostend / Belgium	100
50	Barista Software BVBA	43	Hasselt / Belgium	100
51	ATX Advanced Technology Explained NV	43	Wetteren/Belgium	100
52	Titanium Dental BV	43	Wetteren/Belgium	100
53	CGM LAB Belgium SA	d)	Barchon/Belgium	100
54	CompuGroup Medical UK Limited		London/United Kingdom	100
55	EPSILOG SAS	56	Castries/France	100
56	MB Invest SAS		Aix-en-Provence/France	100
57	CompuGroup Medical Solutions SAS	64	Montpellier/ France	100
58	Intermedix France SAS	64	Nanterre/France	100
59	CompuGroup Medical France SAS		Nanterre/France	100
60	Imagine Editions SAS		Soulac sur mer/France	100
61	CGM LAB France SAS	16	Nanterre/France	100
62	Aatlantide SAS		Meylan/ France	100
63	ADD-LIB SAS		Meylan/ France	100
64	UCF Holding S.a.r.l.	2	Luxembourg/Luxembourg	100
65	CompuGroup Medical Italia SpA		Molfetta/Italy	100
66	CompuGroup Medical Italia Holding S.r.l.	2	Milan/Italy	100
67	CGM XDENT Software S.r.l.	65	Ragusa/Italy	100
68	Studiofarma S.r.l.	66	Milan/Italy	100
69	Pharmaone S.r.l. (vormals: Qualità in Farmacia S.r.l.)	66	Novara/Italy	100
70	Farloyalty s.r.l.	68	Milan/Italy	51
71	Medicitalia S.r.l.	65	Milan/Italy	100
72	Smooove Software S.r.l.	69	Milan/Italy	53
73	Fablab S.r.l.	65	Milan/Italy	100
74	H&S Qualità nel Software S.p.A.	66	Milan/Italy	100
75	4K S.r.l.	66	Milan/Italy	60
76	4K Services Belgium S.a.r.l.	75	Bruxelles/Belgium	100
77	CGM Clinical España, S.L.	28	Madrid/Spain	100
78	Medigest Consultores S.L.		Madrid/Spain	100
Participations in the region Eastern Europe				
79	CompuGroup Medical Polska Sp. z o.o.		Lublin/Poland	100

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Company name		Participation held by	Registered Office	Equity voting rights in %
80	CompuGroup Medical Česká republika s.r.o.	a)	Prague/Czech Republic	100
81	Intermedix Česká republika s.r.o.	80	Prague/Czech Republic	100
82	CGM Software RO SRL	g)	Iasi/Romania	100
83	Portavita LLC	47	Innopolis, Tatarstan/Russia	100
84	CompuGroup Medical Slovensko s.r.o.	80	Bratislava/Slovakia	100
Participations in the region North America				
85	CompuGroup Holding USA, Inc.		Delaware/USA	100
86	CompuGroup Medical, Inc.	85	Delaware/USA	100
87	MDeverywhere Midco Inc.	85	Austin/USA	100
88	eMDs Holding Inc.	87	Austin/USA	100
89	eMDs Inc.	88	Austin/USA	100
Participations in the region Rest of the World				
90	CompuGroup Medical South Africa (Pty) Ltd.	f)	Cape Town/South Africa	100
91	Intermedix SA (PTY) LTD	90	Cape Town/South Africa	100
92	MDeverywhere India Pvt. Ltd	i)	Noida/India	100
93	CompuGroup Medical Bilgi Sistemleri A.S.	e)	Istanbul/Turkey	100
At Equity bilanzierte Beteiligungen				
Joint Ventures				
94	MGS Meine Gesundheit Services GmbH	15	Koblenz	38
95	Solvena GmbH	26	Vienna/ Austria	51
96	Mediaface GmbH		Reinbek	49
97	Secure Farma DB S.r.l.	68	Anagni/Italy	60
Associated companies				
98	AxiService Nice S.a.r.l.	64	Nice/France	28
99	Technosante Nord-Picardie SAS	64	Lille/France	20
100	R56+ Regionalmarketing GmbH & Co. KGaA		Koblenz	19
101	R56+ Management GmbH	h)	Koblenz	20
102	MedEcon Telemedizin GmbH	25	Bochum	25
103	Better@Home Service GmbH	5	Berlin	25
104	New Line Ricerche di Mercato Società Benefit S.p.A.	66	Milan/Italy	20
at cost bilanzierte Beteiligungen				
Other participations				
105	AES Ärzteservice Schwaben GmbH	2	Neckarsulm	10
106	ic med EDV-Systemlösungen für die Medizin GmbH	2	Halle	10
107	Savoie Micro S.a.r.l.	64	Meythet/France	10
108	Technosante Toulouse S.A.S.	64	Toulouse/France	10
109	Daisy-NET S.c.a r.l.	65	Bari/Italy	1
110	Practice Perfect Medical Software (PTY) Limited	90	Hillcrest/South Africa	15

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Company name		Participation held by	Registered Office	Equity voting rights in %
111	Conai System	68	Rome/Italy	0
112	DrugAgency a.s.	80	Praha/Czech Republic	10
113	Bochum Marketing GmbH	25	Bochum	0
114	Qurasoft GmbH	5	Koblenz	15
115	scanacs GmbH	2	Dresden	15

C.5 Debt consolidation

Receivables, liabilities and provisions between the companies included in the consolidated financial statements were offset against each other.

C.6 Consolidation of results

Internal revenues between the consolidated companies were offset against the expenses attributable to them. Other income (including investment income) was offset against the corresponding expenses with the recipient of the services. Intercompany profits from goods and services within the group were eliminated.

C.7 Foreign currency translation

When preparing the financial statements of each individual group company, transactions denominated in currencies other than the respective functional currency of the company are translated at the exchange rates prevailing on the date of the transaction. The functional currency is usually the respective national currency equal to that of the primary business environment. At each reporting date, monetary items in foreign currencies are converted to the currency of the report (euro) using the effective closing rate. Non-monetary items denominated in foreign currencies, which are measured at fair value, are converted at the rates effective at the date on which the fair value was established. Non-monetary items measured at cost are translated at the exchange rate as at the date of their initial recognition.

Exchange differences on monetary items are recognized through profit or loss in the period in which they occur. This does not apply to:

- exchange differences resulting from borrowings denominated in foreign currencies that arise on assets intended for productive use during the production process. These differences are attributed to manufacturing costs if they represent adjustments to the interest paid on borrowings denominated in foreign currency. Such exchange differences had no effect on these consolidated financial statements of CGM, as there were no such circumstances at CGM;
- exchange differences from transactions that were entered into to hedge against certain foreign currency risks.,
- exchange differences from monetary items retained from or payable to a foreign business whose performance is neither planned nor likely to occur and which are thus part of the net investment in that foreign business, that were initially recognized in other comprehensive income and are reclassified to the income statement on the disposal of equity.

When preparing the consolidated financial statements, the assets and liabilities of the affiliated foreign currency operations are converted into euro (EUR) using the exchange rates prevailing as at the reporting date. Income and expenses are translated at the average rate for the period. Strong fluctuations in foreign currencies, which would trigger a translation of income and expenses at the time of a transaction, are not material to these consolidated financial statements. Equity is translated at historic rates.

In the event of a disposal of a foreign business, all accumulated exchange differences attributable to the group recognized in other comprehensive income from this business are reclassified to the income statement. The following transactions are regarded as disposals of foreign business:

- the disposal of the whole group's interest in a foreign business;
- a partial disposal with the loss of control over a foreign subsidiary; or
- a partial disposal of an investment in a joint arrangement or an associated company, which includes a foreign business.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

If parts of a subsidiary are disposed of and those parts include a foreign business without causing a loss of control, the percentage of the amount of exchange differences attributable to the portion disposed of is allocated to non-controlling interests at the time of disposal.

Both goodwill resulting from the acquisition of a foreign business and adjustments to the fair values of identifiable assets and liabilities are treated as assets and liabilities from the foreign business and are translated at the closing rate. The resulting exchange differences are recognized in the currency translation reserve (other comprehensive income).

The following table provides information on the exchange rates of the (essential) currencies used within the CGM group:

1 Euro corresponds to	Closing rates		Average rates Jan 1 - Dec 31	
	Dec 31, 2022	Dec 31, 2021	2022	2021
Switzerland (CHF)	0.98	1.03	1.00	1.08
Czech Republic (CZK)	24.12	24.86	24.57	25.64
Denmark (DKK)	7.44	7.44	7.44	7.44
Great Britain (GBP)	0.89	0.84	0.85	0.86
Norway (NOK)	10.51	9.99	10.10	10.16
Poland (PLN)	4.68	4.60	4.69	4.57
Romania (RON)	4.95	4.95	4.93	4.92
Sweden (SEK)	11.12	10.25	10.63	10.15
Turkey (TRY)	19.96	15.23	17.41	10.51
USA (USD)	1.07	1.13	1.05	1.18
South Africa (ZAR)	18.10	18.06	17.21	17.48
India (INR)	88.17	84.23	82.69	87.44
Russia (RUB)	117.20	85.30	88.40	87.15

D. Summary of the principal accounting and measurement methods and underlying assumptions

Individual items on the statement of financial position and the income statement are summarized and are reported and explained separately in the notes. The items on the statement of financial position are classified as current and non-current items, with non-current items being those expected to be realized after more than twelve months or not within an ordinary business cycle. Deferred taxes are generally classified as non-current items.

D.1 Intangible assets

a) Intangible assets acquired separately and as part of a business combination

CGM recognizes intangible assets with a definite useful life that were acquired separately and not as part of a business combination at cost less accumulated amortization and impairment. Amortization is recognized in profit or loss on a straight-line basis over the expected useful life of the asset. Both the expected useful life and the amortization method are reviewed at the end of each reporting period. All changes resulting from reassessments are taken into account prospectively.

If CGM acquires intangible assets with an indefinite useful life separately, these are recognized at cost less accumulated impairment.

Currently, CGM does not own any separately acquired assets with indefinite useful lives.

Intangible assets acquired as part of a business combination are recognized separately from goodwill and measured at fair value at the acquisition date. Amortization is recognized in profit or loss on a straight-line basis over the expected useful life of the asset. Both the expected useful life and the amortization method are reviewed at the end of each reporting period. All changes resulting from reassessments are taken into account prospectively.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The following useful lives are assumed for the amortization of intangible assets:

	Useful life in years
Acquired software	2 - 15
Customer relationships	10 - 30
Brands	1 - 20
Order backlogs	1 - 3

Amortization as well as any impairment losses and reversals of impairment losses on intangible assets are recognized in the income statement under Amortization of intangible assets.

The majority of the intangible assets reported in the statement of financial position derive from company acquisitions. Currently, with the exception of goodwill, CGM has no assets with indefinite useful lives acquired as part of a business combination.

b) Internally generated software

Costs directly allocated to research activities are recognized as expenses in the period in which they are incurred.

Internally generated intangible assets resulting from development activities or the development phase of an internal software development project are recognized (capitalized) if all the following conditions have been fulfilled:

- Completion of the intangible asset is technically feasible so that it will be available for use or sale.
- There is an intention to complete the intangible asset and to use or sell it.
- The ability to use or sell the intangible asset is present.
- The intangible asset is expected to generate future economic benefit.
- Suitable technical, financial and other resources are available to complete the development and to use or sell the intangible asset.
- The expenses allocated to the development of the intangible asset can be reliably determined (e.g., by means of project-specific time sheets).

An internally generated intangible asset is capitalized for the first time at the amount of the expenses accrued from the date when the intangible asset first fulfils the above conditions. As long as an internally generated intangible asset cannot be capitalized or an intangible asset does not yet exist, development costs are recognized in profit or loss in the period in which they are incurred.

Recognized internally generated intangible assets are measured in subsequent periods at cost less accumulated amortization and impairment losses, in the same way as acquired intangible assets.

Borrowing costs directly attributable to software development (qualifying asset) are capitalized as part of the cost of that asset until all work to prepare the asset for its intended use or sale has essentially been completed.

Internally generated intangible assets (usually software) are amortized on a straight-line basis over their expected useful lives (two to fifteen years). Intangible assets not yet completed are tested annually for impairment. If required, impairment is then recognized.

c) Goodwill

Goodwill is not subject to planned amortization, but is tested annually for impairment on December 31. Goodwill arising from a business combination is recognized at acquisition cost less accumulated impairment.

For the purpose of impairment testing, goodwill upon acquisition is allocated to those cash-generating units (or groups thereof) of the CGM group that are expected to benefit from the synergies generated by the business combination.

Goodwill is allocated to the individual cash-generating units or groups of cash-generating units for which synergies are expected to arise. Since the completion of the transformation of legal form in June 2020, the CGM group has monitored the recoverability of goodwill at the level of the reportable segments. No impaired goodwill was identified in this context.

The recoverable amount is the higher of the two values: the value in use and the fair value less costs to sell. To determine the recoverable amount, the company calculates the value in use of the cash-generating units using a discounted cash flow method (DCF). A subsequent reversal of an impairment loss on goodwill recognized in prior financial years on the grounds that the reasons no longer exist is not permitted.

Even if the recoverable amount exceeds the carrying amount of the CGU to which the goodwill is allocated in future periods, no reversals of impairment losses on goodwill are recognized. Impairment of goodwill is recognized in the income statement under Amortization of intangible assets.

The accounting policy for goodwill arising from the acquisition of an associated company is described under C.3. Associated companies and joint ventures.

d) Impairment of property, plant, and equipment and intangible assets (not including goodwill)

At the end of each reporting period, the group reviews the carrying amounts of its property, plant and equipment and intangible (depreciable) assets to determine whether there is any indication that those assets may be impaired. If there are any such indications, the recoverable amount of the asset is determined in order to assess the extent of the potential impairment loss. If the recoverable amount cannot be determined for the individual asset, the recoverable amount is estimated at the level of the cash-generating unit to which the asset belongs. This also applies if there are indications of an impairment.

The recoverable amount is the higher of value in use and fair value less costs to sell. When determining the value in use, the estimated future cash flows are discounted to their present value using the current market interest rate.

If the estimated recoverable amount of an asset (or cash-generating unit) is lower than its carrying amount, the carrying amount of the asset (cash-generating unit) is reduced to its recoverable amount. The impairment is recognized immediately in profit or loss.

If an impairment is subsequently reversed, the carrying amount of the asset (or cash-generating unit) is increased to its revised estimated recoverable amount.

The increase in the carrying amount is limited to the value that would have been determined if no impairment had been recognized for the asset (cash-generating unit) in prior years. A reversal of the impairment is recognized immediately in profit or loss.

e) Derecognition of intangible assets

Intangible assets are derecognized upon disposal or when no further economic benefits are expected from its use or disposal. The gain or loss arising on derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in the income statement when the asset is derecognized. They are reported under „Other income“ or „Other expenses“.

D.2 Property, plant and equipment

a) Office building and property

Land and buildings held for use in production or supply of goods or provision of services or for administrative purposes are carried at amortized cost less accumulated planned depreciation and accumulated impairment. The cost also includes interest on borrowings eligible for capitalization.

Land and buildings intended for use in production or supply of goods or provision of services or for administrative purposes and are under construction are carried at amortized cost less any impairment losses recognized. Borrowing costs directly attributable to the acquisition, construction or production of a qualifying asset are capitalized as part of the cost of that asset until all work to prepare the asset for its intended use or sale has essentially been completed. Depreciation of these assets begins on the same basis as for other buildings when the asset is ready for use. Property is not subject to planned depreciation. Subsequent expenses are capitalized only if it is probable that the group can obtain the future economic benefits associated with the expenses.

The estimated useful life for the current year and comparative years of significant property, plant and equipment: buildings: up to 60 years.

Depreciation is calculated to allocate the cost of property, plant and equipment, less their estimated residual values, on a straight-line basis over the period of their estimated useful lives. Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if necessary.

b) Other equipment, operating and office equipment

Other fixed assets and office equipment are carried at cost less accumulated depreciation and recognized impairment.

Depreciation is calculated using the straight-line method with the costs or fair value being allocated to the residual carrying amount over the expected useful life of the assets. Expected useful lives, residual values and depreciation methods are reviewed at each reporting date and adjusted if necessary. All changes resulting from reassessments are taken into account prospectively. Depreciation of property, plant and equipment is based on useful lives of 3 to 21 years.

Depreciation and recognized impairment losses and reversals of impairment losses on property, plant and equipment are recognized in the income statement under Depreciation of property, plant and equipment and right-of-use assets.

D.3 Investments in companies accounted for using the equity method

Investments in companies accounted for using the equity method include associated companies and joint ventures.

a) Associated companies

Associated companies are accounted for using the equity method in accordance with IAS 28 Investments in Associates and Joint Ventures.

They are recognized at cost at the acquisition date. The carrying amounts of joint ventures also include goodwill identified at the acquisition date less impairment. Dividend payments from joint ventures are recognized directly in equity in the year of the dividend distribution, thereby reducing the carrying amount of the investment. The company's share in an associated company's profit or loss is recognized as profit or loss in the respective period.

If the group's share of losses in an associated company equals or exceeds its interest in the associated company, including other unsecured receivables, the group does not recognize further losses unless it has incurred obligations or made payments on behalf of the associated company.

Impairment tests are carried out whenever a triggering event occurs (in particular, conspicuous changes in results).

b) Joint ventures

Joint ventures are also accounted for using the equity method in accordance with IAS 28 Investments in Associates and Joint Ventures. They are classified as joint ventures in accordance with the criteria of IFRS 11 Joint Arrangements.

They are recognized at cost at the acquisition date. The carrying amounts of joint ventures also include goodwill identified at the acquisition date less impairment. Dividend payments from joint ventures are recognized directly in equity in the year of the dividend distribution, thereby reducing the carrying amount of the investment.

If the group's share of losses in a joint venture equals or exceeds its interest in this company, including other unsecured receivables, the group does not recognize further losses unless it has incurred obligations or made payments on behalf of the joint venture.

Impairment tests are carried out whenever a triggering event occurs (in particular, conspicuous changes in results).

D.4 Financial assets

a) Classification

The CGM group classifies its financial assets in the following categories: measured at amortized cost (AC) and measured at fair value through profit or loss (FVtPL). The classification depends on the company's business model with regard to the management of financial assets and on the contractual cash flows. The management of the CGM group determines the classification of financial liabilities upon initial recognition.

Measurement of a financial asset at amortized cost

A financial asset is measured at amortized cost if both of the following conditions are met:

- the financial asset is held using a business model that aims to hold financial assets to collect contractual cash flows; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely repayments of principal and interest on the principal outstanding.

Measurement of a financial asset at fair value through profit or loss

A financial asset that is not measured at amortized cost (AC) or at fair value through other comprehensive income (FVOCI) is measured at fair value through profit or loss (FVtPL). Financial assets at fair value through profit or loss also include investments in equity instruments held for trading and investments in equity instruments for which the company has chosen not to recognize changes in fair value in other comprehensive income.

b) Recognition and measurement

A regular purchase or sale of a financial asset is recognized on the trade date – the date on which the group commits to purchase or sell the asset.

Financial assets with the exception of trade receivables, which are accounted at transaction price, are measured at fair value upon initial recognition. Financial assets in the AC measurement category are recognized including any applicable transaction costs. The transaction costs of financial assets measured at fair value through profit or loss are recognized in the income statement. Subsequent measurement of financial assets is based on the measurement methods described under a).

c) Impairment of financial assets

The CGM group has three types of financial assets that are subject to the model of expected credit losses:

- trade receivables;
- contract assets; and
- receivables from finance lease contracts

For further information on the impairment of financial assets to which the group is exposed, see note G. 6. Credit risk.

d) Derecognition of financial assets

The CGM group derecognizes a financial asset only when the contractual right to receive cash flows from the financial asset expires or if the group transfers the financial asset.

e) Offsetting financial instruments

Financial assets and liabilities are offset and disclosed as a net amount in the consolidated statement of financial position when there is a legally enforceable right to offset the recognized amounts against each other and there is an intention either to settle on a net basis, or to realize the asset and settle the liability simultaneously. There were no material transactions as at the reporting date.

D.5 Inventories

Inventories are measured at the lower of cost and net realizable value. The costs of conversion include direct material costs and, if applicable, direct production costs as well as production overheads. The values are calculated using either the weighted average cost formula or the first-in-first-out (FIFO) formula. Net realizable value represents the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution. Impairments and reversals are recognized as a measurement adjustment in the costs of goods and services sold.

D.6 Trade receivables

Trade receivables are amounts owed by customers for goods sold or services rendered in the ordinary course of business. They are generally payable within 14 days and are therefore classified as current assets.

Trade receivables are initially recognized at the amount of the unconditional consideration. If they contain significant financing components, they must instead be recognized at fair value. These do not exist in the CGM group.

The group holds trade receivables in order to collect the contractual cash flows and subsequently measures them at amortized cost using the effective interest method. For further information on the impairment of trade receivables to which the group is exposed, see note G.6. Credit risk.

D.7 Cash and bank deposits

Cash and bank deposits are measured at cost. They comprise cash at hand, bank deposits available on call and other current, highly liquid financial assets with a maturity of three months or less at the time of acquisition. Where the group holds a significant amount of cash and cash equivalents that are not at the group's disposal, a disclosure is made. Cash and cash equivalents are also subject to the impairment provisions of IFRS 9, but the impairment loss identified was immaterial and therefore not recognized.

D.8 Equity

If equity instruments exist, they are recognized in the amount of issue proceeds less any directly attributable issue costs. Issue costs include costs that would not have been incurred if the equity instrument had not been issued.

Shares that are bought back by the CGM group (treasury shares) are deducted directly from equity. There is no recognition in the income statement from the acquisition, sale, issue or redemption of own equity instruments. Any consideration paid or received is recognized directly in equity.

D.9 Accumulated other comprehensive income

Accumulated other comprehensive income includes changes in equity not recognized in profit or loss, provided that such changes are not based on transactions with shareholders that are recognized in equity. Changes recognized in other comprehensive income include the currency translation differences, unrealized gains and losses from the fair value measurement of available-for-sale assets and effects from changes in cash flow hedges.

D.10 Provisions for post-employment benefits

The cost of providing benefits under defined benefit plans is determined using the projected unit credit method, whereby an actuarial valuation is performed at each reporting date. This method takes into account biometric calculation bases as well as the most recent long-term capital market interest rate and current assumptions about future salary and pension increases.

Remeasurements consisting of actuarial gains and losses, as well as changes resulting from the application of the asset ceiling and the return on plan assets (excluding interest on the net defined benefit liability) are recognized directly in other comprehensive income. The remeasurements recognized in other comprehensive income are part of retained earnings and are not reclassified to the income statement.

Past service cost is recognized in profit or loss as an expense as soon as the plan amendment occurs and to the extent that the changes to the pension plan are not conditional on the employee remaining in service for a specified period of time (the vesting period).

Net interest is calculated by multiplying the discount rate used by the net defined benefit liability (pension obligation less plan assets) or the net defined benefit asset at the beginning of the financial year if the plan assets exceed the pension obligation. The defined benefit costs include the following components:

- service cost (including current service cost, past service cost and potential gain or loss result from a plan amendment or curtailment);
- net interest expense or income on net defined benefit liability or asset;
- remeasurement of net defined benefit liability or asset.

The CGM group reports the first two components in the Personnel expenses item in the income statement. Gains or losses from curtailments are recognized as past service cost.

The provision for defined benefit plans recognized in the consolidated statement of financial position equals the present value of the defined benefit obligation at the reporting date less the fair value of plan assets. Any resulting overfunding is limited to the present value of future economic benefits available in the form of (contribution) refunds from the plans or reduced future contribution payments to the plans.

Payments for defined contribution plans are recognized as an expense in personnel expenses when the employees have performed the work that entitles them to the contributions. Payments for state pension plans are treated in the same way as payments for defined contribution plans. The CGM group has no further payment obligations beyond the payment of contributions.

D.11 Other provisions

Provisions are recognized for legal and actual obligations that have arisen or have been incurred at the reporting date, where it is probable that the fulfilment of the obligation will result in an outflow of funds or an outflow of other resources of the company and where there is uncertainty as to the maturity and estimated amount of the obligation.

The measurement is based on the settlement amount with the highest probability of occurrence or, if the probabilities of occurrence are equally distributed, on the expected value of the settlement amounts. Risks and uncertainties inherent in the obligation must be taken into account. If a provision is measured on the basis of the estimated cash flows required to settle the obligation, these cash flows must be discounted if the interest effect is material.

If it can be assumed that parts or all of the economic benefit required to settle the provision will be reimbursed by an external third party, the CGM group capitalizes this as an asset, provided that the reimbursement is virtually certain and the amount of the reimbursement can be reliably estimated.

a) Onerous contracts

Present obligations arising in connection with onerous contracts are recognized as provisions. An onerous contract is deemed to exist if the CGM group is a party to a contract where it is expected that the unavoidable costs of meeting the obligation under the contract will exceed the economic benefits that can be generated from it.

b) Restructuring

A provision for restructuring expenses is recognized when the CGM group has prepared a detailed, formal restructuring plan that has raised a valid expectation in those affected that it will carry out the restructuring by starting to implement that plan or announcing its main features to those affected by it. Only the direct expenses for restructuring are recognized in the measurement of the restructuring provision. Accordingly, only those amounts are recognized that arise as a result of the restructuring and are not related to the group's continuing operations.

c) Warranties

Provisions for the expected expenses from warranty obligations under national sales contract law are recognized at the time of sale of the relevant product. The amount is derived by estimating the expenses required to meet the group's obligation. Where there are a number of similar obligations – as in the case of warranties – the probability that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is also recognized as a liability if the probability of an outflow of resources relating to an individual asset included in this group is low.

d) Severance payments

A liability for severance payments is recognized if the CGM group can no longer withdraw the offer of such benefits. If severance payments are incurred in connection with restructuring, the liability for termination benefits is recognized earlier (before the offer is made).

e) Provisions for anniversaries

Provisions for anniversaries are measured using the projected unit credit method. The provisions for anniversaries are paid out in accordance with the age structure of the workforce on the employees' respective anniversaries. Based on the current number of employees, payments will be made mainly over the next 30 years.

D.12 Financial liabilities

The CGM group recognizes financial liabilities when a group company becomes a contractual party to the financial instrument. Such liabilities are classified depending on the circumstances either as financial liabilities at fair value through profit or loss or as financial liabilities measured at amortized cost.

The CGM group measures financial liabilities at fair value upon initial recognition. Financial liabilities measured at amortized cost are recognized less any transaction costs. The management of the CGM group determines the classification of financial liabilities upon initial recognition.

a) Financial liabilities measured at fair value through profit or loss

Financial liabilities are classified as financial liabilities at fair value through profit or loss if they are either held for trading or are voluntarily designated as at fair value through profit or loss.

A financial liability is classified as held for trading if:

- it was acquired principally for the purpose of being repurchased in the near term; or
- upon initial recognition, it is part of a portfolio of clearly identified financial instruments that are jointly managed by the CGM group and for which there have been indications of short-term profit-taking in the recent past; or
- it is a derivative that is not designated and effective as a hedging instrument and is not a financial guarantee.

Financial liabilities other than financial liabilities held for trading may be designated as at fair value through profit or loss upon initial recognition if:

- such designation eliminates or significantly mitigates a measurement or recognition inconsistency that would otherwise arise; or
- the financial liability belongs to a group of financial assets or financial liabilities that are managed and measured on a fair value basis in accordance with a documented risk or investment management strategy of the group and for which the internal flow of information is based thereon.

Financial liabilities classified as fair value through profit or loss (FVtPL) are measured at fair value. Any gains or losses resulting from the measurement are thus recognized in profit or loss. The net gain or loss recognized in the income statement includes interest paid on the financial liability and is included in the Financial income and expenses item.

b) Other financial liabilities

Other financial liabilities, such as loans, trade payables and other liabilities, are measured at amortized cost (AC) using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and allocating interest expense to the corresponding periods. The effective interest rate is the interest rate that is used to discount estimated future cash outflows, including fees incurred and fees paid or received that are an integral component of the effective interest rate, as well as transaction costs and other premiums or discounts over the expected life of the financial instrument or a shorter period, to the net carrying amount of the financial asset upon initial recognition.

c) Derecognition of financial liabilities

The CGM group derecognizes a financial liability as soon as the respective obligation has been settled, i.e., the obligations specified in the contract are met, canceled or have expired. The difference between the carrying amount of the derecognized financial liability and the consideration received is stated in the income statement.

D.13 Derivative financial instruments (in hedge accounting)

The CGM group enters into derivative financial instruments to manage its interest rate and exchange rate risks. This includes the conclusion of forward exchange transactions as well as interest rate caps and swaps. Derivatives are initially recognized at fair value at the time the contract is entered into and subsequently measured at fair value at the end of each reporting period. The resulting gains or losses are recognized immediately in profit or loss. If the derivative is a hedging instrument in a designated and effective hedging relationship (hedge accounting), the change in value is recognized in other comprehensive income.

In principle, designated hedges belong to one of the following categories:

- fair value hedges of a recognized asset or liability or a firm commitment;
- hedging a specific risk associated with the recognized asset or liability (such as a portion or all the future interest payments on a variable-rate liability) or a risk associated with a highly probable future transaction (cash flow hedge);
- hedging of a net investment in a foreign operation as defined by IAS 21 (Net Investment Hedge).

The relationship between the hedged item and the hedging instrument, including the risk management objectives and the corporate strategy underlying the hedge, is documented at the start of hedge accounting. In addition, both when the hedging relationship is entered into and during the course of the hedging relationship, regular documentation is provided as to whether the hedging instrument designated in the hedging relationship is highly effective in offsetting changes in the fair value or cash flows of the hedged item in accordance with the hedged risk. Recognition through profit or loss of the valuation results depends on the nature of the hedging relationship.

The total fair value of a derivative designated as a hedging instrument is classified as a non-current asset or non-current liability if the hedged item has a remaining term of more than one year and as a current asset or current liability if the hedged item has a remaining term of less than one year.

In accordance with IAS 1.68 and IAS 1.71, trading derivatives with a remaining term of more than one year are classified as non-current assets or liabilities; otherwise they are classified as current.

D.14 Cash flow hedges

The effective amount of the change in the fair value of derivatives that are designated and qualify as cash flow hedges is recognized in other comprehensive income under Cash flow hedges. A gain or loss attributable to the ineffective portion is recognized immediately in profit or loss and reported in the financial result in the income statement.

Amounts recognized in other comprehensive income are transferred to the income statement in the period in which the hedged item is recognized in profit or loss. However, if a hedged expected transaction results in the recognition of a non-financial asset or non-financial liability, the gains and losses previously recognized in other comprehensive income and accumulated in equity are removed from equity and included in the initial measurement of the cost of the asset or liability.

The hedge relationship is no longer recognized in the statement of financial position if the CGM group dissolves, sells, terminates or exercises the hedge or if the hedging instrument is no longer suitable for hedging purposes. The entire gain or loss recognized in other comprehensive income and accumulated in equity at that time remains in equity and is not recognized in profit or loss until the expected transaction is also recognized in the income statement. If the transaction can no longer be expected to be realized, the entire income recognized in equity is immediately recycled to profit or loss in the income statement.

Information on the fair values of derivatives used for hedging purposes is provided under D. 20 i) Fair value of derivative and primary financial instruments.

D.15 Leases

a) The CGM group as lessee

As a lessee, the group mainly leases real estate, motor vehicles, IT equipment as well as operating and office equipment. In accordance with IFRS 16, the CGM group recognizes right-of-use assets and lease liabilities for all leases.

When use of an asset commences or when a contract containing a lease component is amended, the contractually agreed consideration is allocated on the basis of the relative stand-alone prices. The CGM group does not separate the non-lease components for vehicle leases, and instead accounts for lease and related non-lease components (mainly service fees) as a single lease component.

As at the commencement date, the cost of the right-of-use asset is equal to the lease liability, adjusted for prepayments, initial direct costs and estimated costs of dismantling the asset. Incentive payments from the lessor that have already accrued reduce the acquisition cost.

In the scope of subsequent measurement, the right-of-use asset is depreciated on a straight-line basis over the lease term and, if necessary, adjusted for any extraordinary depreciation.

The lease liability is recognized in the amount of the present value of the future lease payments over the reasonably certain term of the lease. It is discounted at the interest rate implicit in the lease. If this cannot be readily determined, it is discounted using the incremental risk-adjusted borrowing rate of the CGM group. This interest rate is adjusted to reflect the nature of the asset and the terms and conditions of the lease. The CGM group currently uses its risk-adjusted incremental borrowing rate for the discounting of all its leases. Similar leases are grouped into portfolios and measured using a uniform discount rate.

Lease payments comprise all fixed and quasi-fixed payments, less any incentives paid by the lessor. In addition, payments are recognized for purchase and termination options the group is reasonably certain to exercise. All other variable payments are recognized as an expense. The lease liability is measured and adjusted using the effective interest method.

The lease term is the reasonably certain period over which an asset is leased. In addition to the non-cancelable basic lease term, extension periods are included if it is reasonably certain they will be exercised. This estimate is reviewed if either events beyond the lessee's control or significant changes in circumstances occur that require a change in the term of the lease.

The lease term is adjusted if it is reasonably certain that an extension option will be exercised or a termination option will not be exercised, and this was not taken into account in the original assessment. The adjustment of the lease term alters the future series of payments, thus resulting in a remeasurement of the lease liability using the current interest rate. The resulting difference is recognized directly in equity in the right-of-use asset.

b) The CGM group as lessor

Leases are classified as a finance lease if they transfer substantially all the risks and rewards incidental to ownership of an underlying asset to the lessee. Leases in which a significant portion of the risks and rewards incidental to ownership of the leased asset remain with the lessor are classified as operating leases.

If assets are leased out under a finance lease (particularly in the PCS segment), the present value of the minimum lease payments is recognized as a lease receivable. The difference between the gross account receivable (minimum lease payments before discounting) and the present value of the receivable is recognized as financial income over the term of the lease. The difference is recognized in revenues. Lease income is recognized over the lease term using the annuity method, which – in relation to the lease receivable – yields a constant annual return.

Assets leased by customers under operating leases are reported under non-current assets. Income from leases is recognized on a straight-line basis over the term of the lease.

D.16 Income taxes and deferred taxes

The income tax expense reported in the CGM group's income statement for the reporting period is the sum of the current tax expense and the deferred taxes recognized in profit or loss. The CGM group determines the current tax expense on the basis of the taxable income of the group companies using the respective current national income tax rates.

In accordance with the provisions of IAS 12, the CGM group recognizes all temporary differences between the tax accounts and the consolidated financial statements as deferred taxes. Deferred tax assets on loss carryforwards are capitalized up to the amount for which it can be assumed that they will be utilized within a medium-term (generally five years) and tax-law permissible time frame.

Deferred tax assets and liabilities are also recognized on temporary differences arising from business acquisitions. An exception to this is temporary differences on goodwill, for which no deferred taxes are recognized.

If goodwill is taken into account for tax purposes, deferred taxes that are only realized upon disposal are recognized in the subsequent measurement.

Deferred tax liabilities arising from temporary differences in connection with investments in subsidiaries and associated companies are not recognized for reasons of materiality.

Deferred taxes are calculated using the respective current national income tax rates of the group companies. Income tax rates that have already been enacted but will only be applied in future periods are also taken into account when determining deferred taxes.

Deferred taxes are generally recognized in profit or loss (exception: first-time consolidation), unless they relate to items recognized directly in equity or in other comprehensive income. In this case, the taxes are also recognized in equity or in other comprehensive income.

D.17 Sales revenues from contracts with customers

Revenues are recognized in accordance with IFRS 15.

IFRS 15 is generally applicable to all contracts with customers. Exceptions to this are the following contracts:

- leases covered by IFRS 16 Leases;
- financial instruments and other contractual rights or obligations within the scope of IFRS 9 Financial Instruments, IFRS 10 Consolidated Financial Statements, IFRS 11 Joint Arrangements, IAS 27 Separate Financial Statements and IAS 28 Investments in Associates and Joint Ventures;
- insurance contracts within the scope of IFRS 4; and
- non-monetary exchanges between entities in the same line of business to facilitate sales to customers or potential customers.

Revenues are determined based on the consideration specified in a contract with a customer. The group recognizes revenues when it transfers the control of goods or services to a customer.

Five steps are derived from the principles set forth in IFRS 15.

Step 1 is to determine whether a customer contract falls within the scope of IFRS 15. This is the case if all the criteria given below in IFRS 15.9 are met:

- (a) the parties to the contract have approved the contract and are committed to perform their respective obligations;
- (b) the company can identify each party's rights regarding the goods or services to be transferred;
- (c) the company can identify the payment terms for the goods or services to be transferred;
- (d) the contract has commercial substance; and
- (e) it is probable that the company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. The assessment of probability must be based solely on the customer's ability and intention to pay when the invoice is due. The amount of consideration to which the company will be entitled may be lower than the price stated in the contract if the consideration is variable because the company may offer the customer a price concession.

Two or more contracts entered into at or near the same time with the same customer shall be combined and accounted for as a single contract if one or more of the following criteria are met:

The contracts are negotiated as a package with a single commercial objective:

- (f) the amount of consideration to be paid in one contract depends on the price or performance of the other contract; or
- (g) the goods or services promised in the contracts are a single performance obligation in accordance with IFRS 15.22-30.

Step 2 is to identify the performance obligations included in the contract, as revenues must be recognized at the level of individual performance obligations. Goods or services are distinct and therefore classified as individual performance obligation if the customer can benefit from them independent of other promises for performance in the contract. In addition, these promises must be separately identifiable from other promises in the contract.

Step 3 is to determine the transaction price, which is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer. Although this price will often be a fixed amount, the transaction price may also include variable components, such as discounts, credits, performance bonuses, penalties, etc. The amount of such variable consideration shall be estimated and included in the transaction price. The associated uncertainty is accounted for by recognizing these variable amounts only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The transaction price also includes potential financing components and non-cash consideration (measured at fair value).

The transaction price determined as previously explained is allocated to the individual performance obligations in **step 4** based on the relative stand-alone selling prices. If these are not directly observable (e.g., from corresponding transactions with the individual performance obligations), these prices must be estimated.

Finally, in **step 5**, revenues must be recognized at the point in time or over the time the underlying performance is satisfied. The performance obligation is satisfied when the control of the goods or services is transferred. Control of an asset refers to the ability to direct the use of, and obtain the benefits from, the asset.

When entering into a contract in accordance with IFRS 15, it must be determined whether the revenues arising from the contract are to be recognized at a point in time or over time. In this regard, it must first be clarified by applying specific criteria, if the control of the individual performance obligations is transferred over time. If this is not the case, revenues are recognized at the point in time when control is transferred to the customer. Indicators of this are, for example, legal transfer of ownership, transfer of significant risks and rewards, or formal acceptance.

If, on the other hand, control is transferred over time, revenues may be recognized over time only if the percentage of completion can be measured reliably using input or output methods. In addition to general revenue recognition principles, the standard provides detailed guidance on topics such as disposals with rights of return, customer options on additional goods or services, principal-agent relationships, and bill-and-hold arrangements. IFRS 15 also includes new guidelines related to costs to obtain or fulfil a contract with a customer and for the question when such costs must be recognized as an asset. Costs that do not meet the defined criteria should be expensed as incurred.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

CGM recognizes its revenues net of sales deductions such as bonuses, cash discounts or rebates.

The following table provides information about the nature and timing of the satisfaction of performance obligations under contracts with customers, including significant payment terms, and the related revenue recognition principles. The group recognizes revenues from the following main sources:

Type of sales revenues	Description and revenue recognition
Software licenses	<p>This includes revenues from the sale of software licenses, which are usually remunerated with a single payment. The license entitles the customer to permanent use of the software. The license fee is contractually fixed and does not trigger any future license payments or usage-based billing. Only extensions of the software modules used trigger further license payments. Revenues from the sale of software licenses are deferred over the minimum contractual term of the maintenance agreement if the requirements for a multi-component transaction are met using the "right to access" approach. This affects practically all license sales in the classic AIS and PCS segment. CGM applies the portfolio approach in accordance with IFRS 15.4 for this purpose. By contrast, license sales in the HIS segment typically do not satisfy the requirements for a multi-component transaction.</p> <p>Revenues from rental and lease transactions that cannot be regarded as sales are recognized on a straight-line basis over the lease period.</p>
Software maintenance and other recurring revenues	<p>This includes revenues from contracts that give customers access to new releases of software products after the latter have already been supplied. These updates serve to rectify bugs, improve performance and other features and also adapt the software to changes in the legal framework.</p> <p>The contractual relationship for software maintenance also usually includes hotline support (either via telephone or online). The minimum contract terms for software maintenance vary depending on the product line (from cancellation possible at any time to cancellation possible for the first time after five years), taking into account the individual cancellation periods. If cancellations are not made in due time as agreed in the contract, the software maintenance contract usually extends by a further twelve months.</p> <p>Revenues from recurring, transaction-specific services and other long-term services, including, for example, multi-year software licensing (SaaS and period-related transfer of use), application service provider services, hosting fees, Internet service provider fees, eServices fees, EDI and remuneration payments, receivables management payments, outsourcing agreements, hardware maintenance and repair agreements, etc. are generally based on a long-term contractual relationship. Revenues from software maintenance and other recurring revenues and from support services are recognized on a pro-rata basis over the period when the services are rendered.</p>
Professional services	<p>Revenues from services that are remunerated on an hourly basis or at contractually agreed fixed prices are included in the revenue type professional services. The activities performed on behalf of the customer include for example, project management, analyses, training, system configuration and customer-related programming.</p> <p>The revenues for services that are remunerated on an hourly basis are recognized at the point in time when the service is rendered. Revenues are generally recognized over time, whereby the CGM group makes use of the practical expedient to recognize them in the amount that the CGM group has a right to invoice.</p> <p>Revenues from service components within the framework of contracts for work and services and other service contracts are recognized over time using the percentage-of-completion method.</p> <p>The percentage of completion is typically determined by dividing the contract costs incurred for work performed to that date by the estimated total contract costs (cost-to-cost method).</p> <p>For complex contracts where it is not possible to reliably estimate the total contract costs and thus the percentage of completion cannot be determined, revenues are recognized only to the extent of the contract costs incurred. Even though it is impossible to estimate the percentage of completion, the CGM group nevertheless expects a positive margin. A pro rata profit is therefore only recognized when the project has been fully completed (zero profit method).</p>
Hardware	<p>Revenues from the sale of hardware and infrastructure components, such as PCs, servers, monitors, printers, switches, racks, network components, etc. These revenues are recognized immediately upon delivery of the hardware components.</p> <p>This is not the case for hardware components which are contractually agreed within the scope of construction awards; these are recognized in the project as a whole according to the percentage of completion.</p> <p>The percentage of completion is typically determined by dividing the contract costs incurred for work performed to that date by the estimated total contract costs (cost-to-cost method).</p> <p>For complex contracts where it is not possible to reliably estimate the total contract costs and thus the percentage of completion cannot be determined, revenues are recognized only to the extent of the contract costs incurred. Even though it is impossible to estimate the percentage of completion, the CGM group nevertheless expects a positive</p>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Type of sales revenues	Description and revenue recognition
	margin. A pro rata profit is therefore only recognized when the project has been fully completed (zero profit method).
	Revenues from rental and lease transactions that cannot be regarded as sales are recognized on a straight-line basis over the lease period.
Advertising, eDetailing and data	<p>This includes revenues from paid advertising and communication services via software or other media. Furthermore, revenues from software services and the associated services that support the sales process of pharmaceutical companies are reported under this revenue type.</p> <p>Revenues from the collection, structuring, and provision of data (e.g., blacklists) for healthcare providers (e.g., health insurers, pharmaceutical companies, etc.) are also allocated to this revenue type. Revenues from advertising, eDetailing and data that take the form of a continuing obligation are recognized on a pro rata basis over time as long as the service is rendered. For services to be rendered on a daily basis, which are remunerated on an hourly basis, revenue is recognized at the point in time when the service is rendered.</p>
Software Assisted Medicine (SAM)	<p>This includes revenues from healthcare management and associated services. In addition, revenues generated from the use of special software modules (i.e., software supporting medical decision-making) within medical practices, hospitals, physician-hospital networks, health insurance companies, patient networks, etc. are allocated to this type of revenue.</p> <p>For services in health management to be rendered on a daily basis, which are remunerated on an hourly basis, revenue is recognized at the point in time when the service is completed. Revenues are generally recognized over time, whereby the CGM group makes use of the practical expedient to recognize them in the amount that the CGM group has a right to invoice.</p> <p>Revenues from sales of SAM software licenses are recognized in part immediately upon delivery, provided that the delivered software only grants the customer a right to access. If revenues from the sale of SAM software licenses fall under the "right to use" approach, the revenues from software licenses, revenues from software maintenance and other recurring revenues in the SAM area as well as support services, are recognized on a pro-rata basis over the minimum contractual term for the provision of the service.</p>
Other revenues	This comprises all revenues that cannot be attributed to any of the aforementioned categories. Revenue recognition is carried out on a case-by-case basis in compliance with the relevant IFRS requirements.

When hardware components are sold at the same time as a hardware maintenance and support contract is signed, a discount is usually applied at the expense of the hardware sale. CGM has identified two performance obligations for this type of multi-component transaction. The amounts allocated to sales for hardware components are increased due to the allocation method prescribed by IFRS 15 (i.e., an allocation based on the stand-alone selling price), while the amounts allocated to hardware maintenance and support contracts are decreased accordingly over their term. Therefore, the revenues have been adjusted to reflect the change in accounting policies. Current and non-current contract assets were recognized for this amount.

On average, the system implementation process for software services takes between three and six months. For very large system implementation contracts (e.g., hospital information system implementation for a chain of hospitals), the implementation process may extend over several years. Depending on the form of the contract, CGM is entitled to invoice the customer on a monthly basis according to time spent, as soon as certain milestones are reached or not before completion of the project (successful acceptance by the client). Under IFRS 15, revenues that are realized before the customer is invoiced are recognized as a contract asset.

CGM incurs commissions that are paid to intermediaries or its own sales employees for arranging purchase agreements and service agreements for software licenses, software maintenance or other service agreements. Whenever CGM expects to be reimbursed for these incremental costs, it capitalizes them and depreciates them over the period in which the performance from the provision of the software license is transferred to the customer together with the software maintenance contract or the provision of services.

Given CGM's business model and the customer groups it addresses, there are no significant reimbursement obligations or corresponding rights to return goods.

A contract asset must be recognized if CGM has recognized revenues as a result of the satisfaction of a contractual performance obligation before the customer has made a payment or before – irrespective of the due date – the conditions for invoicing and thus recognizing the account receivable are met.

A contract liability must be recognized if the customer has made a payment or an account receivable from the customer becomes due before CGM has satisfied a contractual performance obligation and recognized the corresponding revenue. Contract liabilities are to be offset against contract receivables within a customer contract.

D.18 Interest and dividend income

Interest income is accrued periodically taking into account the outstanding loan amount and the applicable interest rate. The applicable interest rate equals the rate that discounts estimated future cash flows over the term of the financial asset to the net carrying amount of the asset.

Dividend income from financial investments is recognized when the shareholder's legal right to receive payment is established.

D.19 Earnings per share and share-based payment transactions

a) Earnings per share

Undiluted earnings per share are calculated by dividing the share of profit or loss for the period attributable to the shareholders of CompuGroup Medical SE & Co. KGaA by the weighted average number of shares issued. If new shares are issued or bought back within a reporting period, they are included in the calculation on a pro rata basis for the period in which they are outstanding. The share options granted by the company lead to a dilution of earnings per share.

b) Share-based payment transactions

The fair value of share options granted is determined in accordance with IFRS 2 Share-based Payment by simulating the future performance of the company's subscribed capital on the basis of market parameters (e.g., volatility and risk-free interest) and normally distributed random numbers (Monte Carlo simulation). The fair value of the share options is offset against capital reserves through profit or loss over the expected option period of up to four years.

The fair value at the grant date is used for measurement purposes.

D.20 Estimates and management judgments

The preparation of the consolidated financial statements in accordance with IFRS requires that assumptions and estimates be made. These affect the amount and recognition of assets and liabilities, income and expenses, and contingent liabilities in the reporting period. The significant estimates and judgments made in the preparation of the consolidated financial statements are discussed below. For the carrying amounts of the above-stated line items, please refer to section E. Notes on items on the statement of financial position and income statement.

a) Purchase price allocation and business acquisitions

Assumptions and estimates are made in particular as part of the purchase price allocations for business acquisitions. User software from business acquisitions is determined using the license price analogy, customer relationships are determined using the multi-period excess earnings method, and trademark rights are determined using the license price analogy. Estimates are also used as a basis for the planned amortization of identified hidden reserves.

b) Estimated impairment of goodwill

Goodwill is tested for impairment on the basis of cash flow projections for the cash-generating units for the next four years and applying a discount rate adjusted for the company risk, both annually and immediately outside the annual period as soon as there is any indication that goodwill is impaired. The CGM group determines the recoverability on the basis of the higher of the fair value less costs to sell and the value in use. The management of the CGM group believes that the assumptions used to calculate the recoverable amount are appropriate. Unforeseen changes in these assumptions could result in impairment losses, which would have a negative impact on the net assets, financial position and results of operations of the CGM group. The calculation of values in use is subject to discretion because of the necessity to make estimates regarding future cash flows.

c) Recoverability of assets

At each reporting date, the CGM group reassesses as part of the impairment test, whether there are any indications that an item of property, plant and equipment or an intangible asset (including intangible assets from internally generated software) may be impaired. The recoverable amount of the asset in question is determined using the best estimates for the input parameters. The recoverable amount corresponds to the higher of the fair value less costs to sell and the value in use, in line with the procedure for goodwill impairment testing. The recoverable amount is determined on the basis of cash flow projections from the asset concerned for the next four years, using a discount rate adjusted for the company risk. The management of the CGM group is of the opinion that the assumptions used to calculate the recoverable amount are appropriate with regard to the economic environment and the industry development; nevertheless, changes in the underlying parameters could lead to an adjustment of the impairment analysis of the asset being tested. This could result in further impairment losses or reversals of impairment losses in future periods if the assumptions and estimates used by management prove to be incorrect.

d) Useful lives of property, plant and equipment

As already stated in the notes on Property, plant and equipment in this section, the CGM group reviews the estimated useful lives of property, plant and equipment at each reporting date to determine whether they are appropriate. In this context, reassessments are made with regard to the remaining useful lives. Changes that result in a reassessment of the remaining useful life may arise, for example, from changes in market conditions (e.g., price erosion) or general technological progress.

e) Assessment of the probability of other provisions

Since other provisions are recognized and measured on the basis of the best estimate of the probability of the future outflow of resources and on the basis of past experience, taking into account the circumstances known at the reporting date, the actual outflow of resources may differ from the other provisions recognized for this purpose.

f) Provisions for post-employment benefits

The present value of the pension obligation depends on a variety of factors that are based on actuarial assumptions. The assumptions used in determining net pension expense (or income) include the discount rate. Any change in these assumptions will have an impact on the carrying amount of the pension obligation.

g) Revenue recognition for project orders

Some of the consolidated subsidiaries of the CGM group enter into project orders with only one performance obligation as part of their business activities. Contractually agreed revenues are recognized over time. This relates in particular to the HIS segment. Under IFRS 15, revenues are recognized when it is highly probable that contract amendments will not result in a significant cancellation. Furthermore, the introduction of IFRS 15 ensures that the new provisions for variable consideration (e.g., incentives) as well as for the accounting of addenda and contract amendments are included in the calculation as contract modifications. The CGM group recognizes provisions for onerous contracts in accordance with IAS 37.66 et seqq. The CGM group regularly reviews the estimates relevant to the measurement of project orders for appropriateness and, if necessary, adjusts the estimates to reflect new findings.

h) Income taxes

Management is also required to make estimates and assumptions when calculating actual and deferred taxes. Deferred tax assets are recognized to the extent that it is probable that future tax benefits will be realized. The actual usability of deferred tax assets depends on the future development of the actual taxable result. This may differ from the assessment at the time the deferred taxes are capitalized. Various factors are used to assess the probability of future usability, including past results of operations, operating projections, loss carryforward periods and tax planning strategies.

i) Fair value of derivative and primary financial instruments

The fair value measurement of derivative and primary financial instruments takes into account expected future developments, such as interest rate and credit risks, and well as the underlying assumptions. Further information on the assumptions and estimates underlying these consolidated financial statements are provided in the notes on the individual items of the financial statements. Judgments must be made when applying accounting principles and measurement methods. These decisions are continually reassessed and are based on historical experience and expectations of future events that are believed to be reasonable under the circumstances.

Fair values of derivative financial instruments are determined on the basis of information available at the balance sheet date using recognized valuation techniques (discounted cash flow method and option valuation method).

j) Contingent liabilities and contingent assets

Contingent liabilities and contingent assets are possible obligations or assets that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the CGM group. Contingent liabilities are also present obligations that arise from past events, for which an outflow of resources embodying economic benefits is unlikely or for which the extent of the obligation cannot be estimated with sufficient reliability. Contingent liabilities are recognized at fair value if they have been acquired as part of a business combination. Contingent liabilities not acquired as part of a business combination are not recognized. Contingent assets are not recognized. However, if the realization of income is virtually certain, the asset in question is no longer considered a contingent asset and is recognized as an asset. Where an outflow of resources embodying economic benefits is not unlikely, information on contingent liabilities is disclosed in the notes to the consolidated financial statements. The same applies to contingent assets if the inflow of economic benefits is probable.

E. Notes on items on the statement of financial position and income statement

E.1 Intangible assets

a) Development of intangible assets

Development of intangible assets as at December 31, 2022:

kEUR	Purchase and manufacturing costs						Dec 31, 2022
	Jan 1, 2022	Additions due to changes in scope of consolidation	Other additions	Reclassifications	Disposals	Exchange rate differences	
Intangible assets	1,688,672	84,471	50,560	0	- 7,231	14,753	1,831,225
Goodwill	607,713	45,108	0	0	0	5,698	658,519
Acquired software rights	322,777	14,198	3,118	478	- 3,840	2,531	339,262
Customer relationships	489,502	23,156	477	0	- 2,657	5,032	515,510
Trademark rights	51,719	405	0	0	- 95	706	52,735
Order backlog	24,870	1,604	0	0	0	56	26,530
Capitalized inhouse services	188,854	0	46,339	0	- 342	745	235,596
Prepayments on software	3,237	0	626	- 478	- 297	- 15	3,073

kEUR	Depreciation and amortization					Net book value		
	Jan 1, 2022	Additions	Disposals	Transfers	Exchange rate differences	Dec 31, 2022	Dec 31, 2022	Jan 1, 2022
Intangible assets	474,325	69,551	- 7,177	0	616	537,315	1,293,910	1,214,347
Goodwill	19,306	0	0	0	50	19,356	639,163	588,407
Acquired software rights	215,242	20,757	- 3,833	0	121	232,287	106,975	107,535
Customer relationships	157,261	30,272	- 2,657	0	593	185,469	330,041	332,241
Trademark rights	32,738	2,603	- 96	0	132	35,377	17,358	18,981
Order backlog	21,659	3,283	0	0	15	24,957	1,573	3,211
Capitalized inhouse services	27,870	12,636	- 342	0	- 295	39,869	195,727	160,984
Prepayments on software	249	0	- 249	0	0	0	3,073	2,988

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Development of intangible assets as at December 31, 2021:

kEUR	Purchase and manufacturing costs						Dec 31, 2021
	Jan 1, 2021	Additions due to changes in scope of consolidation	Other additions	Reclassifications	Disposals	Exchange rate differences	
Intangible assets	1,523,682	132,473	44,393	0	- 37,052	25,176	1,688,672
Goodwill	561,718	35,404	0	0	0	10,591	607,713
Acquired software rights	296,046	23,296	4,798	847	- 5,808	3,599	322,777
Customer relationships	419,496	61,422	0	0	0	8,584	489,502
Trademark rights	40,356	10,271	0	0	- 5	1,097	51,719
Order backlog	22,774	2,029	0	0	0	67	24,870
Capitalized inhouse services	180,678	0	38,105	0	- 31,211	1,281	188,854
Prepayments on software	2,614	51	1,490	- 847	- 28	- 43	3,237

kEUR	Depreciation and amortization					Net book value		
	Jan 1, 2021	Additions	Disposals	Transfers	Exchange rate differences	Dec 31, 2021	Dec 31, 2021	Jan 1, 2021
Intangible assets	435,577	72,876	- 36,998	0	2,870	474,325	1,214,347	1,088,105
Goodwill	19,269	0	0	0	37	19,306	588,407	542,449
Acquired software rights	200,526	19,842	- 5,782	0	656	215,242	107,535	95,520
Customer relationships	128,700	26,684	0	0	1,877	157,261	332,241	290,796
Trademark rights	29,483	2,882	- 5	0	378	32,738	18,981	10,872
Order backlog	13,217	8,429	0	0	12	21,659	3,211	9,557
Capitalized inhouse services	44,132	15,039	- 31,211	0	- 90	27,870	160,984	136,546
Prepayments on software	249	0	0	0	0	249	2,988	2,365

The most significant changes in intangible assets result from acquisitions (note C.4.) and capitalized in-house services (note E.1.e). All amortization and impairments of intangible assets are recognized in profit or loss.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

b) Goodwill

Goodwill is attributable to the individual cash generating units (CGU) as follows:

kEUR	Jan 1, 2022	Changes in the scope of consolidation	Other additions	Disposals	Impairment	Reclassification	Exchange rate differences	Dec 31, 2022
Ambulatory Information Systems	372,063	7,704	0	0	0	-1,814	6,195	384,148
Hospital Information Systems	166,336	730	0	0	0	0	-547	166,519
Consumer and Health Management Information Systems	6,200	31,723	0	0	0	1,049	0	38,972
Pharmacy Information Systems	43,808	4,951	0	0	0	765	0	49,524
Total	588,407	45,108	0	0	0	0	5,648	639,163

The additions due to changes in consolidated group relate to both, business combinations by transferring an entity's interest in its equity (share deal) and business combinations through transfer of net assets (asset deal).

c) Goodwill impairment test

Goodwill is allocated to the individual cash-generating units or groups of cash-generating units for which synergies are expected to arise. Since the completion of the transformation of legal form in June 2020, the CGM group has monitored the recoverability of goodwill at the level of the reportable segments.

The discounted future cash flows of the segments, discounted by using the DCF method, are determined on the basis of the approved planning for 2023 for the net assets, financial position and results of operations and are then verified by using historical values. The results are then extrapolated for three additional years using bottom-up, multi-year planning that reflects the future development of the segments under current conditions. After the four-year time period, a perpetuity value is calculated using a highly conservative group-wide growth rate of 0.5 %. To determine the present value of future cash flows, a discount rate based on the weighted average cost of capital (WACC) is applied. The following table provides information on key assumptions used to compile corporate planning:

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Notes on business planning assumptions

Description of key assumptions of corporate planning	Approach used to determine key assumptions of corporate planning
– Expected development of sales revenues (new customers, cross- selling opportunities, winning project tenders).	Group's own estimates referring to past experiences and expected market trends, market potential analysis. External market studies are also used, if available.
– Expected enforceable price increases for existing customers in relation to software maintenance and other recurring revenues.	
– Application of current and historical organic growth rates for business units or business areas.	
– Consideration of regulatory changes affecting the development of business units.	
– Development of purchased services based on current circumstances (e.g., contractual basis, strategic business model) and the anticipated development of sales activities (expected revenue situation).	
– Expected development of personnel expenses and other operating expenses, based on demand analyses, contractual framework (e.g., collective bargaining agreements) and statistical procedures (e.g., inflation).	

Goodwill is tested for impairment on the basis of euro cash flows. For this purpose, the local currency company planning of the individual group entities are translated into euro and then allocated to the segment to be tested. The estimated future cash flows are derived from the planning approved by the responsible bodies. The assumptions underlying the main planning parameters take into account not only past experience and aspects arising from the operating business, but also the circumstances of the COVID-19 pandemic.

The growth assumptions included for calculating the value in use of the individual segments as at October 31, 2022 are as follows. The EBITDA margin for 2023 and for the continuation period resulting from the application of the assumed planning assumptions is also included for the purpose of transparency of the assumptions made. For the subsequent years 2024 to 2026 (continuation planning period) an average value is calculated based on the respective EBITDA margins.

	EBITDA-Marge		Growth rate	
	2023	Average 2024 - 2026	2023	Average 2024 - 2026
Ambulatory Information Systems (AIS)	20.2%	24.2%	4.1%	4.4%
Hospital Information Systems (HIS)	10.6%	14.1%	14.4%	6.2%
Consumer and Health Management Information Systems (CHS)	20.7%	25.6%	7.1%	3.8%
Pharmacy Information Systems (PCS)	18.0%	21.9%	2.4%	3.9%

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The discount rates (WACC) used to calculate the value in use as at October 31, 2022 have been divided into WACC after tax and WACC before taxes as follows:

	WACC	WACC
	(before taxes)	(after taxes)
	2022	2022
Ambulatory Information Systems (AIS)	11.4%	8.1%
Hospital Information Systems (HIS)	11.1%	8.1%
Consumer and Health Management Information Systems (CHS)	11.5%	7.9%
Pharmacy Information Systems (PCS)	12.5%	8.8%

In financial year 2022, there was no impairment requirement for any of the segments tested on the basis of value in use.

Similarly, there is no need to recognize an impairment loss if the growth rate in the perpetual value were 0.5 percentage points lower. The group-wide surplus would be reduced by mEUR 177.5 if the growth rate in the perpetual value were 0.5 percentage points lower.

An increase in WACC of 1 percentage point would not give rise to an impairment loss. An increase in WACC of 1 percentage point would give rise to a reduction in the group-wide surplus by mEUR 420.5.

An increase in WACC of 2 percentage points the group-wide surplus excluding the HIS segment would decrease by mEUR 615.8.

In the HIS segment, if the WACC is 1.85 percentage points higher, the value in use corresponds to the carrying amount. If the EBITDA margin is reduced by 3 percentage points, the value in use is also equal to the carrying amount.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

d) Acquired software, customer relationships, trademark rights and order backlog

Acquired software, customer relationships and trademark rights represent, in addition to goodwill, the main groups of intangible assets of CompuGroup Medical SE & Co. KGaA. The following table provides an overview of these intangible assets and their useful lives:

kEUR	Dec 31, 2022	Dec 31, 2021	Amortization until latest
Acquired standard and special software for distribution to customers from business combinations			
CGM South Africa	0	145	31.12.2022
Compufit	21	107	31.03.2023
Imagine Editions	226	452	31.12.2023
Qualizorg	371	542	31.03.2025
CGM Deutschland	186	265	30.04.2025
CGM LAB International	2,331	2,719	31.12.2028
Aatlanta Gruppe	2,170	2,505	30.06.2029
Epsilog	4,131	4,728	31.12.2029
Cerner Corporation	27,159	30,780	30.06.2030
INSIGHT Health Group	11,994	0	30.04.2032
eMDs Group	40,026	41,089	31.12.2035
VISUS Group	6,649	7,040	31.05.2039
KMS	3,324	3,608	31.07.2039
Other	8,387	13,555	
Total software	106,975	107,535	

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

kEUR	Dec 31, 2022	Dec 31, 2021	Amortization until latest
Customer contracts			
FARMA3TEC	0	471	31.08.2022
CGM US (formerly Noteworthy Group)	766	985	31.12.2024
Qualizorg	3,151	3,939	31.03.2027
H&S	1,884	2,261	31.12.2027
Fablab	1,748	2,330	31.12.2027
CGM Italy	1,410	2,095	30.06.2029
Innomed	3,974	4,541	31.12.2029
Turbomed Vertrieb und Service	2,960	3,385	30.03.2030
ATX	1,474	1,660	30.11.2030
CGM Netherlands	4,556	5,643	31.12.2030
Aatlanta Group	5,242	5,858	30.06.2031
Vega	2,806	3,130	31.08.2031
Portavita Group	1,824	2,002	31.03.2033
Qualità in Farmacia (incl. Puntofarma)	1,905	2,173	31.07.2033
Imagine Editions	6,821	7,440	31.12.2033
GIS-Group	9,949	10,853	31.12.2033
Epsilog	21,651	23,455	31.12.2034
CGM Clinical Deutschland	1,034	1,141	01.11.2035
eMDs Group	67,913	69,054	31.12.2035
Lauer-Fischer	8,606	9,243	30.06.2036
APeasy	1,132	0	28.02.2037
INSIGHT Health Group	15,090	0	30.04.2037
4K	1,539	0	31.05.2037
CGM South Africa	2,602	3,210	30.06.2038
CGM Norway	3,824	4,071	30.06.2038
CGM Denmark	4,016	4,293	30.06.2038
CGM Sweden	9,091	9,685	30.06.2038
VISUS Group	16,027	17,004	31.05.2039
KMS	11,809	12,521	31.07.2039
Cerner Corporation	68,214	72,112	30.06.2040
CGM US (formerly Visionary Group)	13,653	14,692	31.08.2040
CGM LAB International	6,290	6,610	31.12.2043
Other	27,080	26,384	
Total Customer contracts	330,041	332,241	

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

kEUR	Dec 31, 2022	Dec 31, 2021	Amortization until latest
Brands			
Vega	72	115	31.08.2024
APeasy	142	0	28.02.2027
4K	202	0	31.05.2027
Epsilog	399	457	31.12.2029
Cerner Corporation	2,073	2,349	31.12.2033
VISUS Group	1,687	1888	31.05.2031
KMS	1,636	1,907	31.07.2031
CGM LAB International	1,339	1,461	30.06.2030
eMDs Group	8,385	9,020	31.12.2035
Other	1,423	1,784	
Total Brands	17,358	18,981	

kEUR	Dec 31, 2022	Dec 31, 2021	Amortization until latest
Order backlog			
VISUS Group	0	2335	31.05.2022
Cerner Corporation	0	237	31.08.2022
eMDs Group	320	603	31.12.2023
INSIGHT Health Group	1,247	0	30.04.2025
Other	6	36	
Total Order backlog	1,573	3,211	

e) Internally generated software

In financial year 2022, in-house services (software development) of kEUR 44,819 were capitalized in accordance with IAS 38 (prior year: kEUR 37,294). These were measured at directly attributable production costs. In accordance with the provisions of IAS 23, borrowing costs attributable to in-house services (software development) of kEUR 1,519 (prior year: kEUR 812) were capitalized in financial year 2022. Amortization of capitalized in-house services of kEUR 12,636 (prior year: kEUR 15,039) was incurred in the reporting year.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

f) Accumulated impairment

Intangible assets include accumulated impairment of goodwill from the financial years 2008 to 2022, which, based on the exchange rates as at the December 31, 2022 reporting date, amount to mEUR 19.4.

There is no impairment required for financial years 2021 and 2022.

Furthermore, the Goodwill item includes amortization of mEUR 5.4 that resulted from financial years before the IAS/IFRS conversion.

g) Intangible assets from business acquisitions

The following additions to acquired software, customer relationships, order backlog and trademark rights resulted from business combinations in the 2022 reporting period:

kEUR	Total	Small Business Computers of New England, Inc.	INSIGHT Health group	4K S.r.l.	Other acquisitions
Software	14,198	587	12,847	764	0
Customer relationships	23,156	1,232	15,791	1,601	4,532
Trademark rights	405	176	0	229	0
Order backlog	1,604	0	1,604	0	0
Total	39,363	1,995	30,242	2,594	4,532

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

E.2 Property, plant and equipment

Overview of the development of property, plant and equipment as at December 31, 2022:

kEUR	Purchase and manufacturing costs						Dec 31, 2022
	Jan 1, 2022	Additions due to changes in scope of consolidation	Other additions	Reclassifications	Disposals	Exchange rate differences	
Property, plant and equipment	128,083	447	24,297	0	-8,481	-128	144,218
Land and buildings	79,387	6	5,015	3,627	-1,273	43	86,805
Other fixed assets and office equipment	39,613	441	15,316	-197	-7,152	-171	47,850
Assets under construction	9,083	0	3,966	-3,430	-56	0	9,563

kEUR	Depreciation and amortization					Net book value		
	Jan 1, 2022	Additions	Disposals	Transfers	Exchange rate differences	Dec 31, 2022	Dec 31, 2022	Jan 1, 2022
Property, plant and equipment	28,013	17,046	- 8,119	0	- 200	36,740	107,478	100,070
Land and buildings	19,169	3,006	- 1,270	236	9	21,150	65,655	60,218
Other fixed assets and office equipment	8,788	14,040	- 6,793	- 236	- 209	15,590	32,260	30,825
Assets under construction	56	0	- 56	0	0	0	9,563	9,027

Overview of the development of property, plant and equipment as at December 31, 2021:

kEUR	Purchase and manufacturing costs						Dec 31, 2021
	Jan 1, 2021	Additions due to changes in scope of consolidation	Other additions	Reclassifications	Disposals	Exchange rate differences	
Property, plant and equipment	123,441	1,252	28,599	0	-25,318	109	128,083
Land and buildings	71,072	95	9,574	-518	-964	127	79,387
Other fixed assets and office equipment	47,188	1,157	14,936	702	-24,354	-16	39,613
Assets under construction	5,180	0	4,089	-184	0	-2	9,083

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

kEUR	Depreciation and amortization					Net book value		
	Jan 1, 2021	Additions	Disposals	Transfers	Exchange rate differences	Dec 31, 2021	Dec 31, 2021	Jan 1, 2021
Property, plant and equipment	31,701	16,285	- 19,917	0	- 56	28,013	100,070	91,739
Land and buildings	18,040	1,753	- 648	0	24	19,169	60,218	53,032
Other fixed assets and office equipment	13,606	14,532	- 19,269	0	- 81	8,788	30,825	33,583
Assets under construction	56	0	0	0	0	56	9,027	5,124

The main changes in property, plant and equipment arise from investments in land and buildings at the Koblenz site amounting to approximately mEUR 7.9, investments in operating and office equipment (especially IT hardware) amounting to mEUR 12.4 and acquisitions (note C.4.).

E.3 Right-of-use assets

The group mainly rents office space and the respective car parking spaces. The remaining terms of these leases are between one and ten years. All long-term leases concern sites that are to be retained in the longer term. As any asset retirement obligations under these leases are linked to early termination, it is currently not expected that the group will be required to honor them. Some of the property leases provide for rent increases that are linked to (price) indices. These were measured at the index level valid at the commencement date.

Leases have also been agreed for vehicles. They typically have a term of two to four years.

Leases for hardware, operating and office equipment are of minor importance. These leases typically have a term of three to five years; the underlying values in use accounted for less than 1 % of the total value of the right-of-use assets on December 31, 2022.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Overview of the development of right-of-use assets as at December 31, 2022:

kEUR	Purchase and manufacturing costs						Dec 31, 2022
	Jan 1, 2022	Additions due to changes in scope of consolidation	Other additions	Reclassifications	Disposals	Exchange rate differences	
Right of use assets	96,694	756	20,433	0	- 6,212	76	111,747
Property and buildings - IFRS 16	77,739	353	8,785	- 721	- 1,388	116	84,884
Vehicles - IFRS 16	18,617	403	11,255	721	- 4,757	- 34	26,205
Other - IFRS 16	338	0	393	0	- 67	- 6	658

kEUR	Depreciation and amortization					Net book value		
	Jan 1, 2022	Additions	Disposals	Transfers	Exchange rate differences	Dec 31, 2022	Dec 31, 2022	Jan 1, 2022
Right of use assets	38,764	46,526	- 5,769	0	2,557	82,078	29,669	57,929
Property and buildings - IFRS 16	28,403	0	0	0	37	28,440	56,444	49,336
Vehicles - IFRS 16	10,155	19,842	- 5,782	0	656	24,871	1,334	8,461
Other - IFRS 16	206	26,684	13	0	1,864	28,767	- 28,109	132

Overview of the development of right-of-use assets as at December 31, 2021:

kEUR	Purchase and manufacturing costs						Dec 31, 2021
	Jan 1, 2021	Additions due to changes in scope of consolidation	Other additions	Reclassifications	Disposals	Exchange rate differences	
Right of use assets	70,147	7,823	26,702	0	- 8,607	629	96,694
Property and buildings - IFRS 16	53,723	7,123	20,790	0	- 4,541	644	77,739
Vehicles - IFRS 16	16,007	663	5,864	0	- 3,907	- 10	18,617
Other - IFRS 16	418	37	48	0	- 159	- 6	338

kEUR	Depreciation and amortization					Net book value		
	Jan 1, 2021	Additions	Disposals	Transfers	Exchange rate differences	Dec 31, 2021	Dec 31, 2021	Jan 1, 2021
Right of use assets	25,595	21,551	- 8,593	0	211	38,764	57,930	44,552
Property and buildings - IFRS 16	17,731	15,010	- 4,541	0	203	28,403	49,336	35,991
Vehicles - IFRS 16	7,650	6,388	- 3,894	0	10	10,155	8,461	8,356
Other - IFRS 16	214	153	- 158	0	- 3	206	132	204

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

E.4 Financial investments

a) Investments in associated companies and joint ventures accounted for using the equity method

kEUR	Dec 31, 2022	Dec 31, 2021
Joint ventures:		
MGS Meine Gesundheit-Services-GmbH	0	0
Mediaface GmbH	50	50
Secure Farma DB S.r.l.	637	0
Solvena GmbH	486	0
Associated companies at equity:		
AxiService Nice S.a.r.l.	0	0
Technosante Nord-Picardie SAS	8	8
Smoove Software S.r.l.	0	0
R56+ Regionalmarketing GmbH & Co. KGaA	10	10
R56+ Management GmbH	0	0
MedEcon Telemedizin GmbH	13	13
Better@Home Service GmbH	1,712	1,751
4K S.r.l.	0	3,651
New Line Ricerche di Mercato Società Benefit S.p.A.	4,384	0
Total	7,300	5,483

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MGS Meine-Gesundheit-Services GmbH

The following table summarizes financial data on MGS Meine-Gesundheit-Services GmbH:

kEUR	2022	2021
Revenue	20,596	16,470
Depreciation and amortization	-4,469	-4,333
Interest expense	-780	-816
Other expenses	-14,529	-10,946
Total result	818	375
kEUR	Dec 31, 2022	Dec 31, 2021
Current assets	9,585	6,747
thereof cash and cash equivalents	6,943	6,056
Non-current assets	12,022	15,134
Current liabilities	5,473	3,251
Non-current liabilities	14,000	17,000
Net assets (100%)	2,134	1,630
Group's share of net assets (37,5%)	801	612
Elimination of unrealized gains on downstream sales	-399	-369
Impairments	-402	-243
Carrying amount of the interest in joint venture at the end of the period	0	0

Further disclosures as per IFRS 12 on other investments in associated companies and joint ventures accounted for using the equity method are not made as these companies are of minor significance.

b) Other equity investments

These equity investments are measured at fair value. The investments are as follows:

kEUR	Dec 31, 2022	Dec 31, 2021
scanacs GmbH	2,500	2,500
Qurasoft GmbH	530	530
Other	128	93
Total	3,158	3,123

E.5 Income tax receivables, income tax liabilities and deferred taxes

a) Income tax receivables and liabilities

kEUR	Dec 31, 2022	Dec 31, 2021
Income tax receivables	48,560	30,553
Benefit of tax losses to be carried back to recover taxes paid in prior periods	3,525	0
Income tax receivables	45,035	30,553
Income tax liabilities	32,316	18,675
Income tax liability	26,085	17,987
Other	6,231	688
Total	- 16,244	- 11,878

Income tax receivables (kEUR 48,560; prior year: kEUR 30,553) comprise the group companies' current income tax receivables. Income tax liabilities (kEUR 32,316; prior year: kEUR 18,675) essentially relate to current tax expenses less prepayments made (kEUR 26,085; prior year: kEUR 17,987).

b) Deferred tax receivables and liabilities

Deferred tax rates abroad ranged between 16 %–28 % in financial year 2022 (prior year: 16 %–28 %).

Deferred taxes are calculated using the relevant tax regulations that are effective or enacted as at the end of the reporting period. Deferred tax receivables and liabilities are netted if there is a legally enforceable right to net these items and if the deferred tax receivables and liabilities relate to the same taxation authority.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The deferred tax assets and liabilities by consolidated statement of financial position item as at December 31, 2022 are shown in the table below:

kEUR	Jan 1, 2022		Recognized in profit or loss		Recognized in OCI		Acquisitions/Disposals		Dec 31, 2022	
	Deferred tax assets	Deferred tax liabilities	Deferred tax assets	Deferred tax liabilities	Deferred tax assets	Deferred tax liabilities	Deferred tax assets	Deferred tax liabilities	Deferred tax assets	Deferred tax liabilities
Intangible assets	815	127,727	1,386	- 20,986	0	0	10	3,717*	2,211	110,458
Property, plant and equipment	1,436	743	528	- 297	0	0	0	0	1,964	446
Right-of-use assets	76	15,588	- 76	- 1,034	0	0	0	0	0	14,554
Inventories	5,043	0	3,799	52	0	0	0	0	8,842	52
Trade receivables	3,616	1,064	850	- 847	0	0	0	0	4,466	217
Finance lease receivables	0	5,528	0	236	0	0	0	0	0	5,764
Contract assets	0	5,728	0	- 1,035	0	0	0	0	0	4,693
Other assets	822	2,916	- 820	3,152	6	4,197	0	0	8	10,265
Equity	1,120	0	0	0	0	0	0	0	1,120	0
Provisions for post-employment benefits and other non-current provisions	4,233	25	- 1,269	- 2,061	0	2,039	0	0	2,964	3
Trade payables	702	7,216	- 572	1,632	0	0	0	0	130	8,848
Contract liabilities	6,836	0	5,823	512	0	0	0	0	12,659	512
Other provisions and liabilities	3,020	2,115	- 1,579	1,862	0	0	0	0	1,441	3,977
Leasing liabilities	14,718	73	- 8,769	- 68	0	0	0	0	5,949	5
Tax losses carried forward	30,885	0	- 18,536	0	0	0	0	0	12,349	0
	73,322	168,723	- 19,235	- 18,882	6	6,236	10	3,717	54,103	159,794
Offsetting of deferred tax assets against deferred tax liabilities	- 68,398	- 68,398	0	0	0	0	16,814	16,814	- 51,584	- 51,584
Total	4,924	100,325	- 19,235	- 18,882	6	6,236	16,824	20,531	2,519	108,210

* This includes reclassifications from income tax liabilities of kEUR 3,094.

The netting of deferred tax assets with deferred tax liabilities in the current reporting year amounts to kEUR 16,814 in the acquisitions/ disposals column.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The deferred tax assets and liabilities by consolidated statement of financial position item for the comparative prior-year period as at December 31, 2021 are shown in the table below:

kEUR	Jan 1, 2021		Recognized in profit or loss		Recognized in OCI		Acquisitions/Disposals		Dec 31, 2021	
	Deferred tax assets	Deferred tax liabilities	Deferred tax assets	Deferred tax liabilities	Deferred tax assets	Deferred tax liabilities	Deferred tax assets	Deferred tax liabilities	Deferred tax assets	Deferred tax liabilities
Intangible assets	343	93,440	471	11,215	0	0	1	23,072	815	127,727
Property, plant and equipment	877	740	559	3	0	0	0	0	1,436	743
Right-of-use assets	5	9,975	71	5,613	0	0	0	0	76	15,588
Inventories	5,039	0	4	0	0	0	0	0	5,043	0
Trade receivables	2,245	4,202	1,371	- 3,138	0	0	0	0	3,616	1,064
Finance lease receivables	0	5,065	0	463	0	0	0	0	0	5,528
Contract assets	288	0	- 288	5,728	0	0	0	0	0	5,728
Other assets	380	1,977	442	939	0	0	0	0	822	2,916
Equity	1,120	0	0	0	0	0	0	0	1,120	0
Provisions for post-employment benefits and other non-current provisions	6,147	0	- 885	25	- 1,033	0	4	0	4,233	25
Trade payables	324	3,648	378	3,568	0	0	0	0	702	7,216
Contract liabilities	4,439	0	2,397	0	0	0	0	0	6,836	0
Other provisions and liabilities	1,695	509	1,325	1,606	0	0	0	0	3,020	2,115
Leasing liabilities	9,263	5	5,455	68	0	0	0	0	14,718	73
Tax losses carried forward	9,558	0	21,327	0	0	0	0	0	30,885	0
	41,723	119,561	32,627	26,090	- 1,033	0	5	23,072	73,322	168,723
Offsetting of deferred tax assets against deferred tax liabilities	- 36,770	- 36,770	0	0	0	0	- 31,628	- 31,628	- 68,398	- 68,398
Total	4,953	82,791	32,627	26,090	- 1,033	0	- 31,623	- 8,556	4,924	100,325

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

c) Tax loss carryforwards

kEUR	Dec 31, 2022	Dec 31, 2021
Total losses carried forward	284,842	289,869
thereof tax deductible	46,252	75,882
thereof unused tax losses carried forward	149,844	142,767
thereof not usable for tax purposes	88,746	71,220

The recognized loss carryforwards of kEUR 46,252 (prior year: kEUR 75,882) can currently be carried forward and used without limitation and refer to the USA. As at the reporting date, tax loss carryforwards exist, which are not recognized due to unforeseeable usability. The current estimate may change in future years depending on the results of operations of the companies and tax legislation and may require an adjustment. Due to the macroeconomic development, no deferred tax assets were recognized for these tax loss carryforwards of kEUR 149,844 (prior year: kEUR 142,767), as it is currently assumed that the tax loss carryforwards can probably not be utilized in the context of tax result planning, which is why deferred tax assets were only formed up to the amount of deferred tax liabilities.

Because of their age structure, loss carryforwards of kEUR 88,746 (prior year: kEUR 71,220) can no longer be utilized for tax purposes. The majority of the loss carryforwards not recognized and non-deductible (for tax purposes) originate from US subsidiaries.

For the calculation of loss carryforwards that are non-deductible (for tax purposes), we regularly use the information on the historical view of tax loss carryforwards in the local tax returns of the subsidiaries concerned.

Deferred tax liabilities essentially relate to capitalized internally generated software at group level and acquired software licenses, customer relationships and trademarks from company acquisitions as well as deferred taxes on other consolidation procedures (in particular the elimination of intercompany results).

Deferred taxes break down as follows in relation to their expected future usability:

kEUR	Deferred tax assets		Deferred tax liabilities	
	Dec 31, 2022	Dec 31, 2021	Dec 31, 2022	Dec 31, 2021
Utilization expected within 12 months	2,519	4,856	13,095	2,131
Utilization expected after more than 12 months	0	68	95,115	98,194
Total	2,519	4,924	108,210	100,325

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

E.6 Inventories

kEUR	Dec 31, 2022	Dec 31, 2021
Raw materials and supplies	171	292
Products	29,267	20,350
Total	29,438	20,642

Changes in inventories including impairment on inventories were as follows:

kEUR	Dec 31, 2022	Dec 31, 2021
Inventories as of 1 January	20,642	18,158
Changes in the scope of consolidation	0	195
Write-downs in the reporting period	-3,300	-68
Changes in inventory	12,088	2,349
Changes in exchange rate	8	8
Inventories as of 31 December	29,438	20,642

Impairment on inventories was recognized through profit or loss under expenses for goods and services purchased. There are no inventories pledged as security for liabilities.

E.7 Trade receivables

Trade receivables are amounts owed by customers for goods sold or services rendered in the ordinary course of business. They are generally payable within 14 days and are therefore classified as current assets. They consist exclusively of contracts with customers. Trade receivables are initially recognized at the amount of the unconditional consideration. If they contain significant financing components, they must instead be recognized at fair value. The CGM Group does not have any trade receivables with a significant financing component.

a) Trade receivables

	Dec 31, 2022	Dec 31, 2021
kEUR	current	current
Trade receivables	209,972	164,729
Write-down	- 20,533	- 17,502
Total	189,439	147,227

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Information on impairment from trade receivables is included in note G.6. Credit risk.

b) Trade receivables (by region)

kEUR	Dec 31, 2022	Dec 31, 2021
Trade receivables		
of which domestic	93,062	71,545
of which foreign	96,377	75,682
Total	189,439	147,227

E.8 Finance lease receivables

Finance lease receivables relate primarily to the following group companies, which offer hardware leases to their customers (including all peripheral devices) with terms of up to five years: Lauer-Fischer GmbH, CGM Clinical Österreich GmbH, CGM Arztsysteme Österreich, HCS Health Communication Service GmbH, Innomed Gesellschaft für medizinische Softwareanwendungen GmbH, CGM Denmark A/S, CGM Dentalsysteme GmbH, CGM Italia SpA, Qualità in Farmacia S.r.l., Farma3tec S.r.l., Mondofarma S.r.l., Vega Informatica e Farmacia S.r.l., ATX Advanced Technology Explained NV, CGM Systemhaus GmbH und EPSILOG SAS. Income from these leases is reported in the income statement as revenues. The contracts are classified as finance leases.

The following table provides an overview of the maturities of future lease payments and the interest components of finance lease receivables reported under trade account receivables:

	2022			2021		
kEUR	Future minimum lease payments	Interest component	Present value of future leasing receivables	Future minimum lease payments	Interest component	Present value of future leasing receivables
< 1 year	10,844	1,618	9,226	10,545	1,718	8,827
1-5 years	17,767	1,717	16,050	19,147	2,019	17,128
> 5 years	64	1	63	59	1	58
Total	28,675	3,337	25,339	29,751	3,738	26,013

Finance lease receivables were reduced by the amount of kEUR 203 for expected credit losses. Information regarding the loss allowance for Receivables from finance leases in accordance with IFRS 9 is provided under Note G. 5. Credit risk.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

E.9 Contract assets

Contract assets are broken down as follows:

	Dec 31, 2022	Dec 31, 2021
kEUR	current	current
Contract assets	23,495	26,784
Write-down	- 213	- 218
Total	23,282	26,566

Contract assets originate exclusively from contracts with customers. For information on impairment recognized as per IFRS 9, please see note G.6. Credit risk.

E.10 Other financial assets

Other financial assets are broken down as follows:

	Dec 31, 2022		Dec 31, 2021	
kEUR	current	non-current	current	non-current
Loans	241	18	37	6,745
Creditors with debit balances	1,975	0	2,025	0
Deposits	75	2,005	229	1,754
Other financial assets	551	88	428	817
Total	2,842	2,111	2,719	9,316

The following table provides information on impairment on other financial assets:

	Dec 31, 2022	Dec 31, 2021
kEUR		
Other financial assets	5,348	12,313
Impairment	- 395	- 278
Total	4,953	12,035

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

E.11 Derivative financial instruments

Derivative financial instruments are broken down as follows:

kEUR	Dec 31, 2022		Dec 31, 2021	
	current	non-current	current	non-current
Derivatives classified as Cash flow hedges	574	10,783	0	0
Derivatives without hedging relationship	0	25,777	0	6,594
Assets	574	36,560	0	6,594
Derivatives classified as Cash flow hedges	- 901	0	0	0
Liabilities	- 901	0	0	0
Total	- 327	36,560	0	6,594

Information regarding the interest rate cap (compares Derivative without hedging relationship) and interest swap (compares long-term Derivative classified as Cash flow hedges) can be found under note G. 8. Interest rate risk.

E.12 Other non-financial assets

Other non-financial assets are broken down as follows:

kEUR	Dec 31, 2022		Dec 31, 2021	
	current	non-current	current	non-current
Capitalized sales commissions	800	1,200	800	1,200
Input tax surplus receivables	6,790	0	7,915	0
Prepayments for future periods	18,593	0	17,104	0
Other	820	0	1,152	0
Total	27,003	1,200	26,971	1,200

In the 2022 financial statements, depreciation and impairment of the costs of obtaining a contract amounted to kEUR 800 (prior year: kEUR 800) and were recognized in personnel expenses in the amount of kEUR 600 (prior year: kEUR 600) and in cost of materials in the amount of kEUR 200 (prior year: kEUR 200). Moreover, costs of obtaining a contract amounting to kEUR 800 (prior year: kEUR 800) were again capitalized in the financial year as at December 31, 2022 in line with the carrying amount.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

E.13 Cash and cash equivalents

kEUR	Dec 31, 2022	Dec 31, 2021
Cash and cash equivalents	90,462	107,288
Restricted cash	55	55
Total	90,517	107,343

As at December 31, 2022, cash and cash equivalents include restricted cash held by subsidiaries in countries with restrictions on foreign exchange transactions. These are subject to legal transfer restrictions and are therefore not available to the group for general use. This relates to South Africa.

Cash at banks refers to current accounts. Interest rates as at the reporting date of December 31, 2022 varied between 0.25 % and 1.35 %. Careful cash disposition allowed for depositing the majority of cash and cash equivalents at a minimum of zero percent in financial year 2022 and keeping the burden from negative interest to a minimum. Please see the statement of cash flows for information on changes in cash.

E.14 Equity

a) Subscribed capital

The company's subscribed and authorized capital consists of:

kEUR	Dec 31, 2022	Dec 31, 2021
Issued and fully paid ordinary shares		
53,734,576 nominal shares of € 1.00 each	53,735	53,735
Authorized capital		
26,094,449 nominal shares of € 1.00 each	26,094	26,094

(i) Issued and fully paid ordinary shares

The company has only one class of shares. These do not grant entitlement to a fixed dividend. Subscribed capital is divided into 53,734,576 no-par registered shares, having the securities ID number A28890 (ISIN: DE000A288904). Subscribed capital cannot be repaid.

(ii) Authorized capital

We refer to the explanations on authorized capital in the section Authorization of the general partner to issue and buy back shares in the management report.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(iii) Contingent capital

We refer to the explanations on contingent capital in the section Authorization of the general partner to issue and buy back shares in the management report.

b) Treasury shares

As at December 31, 2022, CompuGroup Medical SE & Co. KGaA held 1,500,000 (prior year: 1,403,878) treasury shares, representing 2.79 % of the share capital. The notional value attributable to the share capital amounts to EUR 1,500,000 (prior year: EUR 1,403,878). The company's holding of treasury shares stems from the following acquisitions and disposals:

Financial year	Period of the buyback program / date of sale of treasury shares	Number of shares repurchased / sold	Interval acquisition cost / sale price in EUR	Weighted average acquisition cost / sale price per share in EUR
2021	February 26 to April 29, 2021	1,000,000	65.6039 to 76.1176	71.3530
2021	November 26 to Dezember 30, 2021	403,878	65.7609 to 71.3793	67.9490
2022	January 3 to January 10, 2022	96,122	62.7451 to 71.7694	66.6764
Gesamt		1,500,000		

CompuGroup Medical SE & Co. KGaA is authorized by resolution of the Annual General Meeting of May 19, 2022 to acquire treasury shares up to a total of 10 % of the share capital existing at the time of the resolution or, if this amount is lower, of the share capital existing at the time this authorization is exercised. Please refer to the detailed information on Authorization to Acquire and Use (Including Cancellation of) Treasury Shares in the management report.

c) Other

The changes in the CGM group's reserves under consolidated equity are as follows:

kEUR	Dec 31, 2022	Dec 31, 2021
Balance as at January 1	664,479	611,259
Group net income	73,411	68,970
Actuarial gains and losses	4,577	6,118
Dividend distribution	-26,117	-26,367
Stock options program	-2,011	4,544
Additional purchase of shares from non-controlling interests after control	-91	-45
Balance as at December 31	714,248	664,479

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The most significant developments in 2022 are described below:

The consolidated net income for the period (attributable to the shareholders of the parent company) of kEUR 73,411 (prior year: kEUR 68,970).

By way of resolution of the Annual General Meeting of May 19, 2022 a dividend of kEUR 26,117 (prior year: kEUR 26,367) was distributed to the shareholders, which translates to a dividend of EUR 0.50 (prior year: EUR 0.50) per dividend-bearing share.

Reserves (capital reserves, retained earnings and dividends on equity instruments) were increased by the actuarial gain of kEUR 4,577 (prior year: kEUR 6,118).

By acquiring additional shares of non-controlling interests after having already held a majority interest, the reserves decreased by kEUR - 91 (prior year: kEUR - 45).

The expenses for share options of the Managing Directors and Senior Management amounted to kEUR - 2,011 (prior year: kEUR 4,544) and were recognized in reserves.

If a final dividend is recommended, it will be conditional on shareholder approval at the Annual General Meeting in 2023; therefore, it is not recognized as a liability in the consolidated financial statements. The company will not experience any income tax effects as the result of a dividend. The amount of the dividend is exclusively dependent on the separate financial statements of CompuGroup Medical SE & Co. KGaA. The dividend expected to be proposed for financial year 2022 is to amount to EUR 0.50 per eligible share, which translates to a total amount of kEUR 26,117. The total distribution amount stated above does not take into account any change in the number of shares entitled to dividends as a result of any further capital measures and share buybacks.

d) Currency translation

kEUR	Dec 31, 2022	Dec 31, 2021
Balance as at January 1	-7,344	-26,327
Currency conversion differences	9,449	18,983
Balance as at December 31	2,105	-7,344

Exchange differences from translating the functional currency of foreign operations into the group's reporting currency (EUR) are recognized in the consolidated financial statements directly in other comprehensive income and accumulated in the foreign currency translation reserve. Exchange differences which were recognized earlier in the foreign currency translation reserve (translation of net assets of foreign operations) are reclassified to the income statement once a partial or complete sale of the corresponding operation has been performed.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

e) Cash flow hedges

Changes in the fair value of derivatives designated in hedging relationships (cash flow hedges) adjusted for deferred taxes in the amount of kEUR – 3.230 (prior year: kEUR 0) changed equity by a total of kEUR 7.537 (prior year: kEUR 0).

f) Non-controlling interests

Non-controlling interests by company

	Medicitalia S.r.l.		Farloyalty S.r.l.		S'moove Software S.r.l.		4K S.r.l.		Total	
kEUR	2022	2021	2022	2021	2022	2021	2022	2021	2022	2021
Amount of shareholding	100%	90%	51%	51%	53%	53%	60%	30%	-	-
Voting interest	100%	90%	51%	51%	53%	53%	60%	30%	-	-
Equity of non-controlling interests	0	-74	197	191	98	93	1,108	0	1,403	210
Dividends paid to non-controlling interests	0	0	175	170	0	0	0	0	175	170
Assets	0	-2,371	1,129	954	429	374	5,916	0	7,474	-1,043
Liabilities	0	-5,476	1,595	1,291	649	-211	8,659	0	10,903	-4,396
Net income of the company	0	-1,121	371	343	10	5	1,300	0	1,681	-773

Changes in non-controlling interests in financial year 2022

kEUR	Dec 31, 2022	Dec 31, 2021
Balance as at January 1	210	270
Share of profit for the year	706	62
Addition S'moove Software S.r.l.	0	91
Addition 4K S.r.l.	588	0
Dividend distribution to non-controlling shareholder	-175	-170
Additional purchase of shares from non-controlling interests after control	74	-45
Balance as at December 31	1,403	210

Acquisition of additional interests in subsidiaries

The CGM group carried out the following transactions with non-controlling shareholders in financial year 2022:

Acquisition of additional interest in Medicialia S.r.l., Italy

As at March 3, 2022, it was resolved to transfer another 10 % in Medicialia S.r.l. to CompuGroup Medical Italia SpA. The purchase price amounted to kEUR 17 and has been paid in full as at the reporting date. CompuGroup Medical Italia SpA now holds 100 % of the shares in Medicialia S.r.l.

The effect of the change in the CGM group's interest in the equity attributable to shareholders of the parent company in financial year 2022 is as follows:

	2022	2021
kEUR	Medicialia S.r.l.	HABA Computer AG
Book value of acquired non-controlling interests	-91	-45
Purchase price paid to non-controlling shareholders	17	90

E.15 Retirement plans and provisions for post-employment benefits and other non-current provisions

a) Defined benefit plans

The CGM group offers defined benefit plans in various countries with different characteristics.

Germany:

There are vested pension obligations for current and former employees in Germany, which are partially covered by reinsurance instruments. The pension obligations here comprise retirement and disability pensions as well as survivors' and death benefits, depending on specifics of the respective contract. The acquisition of the German Cerner portfolio in financial year 2020 also meant that obligations were assumed under Siemens pension plans (BSAV) and under partial retirement agreements already concluded. The majority of the employees taken over participate in the BSAV pension plan, which means that future benefits will be based primarily on nominal contributions and their investment income, as well as a guaranteed minimum interest rate. The BSAV plans are partially covered by assets and reinsurance in contractual trust arrangements (CTA).

Austria:

Severance payment provisions have been made for the majority of Austrian employees (in accordance with section 23 of the Angestelltengesetz (Austrian Salaried Employees Act) and section 2 of the Arbeiterabfertigungsgesetz (Austrian Employees Severance Pay Act)) that are considered post-employment benefits in accordance with IAS 19. These severance payment provisions constitute a severance payment in relation to payments that eligible employees receive when they leave the company or upon death.

Switzerland:

Employees at the subsidiary CGM Schweiz AG are granted pensions financed by a pension fund consisting of employer and employee contributions and income generated on investments. Given the inclusion of the statutory minimum pension provision in accordance with Swiss law through Swiss occupational pension plans (BVG), the pension plan is recognized as a defined benefit plan. All benefits vest immediately. Under the legal requirements, the employer is required to pay employer contributions that enable the pension fund to finance the minimum level of provision. The pension fund is managed through a trust board comprising employee and employer representatives, which manages and monitors the benefit plan and asset investment.

Italy:

Obligations also exist in Italy within the scope of the TFR-Fund (Italian Civil Code Article 2120), which are considered as post-employment benefits in accordance with IAS 19. The TFR-Fund is equivalent to severance pay based on the years of service that eligible employees receive when they leave the company.

The Netherlands:

In the Netherlands, the existing defined benefit plans, generally based on length of service and salary, and the so-called legacy plans were sold to an external service provider in the reporting year. Obligations recognized as at December 31 of the prior year approximated the transaction price.

Other countries:

There are also obligations at other foreign subsidiaries for statutory programs in France, India, Poland, and Turkey. They have a similar structure to the obligations in Italy or Austria and should thus be considered as post-employment benefits in accordance with IAS 19.

Risks:

In general, the CGM group is exposed to the following actuarial risks with regard to the existing CGM group defined benefit plans:

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

- Longevity risk:

The present value of the defined benefit obligation for the corresponding defined benefit plans is determined based on the best estimate of mortality of each beneficiary both during employment and after termination. An increase in the life expectancy of eligible employees leads to an increase in the plan liability.

- Salary risk:

The present value of the defined benefit obligation for appropriate benefit plans is determined based on the expected future salaries of eligible employees. Accordingly, salary increases of eligible employees raise the defined benefit obligation associated with the plan.

- Inflation risk:

An increase in the long-term inflation assumption would primarily affect the expected pension trend and the expected increase in pensionable salaries.

Risks arising from the payment of benefits to family members (surviving dependent benefits) of eligible employees are partially reinsured by an external insurance company.

Accounting and measurement

Provisions for post-employment benefits are accounted for using the current pension reports, all of which were compiled by external service providers (actuaries).

The following actuarial parameters were taken as a basis for determining the defined benefit obligation and related plan assets:

	Discount rate(s) in %		Expected rate(s) of salary increase in %		Pension growth rate(s) in %	
	Dec 31, 2022	Dec 31, 2021	Dec 31, 2022	Dec 31, 2021	Dec 31, 2022	Dec 31, 2021
Germany	3.23%	0.60%	3.00%	3.00%	2.20%	1.81%
Austria	3.49%	0.90%	3.00%	2.50%	n/a	n/a
Switzerland	1.95%	0.15%	2.60%	1.60%	n/a	n/a
France	3.20%	0.80%	3.90%	2.60%	n/a	n/a
India	7.50%	1.00%	9.20%	5.00%	n/a	n/a
Italy	3.20%	0.85%	3.50%	2.80%	n/a	n/a
Netherlands	n/a	0.93%	n/a	n/a	n/a	2.00%
Poland	6.80%	1.16%	7.30%	3.50%	n/a	n/a
Turkey	11.00%	18.80%	14.40%	14.90%	n/a	n/a

Domestic pension obligations are based on the mortality rates (based on the 2018 G Heubeck mortality tables).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The development of the defined benefit obligation in the year under review and the prior year is as follows:

kEUR	2022			2021		
	Present value of pension commitment	Fair value of plan assets	Total	Present value of pension commitment	Fair value of plan assets	Total
Balance as at 1 January	57,479	- 22,673	34,806	51,870	- 13,178	38,692
Current service costs	4,261	20	4,281	4,084	- 110	3,974
Interest income/cost	389	- 94	295	203	- 44	159
Past service cost, including losses/(gains) on curtailments	- 703	52	- 651	1,304	0	1,304
Components of defined costs recognised in profit or loss	3,947	- 22	3,925	5,591	- 154	5,437
Return on plan asset (excluding amounts included in net interests)	0	303	303	0	- 911	- 911
Actuarial gains and losses arising from changes in demographic assumptions	1	0	1	- 1,355	0	- 1,355
Actuarial gains and losses arising from changes in financial assumptions	- 8,562	0	- 8,562	- 1,515	- 35	- 1,550
Actuarial gains and losses arising from experience adjustments	1,634	0	1,634	- 3,494	56	- 3,438
Other effects	8	0	8	5	0	5
Components of defined benefit costs recognised in other comprehensive income	- 6,919	303	- 6,616	- 6,359	- 890	- 7,249
Payment of debts/disposal of assets by plan settlement	- 2,666	1,276	- 1,390	17	- 17	0
Liabilities assumed in a business combination / acquisitions	60	0	60	61	0	61
Liabilities assumed in mergers and transfers	0	0	0	234	0	234
Exchange rate differences on foreign pension plans	660	- 655	5	1,222	- 508	714
Benefits paid	- 2,672	1,478	- 1,194	- 582	- 1,288	- 1,870
Contributions from the employer	- 803	- 1,292	- 2,095	- 520	- 693	- 1,213
Contributions from plan participant	259	- 259	0	220	- 220	0
Reclassification	0	0	0	5,725	- 5,725	0
Other Reconciliation items and Payments	- 5,162	548	- 4,614	6,377	- 8,451	- 2,074
Balance as at 31 December	49,345	- 21,844	27,501	57,479	- 22,673	34,806

The annual cost of kEUR 3,925 (prior year: kEUR 5,437) is recognized in personnel expenses of the CGM group. Defined benefit costs arising from the remeasurement of the net liability for defined benefit plans in the amount of kEUR 6,616 (prior year: kEUR 7,249) were recognized in other comprehensive income.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The fair values of plan assets to secure the pension obligations are broken down as follows:

		Dec 31, 2022			Dec 31, 2021		
kEUR		with quoted market price	do not have quoted market price	Total	with quoted market price	do not have quoted market price	Total
Germany	Cash and cash equivalent	108	0	108	1,011	0	1,011
	Equity instruments (shares)	5,738	0	5,738	2,144	0	2,144
	Debt instruments (annuity bonds)	12	0	12	2,933	0	2,933
	Liability insurance	0	2,234	2,234	683	1,650	2,333
Switzerland	Other (Pension fund)	0	13,752	13,752	0	12,976	12,976
Netherlands	Liability insurance	0	0	0	0	1,276	1,276
Total		5,858	15,986	21,844	6,771	15,902	22,673

The average weighted duration of the pension obligation is 23 years for Poland, 22 years for India, 17 years for France, 17 years for Turkey, 14 years for Switzerland, 13 years for Italy, 11 years for Austria and 5 years for Germany.

Changes in provisions for post-employment benefits in the last five years are shown in the following table:

	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022
Present value of pension commitment	23,231	24,095	24,966	32,298	57,479	49,345
Fair value of plan assets	- 3,094	- 2,926	- 3,908	- 5,683	- 22,673	- 21,844
Shortfall	20,137	21,169	21,058	26,615	34,806	27,501

A total of kEUR 4,750 (prior year: kEUR 4,416) is expected to be paid into defined benefit pension plans in the coming financial year 2023 and recognized in profit or loss accordingly.

Sensitivity analysis

The primary actuarial assumptions used to determine the defined benefit obligation in the CGM group are the discount rate, expected salary increases, and inflation expectations. The sensitivity analyses presented below are based on the best estimate of potential changes in the assumptions as at the reporting date of December 31, 2022. In the event of a change in one actuarial assumption in the sensitivity analysis, the other actuarial assumptions remain unchanged.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

	Increase		Decrease	
	in %	kEUR	in %	kEUR
Impact of the discount rate on pension commitment	0.50%	- 2,107	0.50%	2,297
Impact of future salary increases on pension commitment	0.50%	737	0.50%	- 734
Impact of future pension development on pension commitment	0.50%	828	0.50%	- 780

For the above sensitivity analysis, it is unlikely that the scenario in question will occur in reality because it is likely that a change in one actuarial parameter assumption will correlate with others. The sensitivity analysis of the defined benefit obligations applies the same method used to calculate pension provisions recognized in the statement of financial position.

b) Defined contribution plans and state plans

On the basis of statutory or contractual provisions, contributions to the defined contribution plans are paid to state or private pension funds. Expenses recognized in profit or loss totaled kEUR 28,986 in financial year 2022 (prior year: kEUR 23,862).

In financial year 2022, contributions in the amount of kEUR 18,911 (prior year: kEUR 16,338) were paid to the German pension insurance.

c) Anniversary provisions

The anniversary provisions for the German companies (kEUR 4,893; prior year: kEUR 5,526) are calculated with a discount rate of 3.3 % (prior year: 0.6 %). In addition, anniversary provisions for the Dutch companies (kEUR 262; prior year: kEUR 301) are recognized with a weighted discount rate of 3.2 % (prior year: 0.5 %).

In accordance with the option in IAS 19, the interest component is not accounted as part of net interest result but as part of the operating cost. The calculation of the German anniversary provisions was based on the "2018 G" mortality tables by Professor Dr. Klaus Heubeck and the "AG2020" guidance table for the Dutch, and take social security contributions into consideration at a flat rate.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

E.16 Financial liabilities (current and non-current)

The financial liabilities of the CGM group break down as follows:

kEUR	Dec 31, 2022		Dec 31, 2021	
	Current	Non-current	Current	Non-current
Current liabilities to banks	29,104	699,371	92,476	582,441
Other loans	4,594	53	4,532	4,640
Total	33,698	699,424	97,008	587,081

In financial year 2022, new liabilities to banks and other loans amounting to kEUR 340,000 (prior year kEUR 265,081) were taken out, while an amount of kEUR 295,411 (prior year: kEUR 91,142) was repaid. Financial liabilities increased by kEUR 52 as a result of changes in the consolidation group.

a) Liabilities to banks

Liabilities to banks break down as follows:

kEUR	Book value as at Dec 31, 2021	Interest rate as at Dec 31, 2022 in %	Currency	Due Year	Book value as at Dec 31, 2022	Fair value as at Dec 31, 2022
Syndicated loan	580,000	1.88% - 2.28%	EUR	2025-2027	450,000	450,000
EIB loan	0	2.03%	EUR	2028	200,000	200,000
Other secured bank loans	4,340	1.00% - 2.85%	EUR	2023	1,719	1,678
Other unsecured bank loans	90,577	1.79% - 3.10%	EUR	2023-2025	76,756	76,705
Total	674,917		EUR		728,475	728,383

On January 28, 2020, CGM took out a credit facility of mEUR 1,000 with a term of at least five years; the facility comprises a revolving multi-currency credit facility (RCF) of mEUR 600 and a mEUR 400 term loan (TLF).

The syndicated loan has a total term of five years with two renewal options of one year each for the revolving credit facility. The second option was exercised in January 2022. The interest rate is based on EURIBOR (LIBOR for foreign currency loans) for the selected interest period plus a margin that can change in contractually agreed stages in line with the leverage ratio. As at December 31, 2022, the TLF was utilized in the amount of mEUR 400 and the RCF in the amount of mEUR 50. The interest rate was 2.28 % for the TLF and 1.88 % for the RCF as at December 31, 2022.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Transaction costs in the amount of kEUR 659 were released in 2022 (prior year: kEUR 679). In addition, loan commitment fees of kEUR 1,999 (prior year: kEUR 1,249) were also incurred in 2022. In order to hedge interest rate risks, CGM concluded in 2021 an interest rate cap with a nominal volume of mEUR 400 and a remaining term to maturity until May 7, 2031. In addition, an interest rate swap with a remaining term until July 11, 2028 and a notional amount of mEUR 200 was concluded in October 2022. The loans are subject to compliance with contractually agreed financial covenants (leverage ratio).

Various German group companies have issued joint and several payment guarantees for this loan agreement (default liability for nonpayment by CompuGroup Medical SE & Co. KGaA).

In financial year 2022, CGM fully complied with all financial covenants in the existing loan agreements.

b) Other loans

Other loans as at December 31, 2022 amounted to kEUR 4,647 (prior year: kEUR 9,172). This mainly relates to the financing of the "OneGroup Project" in the form of a "sale and hire-purchase back" transaction, which is reported under other financial liabilities.

c) Expected payments for financial liabilities

kEUR	Total financial debt	of which: liabilities to banks
< 1 year	33,698	29,104
1–5 years	499,424	499,371
> 5 years	200,000	200,000
Total	733,122	728,475

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

E.17 Lease liabilities (current and non-current)

Lease liabilities break down as follows:

kEUR	Dec 31, 2022		Dec 31, 2021	
	current	non-current	current	non-current
Liabilities Land and Buildings - IFRS 16	13,771	28,027	14,342	34,963
Liabilities Vehicles - IFRS 16	5,675	5,564	4,256	3,531
Liabilities Other - IFRS 16	157	149	76	50
Total	19,603	33,741	18,673	38,544

For further details, please refer to note 15 in section D. Leases. The lease liabilities from companies acquired during financial year 2022 amounted to kEUR 756.

E.18 Purchase price liabilities (current and non-current)

kEUR	Dec 31, 2022			Dec 31, 2021		
	current	non-current	Total	current	non-current	Total
Fablab S.r.l.	0	0	0	0	2,603	2,603
INSIGHT Health GmbH	10,000	4,500	14,500	0	0	0
Innomed GmbH	2,871	0	2,871	5,192	0	5,192
Schuyler House Inc.	965	0	965	118	909	1,027
Meta-it GmbH	375	375	750	750	750	1,500
Other	1,835	664	2,499	1,393	0	1,393
Total	16,046	5,539	21,585	7,453	4,262	11,715

Changes to prior year

Fablab S.r.l.: In 2022, kEUR 2,590 of the contingent consideration was paid, resulting from the acquisition of 100 % of the shares in Fablab S.r.l. in 2019.

Innomed Gesellschaft für medizinische Softwareanwendungen GmbH: In 2022, CGM paid current purchase price liabilities of kEUR 2,778 that resulted from the exercise of the put option on the part of the non-controlling shareholders for 9.9 % of the shares in Innomed Gesellschaft für medizinische Softwareanwendungen GmbH. The exercise price is based on clearly defined revenue amounts.

Meta-it GmbH: In the first half of 2022, current purchase price liabilities of kEUR 750 were paid, resulting from the acquisition of 100 % of the shares in Meta-it GmbH in 2021.

Current purchase price liabilities (due in less than one year)

INSIGHT Health GmbH: Contingent considerations were agreed in the purchase agreement that provide for further purchase price payments. The amount of the expected payment amount still totals kEUR 14,500 and is reported under both current and non-current purchase price liabilities.

Innomed Gesellschaft für medizinische Softwareanwendungen GmbH: The put option of the non-controlling shareholder for the outstanding 9.9 % of the shares in Innomed was exercised. The purchase price was based on the average EBITDA for the years 2021 and 2022 multiplied by the factor six. Furthermore, the undistributed profits totaling kEUR 3,614 since financial year 2010 are recognized pro rata (9.9 %) in the purchase price liability (kEUR 2,871). Following a contractual extension, the put options can be exercised until December 31, 2023.

Schuyler House Inc.: Contingent considerations were agreed in the purchase agreement that foresee a further two additional purchase price payments which are based on pre-defined earnings figures. The total amount expected to be paid out is kEUR 965.

Meta-it GmbH: Contingent considerations were agreed in the purchase agreement that provide for further purchase price payments. The amount of the expected payment amount still totals kEUR 750, kEUR 375 is reported under current purchase price liabilities.

Non-current purchase price liabilities (due in more than one year)

INSIGHT Health GmbH: Non-current share of the reported purchase price liabilities in the amount of kEUR 4,500 as at December 31, 2022.

Meta-it GmbH: Non-current share of the reported purchase price liabilities in the amount of kEUR 375 as at December 31, 2022.

The sensitivity analyses of the purchase price liabilities did not reveal any significant effects. Adjusted for exchange rate effects and payments made in the financial year, the changes were recognized in profit or loss.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

E.19 Trade payables

kEUR	Dec 31, 2022	Dec 31, 2021
Trade payables	112,613	93,193

Trade payables all have a remaining term to maturity of up to one year. The trade payables from businesses acquired amount to kEUR 3,475 in financial year 2022.

E.20 Contract liabilities

Contract liabilities break down as follows:

	Dec 31, 2022		Dec 31, 2021	
kEUR	current	non-current	current	non-current
Contract liabilities	66,898	15,529	79,086	9,307

Contract liabilities originate exclusively from contracts with customers. The revenues recognized in 2022, which were included in the balance of contract liabilities at the beginning of the financial year, amount to kEUR 79,086 (prior year: kEUR 63,894), kEUR 15,115 (prior year: kEUR 11,771) of which relates to performance obligations that were fulfilled or partially fulfilled in earlier periods.

The effect of the acquisition of subsidiaries on contract liabilities was kEUR 2,720 (prior year: kEUR 13,132).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

E.21 Other provisions

The development of short-term provisions for personnel and other provisions for the financial year 2022 is as follows:

kEUR	Personnel expenses	Guarantee and sales commitments	External year-end accounting costs	Legal charges	Others	Total
Balance as at Jan 1, 2022	40,635	2,000	2,406	3,717	2,998	51,756
Exchange rate differences	99	-8	-6	-5	72	152
Addition from first-time consolidation	576	185	21	26	60	868
Arising during the year	37,702	1,448	1,884	3,543	5,096	49,673
Utilized	-30,160	-312	-1,743	-446	-1,653	-34,314
Unused amounts reversed	-6,068	-303	-98	-545	-201	-7,215
Balance as at Dec 31, 2022	42,784	3,010	2,464	6,290	6,372	60,920

The development of short-term provisions for personnel and other provisions for the prior-year period 2021 is as follows:

kEUR	Personnel expenses	Guarantee and sales commitments	External year-end accounting costs	Legal charges	Others	Total
Balance as at Jan 1, 2021	37,816	1,779	2,237	2,538	2,907	47,277
Exchange rate differences	161	-4	0	-3	138	291
Addition from first-time consolidation	2,413	174	49	-221	1,611	4,025
Arising during the year	35,880	667	1,814	2,169	1,146	41,676
Utilized	-31,050	-159	-1,328	-178	-2,380	-35,096
Unused amounts reversed	-4,585	-456	-366	-588	-423	-6,418
Balance as at Dec 31, 2021	40,635	2,000	2,406	3,717	2,998	51,756

Provisions for employee benefits primarily result from provisions for wages/salaries as well as bonuses/commission (2022: kEUR 32,698; prior year: kEUR 30,652). This item also includes provisions for vacation (2022: kEUR 8,578; prior year: kEUR 8,611) and for overtime (2022: kEUR 1,508; prior year: kEUR 1,372). These are calculated on the basis of the underlying hourly rates and social security deductions.

The provisions for guarantees mainly relate to contractual commitments in connection with the installation of hardware components.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The provisions recognized for litigation costs in financial year 2022 pertain to contractual risks of the German subsidiary CompuGroup Medical Software GmbH in the amount of kEUR 3,080 as well as to legal disputes with former employees and customers of the subsidiaries in France (2022: kEUR 1,884; prior year: kEUR 2,011) and legal disputes of the German subsidiary Lauer-Fischer GmbH in connection with a service product that was discontinued in 2021 (2022: kEUR 707; prior year: kEUR 1,204).

Provisions for guarantees and litigation costs are, by their very nature, subject to higher levels of uncertainty. Other provisions exclusively relate to short-term provisions.

E.22 Other financial and non-financial liabilities

a) Other financial liabilities

Other financial liabilities break down as follows:

kEUR	Dec 31, 2022		Dec 31, 2021	
	current	non-current	current	non-current
Loans	4,594	53	4,532	4,640
Debitors with credit balances	2,081	0	4,310	0
Other financial liabilities	1,803	0	6,288	0
Total	8,478	53	15,130	4,640

Loans essentially include the financing of the SAP One Group project.

b) Other non-financial liabilities

Other non-financial liabilities break down as follows:

kEUR	Dec 31, 2022		Dec 31, 2021	
	current	non-current	current	non-current
VAT, payroll tax	20,720	0	13,898	0
Guarantees	0	42	0	37
Liabilities from social security costs	4,510	0	3,796	0
Liabilities from wages and salaries	2,648	0	3,608	0
Other non-financial liabilities	717	0	601	0
Total	28,595	42	21,903	37

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

E.23 Revenues

Revenues break down as follows:

kEUR	2022	2021
Software licenses	82,394	86,909
Software maintenance and other recurring revenues	729,876	666,450
Services	123,986	108,024
Hardware	110,007	110,995
Advertising, e-detailing and data	70,212	43,196
Other revenues	13,264	9,748
Total	1,129,739	1,025,322

Group revenues are essentially generated from contracts with customers within the meaning of IFRS 15. Other revenues that are not covered by the scope of IFRS 15 (kEUR 9,854; prior year: kEUR 9,863) refer to leases with customers.

Please refer to the segment report for a breakdown of revenues in accordance with IFRS 15.114.

No information is provided on the remaining performance obligations as at December 31, 2022, which have an original expected duration of one year or less according to IFRS 15.

The total amount of the transaction price of the unfulfilled or partially unfulfilled performance obligations as at December 31, 2022 is kEUR 180,761 (prior year: kEUR 150,747). Management expects that this will result in the recognition of the following amounts of revenues in the coming financial years:

	within 1 year kEUR	1 - 5 years kEUR
	83,952	96,809

E.24 Research and development expenses and capitalized in-house services

a) Research and development expenses

Research and development expenses include all costs arising in the course of software research and development activities. In financial year 2022, these costs amounted to mEUR 237.8 (prior year: mEUR 202.5), mEUR 131.6 (prior year: mEUR 123.6) of which relates to development costs incurred due to statutory or contractually contracted ongoing development work (updates, maintenance, etc.), which cannot be predetermined or controlled by the CGM group.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The other expenses for research and development, which were recognized in profit or loss, amounted to mEUR 106.2 (prior year: mEUR 78.9), mEUR 44.8 of which (prior year: mEUR 37.3) was capitalized as internally generated software.

b) Capitalized in-house services

The capitalized in-house services of the CGM group consist of capitalized expenses for internally generated software in accordance with the criteria stated in IAS 38.

Approximately 804 thousand working hours were rendered in financial year 2022 (prior year: approximately 714 thousand working hours) and capitalized accordingly at their applicable cost rates. The hourly rate for capitalization ranges between EUR 26 and EUR 84, depending on the country. Assets in progress were tested for impairment leading to impairment losses of kEUR 342 in financial year 2022. The impairments refer to two projects that were written off in full.

E.25 Other income

kEUR	2022	2021
Income from services performed	1,027	427
thereof rental income	751	106
thereof services related income	250	83
thereof investment grants	26	238
Remaining other operating income	18,369	24,344
thereof compensation received from damages	370	275
thereof gain on sale of fixed assets	270	2,022
thereof revenues from valuation allowances/reversals	8,892	18,086
thereof other	8,837	3,961
Total	19,396	24,771

The increase in income in the Other item in financial year 2022 is mainly due to one-off insurance payments in the USA of kEUR 4,073.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

High one-off income, on the other hand, resulted from the disposal of non-current assets in financial year 2021, especially from the sale of the group-owned aircraft for kEUR 1,718. In addition, the Revenues from valuation allowances/reversals item included income of kEUR 11,014 from the reversal of provisions for risk provisioning and bonus payments as well as for outstanding invoices.

E.26 Expenses for goods and services purchased

kEUR	2022	2021
Software licenses	12,739	13,421
Software maintenance and other recurring revenues	88,414	86,689
Professional services	28,721	17,191
Hardware	64,626	65,753
Advertising, eDetailing and data	16,875	5,941
Other cost of goods	5,022	2,431
Total	216,397	191,426

Purchased services for software maintenance and other recurring revenues primarily relates to the cost of external service providers operating the customer service hotline and sales activities.

E.27 Personnel expenses and employees

a) Personnel expenses

kEUR	2022	2021
Salaries	432,966	389,433
Employer social security costs	92,459	86,737
of which net pension expenses – Benefits	3,925	5,437
of which net pension expenses – Contribution	28,986	23,862
Termination benefits	5,664	4,100
Other personnel expenses	15,615	17,454
Total	546,704	497,723

Acquisitions contributed kEUR 10,080 (prior year: kEUR 72,970) to the increase in personnel expenses in financial year 2022. Contributions to domestic statutory pension insurance amounted to kEUR 18,911 in 2022 (prior year: kEUR 16,338).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

b) Employees

The average number of the CGM group's employees in financial years 2022 and 2021 breaks down as follows:

	2022	2021
Full-time employees	7,771	7,118
Apprentices	202	187
Part time	1,120	1,030
Total	9,093	8,335

The average number of employees in a managerial role within the CGM group amounts to 103 (prior year: 112). The Managing Directors were not counted.

E.28 Other expenses

Other expenses breaks down as follows:

kEUR	2022	2021
Outsourcing	78,954	66,364
Legal and consulting fees	25,162	24,747
Advertising/entertainment	11,717	12,229
Travel expenses	8,091	5,030
IT (software, maintenance etc.)	26,144	17,322
Company cars	10,005	7,839
Occupancy	11,634	10,780
Losses on disposal of fixed assets	107	332
Telephone costs	5,378	6,016
Office supplies	3,546	2,588
Insurances	2,715	3,250
Other	26,088	20,973
Total	209,541	177,470

After the conversion of CompuGroup Medical SE into a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) as at June 18, 2020, all previous management board members of CGM SE were appointed as Managing Directors of CompuGroup Medical Management SE. As at that date, their remuneration is no longer included in personnel expenses, but as external service under Other expenses.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The Other expenses item also includes additional expenses for contract and project risks in the amount of kEUR 6,040 in financial year 2022.

E.29 Depreciation and amortization

Depreciation of property, plant and equipment breaks down as follows:

kEUR	2022	2021
Property and buildings	3,006	1,753
Other fixed assets and office equipment	14,040	14,532
Total	17,046	16,285

Depreciation of intangible assets breaks down as follows:

kEUR	2022	2021
Acquired software rights	20,757	19,842
Customer relationships	30,272	26,684
Trademark rights	2,603	2,882
Order backlog	3,283	8,429
Capitalized inhouse services	12,636	15,039
Total	69,551	72,876

Of this amount, kEUR 45,882 relates to amortization from purchase price allocations (prior year: kEUR 48,900). Of the amortization of internally generated software, kEUR 342 (prior year: kEUR 6,153) relates to impairment losses. In addition, impairment losses of kEUR 1,727 were incurred in the financial year due to the discontinuation of a business unit in Spain.

Depreciation of right-of-use assets breaks down as follows:

kEUR	2022	2021
Property and buildings - IFRS 16	17,708	15,010
Vehicles - IFRS 16	7,792	6,388
Other - IFRS 16	224	153
Total	25,724	21,551

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

E.30 Result from companies accounted for using the equity method

The results from companies accounted for using the equity method in financial year 2022 amount to kEUR - 99 (prior year: kEUR 33). The result in the prior year was mainly attributable to recognizing Better@Home Service GmbH in accordance with the equity method.

E.31 Financial income and financial expenses

a) Financial income

Financial income breaks down as follows:

kEUR	2022	2021
Write-up of derivatives without hedge accounting relationship	19,181	2,875
Currency gains	2,031	114
Interest income on loans	342	340
Interest income on cash at bank	235	253
Interest income on taxes	232	131
Income from the reversal of purchase price liabilities	13	112
Other	685	29
Total	22,719	3,854

Further information on derivatives not designated as hedging instruments is provided under note G. 8. Interest rate risk.

b) Financial expenses

Financial expenses break down as follows:

kEUR	2022	2021
Bank interest	10,054	5,271
Capitalized borrowing costs on qualified assets	- 1,519	- 812
Transaction costs/loan commitment fees	2,658	1,928
Increase/change in purchase price liabilities	1,514	111
Interest on lease liabilities	583	940
Currency losses	950	506
Other	344	746
Total	14,584	8,690

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

c) Impairment losses on financial assets

Impairment losses on financial assets break down as follows:

kEUR	2022	2021
Write-offs on loans issued	5,250	0
Total	5,250	0

The write-downs on loans issued relate exclusively to a loan granted to MGS Meine Gesundheit Services GmbH.

E.32 Income taxes

Income taxes break down as follows according to their origin:

kEUR	2022	2021
Current income taxes	32,346	35,379
Germany	12,308	14,550
Other countries	20,038	20,829
Deferred taxes	353	- 6,537
Total	32,699	28,842

Current tax expenses include a tax expense of kEUR 4,184 for prior financial years (prior year: kEUR 1,139). The deferred tax result includes effects from loss carryforwards of kEUR 18,536 (prior year: kEUR –21,327) counteracted by temporary effects of kEUR – 18,183 (prior year: kEUR –14,790).

(Deferred) income taxes, which are recognized directly in other comprehensive income, break down as follows:

kEUR	2022	2021
Deferred taxes	6,230	1,033
Arising in connection with income and expenses recognized in other comprehensive income:	6,230	1,033
Remeasurement of defined benefit obligation	2,039	1,033
Cashflow hedges	3,230	0
Effects from currency translation	961	0
Deferred tax recognized in other operating income	6,230	1,033

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The consolidated tax rate is used as a measure for group management and strategic planning. The consolidated tax rate is understood as the measure providing information on the (income) tax burden of the company. The consolidated tax rate is calculated by dividing the reported income tax expense by the result for the year before taxes. Consequently, the consolidated tax expense is the total amount of current and deferred taxes whereby the utilization of loss carryforwards, the use of tax credits and tax allowances and ensuring that deferred tax assets are not impaired have a favorable effect on the final consolidated tax rate.

The weighted average tax rate was 30 % (prior year: 30 %), which is equal to the corporate tax rate on taxable profits to be paid by CompuGroup Medical SE & Co. KGaA in Germany. Under German tax law, income taxes consist of corporation tax, trade tax and the solidarity surcharge for the former East Germany. The corporate tax rate for domestic companies in the CGM group is composed of corporation tax of 15 % (prior year: 15 %), the solidarity surcharge in the amount of 5.5 % on corporation tax (prior year: 5.5 % on corporation tax) and trade tax in the amount of 14 % (prior year: 14 %). For the foreign subsidiaries, the effective national tax rates are applied for the financial year.

The reconciliation between the statutory tax rate (nominal) and the actual tax rate is shown below:

	2022		2021	
kEUR	in %		in %	
Earnings before taxes (EBT)	106,816		97,874	
Tax expense at a tax rate of 30%	32,045	30.00 %	29,362	30.00 %
Effects of differing national tax rates	- 5,882	- 5.51 %	- 5,206	- 5.32 %
Effects of changes in tax rates on deferred taxes	109	0.10 %	223	0.23 %
Effects from tax losses and offset options for which no deferred tax asset was recognized	8,530	7.99 %	3,348	3.42 %
Effects from the previously unrecognized and unused tax losses and offset options that are now recognized as deferred tax assets	18,930	17.72 %	- 7,210	- 7.37 %
Effects from the use of previously unrecognized tax loss carryforwards	- 13,208	- 12.37 %	- 713	- 0.73 %
Effects of non-tax-deductible expenses	3,249	3.04 %	1,989	2.03 %
Effects of tax-free earnings	- 1,112	- 1.04 %	- 44	- 0.04 %
Impact of non taxable goodwill amortization/ impairment	1,199	1.12 %	0	0.00 %
Tax expense from previous years (True-Up's)	1,090	1.02 %	- 2,156	- 2.20 %
Effects from the previously unrecognized tax assets that are now recognized as deferred tax assets	- 13,868	- 12.98 %	0	0.00 %
Effects on tax expense from previous years due to tax audits	1,003	0.94 %	2,221	2.27 %
Effects from stock option programs	- 603	- 0.56 %	4,544	4.64 %
Other differences	1,217	1.14 %	2,484	2.54 %
Effective income tax expense	32,699	30.61 %	28,842	29.47 %

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Effects from deferred tax assets not recognized on tax loss carryforwards and temporary differences result mainly from CompuGroup Medical Inc, USA, and eMDs Inc., USA.

The effects on tax expenses from prior years due to tax audit result from risks based on expected results from changed findings of external audits.

The actual tax expense includes tax expenses of domestic and foreign companies that are related to other periods.

E.33 Earnings per share

	Dec 31, 2022	Dec 31, 2021
Consolidated net income for the period allocated to the parent company in kEUR	73,411	68,970
Number of ordinary shares	53,734,576	53,734,576
Treasury shares	1,500,000	1,403,878
Outstanding ordinary shares at closing date	52,234,576	52,330,698
Earnings per share (in EUR)		
– undiluted	1.41	1.30
– diluted	1.40	1.30

The (undiluted) earnings per share are calculated by dividing the consolidated net income for the year by the weighted average number of shares issued. The share options granted by the company lead to a dilution of earnings per share.

The time-weighted number of shares issued as at the reporting date, including share options, amounts to 52,288,547 (prior year: 52,970,723).

F. Segment reporting

For the definition of the business segments, the Managing Directors draw on internal reports that are also available to the Supervisory Board and analysts for their strategic decisions. In order to reflect regional differences of the healthcare industry with regard to organization and regulation, the reporting covers product and service-related financial data and regional information. For management purposes and resource allocation, the product and service-related structure is a decisive parameter and is divided into a total of four business segments.

For the purpose of assessing and evaluating the operating segments, the Managing Directors use the earnings indicator "earnings before interest, taxes, depreciation and amortization (EBITDA)", which therefore represents the segment result.

The activities included under All other segments (IFRS 8.16) mainly comprise income and expenses from the software development department based centrally in Koblenz and corporate functions managed centrally from the Koblenz site (e.g., IT, Human Resources, Legal).

The column Consolidation shows the consolidation adjustments between the segments.

The segment information is based on the same reporting and measurement methods as the consolidated financial statements. The business relationships between the companies of the group's segments are generally based on prices that would also be agreed with third parties.

For further detailed information on segment reporting, please refer to the management report, section 1.1 Group business model.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Segment report

	Segment AIS Ambulatory Information Systems		Segment HIS Hospital Information Systems		Segment CHS Consumer and Health Management Information Systems		Segment PCS Pharmacy Information Systems	
	2022	2021	2022	2021	2022	2021	2022	2021
kEUR	01.01 - 31.12.	01.01. - 31.12	01.01 - 31.12.	01.01. - 31.12	01.01 - 31.12.	01.01. - 31.12	01.01 - 31.12.	01.01. - 31.12
Revenues to third parties	502,287	475,846	277,217	257,426	219,594	173,664	130,547	118,240
thereof Software license	45,756	50,298	29,910	30,818	1,044	990	5,685	4,803
thereof Hardware	19,612	21,945	9,583	12,481	53,327	51,374	27,484	25,196
thereof Professional Services	41,409	35,445	47,358	48,013	22,897	15,237	12,228	9,195
thereof Software Maintenance & hotline	278,491	259,373	140,137	123,488	14,096	11,881	42,185	38,241
thereof Other recurring revenues	107,206	100,705	49,795	42,194	56,180	50,194	41,787	40,375
thereof Adverting, eDetailing and Data	682	765	0	3	69,039	42,136	490	293
hereof Other revenues	9,131	7,315	434	430	3,011	1,851	688	138
Point in time of revenue recognition								
at a specific point in time	35,858	33,052	14,880	18,152	56,463	53,404	29,812	26,755
over a period of time	466,429	442,794	262,337	239,274	163,130	120,260	100,735	91,485
	502,287	475,846	277,217	257,426	219,593	173,664	130,547	118,240
thereof recurring revenues	385,697	360,078	189,932	165,681	70,276	62,076	83,972	78,616
Revenues between segments	84,009	59,966	5,347	4,273	47,073	15,784	4,160	5,002
Segment Revenues	586,296	535,812	282,564	261,699	266,667	189,448	134,707	123,242
Capitalized inhouse services	11,322	7,397	18,491	17,775	10,791	7,568	4,215	4,555
Other income	11,315	7,084	6,197	9,894	1,299	1,613	2,822	1,577
Expenses for goods and services purchased	-145,451	-122,795	-48,076	-46,928	-133,863	-77,410	-35,242	-32,934
Personnel costs	-221,708	-212,385	-161,768	-143,748	-60,128	-46,524	-46,374	-43,572
Other expenses	-109,937	-98,375	-72,928	-55,722	-43,477	-34,804	-20,776	-19,168
EBITDA	131,837	116,738	24,480	42,970	41,289	39,891	39,352	33,699
in % of revenues	26.2%	24.5%	8.8%	16.7%	18.8%	23.0%	30.1%	28.5%
Depreciation of property, plant and equipment and rightof-use assets								
Amortization of intangible assets								
EBIT								
Result from companies accounted for using the equity method								
Financial income								
Financial expenses								
Net impairment losses on financial assets								
EBT								
Income taxes for the period								
Consolidated net income for the period								
in % of revenues								

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Segment report

	All other segments		Sum Segments		Consolidation		CGM Group	
	2022	2021	2022	2021	2022	2021	2022	2021
kEUR	01.01 - 31.12.	01.01. - 31.12	01.01 - 31.12.	01.01. - 31.12	01.01 - 31.12.	01.01. - 31.12	01.01 - 31.12.	01.01. - 31.12
Revenues to third parties	94	146	1,129,739	1,025,322	0	0	1,129,739	1,025,322
thereof Software license	0	0	82,395	86,909	0	0	82,395	86,909
thereof Hardware	0	0	110,006	110,996	0	0	110,006	110,996
thereof Professional Services	94	133	123,986	108,023	0	0	123,986	108,023
thereof Software Maintenance & hotline	0	0	474,909	432,983	0	0	474,909	432,983
thereof Other recurring revenues	0	0	254,968	233,468	0	0	254,968	233,468
thereof Adverting, eDetailing and Data	0	0	70,211	43,197	0	0	70,211	43,197
hereof Other revenues	0	13	13,264	9,747	0	0	13,264	9,747
Point in time of revenue recognition								
at a specific point in time	0	13	137,013	131,376	0	0	137,013	131,376
over a period of time	94	133	992,725	893,946	0	0	992,725	893,946
	94	146	1,129,738	1,025,322	0	0	1,129,738	1,025,322
thereof recurring revenues	0	0	729,877	666,451	0	0	729,877	666,451
Revenues between segments	10,247	8,650	150,836	93,675	-150,836	-93,675	0	0
Segment Revenues	10,341	8,796	1,280,575	1,118,997	-150,836	-93,675	1,129,739	1,025,322
Capitalized inhouse services	0	0	44,819	37,294	0	0	44,819	37,294
Other income	96,853	92,081	118,486	112,249	-99,090	-87,478	19,396	24,771
Expenses for goods and services purchased	-3,173	-3,493	-365,805	-283,560	149,408	92,134	-216,397	-191,426
Personnel costs	-57,572	-51,778	-547,550	-498,007	846	284	-546,704	-497,723
Other expenses	-67,020	-65,126	-314,138	-273,196	99,636	88,348	-214,502	-184,847
EBITDA	-20,571	-19,521	216,387	213,777	-36	-387	216,351	213,390
in % of revenues			19.2%	20.8%			19.2%	20.8%
Depreciation of property, plant and equipment and rightof-use assets							-42,770	-37,837
Amortization of intangible assets							-69,551	-72,876
EBIT							104,030	102,677
Result from companies accounted for using the equity method							-99	33
Financial income							22,719	3,854
Financial expenses							-14,584	-8,690
Net impairment losses on financial assets							-5,250	0
EBT							106,816	97,874
Taxes on income for the period							-32,699	-28,842
Consolidated net income for the period							74,117	69,032
in % of revenues							6.6%	6.7%

G. Other disclosures

G.1 Notes on cash and the cash flow statement

The CGM group prepares the consolidated cash flow statement in accordance with International Accounting Standard IAS 7 Statement of Cashflows. The CGM group discloses its cash flows in order to reveal the sources and uses of cash and cash equivalents. It distinguishes between cash flows from operating activities, investing activities and financing activities.

Cash and cash equivalents in the cash flow statement include cash on hand, checks, cash at banks and other financial assets with a remaining term to maturity of no more than three months and correspond to the amount of cash and cash equivalents reported in the statement of financial position as at the end of the period. Therefore, only short-term securities that are not subject to a significant risk of price fluctuations are carried in cash and cash equivalents. In addition, cash and cash equivalents include bank balances (kEUR 55), which are mainly classified as restricted cash due to capital export restrictions (see also note E.13 Cash and cash equivalents). Effects from currency translation of cash and cash equivalents are adjusted in the calculation and reported separately in the statement of cash flows.

Cash flow from operating activities is determined by first adjusting consolidated net income for the period for non-cash items such as depreciation, impairment, write-ups of intangible assets and property, plant and equipment while including changes in provisions and changes in other assets and liabilities and in net current assets.

Cash flow from investing activities relates to cash outflows for investments in intangible assets, property, plant and equipment, subsidiaries and other business units and investments accounted for using the equity method and jointly controlled entities. This item also includes cash inflows from the disposal of intangible assets, property, plant and equipment, subsidiaries and other business units.

Outflows for acquisitions of subsidiaries and other business units relate to business acquisitions shown in the section C.4 b) Company acquisitions and disposals.

In the cash flows from financing activities we report both paid and received dividends, the repayment of debt and new borrowing, payments for the acquisition of non-controlling interests and other financing transactions, and cash outflows for the principal portions of other loans. The change in financial liabilities in the reporting year was dominated by additional borrowings. Furthermore, borrowings and liabilities from other loans have been settled as scheduled.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Income tax payments are already included in the consolidated net income for the period, which is the starting point for the calculation of cash flow from operating activities. Income taxes actually paid in the reporting period are disclosed as additional information below the statement of cash flows. The same applies to the reporting of interest paid and received.

kEUR	Dec 31, 2021	Cash flow from financing activities	Non-Cash				Dec 31, 2022
			changes in scope of consolidation	currency effects	other effects*	change of fair value	
Liabilities to banks	674,917	49,121	52	0	4,385	0	728,475
Lease liabilities	57,217	-25,530	756	82	20,819	0	53,344
Other loans	9,172	-4,532	0	0	7	0	4,647
Total financial liabilities	741,306	19,059	808	82	25,211	0	786,466

* Includes, among others, additions to leases, changes in other loans, accrued interest and transaction costs.

The reconciliation shows changes in financial liabilities where the cash inflows and outflows are shown in the statement of cash flows under Cash flow from financing activities.

G.2 Capital management

The CGM group aims to strengthen its equity base sustainably and to generate an adequate return on capital invested. However, the group's accounting capital is only a passive risk control criterion, while the key performance indicators stated in the section Main financial indicators of the management report are active control elements.

The CGM group's capital structure is measured using financial liabilities less cash and cash equivalents in relation to the consolidated equity. A detailed breakdown of consolidated equity can be found in the Statement of changes in equity or in note E.14 Equity.

Both the aims and the strategy of capital management are to maintain or optimize the financial covenants specified in the credit agreements in order to continue financing on unchanged or improved terms as well as to distribute a dividend.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The consolidated equity ratio according to the consolidated financial statements as at December 31, 2022 amounts to 35 % (prior year: 34 %), which is due in particular to

- the addition of consolidated net income allocated to shareholders of the parent company (kEUR 73,411; prior year: kEUR 68,970);
- the distribution of dividends (kEUR - 26,117; prior year: kEUR - 26,367);
- the currency translation differences (kEUR 9,449; prior year: kEUR 18,984);
- actuarial gains and losses (kEUR 4,577; prior year: kEUR 6,118); and
- cash flow hedges (kEUR 7,537; prior year: kEUR 0).

The CGM group's capital structure as at December 31, 2022 breaks down as follows:

kEUR	Dec 31, 2022	Dec 31, 2021
Financial liabilities*	733,122	684,089
Cash and cash equivalents	90,517	107,343
Net liabilities	642,605	576,746
Equity**	673,823	612,284
Net debt to equity ratio	95%	94%

* Financial liabilities are defined as current and non-current financial liabilities to banks (not including derivatives and financial guarantees) and other loans.

** Equity comprises all the group's capital and reserves (including non-controlling interests).

The leverage ratio is described in the section Main financial indicators of the management report.

G.3 Financial instruments

a) Financial instruments by class and category

A financial instrument is a contract that simultaneously gives rise to a financial asset at one company and a financial liability or equity instrument at another company. Financial instruments are recognized when CGM becomes a party to the financial instrument.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The CGM group's financial instruments to be classified as financial assets consist of Cash and cash equivalents, Trade receivables, Other financial assets and Other investments.

Financial instruments to be classified as financial liabilities comprise Liabilities to banks, Purchase price liabilities, Trade payables and Other financial liabilities.

The fair value is not always available as a market value, which often necessitates a determination based on various measurement parameters. Depending on the availability of observable parameters and the relevance of these parameters for determining the fair value as a whole, fair value is assigned to Level 1, 2 or 3. The following factors determine the assignment within these levels:

- Level 1 parameters: the market value of assets and liabilities is calculated on the basis of quoted and unadjusted prices for these or identical assets and liabilities in active markets. Tradability on the principal or the most advantageous market on the measurement date is key.
- Level 2 parameters: The market value of assets and liabilities is calculated using parameters for which either directly or indirectly derived quoted prices are available on an active market. Examples: price quotations in non-active markets; observable interest rates and curves; implied volatilities and credit spreads.
- Level 3 parameters: The market value of assets and liabilities is calculated using parameters for which no observable market data is available.

For financial instruments in the CGM group to be measured at fair value, the calculation was based on the market information available on the reporting date, using the following methods and assumptions:

–Financial instruments at fair value through profit or loss (FVtPL) are financial assets that do not meet the criteria of IFRS 9 for the categories at amortized cost (AC) or at fair value through other comprehensive income (FVOCI), or financial investments in equity instruments for which the FVOCI option was not applied upon initial recognition. As no companies in the CGM group have exercised this FVOCI option to date, investments with an ownership interest of less than 20 % are reported as Other investments and measured accordingly. For the measurement of Other investments, the acquisition cost as at the balance sheet date represents an appropriate estimate of the fair value.

–Derivatives with no hedging relationships are measured at the fair value through profit or loss (FVtPL) method.

–Derivatives with hedging relationships are classified as cash flow hedges and measured at their fair value as at the reporting date.

All other financial assets and financial liabilities are carried at amortized cost based on the effective interest method.

- Financial assets in the at amortized cost category are assets held in order to collect the contractual cash flows which solely represent payments of principal and interest. Interest income from these financial assets is reported in financial income based on the effective interest method. Gains or losses from derecognition are recognized directly in the income statement and, together with foreign currency gains and losses, are reported under other gains/losses.
- Under financial assets, the CGM group reports Cash and cash equivalents, Trade receivables and Other financial assets. The carrying amount of financial instruments classified as financial assets corresponds to the fair value of the proportion of short-term positions they contain, as a result of their short maturity.
- Financial liabilities in the CGM group are generally measured at amortized cost using the effective interest method and assigned to the measurement category at amortized cost (AC). The carrying amount of financial instruments reported as Trade payables or Other financial liabilities is almost the same as the fair value. The item Liabilities to banks under financial liabilities is divided into fixed rate debt and variable rate debt. The estimates of the fair values of the purchase price liabilities are based on the contractually defined influencing factors, which condition the future payments and the expectations that the CGM Group has with respect to these values (Level 3). The probability of achieving the defined targets and their timing is assessed. The assumptions made are reviewed at regular intervals.
- The fair value of fixed rate liabilities is calculated as the present value of the expected future cash flows, discounted using the interest rates (including CGM-specific margin) appropriate on the reporting date. The fair value of the variable-rate liabilities corresponds approximately to the carrying amount.

The financial assets and liabilities from Receivables from finance leases, Derivatives classified as cash flow hedges and the financial liabilities from Lease liabilities do not fall into the classification categories under IFRS 9, but are reported under Financial instruments in the table below. Financial assets in Receivables from finance leases and Financial liabilities from lease liabilities are measured at amortized cost in accordance with the provisions of IFRS 16. These are included in the impairment after expected credit losses. The fair value is determined on the basis of a market interest rate and the average term of the leases.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The following table shows the carrying amounts and valuations of the group's existing financial instruments in accordance with the measurement categories in accordance with IFRS 9 as at December 31, 2022:

	Measurement category according to IFRS 9	Book value as at Dec, 31 2022	IFRS 9 valuation			IFRS16 valuation	
			Amortized costs	Fair value through profit or loss	Fair value through equity	Amortized costs	Fair value* as at Dec, 31 2022
kEUR							
Financial assets							
Cash and cash equivalents	AC	90,517	90,517	0	0	0	-
Trade receivables	AC	189,439	189,439	0	0	0	-
Other financial assets	AC	4,953	4,953	0	0	0	-
Finance lease receivables	n/a	25,136	0	0	0	25,136	-
Derivatives classified as Cashflow Hedges	n/a	11,357	0	0	11,357	0	11,357
Derivatives without hedge accounting	FVtPL	25,777	0	25,777	0	0	25,777
Other investments	FVtPL	3,158	0	3,158	0	0	3,158
Total financial assets		350,337	284,909	28,935	11,357	25,136	-
thereof Financial instruments at fair value through profit or loss	FVtPL	28,935	0	28,935	0	0	28,935
thereof Amortized costs	AC	284,909	284,909	0	0	0	-
Financial liabilities							
Liabilities to banks	AC	728,475	728,475	0	0	0	728,383
Purchase price liabilities	AC	21,585	21,585	0	0	0	-
Trade payables	AC	112,613	112,613	0	0	0	-
Lease Liabilities	n/a	53,344	0	0	0	53,344	-
Derivatives classified as Cashflow Hedges	n/a	901	0	0	901	0	901
Other financial liabilities	AC	8,531	8,531	0	0	0	-
Total financial liabilities		925,449	871,204	0	901	53,344	-
Amortized costs	AC	871,204	871,204	0	0	0	-

* The table contains no information regarding the fair value of Cash and cash equivalents, Trade receivables, Other financial assets, Finance lease receivables, Purchase price liabilities, Trade payables, Lease liabilities and other financial liabilities. The carrying amounts corresponds approximately to the fair value.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The financial instruments by measurement category for the prior-year period ended December 31, 2021, adjusted to the currently applicable definition, are as follows:

kEUR	Measurement category according to IFRS 9	Book value as at Dec, 31 2021	IFRS 9 valuation			IFRS16 valuation	
			Amortized costs	Fair value through profit or loss	Fair value through equity	Amortized costs	Fair value* as at Dec, 31 2021
Financial assets							
Cash and cash equivalents	AC	107,343	107,343	0	0	0	-
Trade receivables	AC	147,227	147,227	0	0	0	-
Other financial assets	AC	12,035	12,035	0	0	0	-
Finance lease receivables	AC	25,805	0	0	0	25,805	-
Derivatives without hedge accounting	FVtPL	6,594	0	6,594	0	0	6,594
Other investments	FVtPL	3,123	0	3,123	0	0	3,123
Total financial assets		302,127	266,605	9,717	0	25,805	-
thereof Financial instruments at fair value through profit or loss	FVtPL	9,717	0	9,717	0	0	9,717
thereof Amortized costs	AC	292,410	266,605	0	0	25,805	-
Financial liabilities							
Liabilities to banks	AC	674,917	674,917	0	0	0	674,917
Purchase price liabilities	AC	11,715	11,715	0	0	0	-
Trade payables	AC	93,193	93,193	0	0	0	-
Lease Liabilities	AC	57,217	0	0	0	57,217	57,217
Other financial liabilities	AC	19,770	19,770	0	0	0	-
Total financial liabilities		856,812	799,595	0	0	57,217	732,134
Amortized costs	AC	856,812	799,595	0	0	57,217	

* The table contains no information regarding the fair value of Cash and cash equivalents, Trade receivables, Other financial assets, Finance lease receivables, Purchase price liabilities, Trade payables, Lease liabilities and other financial liabilities. The carrying amounts corresponds approximately to the fair value.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

b) Fair value of financial assets and liabilities (according to valuation hierarchies)

The financial assets and liabilities that are measured at fair value as at December 31, 2022 are as follows:

kEUR	2022	Level 1	Level 2	Level 3
Financial assets valued at fair value				
Derivate klassifiziert als Cashflow Hedges	11,357	0	11,357	0
Derivatives without hedge accounting	25,777	0	25,777	0
Other investments	3,158	0	0	3,158
Total	40,292	0	37,134	3,158
Financial liabilities valued at fair value				
Liabilities to banks	728,383	0	728,383	0
Purchase price liabilities	21,585	0	0	21,585
Derivate klassifiziert als Cashflow Hedges	901	0	901	0
Total	750,869	0	729,284	21,585

The financial assets and liabilities measured at fair value as at December 31, 2021, adjusted to the currently applicable definition, are as follows:

kEUR	2021	Level 1	Level 2	Level 3
Financial assets valued at fair value				
Derivatives without hedge accounting	6,594	0	6,594	0
Other investments	3,123	0	0	3,123
Total	9,717	0	6,594	3,123
Financial liabilities valued at fair value				
Liabilities to banks	675,268	0	675,268	0
Purchase price liabilities	11,715	0	0	11,715
Total	686,983	0	675,268	11,715

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

c) Derivative financial instruments and hedge accounting

The following table shows the effects of cash flow hedging relationships in financial year 2022:

kEUR	Financial asset	Financial liability	Nominal value	Cashflow Hedge reserve		
				Cumulative Amounts for Continuing Hedging Relationships	Hedging effects recognized in other comprehensive income	Amounts reclassified to profit or loss for realized hedges*
Currency risks	574	- 901	41,260	327	0	0
Interest rate risks	10,783	0	200,000	- 11,095	0	311
Total	11,357	- 901	241,260	- 10,768	0	311

*Shown under financial expenses in the income statement

CGM held the following financial instruments, to hedge against currency and credit risk:

	2022			2021		
	Maturity			Maturity		
	1 - 6 months	6 - 12 months	greater than one year	1 - 6 months	6 - 12 months	greater than one year
Currency risks						
Nominal value (in kEUR)	41,260	-	-	-	-	-
Average forward rate EUR : CHF	0.98	-	-	-	-	-
Average forward rate EUR : PLN	4.71	-	-	-	-	-
Average forward rate EUR : GBP	0.88	-	-	-	-	-
Average forward rate EUR : USD	1.00	-	-	-	-	-
Average forward rate EUR : CZK	24.31	-	-	-	-	-
Average forward rate EUR : NOK	9.81	-	-	-	-	-
Average forward rate EUR : SEK	10.67	-	-	-	-	-
Interest rate risks						
Nominal value (in kEUR)	-	-	200,000	0	0	0
Average interest rate secured	-	-	2.04%	0	0	0

The financial assets and liabilities from currency risks and interest rate risks are reported in the balance sheet item Derivative financial instruments.

Due to the deviation in maturities between the hedged item and the hedging instrument, the derivative for the new interest rate swap concluded in 2022 was designated at the second term interest rate. Therefore, it was already completely effective from the point in time of designation onwards. As at the reporting date of December 31, 2022, all currency hedging relationships, with the exception of credit risk and forward components that are not material, are considered fully effective.

G.4 Net gains and losses on financial assets and liabilities

kEUR	2022	2021
Net gain/loss foreign currency translation (AC)	521	-506
Net gain/loss from compounding/reversal of purchase price liability (AC)	-1,514	1
Net gain/loss from derivatives not designed as hedging instruments (FVtPL)	19,183	2,875
Total	18,190	2,370

The net gain/loss from the foreign currency translation is recognized according to the origin in other income and other expenses or financial income and financial expenses. The effective portion of the net gain/loss from derivatives classified as cash flow hedges is recognized in other comprehensive income. The ineffective portion of cash flow hedges is recognized in financial income and financial expenses in the income statement.

Furthermore, loss allowances for receivables are stated under other expenses in the amount of kEUR –4,961 (prior year: kEUR - 7,378), which are allocated to the category at amortized cost (AC).

G.5 Risks related to financial instruments

The CGM Group is exposed, with respect to default risks, price change risks and cash flow fluctuation risks on the assets, liabilities and planned transactions, primarily to liquidity and default risks as well as the risk of changes in foreign exchange rates and interest rates. Risks arising from the use of financial instruments are continuously monitored as part of risk management.

Currency and interest rate risks are minimized in part through the use of derivative hedging instruments. Derivative financial instruments are used exclusively for micro hedges of risks arising in the normal course of business. Derivative financial instruments are used exclusively for hedging purposes, never for speculative purposes, and are only concluded with established financial institutions whose risk profile is solid and is reviewed on a daily basis. The effectiveness of the hedging relationship between the underlying transactions and the hedging instrument is verified by using effectiveness tests.

Foreign currency risks result from investments, financing measures and operating activities. CGM currently hedges only intercompany financial loans and deposits through derivative financial instruments in order to minimize intercompany currency risks. The hedging relationships used by CGM are presented in the consolidated financial statements as hedge accounting.

Interest rate risks result primarily from Group financing. CGM currently uses derivative financial instruments to hedge long-term loans with final maturities against possible negative interest rate developments. These interest rate derivatives are partly designated as cash flow hedges and are contracted in order to fix or cap the amount of interest payments for variable-interest liabilities.

CGM strives to minimize related credit risks. Measures taken by the company to achieve this goal include the establishment of a dunning system. Furthermore, credit risks are avoided by agreeing prepayments for a significant share of the contracts relevant to recurring revenues. The maximum (earnings) risk resulting from financial instruments basically corresponds to the carrying amounts of the respective capitalized financial instruments.

For further detailed information on market risks, default risks and liquidity risks, please refer to G.6 Credit risk, G.7 Currency risk, G.8 Interest rate risk and G.9 Liquidity risk of the notes to the consolidated financial statements.

G.6 Credit risk

The rules for recognizing impairment included in IFRS 9 are based on expected credit losses ("expected loss model"). A three-step model is provided for determining the extent of risk provisioning. A provision for expected credit losses is recognized in the statement of financial position for financial assets carried at amortized cost. For Trade receivables, Contract assets and Finance lease receivables, the simplified approach is based on lifetime expected credit losses. Trade receivables, Finance lease receivables and Contract assets were calculated on the basis of common risk characteristics to measure expected credit losses, taking into account the corresponding industry and country risks. For the calculation of the expected credit losses, historical loss rates are determined, which are adjusted on the basis of future macroeconomic data.

The group's default risk arises primarily from trade receivables. Trade receivables result from contracts with customers. The amounts reported in the statement of financial position are net of impairment on expected future losses ("expected loss model"). Contract assets are essentially work in progress that has not been invoiced and that has the same risk characteristics as trade receivables due to the same types of contract.

The CGM group's procedure for calculating allowances for doubtful receivables is as follows:

For receivables not yet due and those past due by between 0 and 12 months, a write-down of 0.8 percentage points is recognized as the loss allowance for expected credit losses. An individual write-down (management judgement) is recognized for all receivables past due by between 13–24 months. All receivables past due by 24 months are written down in full. For receivables that are past due by 14 days, the internal company dunning process is triggered. We assume a risk of default in particular if the debtor/contractual partner is insolvent or our receivable is more than 12 months overdue. Financial assets are derecognized if the receivable is uncollectible. If recoveries are made after the write-off of a receivable, these are recognized in profit or loss. The age structure of the receivables is classified as not critical within the group. The default rate is reassessed at each reporting date, taking into account the sector and country risks.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Allowances for Trade receivables, Contract assets and Finance lease receivables were calculated on this basis. The CGM group therefore recognizes a loss allowance for expected credit losses of 0.8 percentage points on all financial assets from day one.

The table shows the gross carrying amounts as at December 31, 2022 representing the maximum credit risk:

kEUR	0-12 months overdue (0.8 %)	13-24 months overdue (individual)	more than 24 months overdue (100 %)
Trade receivables	187,871	10,643	11,457
Contract assets	23,495	0	0
Finance lease receivables	25,339	0	0
Total	236,705	10,643	11,457
Individually impaired	- 986	- 6,611	- 11,457
Loss allowances for expected credit losses	- 1,894	0	0
Total Amount	- 2,880	- 6,611	- 11,457

The table shows the gross carrying amounts as at December 31, 2021:

kEUR	0-12 months overdue (0.8 %)	13-24 months overdue (individual)	more than 24 months overdue (100 %)
Trade receivables	147,802	7,693	9,234
Contract assets	26,784	0	0
Finance lease receivables	26,013	0	0
Total	200,599	7,693	9,234
Individually impaired	- 1,619	- 5,470	- 9,234
Loss allowances for expected credit losses	- 1,605	0	0
Total Amount	- 3,224	- 5,470	- 9,234

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The table shows the development of the loss allowance for Trade receivables, Contract assets and Finance lease receivables from December 31, 2021 to December 31, 2022.

kEUR	Trade Receivables	Contract Assets	Finance Lease Receivables
Opening balance of write-down as at Jan 1, 2022	- 17,502	- 218	- 208
Loss allowances for expected credit losses	- 299	5	5
Arising during the year	- 19,055	0	0
Utilized	1,427	0	0
Unused amounts reversed	14,896	0	0
Write-down as at Dec 31, 2022	- 20,533	- 213	- 203

kEUR	Trade Receivables	Contract Assets	Finance Lease Receivables
Opening balance of write-down as at Jan 1, 2021	- 12,870	- 118	- 192
Loss allowances for expected credit losses	- 91	- 100	- 16
Arising during the year	- 16,323	0	0
Utilized	926	0	0
Unused amounts reversed	10,856	0	0
Write-down as at Dec 31, 2021	- 17,502	- 218	- 208

The CGM group has no significant concentration of default risk as it is spread across a large number of contracting parties and customers.

Impairment losses on Trade receivables and Contract assets are shown in the operating result as impairment losses. Amounts generated in subsequent periods that were previously written down are recognized in the same item.

The loss of major customers in the hospitals, laboratories and pharmaceuticals business can have an adverse effect on the liquidity of the group. The tendering procedures for major customers and project business are closely monitored to detect and address changes in the market.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The maximum credit risk of investments in equity instruments at the reporting sheet date equals the carrying amounts of all investments below 20 %, which have been classified accordingly.

The credit risk is limited in the case of cash and cash equivalents, as these are due in the short term and are held with banks that have been given high credit ratings by international rating agencies.

The following table shows a summary of cash and cash equivalents by classification from the international rating agencies Standard & Poor's (S&P) and Moody's and Fitch as at the reporting date:

kEUR	Dec 31, 2022	Dec 31, 2021
AA	0	222
AA-	1,869	5,416
A+	30,370	48,996
A	11,662	19,230
A-	13,677	7,345
BBB+	24,267	12,814
BBB	2,082	2,339
BBB-	1,461	753
BB+	34	2
BB	0	74
BB-	4,254	8,163
B+	0	380
B	291	0
Not rated	550	1,609
Total amount	90,517	107,343

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

G.7 Currency risk

The market success and gross sales revenues of exporting companies are influenced by fluctuating exchange rates. In 2022, approximately 79 % of revenues were denominated in euro (prior year: 79 %) and approximately 21 % of revenues were denominated in foreign currencies (prior year: 21 %).

The carrying amount of the group's monetary assets and liabilities denominated in foreign currencies is as follows:

	Assets		Liabilities	
	De 31, 2022	Dec 31, 2021	Dec 31, 2022	Dec 31, 2021
TEUR				
US Dollar	52,346	42,955	18,182	19,542
Norwegian Kroner	3,492	18,748	1,125	1,444
Swedish Krona	9,468	21,969	4,532	5,768
Polish Zloty	9,423	6,941	3,824	3,395
Turkish Lira	754	648	721	247
Czech Crowns	4,377	5,158	1,093	1,276
Swiss Franc	3,098	4,800	2,324	1,439
Danish Kroner	2,528	2,915	2,150	2,190
British Pound	11	7	12	14
South African Rand	4,772	8,848	556	665
Romanian Leu	97	118	987	1,346
Indian Rupee	1,321	1,094	2,096	3,793

a) Effects from the sensitivity analysis on net income in the event of a ten percent rise or fall in the euro against the respective foreign currency:

The following table shows the sensitivity of a ten percent rise or fall in the euro against the respective foreign currency from the perspective of the group. The assumption of a ten percent change represents management's best estimate of a rationally possible change in the exchange rate. The sensitivity analysis only includes outstanding monetary items denominated in foreign currencies and adjusts their translation in accordance with a ten percent change in exchange rates.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Currency impact net income

kEUR	2022			2021		
	+/- 0 percent	+10 percent	-10 percent	+/- 0 percent	+10 percent	-10 percent
US Dollar	-26,771	-29,448	-24,094	-6,491	-7,141	-5,842
Norwegian Kroner	-14,257	-15,683	-12,832	-13,569	-14,926	-12,212
Swedish Krona	-11,185	-12,303	-10,066	-9,587	-10,546	-8,629
Polish Zloty	-2,492	-2,741	-2,243	-1,704	-1,875	-1,534
Turkish Lira	1,517	1,669	1,365	966	1,062	869
Czech Crowns	-2,458	-2,704	-2,212	-2,670	-2,937	-2,403
Swiss Franc	3,600	3,960	3,240	1,994	2,193	1,794
Danish Kroner	-2,663	-2,930	-2,397	-4,010	-4,411	-3,609
British Pound	-32	-35	-29	-44	-48	-39
South African Rand	-261	-288	-235	-677	-745	-610
Romanian Leu	-859	-945	-773	-166	-183	-149
Indian Rupee	-2,197	-2,416	-1,977	-1,096	-1,206	-987

b) Effects from the sensitivity analysis on equity in the event of a ten percent rise or fall in the euro against the respective foreign currency:

Currency impact equity

kEUR	2022			2021		
	+/- 0 percent	+10 percent	-10 percent	+/- 0 percent	+10 percent	-10 percent
US Dollar	-390,191	-429,210	-351,172	-359,994	-395,994	-323,995
Norwegian Kroner	-37,361	-41,097	-33,625	-38,191	-42,010	-34,372
Swedish Krona	-23,058	-25,364	-20,753	-20,981	-23,079	-18,883
Polish Zloty	-5,453	-5,998	-4,908	-4,717	-5,189	-4,245
Turkish Lira	2,038	2,242	1,834	612	673	551
Czech Crowns	-3,079	-3,386	-2,771	-3,136	-3,450	-2,823
Swiss Franc	4,079	4,487	3,671	2,764	3,041	2,488
Danish Kroner	-5,177	-5,695	-4,659	-6,141	-6,755	-5,527
British Pound	-83	-91	-75	-81	-89	-73
South African Rand	5,408	5,949	4,868	5,659	6,225	5,093
Romanian Leu	-1,668	-1,835	-1,501	-854	-940	-769
Indian Rupee	-5,900	-6,490	-5,310	-4,169	-4,585	-3,752

Due to the high scalability of the CGM group's revenues and general business activities, management considers the sensitivity analysis to be an appropriate means of mapping exchange rate risks.

G.8 Interest rate risk

The CGM group's interest rate risk arises from long-term borrowings with variable interest rates. The liabilities to banks amount to mEUR 728 as at December 31, 2022. In order to hedge interest rate risks, the group concluded an interest rate cap in 2021 with a nominal volume of mEUR 400 and a remaining term to maturity until May 7, 2031. In addition, an interest rate swap with a remaining term until July 11, 2028 and a notional amount of mEUR 200 was concluded in October 2022.

Where required, the CGM group uses relevant financial instruments to hedge against interest rate increases in order to counter interest rate risks. The effects of interest rate fluctuations are explained in more detail below. Borrowings with fixed interest rates are not included in this analysis.

The CGM group's expected future interest payments are shown below:

kEUR	2022			2021		
	< 1 year	1-5 years	> 5 years	< 1 year	1-5 years	> 5 years
Liabilities to banks	22,626	45,354	2,946	6,590	16,500	144
Lease liabilities	489	889	420	866	1,457	248
Other loans	33	0	0	94	33	0
Other financial liabilities	0	0	0	0	0	0
Trade payables	0	0	0	0	0	0
Purchase price liabilities	0	0	0	0	0	0

If the variable interest rate (here 3-month EURIBOR) in the interest rate sensitivity analysis is changed by + 100 basis points/ - 100 basis points, this has an impact on the effective interest payments to be made of kEUR 9,663/ kEUR - 10,925, and if it is changed by + 200 basis points/ - 200 basis points, the impact is kEUR 12,800/ kEUR - 21,851.

G.9 Liquidity risk

To ensure that financial obligations can be met on an ongoing basis, the CGM group has negotiated adequate overdraft facilities and syndicated loans. As at December 31, 2022, the group has short-term credit lines not yet exhausted of mEUR 94 and a not fully utilized revolving credit facility of mEUR 550.

Liquidity risk differs between the countries in which the CGM group operates. In the companies operating in Germany, liquidity is generally supplied via direct debit agreements, which minimizes the liquidity risk. The same applies to companies operating in countries where direct debit is the predominant payment method (e.g., Austria, Norway, Sweden and France).

Cash-pooling arrangements exist for parts of the group. These arrangements provide a needs-based cash management and ensure that sufficient liquidity is available in the individual companies to meet their operational needs. Cash pooling is managed centrally at the group's headquarters in Koblenz. For areas of the group which have no cash-pooling arrangements, liquidity levels are managed by means of medium-term cash requirement planning.

Cash held by group companies (excluding the cash pooling agreement) that exceed the level of working capital required is generally transferred to the group's cash management on a quarterly basis.

Furthermore, the CGM group considers any restriction with respect to its ability to incur debt and raise capital to be a liquidity risk. Restrictions place a significant risk on the achievement of corporate goals and affect overall financial flexibility. The CGM group understands liquidity risk management as performing regular risk analysis involving the use of financial instruments to ensure that potential risks can be adequately addressed.

Debt financing is largely secured by the syndicated credit facility and the EIB loan. Risk concentrations in refinancing are identified promptly through continuous monitoring and reporting. Further information regarding the syndicated credit facility and the EIB loan are available in the management report under 2.3.2.3 Capital structure and 2.3.2.5 Liquidity and in the notes to the consolidated financial statements under note E. 16 a) Liabilities to banks.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The following tables show the contractual remaining terms to maturity of the CGM group's financial liabilities. The tables are based on undiscounted cash flows of financial liabilities. They include both the payments of both interest and principal. Where interest payments are based on variable parameters, the undiscounted amount was determined on the basis of the yield curves at the end of the reporting period. The contractual maturities are based on the earliest date on which the group can be required to make payments.

kEUR	2022			2021		
	< 1 year	1–5 years	> 5 years	< 1 year	1–5 years	> 5 years
Liabilities to banks	51,730	544,725	202,946	99,066	418,940	180,144
Lease liabilities	20,092	27,656	7,394	19,540	33,134	7,115
Other loans	4,627	53	0	4,626	4,674	0
Other financial liabilities	3,884	0	0	10,598	0	0
Trade payables	112,613	0	0	93,193	0	0
Purchase price liabilities	16,046	5,539	0	6,703	5,012	0

G.10 Contingent liabilities

The following table provides information on the CGM group's existing contingent liabilities:

kEUR	Maximum liability		Liability reserves	
	2022	2021	2022	2021
Guarantees for warranties and contract execution	5,635	4,176	0	0
Guarantees	207	377	0	0
Other liability statements	171	170	0	0
Total	6,013	4,723	0	0

There are no major purchase commitments from operating activities. The warranty and contract performance guarantees consist mainly of the performance guarantee of kEUR 1,000 at CGM Clinical Österreich GmbH in connection with the "NÖKIS" project and warranties for bank guarantees referring in particular to contract performance and rent deposits of CGM SE & Co KGaA in the amount of kEUR 4,329. Disclosures in accordance with IAS 37.86 have been omitted due to reasons of practicality.

G.11 Disclosures on related parties

During the financial year, group companies entered into the following transactions with related parties outside the consolidated group.

These were conducted under conditions which are equivalent to those applied to third parties to stay in accordance with the arm's length principle.

In addition, the following amounts were outstanding at the end of the reporting period:

	Sale of goods		Purchase of goods		Receivables		Liabilities	
kEUR	2022	2021	2022	2021	Dec 31, 2022	Dec 31, 2021	Dec 31, 2022	Dec 31, 2021
Frank Gotthardt	0	36	0	0	0	10	0	0
Dr. Brigitte Gotthardt	0	2	0	0	0	0	0	0
Prof. Dr. Daniel Gotthardt	0	0	0	0	0	0	0	0
CompuGroup Medical Management SE	115	3	14,573	8,453	32	0	103	657
further Administrative Board	1	1	2	0	0	0	0	0
further related companies	1,848	8,437	2,667	3,991	105	145	347	161
Associated companies and joint ventures	11,153	10,783	90	65	1,750	984	12	0

Payments amounting to kEUR 14,573 (prior year: kEUR 8,453) were made to the personally liable company CompuGroup Medical Management SE, which is controlled by Frank Gotthardt via GT 1 Vermögensverwaltung GmbH, in the reporting year for remuneration of the Managing Directors, the Administrative Board and other expense allowances.

Furthermore, Frank Gotthardt directly and indirectly holds a significant shareholding in CompuGroup Medical SE & Co. KGaA as at December 31, 2022 (cf. Shareholder structure). As a result, in addition to the associated companies stated in the list of shareholdings, also all companies having a corporate relationship with Frank Gotthardt, Dr. Brigitte Gotthardt or Professor Dr. Daniel Gotthardt are related to CompuGroup Medical SE & Co. KGaA.

Other related persons:

Remuneration paid to current and former members of the Supervisory and the Administrative Board can be found in the remuneration report (cf. remuneration report in the management report) and has not been restated here.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Administrative Board

Business relationships with Frank Gotthardt and Professor Dr. Daniel Gotthardt are shown separately and not included in this list.

Supervisory Board and Senior Management

Beyond this, there were no significant direct business relationships with members of the Supervisory Board or the Senior Management in the reporting year.

Other related companies:

The following business relationships with related companies are particularly noteworthy:

Gotthardt Bürotechnik GmbH

CompuGroup obtained services in the form of leases for copiers from Gotthardt Bürotechnik GmbH in the amount of kEUR 116 (prior year: kEUR 118).

Gotthardt Healthgroup AG

The main services provided to Gotthardt Healthgroup AG were hosting and maintenance services in the total amount of kEUR 141 (prior year: kEUR 168). Services received amount to kEUR 511.

INFOSOFT Informations- und Dokumentationssysteme GmbH

The goods and services received from Infsoft Informations- und Dokumentationssysteme GmbH include both the purchase of licenses and services in the form of software maintenance totaling kEUR 173 (prior year: kEUR 272).

KEC Vertriebs GmbH & Co. KG

The services received from KEC Vertriebs GmbH & Co. KG mainly consisted of advertising and sponsoring services totaling kEUR 316 (prior year: kEUR 82).

mps public solution GmbH

The goods and services received (kEUR 605; prior year: kEUR 638) and provided in the amount of kEUR 1,613 (prior year: kEUR 1,423) mainly comprise software maintenance services for software licenses between CompuGroup Medical Clinical Deutschland GmbH and mps public solution GmbH.

Fährhaus Koblenz GmbH & Co. KG

This mainly relates to the use of the Fährhaus for meetings, conventions and conferences for a total of kEUR 87 (prior year: kEUR 130).

Gotthardt Grundstücksgesellschaft GbR

Payments that are primarily attributable to employee parking spaces amount to kEUR 47 (prior year: kEUR 49).

GT Transportation Service GmbH

Payments amount to kEUR 220 in the financial year, mainly for onward charging of travel expenses (prior year: kEUR 30).

KSM KoWaDi Security Management GmbH

This mainly relates to the use of security services totaling kEUR 329 thousand (prior year: kEUR 107).

Stepstone Deutschland GmbH

Payments amount to kEUR 250 for HR services. The company had not been a related party in the prior year.

Associated companies and joint ventures:

Business relationships with associated companies and joint ventures relate primarily to goods and services exchanged with MGS Meine Gesundheit Services GmbH for software developments in the amount of kEUR 11,140 (prior year: kEUR 9,740).

G.12 Declaration of Conformity with the German Corporate Governance Code

The declaration of compliance required by section 161 of the German Stock Corporation Act (AktG) was issued by the Managing Directors and the Supervisory Board and made publicly available to shareholders on the company's website at (https://www.cgm.com/corp_de/unternehmen/investor-relations/CG-de.html).

G.13 Auditor's fees in accordance with section 314 (1) no. 9 German Commercial Code (HGB)

The following table shows the total fees payable, including expenses and all additional costs, to KPMG AG Wirtschaftsprüfungsgesellschaft, Berlin, for financial year 2022. The Auditing financial statements item includes the fees for auditing the single-entity financial statements, the consolidated financial statements including the dependency report and the remuneration report of CompuGroup Medical SE & Co. KGaA. These items also include fees for auditing the financial statements of five subsidiaries. Other advisory services relate, as in the prior year, to the external audit to achieve limited assurance regarding the combined separate non-financial report. Other services in financial year 2022 relate to support services in respect of a BaFin audit.

kEUR	2022	2021
Auditing financial statements	932	885
Other advisory services	70	33
Tax advisory	0	0
Other services	21	31
Total	1,023	949

G.14 Events after the reporting date

Acquisition of the GHG business

CGM agreed to acquire the GHG business operations a related company of Prof. Dr. Daniel Gotthardt (100 % of the shares in GHG Services GmbH and the GHG business units "GHG Praxisdienst" and "GHG medical brain") on November 22, 2022. The acquisition complements CGM's portfolio of innovative, data-based solutions for the healthcare sector. The company is domiciled in Heidelberg, Germany and offers electronic health applications that improve the quality of life of patients and help doctors provide the best possible treatment with the aid of digital solutions. With these acquisitions, CGM is expanding its product and service portfolio with differentiated technological and medical expertise, medical data analysis and communication for physicians.

The transaction was completed on January 2, 2023. The GHG business operations will be included in consolidation for the first time as at January 1, 2023. The purchase price consists of a fixed component amounting mEUR 22 and several variable purchase price components, which are calculated on the basis of fixed defined sales revenues for the following years. The total amount expected to be paid out under the earn-out agreements is approximately mEUR 6 and has a term of five years. Fair values cannot be stated at the time of publication of the annual report as the purchase price allocation has not yet been completed.

CGM Clinical project in Lower Austria

In May 2019, Niederösterreichische Landeskliniken-Holding (NÖLKH) signed a contract with CompuGroup Medical to install the hospital information system CGM Clinical. In February 2023, the Niederösterreichische Landesgesundheitsagentur (Lower Austrian Provincial Health Agency), as the legal successor to NÖLKH, informed us that it was exercising its right of termination with respect to certain services, while the underlying general services agreement would remain in effect. The financial impact of this termination cannot be conclusively assessed at present.

G.15 Managing Directors and Supervisory Board

Managing Directors:

Last name	First name	Occupation/membership of Supervisory Boards and other supervisory bodies
Rauch	Michael	Managing Director, Spokesman for the Managing Directors (since July 1, 2022) and Chief Financial Officer (CFO) Chairman of the Supervisory Board of edding AG, Ahrensburg Chairman of the Supervisory Board of CompuGroup Medical Deutschland AG, Koblenz
Mazza Teufer	Angela	Managing Director Ambulatory Information Systems DACH (since February 15, 2022) Board member (none-executive), of TietoEvy Corp., Helsinki, Finland
Mugnani	Emanuele	Managing Director for Ambulatory Information Systems Europe (since February 15, 2022)
Pech	Eckart, Dr.	Managing Director Consumer and Health Management Information Systems
Reichl	Hannes	Managing Director for Inpatient and Social Care
Wössner	Dirk, Dr.	Managing Director, Chief Executive Officer (CEO) (until June 30, 2022)
Brecher	Frank	Managing Director, Chief Technology Officer (CTO) (until May 31, 2022)

Members of the Supervisory Board:

Members of the Supervisory Board of CompuGroup Medical SE & Co. KGaA as at the reporting date:

Last name	First name	Occupation/membership of Supervisory Boards and other Supervisory Bodies
von Ilberg	Philipp (Chair)	Geschäftsführer der Mayer Sitzmöbel Verwaltungs-GmbH, the general partner of Mayer Sitzmöbel GmbH & Co. KG (since June 18, 2020, Chairman (Member of the CGM Supervisory Board since June 18, 2020)
Weinmann	Stefan (Vice Chair)	Sales Professional at CGM Clinical Deutschland GmbH (Member of the CGM Supervisory Board since September 30, 2021; Vice Chairman since September 30, 2021)
Fuchs	Michael, Dr.	- deceased on December 25, 2022 - Freelance consultant Member Chairman of the Supervisory Board of Schmiedewerke Gröditz GmbH (Member of the CGM Supervisory Board from June 18, 2020 until December 25, 2022)
Handel	Ulrike, Dr.	Supervisory Board member and Senior Advisor Member of the Board of Directors of Sparks Networks SE (Member of the CGM Supervisory Board since June 18, 2020; Vice Chairwoman from June 18 until July 29, 2020)
Köhrmann	Martin, Professor Dr.	Deputy Director of the Department of Neurology at Essen University Hospital (Member of the CGM Supervisory Board since June 18, 2020)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Last name	First name	Occupation/membership of Supervisory Boards and other Supervisory Bodies
Störmer	Matthias	Freelance consultant (Member of the CGM Supervisory Board since June 18, 2020)
Volkens	Bettina, Dr.	Supervisory Board member/Start up founder Advisor at Quantum Seven AG Member of the Supervisory Board of Bilfinger SE Member of the Supervisory Board Vossloh AG Member of the Supervisory Board of Elektrobau Muldingen GmbH (Member of the CGM Supervisory Board since June 18, 2020)
Basal	Ayfer (Employee representative)	Quality Assurance Professional at CGM Lauer-Fischer GmbH (Member of the CGM Supervisory Board since September 30, 2021)
Betz	Frank (Employee representative)	Marketing Professional at CGM Clinical Europe GmbH (Member of the CGM Supervisory Board since September 30, 2021)
Hegemann	Adelheid (Employee representative)	Senior Service Manager at CGM Clinical Deutschland GmbH (Member of the CGM Supervisory Board since September 30, 2021)
Johnke	Lars (Union representative)	Trade union secretary at IG Metall Munich (Member of the CGM Supervisory Board since September 30, 2021)
Mole	Julia (Union representative)	Trade Union Secretary of Vereinte Dienstleistungsgewerkschaft ver.di Rheinland-Pfalz/Saarland (Member of the CGM Supervisory Board since January 15, 2021)

G.16 Remuneration for the Managing Directors

The total remuneration for the Managing Directors is as follows:

Remuneration for the Managing Directors 2022 pursuant to IAS 24.17

kEUR	Short-term benefits	Other long-term benefits	Total compensation
Rauch, Michael	3,158	3,546	6,704
Mazza Teufer, Angela	730	2,089	2,819
Mugnani, Emanuele	706	2,089	2,795
Pech, Eckart, Dr.	801	0	801
Reichl, Hannes	2,693	242	2,935
Wössner, Dirk, Dr.*	4,571	0	4,571
Brecher, Frank **	231	0	231
Total	12,890	7,966	20,856

* Left the company effective from June 30, 2022.

** No longer Managing Director since June 1, 2022.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Remuneration for the Managing Directors 2021 pursuant to IAS 24.17

kEUR	Short-term benefits	Other long-term benefits	Total compensation
Wössner, Dirk, Dr.	1,656	22,521	24,177
Brecher, Frank	611	0	611
Pech, Eckart, Dr.	833	0	833
Rauch, Michael	974	0	974
Reichl, Hannes	809	0	809
Körfigen, Ralph, Dr.*	2,922	0	2,922
Total	7,805	22,521	30,326

* Left the company effective from November 1, 2021.

Remuneration disclosure Managing Directors 2022 pursuant to section 314 (1) no. 6 German Commercial Code (HGB)

kEUR	Fixed compensation	Variable bonus (performance)	One-time payments	Share options (fair value)	Fringe benefits	Total compensation
Rauch, Michael	613	710	2,000	3,296	14	6,633
Mazza Teufer, Angela	438	280	0	2,089	13	2,820
Mugnani, Emanuele	438	269	0	2,089	0	2,796
Pech, Eckart, Dr.	417	311	0	0	22	750
Reichl, Hannes	425	476	2,000	0	9	2,910
Wössner, Dirk, Dr.*	400	153	5,764	0	5	6,322
Brecher, Frank **	167	34	0	0	9	210
Total	2,898	2,233	9,764	7,474	72	22,441

* Left the company effective from June 30, 2022.

** No longer Managing Director since June 1, 2022.

Remuneration disclosure Managing Directors 2021 pursuant to section 314 (1) no. 6 German Commercial Code (HGB)

kEUR	Fixed compensation	Variable bonus (performance)	Share options (fair value)	Fringe benefits	Total compensation
Wössner, Dirk, Dr.	800	846	22,521	10	24,177
Brecher, Frank	400	104	0	20	524
Pech, Eckart, Dr.	400	369	0	18	787
Rauch, Michael	425	522	0	19	966
Reichl, Hannes	400	432	0	9	841
Körfigen, Ralph, Dr.*	333	2501	0	13	2,847
Total	2,758	4,774	22,521	89	30,142

* Left the company effective from November 1, 2021.

Remuneration for former Managing Directors / members of the Management Board of CompuGroup Medical SE & Co.

KGaA

Remuneration granted in 2022 to former Managing Directors/members of the Management Board of CompuGroup Medical SE & Co. KGaA amounted to mEUR -0.8.

Revision of the remuneration system for the Managing Directors

The Supervisory Board and the Administrative Board, supported by an independent remuneration expert and taking into account the requirements of the newly created Section 87a para. 1 AktG and the corresponding recommendations of the German Corporate Governance Code (DCGK) in the version of 16 December 2019, addressed this issue in detail and resolved a new remuneration system at the meeting of the Administrative Board on March 2, 2021, which was approved by the Annual General Meeting of CompuGroup Medical in accordance with section 120a (1) German Stock Corporation Act (AktG) on May 19, 2021.

The current remuneration system was derived from the system introduced in 2021 and adopted at the meeting of the Administrative Board on March 7, 2022 and approved by the Annual General Meeting of CGM in accordance with Section 120a (1) of the German Stock Corporation Act (AktG) on May 19, 2022.

G.17 Share option programs

The Managing Directors receive option rights as long-term variable remuneration in accordance with the conditions of the authorization to issue option rights for CompuGroup Medical SE & Co. KGaA decided upon under agenda item 6 at the Annual General Meeting on May 15, 2019. The option conditions adopted by the Annual General Meeting apply equally to all Managing Directors. Any deviating conditions are described below.

The price per share to be paid when exercising a share option (exercise price) corresponds, in accordance with the general option conditions, to the volume-weighted average price of the company's shares in XETRA (or a similarly functioning system that replaces XETRA) on the Frankfurt Stock Exchange for a period beginning 45 calendar days before and ending 45 calendar days after the respective issue date, but at least the pro rata amount of the company's share capital attributable to the share (section 9 (1) German Stock Corporation Act (AktG)).

The option rights can only be exercised if the employment contract of the respective Managing Director is extended beyond the existing term of their respective first employment contract and if the employment contract is still valid at the time the option rights can be exercised for the first time.

Furthermore, the option rights can only be exercised if (i) the company's share price has increased by an average of at least 5 % annually compared to the exercise price within a period of three years from the issue date of the respective share options or (ii) within a period of three years prior to the date on which the respective share options can be exercised for the first time ("performance target"). The relevant reference price for measuring the minimum price increase is the volume-weighted average

price of the company's shares on the XETRA trading system during a period of three months prior to the date on which option rights may be exercised for the first time.

The target that must be achieved for Michael Rauch, Emanuele Mugnani and Angela Mazza Teufer to be able to exercise all the share options newly granted in 2022 is that the share price of CompuGroup Medical SE & Co. KGaA must have risen by at least 20 % either (i) within three years of the issue date of the respective share options or (ii) within the three years prior to the day on which the respective share options can be exercised for the first time.

As part of his appointment as spokesperson for the Managing Directors in addition to his position as Chief Financial Officer as of July 1, 2022, Michael Rauch was granted 400,000 share options. 100,000 share options are allocated to each of the financial years 2022 to 2025 for the purposes of allocation to remuneration for a particular financial year (in particular for the purposes of determining the maximum remuneration or calculating the waiting period) and assessing potential forfeiture. The waiting period ends in accordance with the general option conditions exactly four years after the issue date. By way of deviation from the general option conditions, there is no need to renew the employment contract again beyond July 31, 2027 in order to exercise the option.

Dr. Dirk Wössner (Chief Executive Officer until June 30, 2022) had been given 1,250,000 share options. These options have expired due to his departure and been replaced, in accordance with the terms of the employment contract, by a cash compensation payment.

Angela Mazza Teufer (Managing Director of Ambulatory Information Systems DACH, Connectivity & CLICKDOC) and Emanuele Mugnani (Managing Director of Ambulatory Information Systems Europe and Pharmacy Information Systems Europe) were granted 250,000 share options in February 2022 when they were appointed to their respective positions of Managing Director. The waiting period ends in accordance with the general option conditions exactly four years after the issue date. The amount applies both to the entire term of the employment contract (three years) to any potential renewal thereof (a further two years for Emanuele Mugnani; a further three years for Angela Mazza Teufer). Emanuele Mugnani is allocated 50,000 share options each over five years and Angela Mazza Teufer is allocated 41,666 share options each over six years for the purposes of these being allocated to remuneration for a given financial year (in particular for the purposes of determining the maximum remuneration, assessing potential forfeiture, calculating the waiting period or calculating the number of share options that vest in the event of termination for change of control). In addition to the general terms and conditions of the share option program set out below, the share options will expire without replacement if the short-term variable remuneration determined from 2023 until the end of the appointment has not reached at least 70 % of the target amount. This does not apply to the share options granted on a proportionate basis for financial year 2022.

In connection with their office, Dr. Eckart Pech (Managing Director Consumer and Health Management Information Systems) and Hannes Reichl (Managing Director Inpatient and Social Care), were each awarded long-term variable remuneration (LTI) of 250,000 option rights. The waiting period ends in accordance with the general option conditions four years after the issue date.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

It has also been determined for Hannes Reichl that a long-term bonus in the amount of the difference between the exercise price for the virtual option rights allocated on November 1, 2018 and the aforementioned XETRA average price for the option rights allocated on June 29, 2019, in each case multiplied by a factor of 250,000, will be paid out (cash settled). This entitlement exists if the performance targets specified for the option rights (which are derived from the general option conditions) are achieved, and is due and payable at the time the option rights are exercised. The background for this provision, which deviates from the general option conditions, is that the exercise price of EUR 65.5270 newly determined by the Supervisory Board in June 2019 was above the XETRA average price for the period from 45 calendar days before November 1, 2018 to 45 calendar days after November 1, 2018 (EUR 45.1191).

In the event that the performance targets set for option rights have not been met, but all other requirements for exercising the option rights have been fulfilled, Hannes Reichl remains – if the relevant average share price has increased by at least 15 % compared with the average November share price – entitled to a long-term cash bonus amounting to 50 % of the difference between the relevant average share price and the average November share price multiplied by a factor of 250,000, due and payable at the time the option rights could have been exercised for the first time.

The equity-settled share option programs of the individual Managing Directors are recognized over the remaining term in profit or loss up to the fixed fair value on a straight-line basis by offsetting against the capital reserve. The volatility used in the calculation was determined retrospectively over the last seven years since the issue date. The capital reserve for the forfeited options of Dr. Dirk Wössner and Michael Rauch amounting to mEUR 4.3 was reversed and recognized through profit or loss.

For share-based remuneration components that are cash settled, on the other hand, the fair value is recalculated at each reporting date based on current market parameters and recognized in profit or loss as an expense. As at December 31, 2022, mEUR 1.2 (prior year: mEUR 1.2) was recognized for Hannes Reichl through profit or loss as an expense.

a) Managing Directors

Share Option Program Michael Rauch	Dec 31, 2022	Dec 31, 2021
Total number of outstanding share options	400,000	250,000
of which vested	0	0
of which exercisable	0	0
Exercise price (EUR)	42,77	56,27
Weighted average remaining term of outstanding rights in years	3,5	1,67
Weighted average fair value of an option (EUR)	8.24	9.60
Share price volatility applied (in %)	31.21%	29.79%
risk-free interest rate (in %)	-0.58%	-0.55%

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Share Option Program Hannes Reichl	Dec 31, 2022	Dec 31, 2021
Total number of outstanding share options	250,000	250,000
of which vested	0	0
of which exercisable	0	0
Exercise price (EUR)	65,53	65,53
Weighted average remaining term of outstanding rights in years	0.50	1.50
Weighted average fair value of an option (EUR)	16,85	16,85
Share price volatility applied (in %)	29.65%	29.65%
risk-free interest rate (in %)	-0.45%	-0.45%

Share Option Program Dr. Eckart Pech	Dec 31, 2022	Dec 31, 2021
Total number of outstanding share options	250,000	250,000
of which vested	0	0
of which exercisable	0	0
Exercise price (EUR)	56,93	56,93
Weighted average remaining term of outstanding rights in years	0,83	1,83
Weighted average fair value of an option (EUR)	12,91	12,91
Share price volatility applied (in %)	30.00%	30.00%
risk-free interest rate (in %)	-0.55%	-0.55%

Share Option Program Angela Mazza Teufer	Dec 31, 2022
Total number of outstanding share options	250,000
of which vested	0
of which exercisable	0
Exercise price (EUR)	42,77
Weighted average remaining term of outstanding rights in years	3,5
Weighted average fair value of an option (EUR)	8,36
Share price volatility applied (in %)	31.21%
risk-free interest rate (in %)	-0.58%

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Share Option Program Emanuele Mugnani	Dec 31, 2022
Total number of outstanding share options	250,000
of which vested	0
of which exercisable	0
Exercise price (EUR)	42,77
Weighted average remaining term of outstanding rights in years	3,5
Weighted average fair value of an option (EUR)	8,36
Share price volatility applied (in %)	31.21%
risk-free interest rate (in %)	-0.58%

b) Former Managing Directors

Share Option Program Frank Brecher	Dec 31, 2022	Dec 31, 2021
Total number of outstanding share options	150,000	150,000
of which vested	0	0
of which exercisable	0	0
Exercise price (EUR)	71,87	71,87
Weighted average remaining term of outstanding rights in years	1,58	2,58
Weighted average fair value of an option (EUR)	18,63	18,63
Share price volatility applied (in %)	31.31%	31.31%
risk-free interest rate (in %)	-0.55%	-0.55%

Share Option Program Dr. Dirk Wössner	Dec 31, 2022	Dec 31, 2021
Total number of outstanding share options	0	1,250,000
of which vested	0	0
of which exercisable	0	0
Exercise price (EUR)	0	78,6
Weighted average remaining term of outstanding rights in years	0.00	3
Weighted average fair value of an option (EUR)	0	18,02
Share price volatility applied (in %)	0.00%	31.01%
risk-free interest rate (in %)	0.00%	-0.57%

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

c) Senior Management (group 2)

Overview share option program as at December 31, 2022:

Date of allocation	Dec 1, 2020	Jul 1, 2021	Sep 3, 2021	Jul 1, 2022
Total number of outstanding share options	20,000	142,500	20,000	30,000
of which vested	0	0	0	0
of which exercisable	0	0	0	0
Exercise price (EUR)	76,91	68,5	74,65	42,77
Weighted average remaining term of outstanding rights in years	1,92	2,5	2,68	3,5
Weighted average fair value of an option (EUR)	23,83	13,43	19,26	8,57
Share price volatility applied (in %)	30.23%	30.69%	30.59%	31.21%
risk-free interest rate (in %)	-0.56%	-0.57%	-0.57%	-0.58%

Overview share option program as at December 31, 2021:

Date of allocation	Dec 1, 2020	Jan 4, 2021	Jul 1, 2021	Jul 27, 2021	Sep 3, 2021
Total number of outstanding share options	20,000	25,000	220,000	10,000	20,000
of which vested	0	0	0	0	0
of which exercisable	0	0	0	0	0
Exercise price (EUR)	76,91	78,6	68,5	72,23	74,65
Weighted average remaining term of outstanding rights in years	2,92	3,01	3,5	3,57	3,68
Weighted average fair value of an option (EUR)	23,83	18,28	13,43	12,87	19,26
Share price volatility applied (in %)	30.23%	30.39%	30.69%	30.51%	30.59%
risk-free interest rate (in %)	-0.56%	-0.57%	-0.57%	-0.56%	-0.57%

G.18 Remuneration for the Supervisory Board and the Administrative Board

The compensation amounts for the members of the Supervisory Board of CompuGroup Medical SE & Co. KGaA are provided for in article 15 of the company's Articles of Association and are approved by the Annual General Meeting with the consent of the general partner pursuant to article 26 (4) of the Articles of Association of the company. Pursuant to the resolution of the (virtual) Annual General Meeting of CompuGroup Medical SE & Co. KGaA of May 13, 2020, the members of the Supervisory Board have been receiving fixed compensation of kEUR 40 and reimbursement of expenses since the conversion into an SE & Co. KGaA was registered. The Chair of the Supervisory Board receives kEUR 80, twice the fixed remuneration, while the Vice Chair receives kEUR 60, 1.5 times the fixed remuneration. For membership in a Supervisory Board committee, a member receives an additional fixed remuneration of kEUR 10, and the chair of a committee receives twice that amount, namely kEUR 20.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The remuneration of the Administrative Board of the general partner, CompuGroup Medical Management SE, is provided for in article 13 of the Articles of Association and is approved by the Annual General Meeting of CompuGroup Management SE pursuant to article 21 (3) of the Articles of Association. The members of the Administrative Board of the general partner receive an annual fixed remuneration of kEUR 60 unrelated to performance as well as the reimbursement of expenses. The chair of the Administrative Board receives twice the amount of the fixed remuneration, namely kEUR 120. Pursuant to article 8 (3) of the Articles of Association of CompuGroup Medical SE & Co. KGaA regarding the remuneration of the Administrative Board of CompuGroup Medical Management SE, the charges have been passed on to CompuGroup Medical SE & Co. KGaA.

The total remuneration (excluding any VAT) of the Supervisory Board of CompuGroup Medical SE & Co. KGaA for the year 2022, including the charges passed on by CompuGroup Medical Management SE for the Administrative Board, amount to (in EUR):

Remuneration 2022 for the Supervisory Board

Name	kEUR
von Ilberg, Philipp, Chair	100
Weinmann, Stefan, Vice Chair, employee representative	60
Handel, Ulrike, Dr.	40
Köhrmann, Martin, Prof. Dr.	40
Störmer, Matthias	60
Volkens, Bettina, Dr.	40
Basal, Ayfer, employee representative	50
Betz, Frank, employee representative	50
Hegemann, Adelheid, employee representative	40
Johnke, Lars, IG Metall	50
Mole, Julia, ver.di	40
Total	570

Remuneration 2022 for former members of the Supervisory Board

Name	kEUR
Fuchs, Michael, Dr. (died December 25, 2022)	49
Total	49

Remuneration 2021 for the Supervisory Board

Name	kEUR
von Ilberg, Philipp (since June 18, 2020) Chair	100
Weinmann, Stefan (since September 30, 2021), Deputy Chairman, employee representative	14
Fuchs, Michael, Dr. (since June 18, 2020)	50
Handel, Ulrike, Dr. (since June 18, 2020)	40
Köhrmann, Martin, Prof. Dr. (since June 18, 2020)	40
Störmer, Matthias (since June 18, 2020)	60

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Name	kEUR
Volkens, Bettina, Dr. (since June 18, 2020)	40
Basal, Ayfer (since September 30, 2021), employee representative	12
Betz, Frank (since September 30, 2021), employee representative	12
Hegemann, Adelheid (since September 30, 2021), employee representative	10
Johnke, Lars (since September 30, 2021), IG Metall	12
Mole, Julia (since January 15, 2021), ver.di	38
Total	428

Remuneration 2021 for former members of the Supervisory Board

Name	kEUR
Müller, Sven Thomas (from July 3, 2020 until September 30, 2021)	51
Veith, Thomas (from July 3, 2020 until January 15, 2021)	2
Becker, Andrea (from July 3, 2020 until January 15, 2021)	2
Keller, Ursula (from July 3, 2020 until September 30, 2021)	37
Kohl, Volker (from July 3, 2020 until September 30, 2021)	30
Frevel, Claudia (from July 3, 2020 until September 30, 2021)	30
Wiese, Andreas (from January 15, 2021 until September 30, 2021)	34
Total	187

These overviews contain the summarized remuneration for all members of the Supervisory Board in the past two years. In addition, any remuneration for membership of the Joint Committee and Audit Committee of the Supervisory Board is also included. More detailed information on the members and organizational structure can be found in the separate report of the Supervisory Board.

The additional remuneration for the employee representatives on the Supervisory Board for activities outside of their Supervisory Board duties is customary in the market. For reasons of materiality, no individualized information is provided.

Remuneration 2022 for the Administrative Board

Name	kEUR
Gotthardt, Frank	120
Esser, Klaus, Dr.	60
Gotthardt, Daniel, Prof. Dr.	60
Peters, Stefanie	60
Rauch, Michael (from July 1, 2022)	0
Total	300

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Remuneration 2022 for former members of the Administrative Board

Name	kEUR
Wössner, Dirk, Dr. (from January 1, 2021 until June 30, 2022)	0
Total	0

Remuneration 2021 for the Administrative Board

Name	kEUR
Gotthardt, Frank	120
Esser, Klaus, Dr.	60
Gotthardt, Daniel, Prof. Dr.	60
Peters, Stefanie	60
Wössner, Dirk, Dr.	0
Total	300

Review of the Supervisory Board remuneration system

On the occasion of the entry into force of the law for the implementation of the Second Shareholder Rights Directive (ARUG II), the Supervisory Board remuneration system is also to be submitted to the Annual General Meeting for approval pursuant to section 113 (3) German Stock Corporation Act (AktG). This took place at the Annual General Meeting on May 19, 2021.

G.19 Risk management system

Please refer to the management report for information on the principles of the risk management system.

G.20 Release from disclosure requirement

All German corporations with profit transfer agreements or with a voluntary obligation to assume losses provided by the parent company exercise the exemption under section 264 (3) German Commercial Code (HGB) regarding the preparation and publication of a management report and annual financial statements. This concerns the following companies:

- CGM Clinical Deutschland GmbH, Koblenz
- CompuGroup Medical Deutschland AG, Koblenz
- CompuGroup Medical Software GmbH, Koblenz
- Ifap Service-Institut für Ärzte und Apotheker GmbH, Martinsried
- LAUER-FISCHER GmbH, Fürth
- CGM IT Solutions und Services GmbH, Koblenz
- CompuGroup Medical Mobile GmbH, Koblenz
- LAUER-FISCHER ApothekenService GmbH, Koblenz
- Meditec Marketingservices im Gesundheitswesen GmbH, Koblenz
- docmetric GmbH, Koblenz
- CGM Clinical Europe GmbH, Koblenz
- AESCU DATA Gesellschaft für Datenverarbeitung mbH, Winsen
- CompuGroup Medical Dentalsysteme GmbH, Koblenz
- Intermedix Deutschland GmbH, Koblenz
- CGM Systemhaus GmbH, Koblenz
- Visus Health IT GmbH, Bochum
- INSIGHT Health GmbH, Waldems-Esch

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

G.21 Disclosures by region

kEUR	Sales to third parties		Non current assets without deferred taxes	
	2022	2021	2022	2021
Germany	626,742	556,603	798,238	700,008
Western Europe	332,727	319,387	393,891	399,889
Eastern Europe	25,877	24,087	7,939	7,452
North America	135,141	116,196	310,590	295,011
Rest of the World	9,252	9,049	10,454	12,750
Foreign countries	502,997	468,719	722,874	715,102
CGM Group	1,129,739	1,025,322	1,521,112	1,415,110

Koblenz, March 20, 2023

CompuGroup Medical SE & Co. KGaA

Represented by the Managing Directors
of CompuGroup Medical Management SE



Michael Rauch



Angela Mazza Teufer



Emanuele Mugnani



Dr. Eckart Pech



Hannes Reichl

FURTHER INFORMATION

Responsibility statement

To the best of our knowledge and in accordance with the applicable accounting principles, the consolidated financial statements give a true and fair view of the net assets, financial position and results of operations of the group, and the management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group.

Koblenz, March 20, 2023

CompuGroup Medical SE & Co. KGaA

**Represented by the Managing Directors
of CompuGroup Medical Management SE**



Michael Rauch



Angela Mazza Teufer



Emanuele Mugnani



Dr. Eckart Pech



Hannes Reichl

Independent Auditor's Report

To CompuGroup Medical SE & Co. KGaA, Koblenz

Report on the Audit of the Consolidated Financial Statements and of the Combined Management Report

Opinions

We have audited the consolidated financial statements of CompuGroup Medical SE & Co. KGaA, Koblenz, and its subsidiaries (the Group), which comprise the consolidated statement of financial position as of December 31, 2022, and the consolidated income statement, consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the financial year from January 1 to December 31, 2022, and notes to the consolidated financial statements, including a summary of significant accounting policies. In addition, we have audited the management report of CompuGroup Medical SE & Co. KGaA and the Group (combined management report) for the financial year from January 1 to December 31, 2022.

In accordance with German legal requirements, we have not audited the content of those components of the combined management report specified in the "Other Information" section of our auditor's report.

In our opinion, on the basis of the knowledge obtained in the audit,

- the accompanying consolidated financial statements comply, in all material respects, with the IFRSs as adopted by the EU, and the additional requirements of German commercial law pursuant to Section 315e (1) HGB [Handelsgesetzbuch: German Commercial Code] and, in compliance with these requirements, give a true and fair view of the assets, liabilities, and financial position of the Group as of December 31, 2022, and of its financial performance for the financial year from January 1 to December 31, 2022, and
- the accompanying combined management report as a whole provides an appropriate view of the Group's position. In all material respects, this combined management report is consistent with the consolidated financial statements, complies with German legal requirements and appropriately presents the opportunities and risks of future development. Our opinion on the combined management report does not cover the content of those components of the combined management report specified in the "Other Information" section of the auditor's report.

Pursuant to Section 322 (3) sentence 1 HGB, we declare that our audit has not led to any reservations relating to the legal compliance of the consolidated financial statements and of the combined management report.

Independent Auditor's Report

Basis for the Opinions

We conducted our audit of the consolidated financial statements and of the combined management report in accordance with Section 317 HGB and the EU Audit Regulation No 537/2014 (referred to subsequently as "EU Audit Regulation") and in compliance with German Generally Accepted Standards for Financial Statement Audits promulgated by the Institut der Wirtschaftsprüfer [Institute of Public Auditors in Germany] (IDW). Our responsibilities under those requirements and principles are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Statements and of the Combined Management Report" section of our auditor's report. We are independent of the group entities in accordance with the requirements of European law and German commercial and professional law, and we have fulfilled our other German professional responsibilities in accordance with these requirements. In addition, in accordance with Article 10 (2)(f) of the EU Audit Regulation, we declare that we have not provided non-audit services prohibited under Article 5 (1) of the EU Audit Regulation. We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinions on the consolidated financial statements and on the combined management report.

Key Audit Matters in the Audit of the Consolidated Financial Statements

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements for the financial year from January 1 to December 31, 2022. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, we do not provide a separate opinion on these matters.

Acquisition and first-time consolidation of the Insight Health Group

Please refer to Section "C.2 b. Acquisition of subsidiaries" in the notes to the consolidated financial statements for more information on the accounting policies applied.

Disclosures on the acquisition of the Insight Health Group are presented in the notes to the consolidated financial statements in Section "C.4 b. Company acquisitions and disposals".

THE FINANCIAL STATEMENT RISK

On May 10, 2022, the CompuGroup Medical SE & Co. KGaA Group acquired 100% of the shares in the Insight Health Group. The purchase price amounted to EUR 60.8 million. With due regard to the net assets acquired in the amount of EUR 29.1 million, goodwill amounts to EUR 31.7 million.

The acquired identifiable assets and assumed liabilities are usually recognized at fair value pursuant to IFRS 3 on the date of acquisition. The Group engaged an external expert to identify and measure the assets acquired and the liabilities assumed.

FURTHER INFORMATION

Independent Auditor's Report

The identification and measurement of acquired (especially intangible) assets and assumed liabilities is complex and based on management's assumptions that require judgment. The significant assumptions include the projections of the acquired business's revenue and margins, the license fees utilized, useful lives applied as well as the cost of capital.

There is the risk for the consolidated financial statements that the assets acquired and liabilities assumed are identified improperly or measured inaccurately. There is also the risk that the disclosures in the notes to the consolidated financial statements are not complete and accurate.

OUR AUDIT APPROACH

We first gained an understanding of the acquisition by evaluating the relevant agreements and by interviewing employees from the finance function.

We assessed the competency, skills and objectivity of the independent expert engaged by CompuGroup. Furthermore, we assessed the process for identifying the assets acquired and liabilities assumed in terms of conformity with the requirements of IFRS 3 using our knowledge of the business model of the acquired activities. We investigated the valuation methods used for their compliance with the accounting policies.

With the involvement of our own valuation experts, we assessed the appropriateness of the identification and valuation methods along with the key assumptions.

We discussed projected revenue and margin development with those responsible for planning. Furthermore, we reconciled these with the budgets prepared by management and assessed the consistency of the assumptions with the market data. The license rates utilized to measure the intangible assets were compared with benchmarks from relevant databases. We compared the assumptions and data underlying the capital costs, in particular the risk-free rate, the market risk premium and the beta factor with our own assumptions and publicly available data.

To assess computational accuracy, we verified selected calculations based on risk criteria. Finally, we assessed whether the disclosures in the notes regarding the acquisition of the Insight Health Group were complete and accurate.

OUR OBSERVATIONS

The approach used for identifying and measuring the assets acquired and liabilities assumed is appropriate and in line with the accounting policies to be applied. The key assumptions and data underlying the purchase price allocation are appropriate and the presentation in the notes to the consolidated financial statements is complete and appropriate.

Independent Auditor's Report

Impairment testing of goodwill

Please refer to Section "D.1.c) Goodwill" in the notes to the consolidated financial statements for more information on the accounting policies applied.

Information on the amount and development of goodwill can be found in the notes to the consolidated financial statements under Section "E.1 Intangible assets".

THE FINANCIAL STATEMENT RISK

As of December 31, 2022, goodwill amounted to EUR 639.2 million and, at 32.9% of total assets, accounts for a substantial share of assets.

Impairment of goodwill is tested annually at the level of business segments. For this purpose, the carrying amount of the assets is compared with their recoverable amount of the respective segment. If the carrying amount exceeds the recoverable amount, there is a need for impairment.

The Company generally takes the value in use of the respective segment as the recoverable amount. The Company calculates this using discounted cash flow models based on the present values of the expected future cash flows, which stem from the budgets prepared by management for the coming year, extrapolated using assumptions about future growth rates. The respective capitalization rate is derived from the return on a risk-appropriate alternative investment. The effective date for the impairment test is October 31, 2022.

Calculation of value in use is complex and, as regards the assumptions made, based largely on estimates and assessments of the Company. This applies particularly to estimates of future cash flows and long-term growth rates as well as the determination of the capitalization rate.

The calculated values did not provide any indications for the need to recognize an impairment. There is the risk for the consolidated financial statements that an existing impairment loss is not recognized in the amount required. There is also the risk that the related disclosures in the notes are not appropriate.

OUR AUDIT APPROACH

Using the information obtained in our audit, we first assessed whether goodwill indicated a need for impairment. With the involvement of our valuation experts, we assessed the appropriateness of the significant assumptions and the valuation model of the Group. In addition, we discussed the expected cash flows and the assumed growth rates with those responsible for planning. Furthermore, we reconciled the budget with the budget approved by the Joint Committee for financial year 2023 and assessed whether the budget amounts and growth rates applied are in line with sector development.

Independent Auditor's Report

We also confirmed the accuracy of the Company's previous forecasts by comparing the budgets of previous financial years with actual results and analyzed deviations.

We compared the assumptions and parameters underlying the capitalization rate, in particular the risk-free rate, the market risk premium and the beta factor, with our own assumptions and publicly available data. In order to take account of forecast uncertainty and the early closing date for the impairment test, we also investigated the impact of potential changes to the capitalization rate and the terminal value growth rate on the value in use by calculating alternative scenarios and comparing these with the Group's measurements (sensitivity analysis). To ensure the computational accuracy of the valuation model used, we verified the Company's calculations on the basis of selected risk-based elements.

Finally, we assessed whether the disclosures in the notes regarding impairment of goodwill are appropriate. This also included an assessment of the appropriateness of the disclosures pursuant to IAS 36.134(f) on sensitivities in the event of a reasonably possible change in key assumptions underlying the evaluation.

OUR OBSERVATIONS

The process used by the Company for impairment testing of goodwill is appropriate and in line with the accounting policies. The Company's assumptions and parameters are appropriate. The related disclosures in the notes are appropriate.

Impairment testing of internally generated software

Please refer to Section "D.1.b) Internally generated software" in the notes to the consolidated financial statements for more information on the accounting policies applied.

Information on the amount and development of internally generated software can be found in the notes to the consolidated financial statements under Section "E.1 Intangible assets".

THE FINANCIAL STATEMENT RISK

Capitalized development costs for internally generated software reported under intangible assets amounted to EUR 195.7 million as of December 31, 2022, and, at 10.0% of total assets, have a considerable relevance for assets and liabilities.

Assets that are not ready for use are tested annually for impairment in accordance with the requirements of IASD 36.10. In addition, capitalized development costs for internally generated software at project level are compared with the recoverable amount. A need to recognize impairment arises when the carrying amount exceeds the recoverable amount. The Company uses the value in use of the respective software project as the recoverable amount. Value in use is determined using the budget figures allocable to a development project, taking account of a company-specific capitalization rate.

FURTHER INFORMATION

Independent Auditor's Report

The capitalized development costs for internally generated software are amortized over a period of two to fifteen years starting from use of the assets. In accordance with the requirements of IAS 36.9, the Group also analyzed whether there is an indication of possible impairment of an asset. Pursuant to IAS 36.12, if there is an indication of impairment, an impairment test is conducted. No need for impairment was identified for financial year 2022.

The determination of value in use is complex and based on a range of assumptions that require judgment. These also include the expected revenue and earnings contributions of the software projects and the capitalization rate used.

There is the risk for the consolidated financial statements that impairment existing as of the reporting date was not recognized or that the calculated impairment losses are not adequate.

OUR AUDIT APPROACH

On the basis of the understanding of the process activities that we obtained, we initially assessed the design and implementation of the identified internal controls regarding impairment testing of capitalized development costs for internally generated software.

We assessed the appropriateness of the significant assumptions and the valuation model for a selective sample of significant assets. In addition, we discussed the expected cash flows and the assumed growth rates with those responsible for planning. Furthermore, we reconciled the expected cash flows with the budget approved by the managing directors and assessed whether the budget amounts and growth rates used are in line with sector development.

We also confirmed the accuracy of the Group's previous forecasts by comparing the budgets of previous financial years with actual results and by analyzing deviations.

We compared the assumptions and data underlying the capitalization rate, in particular the risk-free rate, the market risk premium and the beta coefficient, with our own assumptions and publicly available data.

To ensure the computational accuracy of the valuation model used, we verified the Company's calculations on the basis of selected risk-based elements.

Independent Auditor's Report

OUR OBSERVATIONS

The underlying approach for impairment testing capitalized development costs is appropriate and in line with the accounting policies to be applied. The Company's assumptions and parameters are appropriate.

Other Information

Management and/or the Supervisory Board are/is responsible for the other information. The other information comprises the following components of the combined management report, whose content was not audited:

- the separate combined non-financial report, which is referred to in the combined management report,
- the combined corporate governance statement, which is referred to in the combined management report, and
- information extraneous to management reports and marked as unaudited.

The other information also includes the remaining parts of the annual report. The other information does not include the consolidated financial statements, the combined management report information audited for content and our auditor's report thereon.

Our opinions on the consolidated financial statements and on the combined management report do not cover the other information, and consequently we do not express an opinion or any other form of assurance conclusion thereon.

In connection with our audit, our responsibility is to read the other information and, in so doing, to consider whether the other information

- is materially inconsistent with the consolidated financial statements, with the combined management report information audited for content or our knowledge obtained in the audit, or
- otherwise appears to be materially misstated.

Independent Auditor's Report

Responsibilities of Management and the Supervisory Board for the Consolidated Financial Statements and the Combined Management Report

Management is responsible for the preparation of consolidated financial statements that comply, in all material respects, with IFRSs as adopted by the EU and the additional requirements of German commercial law pursuant to Section 315e (1) HGB and that the consolidated financial statements, in compliance with these requirements, give a true and fair view of the assets, liabilities, financial position, and financial performance of the Group. In addition, management is responsible for such internal control as they have determined necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud (i.e., fraudulent financial reporting and misappropriation of assets) or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern. They also have the responsibility for disclosing, as applicable, matters related to going concern. In addition, they are responsible for financial reporting based on the going concern basis of accounting unless there is an intention to liquidate the Group or to cease operations, or there is no realistic alternative but to do so.

Furthermore, management is responsible for the preparation of the combined management report that, as a whole, provides an appropriate view of the Group's position and is, in all material respects, consistent with the consolidated financial statements, complies with German legal requirements, and appropriately presents the opportunities and risks of future development. In addition, management is responsible for such arrangements and measures (systems) as they have considered necessary to enable the preparation of a combined management report that is in accordance with the applicable German legal requirements, and to be able to provide sufficient appropriate evidence for the assertions in the combined management report.

The Supervisory Board is responsible for overseeing the Group's financial reporting process for the preparation of the consolidated financial statements and of the combined management report.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements and of the Combined Management Report

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and whether the combined management report as a whole provides an appropriate view of the Group's position and, in all material respects, is consistent with the consolidated financial statements and the knowledge obtained in the audit, complies with the German legal requirements and appropriately presents the opportunities and risks of future development, as well as to issue an auditor's report that includes our opinions on the consolidated financial statements and on the combined management report.

Independent Auditor's Report

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Section 317 HGB and the EU Audit Regulation and in compliance with German Generally Accepted Standards for Financial Statement Audits promulgated by the Institut der Wirtschaftsprüfer (IDW) will always detect a material misstatement. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements and this combined management report.

We exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements and of the combined management report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinions. The risk of not detecting a material misstatement resulting from fraud is higher than the risk of not detecting a material misstatement resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
- Obtain an understanding of internal control relevant to the audit of the consolidated financial statements and of arrangements and measures (systems) relevant to the audit of the combined management report in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of these systems.
- Evaluate the appropriateness of accounting policies used by management and the reasonableness of estimates made by management and related disclosures.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in the auditor's report to the related disclosures in the consolidated financial statements and in the combined management report or, if such disclosures are inadequate, to modify our respective opinions. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to be able to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements present the underlying transactions and events in a manner that the consolidated financial statements give a true and fair view of the assets, liabilities, financial position and financial performance of the Group in compliance with IFRSs as adopted by the EU and the additional requirements of German commercial law pursuant to Section 315e (1) HGB.

Independent Auditor's Report

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express opinions on the consolidated financial statements and on the combined management report. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our opinions.
- Evaluate the consistency of the combined management report with the consolidated financial statements, its conformity with [German] law, and the view of the Group's position it provides.
- Perform audit procedures on the prospective information presented by management in the combined management report. On the basis of sufficient appropriate audit evidence we evaluate, in particular, the significant assumptions used by management as a basis for the prospective information, and evaluate the proper derivation of the prospective information from these assumptions. We do not express a separate opinion on the prospective information and on the assumptions used as a basis. There is a substantial unavoidable risk that future events will differ materially from the prospective information.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with the relevant independence requirements, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, the actions taken or safeguards applied to eliminate independence threats.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter.

Independent Auditor's Report

Other Legal and Regulatory Requirements

Report on the Assurance on the Electronic Rendering of the Consolidated Financial Statements and the Combined Management Report Prepared for Publication Purposes in Accordance with Section 317 (3a) HGB

We have performed assurance work in accordance with Section 317 (3a) HGB to obtain reasonable assurance about whether the rendering of the consolidated financial statements and the combined management report (hereinafter the 'ESEF documents') contained in the electronic file „compugroupmedicalsecokgaa-2022-12-31-de.zip“ (Hashwert:1e670c2cc573f020f5562c0a3ee8320f2ad12366e1a8ff34a559beda4a5addfb) made available and prepared for publication purposes complies in all material respects with the requirements of Section 328 (1) HGB for the electronic reporting format ('ESEF format'). In accordance with German legal requirements, this assurance work extends only to the conversion of the information contained in the consolidated financial statements and the combined management report into the ESEF format and therefore relates neither to the information contained in these renderings nor to any other information contained in the file identified above.

In our opinion, the rendering of the consolidated financial statements and the combined management report contained in the electronic file made available, identified above and prepared for publication purposes complies in all material respects with the requirements of Section 328 (1) HGB for the electronic reporting format. Beyond this assurance opinion and our audit opinion on the accompanying consolidated financial statements and the accompanying combined management report for the financial year from January 1 to December 31, 2022, contained in the "Report on the Audit of the Consolidated Financial Statements and the Combined Management Report" above, we do not express any assurance opinion on the information contained within these renderings or on the other information contained in the file identified above.

We conducted our assurance work on the rendering of the consolidated financial statements and the combined management report contained in the file made available and identified above in accordance with Section 317 (3a) HGB and the IDW Assurance Standard: Assurance Work on the Electronic Rendering of Financial Statements and Management Reports Prepared for Publication Purposes in Accordance with Section 317 (3a) HGB (IDW AsS 410 (06.2022)). Our responsibility in accordance therewith is further described below. Our audit firm applies the IDW Standard on Quality Management 1: Requirements for Quality Management in Audit Firms (IDW QS 1).

The Company's management is responsible for the preparation of the ESEF documents including the electronic rendering of the consolidated financial statements and the combined management report in accordance with Section 328 (1) sentence 4 item 1 HGB and for the tagging of the consolidated financial statements in accordance with Section 328 (1) sentence 4 item 2 HGB.

In addition, the Company's management is responsible for such internal control that they have considered necessary to enable the preparation of ESEF documents that are free from material intentional or unintentional non-compliance with the requirements of Section 328 (1) HGB for the electronic reporting format.

The Supervisory Board is responsible for overseeing the process of preparing the ESEF documents as part of the financial reporting process.

Independent Auditor's Report

Our objective is to obtain reasonable assurance about whether the ESEF documents are free from material intentional or unintentional non-compliance with the requirements of Section 328 (1) HGB. We exercise professional judgment and maintain professional skepticism throughout the assurance work. We also:

- Identify and assess the risks of material intentional or unintentional non-compliance with the requirements of Section 328 (1) HGB, design and perform assurance procedures responsive to those risks, and obtain assurance evidence that is sufficient and appropriate to provide a basis for our assurance opinion.
- Obtain an understanding of internal control relevant to the assurance on the ESEF documents in order to design assurance procedures that are appropriate in the circumstances, but not for the purpose of expressing an assurance opinion on the effectiveness of these controls.
- Evaluate the technical validity of the ESEF documents, i.e. whether the file made available containing the ESEF documents meets the requirements of the Commission Delegated Regulation (EU) 2019/815, as amended as of the reporting date, on the technical specification for this electronic file.
- Evaluate whether the ESEF documents provide an XHTML rendering with content equivalent to the audited consolidated financial statements and the audited combined management report.
- Evaluate whether the tagging of the ESEF documents with Inline XBRL technology (iXBRL) in accordance with the requirements of Articles 4 and 6 of the Commission Delegated Regulation (EU) 2019/815, as amended as of the reporting date, enables an appropriate and complete machine-readable XBRL copy of the XHTML rendering.

Further Information pursuant to Article 10 of the EU Audit Regulation

We were elected as group auditor at the Annual General Meeting on May 19, 2022. We were engaged by the Supervisory Board on December 12, 2022. We have been the group auditor of CompuGroup Medical SE & Co. KGaA without interruption since financial year 2019.

We declare that the opinions expressed in this auditor's report are consistent with the additional report to the Audit Committee pursuant to Article 11 of the EU Audit Regulation (long-form audit report).

FURTHER INFORMATION

Independent Auditor's Report

Other Matter – Use of the Auditor's Report

Our auditor's report must always be read together with the audited consolidated financial statements and the audited combined management report as well as the examined ESEF documents. The consolidated financial statements and combined management report converted to the ESEF format – including the versions to be entered in the company register – are merely electronic renderings of the audited consolidated financial statements and the audited combined management report and do not take their place. In particular, the ESEF report and our assurance opinion contained therein are to be used solely together with the examined ESEF documents made available in electronic form.

German Public Auditor Responsible for the Engagement

The German Public Auditor responsible for the engagement is Alexander Bock.

Frankfurt am Main, March 20, 2023

KPMG AG

Wirtschaftsprüfungsgesellschaft

[signature] Bock

Wirtschaftsprüfer

[German Public Auditor]

[signature] Jennes

Wirtschaftsprüfer

[German Public Auditor]

FINANCIAL CALENDAR

Date	Event
May 10, 2023	Interim Report Q1 2023
May 17, 2023	Annual General Meeting
August 10, 2023	Interim Report Q2 2023
September 7, 2023	Capital Markets Day
November 9, 2023	Interim Report Q3 2023

Published by:

CompuGroup Medical SE & Co. KGaA

Maria Trost 21

56070 Koblenz

Phone +49 261 8000-0

www.cgm.com

Managing Directors:

Michael Rauch, Angela Mazza Teufer, Emanuele Mugnani, Dr. Eckart Pech, Hannes Reichl

Chairman of the Supervisory Board:

Philipp von Ilberg

Registered office:

Koblenz, commercial register number HRB 27430

VAT identification number:

DE 114 134699

Contact Investor Relations:

E-mail: investor@cgm.com

The non-financial report is published separately from the annual report. Publication date: March 24, 2023.



CompuGroup Medical SE & Co. KGaA

Maria Trost 21
56070 Koblenz
Germany

www.cgm.com